ticagrelor profile

Ticagrelor: An adenosine triphosphate analogue and reversible P2Y12 PURINORECEPTOR antagonist that inhibits ADP-mediated PLATELET AGGREGATION. It is used for the prevention of THROMBOEMBOLISM by patients with ACUTE CORONARY SYNDROME or a history of MYOCARDIAL INFARCTION. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ticagrelor : A triazolopyrimidine that is an adenosine isostere; the cyclopentane ring is similar to ribose and the nitrogen-rich [1,2,3]triazolo[4,5-d]pyrimidine moiety resembles the nucleobase adenine. A platelet aggregation inhibitor which is used for prevention of thromboembolic events in patients with acute coronary syndrome. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	9871419
CHEMBL ID	398435
CHEBI ID	68558
SCHEMBL ID	1979652
MeSH ID	M0513890

Synonym
azd 6140
azd6140
HY-10064
gtpl1765
(1s,2s,3r,5s)-3-[7-[[(1r,2s)-2-(3,4-difluorophenyl)cyclopropyl]amino]-5-propylsulfanyltriazolo[5,4-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol
compound 17 [pmid: 17827008]
azd-6140
brilinta
ticagrelor
brilique
ar-c126532
chebi:68558 ,
possia
CHEMBL398435
ar-c126532xx
ticagrelor (jan/usan/inn)
274693-27-5
D09017
brilinta (tn)
(1s,2s,3r,5s)-3-[7-[[(1r,2s)-2-(3,4-d1,2-cyclopentanediolifluorophenyl)cyclopropyl]amino]-5-(propylthio)-3h-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)-1,2-cyclopentanediol
ar-c 126532xx
EX-6274
S4079
bdbm50397205
unii-glh0314rvc
1,2-cyclopentanediol, 3-(7-(((1r,2s)-2-(3,4-difluorophenyl)cyclopropyl)amino)-5-(propylthio)-3h-1,2,3-triazolo(4,5-d)pyrimidin-3-yl)-5-(2-hydroxyethoxy)-, (1s,2s,3r,5s)-
ticagrelor [usan:inn:ban]
glh0314rvc ,
(1s,2s,3r,5s)-3-(7-((1r,2s)-2-(3,4-difluorophenyl)cyclopropylamino)-5-(propylthio)-3h-(1,2,3)triazolo(4,5-d)pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol
hsdb 8306
ticargrelor
(1s,2s,3r,5s)-3-[7-[[(1r,2s)-2-(3,4-difluorophenyl)cyclopropyl]amino]-5-(propylthio)-3h-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)-1,2-cyclopentanediol
ticagrelor [orange book]
ticagrelor [usp-rs]
ticagrelor [usan]
ticagrelor [ema epar]
(1s,2s,3r,5s)-3-(7-((1r,2s)-2-(3,4-difluorophenyl)cyclopropylamino)-5-(propylthio)-3h-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol
ticagrelor [inn]
ticagrelor [ep monograph]
ticagrelor [jan]
ticagrelor [mart.]
ticagrelor [who-dd]
ticagrelor [mi]
ticagrelor [vandf]
CS-0619
(1s,2s,3r,5s)-3-[7-{[(1r,2s)-2-(3,4-difluorophenyl)cyclopropyl]amino}-5-(propylsulfanyl)-3h-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol
AKOS015900739
DB08816
OEKWJQXRCDYSHL-FNOIDJSQSA-N
(1s,2s,3r,5s)-3-(7-((1r,2s)-2-(3,4-difluorophenyl)cyclopropylamino)-5-(propylthio)-3h-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2 diol
(1s,2s,3r,5s)-3-(7-((1r,2s)-2-(3,4-difluorophenyl)cyclopropylamino)-5-(propylthio)-3h-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy) cyclopentane-1,2-diol
SCHEMBL1979652
(1s,2s,3r,5s)-3-(7-(((1r,2s)-2-(3,4-difluorophenyl)cyclopropyl)amino)-5-(propylthio)-3h-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol
AM85693
[14c]-ticagrelor
AC-24755
c23h28f2n6o4s
AB01565855_02
mfcd09954148
(1s,2s,3r,5s)-3-(7-{[(1r,2s)-2-(3,4-difluorophenyl)cyclopropyl]amino}-5-(propylsulfanyl)-3h-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol
J-524969
EX-A503
J-016772
ticagrelor form
NCGC00379052-02
ticagrelor (brilinta,azd6140)
(1s,2s,3r,5s)-3-[7-[[(1r,2s)-2-(3,4-difluorophenyl)cyclopropyl]amino]-5-(propylthio)-3h-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol
(1s,2s,3r,5s)-3-[7-[[(1r,2s)-2-(3,4-difluorophenyl)-cyclopropyl]amino]-5-(propylthio)-3h-[1,2,3]-triazolo[4,5-d]pyrimidine-3-yl]-5-(2-hydroxyethoxy) cyclopentane-1,2-diol
ar-c 126532xx;azd6140
Q420542
(1s,2s,3r,5s)-3-[7-[(1r,2s)-2-(3,4-difluorophenyl)cyclopropylamino]-5-(propylthio)- 3h-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol
AS-19943
1,2-cyclopentanediol,3-[7-[[(1r,2s)-2-(3,4-difluorophenyl)cyclopropyl]amino]-5-(propylthio)-3h-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)-,(1s,2s,3r,5s)-
(1s,2s,3r,5s)-3-[7-[[(1r,2s)-2-(3,4-difluorophenyl)cyclopropyl]amino]-5-propylsulfanyltriazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol
HMS3885B03
CCG-269870
NCGC00379052-01
(1s,2s,3r,5s)-3-(7-(((1r)-2-(3,4-difluorophenyl)cyclopropyl)amino)-5-(propylthio)-3h-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol
DTXSID901009337 ,
(1s,2s,3r,5s)-3-(7-(((1s,2s)-2-(3,4-difluorophenyl)cyclopropyl)amino)-5-(propylthio)-3h-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol
A850981
EN300-19659674
BT164470
ticagrelor- bio-x
(1s,2s,3r,5s)-3-(7-(((1r,2s)-2-(3,4-difluorophenyl)cyclopropyl)amino)-5-(propylsulfanyl)-3h-(1,2,3)triazolo(4,5-d)pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol
ticagrelorum
ticagrelor (mart.)
ticagrelor (ep monograph)
ticagrelor (usp-rs)
compound 17 (pmid: 17827008)
b01ac24
dtxcid501436166
Z2235802088

Excerpt	Reference	Relevance
"Ticagrelor is a potent, oral P2Y12 inhibitor used as a part of dual antiplatelet therapy (DAPT) in acute coronary syndromes (ACS). "	( Expert Opinion on P2Y12 Inhibitors Use in Management of Acute Coronary Syndromes: Focus on Ticagrelor. Banerjee, S; Bp, P; C, SO; Chandra, S; Hardas, S; Hiremath, MS; Magarkar, V; Makhale, CN; Mishra, H; Navasundi, GB; Ponde, CK; R, B; Rath, PC; Ray, S; Sathe, S; Sathyamurthy, I; Sawhney, JP; Sen, AK; Vaidyanathan, PR, 2021)	2.28
"Ticagrelor is a more potent adenosine diphosphate (ADP) receptor blocker proven to be superior to clopidogrel among patients with acute coronary syndromes."	( Effects of Ticagrelor and Clopidogrel on Coronary Microcirculation in Patients with Acute Myocardial Infarction. Aguiar, MO; Azevedo, L; Baracioli, LM; Berwanger, O; Chiang, HP; Dalcoquio, TF; de Luca, F; Ferrari, AG; Furtado, RHM; Giugliano, RP; Goodman, S; Lima, FG; Matthias, W; Menezes, FR; Nicolau, JC; Scanavini-Filho, MA, 2022)	1.83
"Ticagrelor is a first-line drug for the treatment of acute ST elevation myocardial infarction (STEMI). "	( Gut microbiota induces high platelet response in patients with ST segment elevation myocardial infarction after ticagrelor treatment. Cai, Y; Han, Y; Song, H; Tian, X; Tong, F; Yan, C; Zhang, X; Zhang, Y, 2022)	2.38
"Ticagrelor is an effective and well-tolerated option to attain a meaningful and clinically relevant reduction in cardiovascular mortality in both acute and chronic settings across a broad range of high-risk patient subpopulations with an acceptable payoff in terms of bleeding risk."	( Cardiovascular mortality in patients with acute and chronic coronary syndrome: insights from the clinical evidence on ticagrelor. Esposito, G; Gargiulo, G; Serino, F, 2022)	2.37
"Ticagrelor is a cyclopentyl-triazole pyrimidine antiplatelet drug that was the first reversible oral P2Y12 receptor antagonist."	( A Review of the Role of the Antiplatelet Drug Ticagrelor in the Management of Acute Coronary Syndrome, Acute Thrombotic Disease, and Other Diseases. Chen, C; Chen, Z; Gu, X; Liu, W; Mao, X; Ren, S; Tao, L; Zhang, L; Zhao, Y, 2022)	1.7
"Ticagrelor is a platelet inhibitor known to reduce major adverse cardiovascular events (MACE) in AMI patients."	( In-vivo platelet activation and aggregation during and after acute atherothrombotic myocardial infarction in patients with and without Type-2 diabetes mellitus treated with ticagrelor. AlAdili, B; Amraotkar, AR; Coulter, AR; Daham, ON; DeFilippis, AP; Kulkarni, S; Mitra, R; Singam, NSV; Singh, A; Smith, AE, 2022)	1.64
"Ticagrelor is a widely used anti-platelet drug. "	( Ticagrelor Protects against Sepsis-Induced Acute Kidney Injury through an Adenosine Receptor-Dependent Pathway. Cao, YH; Fu, C; Ling, Y; Wang, YW; Xu, QC, 2022)	3.61
"Ticagrelor is a relatively new agent which functions as a reversible inhibitor of the P2Y12 receptor working to prevent platelet aggregation and is used with or without aspirin in patients with acute coronary syndrome to reduce the risk of myocardial infarction and stroke."	( An 80-Year-Old Man with Ischemic Heart Disease Who Developed Thrombotic Thrombocytopenic Purpura Following Treatment with Ticagrelor. Al Madani, M; Chiang, B; Jarrett, SA; Varadi, G; Wattoo, A, 2022)	1.65
"Ticagrelor is a frequently prescribed platelet aggregation inhibitor used in patients with acute coronary syndrome. "	( [Dyspnoea due to ticagrelor after recent myocardial infarction]. Schellings, DAAM; van Gorselen, EOF, 2022)	2.5
"Ticagrelor and aspirin is a common dual antiplatelet therapy regimen for patients who undergo percutaneous coronary intervention. "	( Ticagrelor and primidone interaction masquerading as dual antiplatelet therapy noncompliance. Ghani, A; Haider, J; McKay, R; Nagle, C; Patail, H; Rizvi, A, 2023)	3.8
"Ticagrelor and aspirin is a common antiplatelet regimen for patients who undergo coronary intervention and stent implantation. "	( Ticagrelor and primidone interaction masquerading as dual antiplatelet therapy noncompliance. Ghani, A; Haider, J; McKay, R; Nagle, C; Patail, H; Rizvi, A, 2023)	3.8
"Ticagrelor is a direct oral P2Y12 inhibitor that may achieve rapid platelet suppression than standard oral therapies."	( Emergent use of ticagrelor during endovascular reperfusion in large arterial occlusions. Al-Bayati, AR; Chester, KW; English, SW; Frankel, MR; Haussen, DC; Kim, SJ; Morgan, OJ; Nogueira, RG, 2023)	1.98
"Ticagrelor is an oral, direct-acting, and reversible adenosine diphosphate P2Y"	( Ticagrelor versus placebo for the reduction of vaso-occlusive crises in pediatric sickle cell disease: Rationale and design of a randomized, double-blind, parallel-group, multicenter phase 3 study (HESTIA3). Abboud, MR; Amilon, C; Andersson, M; Berggren, AR; Githanga, J; Heeney, MM; Inusa, B; Kanter, J; Leonsson-Zachrisson, M; Michelson, AD, 2019)	2.68
"Ticagrelor is a drug widely used in patients with acute coronary syndromes (ACS) that specifically increases the plasma level of adenosine, which is likely to cause atrial fibrillation (AF). "	( Comparison of atrial fibrillation predictors in patients with acute coronary syndrome using ticagrelor or clopidogrel Açıkel, S; Aker, M; Algül, E; Çimen, T; Dural, M; Erat, M; Felekoğlu, MA; Guliyev, İ; Sunman, H; Tulmaç, M, 2019)	2.18
"Ticagrelor is an antiplatelet agent used for treatment of coronary artery disease via inhibition of the P2Y12 receptor. "	( Successful intravenous thrombolysis for ischemic stroke as a complication of coronary intervention in patients with ticagrelor pretreatment. Choi, PMC; Fink, JN; Ho, R; Jahangiri, B; Smyth, DW; Wright, SL; Wu, TY, 2020)	2.21
"Ticagrelor is an antagonist of both platelet adenosine diphosphate (ADP) receptor P2Y"	( Offset of ticagrelor prior to coronary artery bypass graft surgery for acute coronary syndromes: effects on platelet function and cellular adenosine uptake. Briffa, NP; Hanson, J; Judge, HM; Ow, KW; Parker, WAE; Porter, MM; Storey, RF; Thomas, MR, 2020)	2.4
"Ticagrelor is a reversibly binding, direct-acting, oral, P"	( Ticagrelor and preconditioning in patients with stable coronary artery disease (TAPER-S): a randomized pilot clinical trial. Aurigemma, C; Borovac, JA; Buffon, A; Burzotta, F; Canonico, F; Ceccarelli, I; Crea, F; D'Amario, D; Flex, A; Franceschi, F; Francese, F; Galli, M; Leone, AM; Limbruno, U; Migliaro, S; Montone, RA; Niccoli, G; Porto, I; Restivo, A; Tinelli, G; Trani, C; Vergallo, R, 2020)	3.44
"Ticagrelor is a safe and effective SAPT for the prevention of TEE after FD. "	( Safety and efficacy of ticagrelor as single antiplatelet therapy in prevention of thromboembolic complications associated with the Pipeline Embolization Device (PED): multicenter experience. Elbassiouny, A; English, SW; Hegazy, A; Khedr, E; Mohammaden, MH; Shoyb, A; Stapleton, CJ, 2020)	2.31
"Ticagrelor is an antiplatelet agent acting through direct and reversible competitive inhibition of the platelet P2Y"	( An updated drug profile of ticagrelor with considerations on the treatment of patients with coronary artery disease and diabetes mellitus. Angiolillo, DJ; Calderone, D; Capodanno, D, 2020)	2.3
"Ticagrelor is a potent and orally active P2Y"	( Ticagrelor in the management of coronary artery disease. Adamson, PD; Loganath, K; Moss, AJ, 2021)	3.51
"Ticagrelor is an antiplatelet agent approved for the treatment of patients with an acute coronary syndrome or a history of myocardial infarction. "	( An evaluation of ticagrelor for the treatment of sickle cell anemia. Adorno, EV; Barbosa, CG; Ferreira, JRD; Goncalves, MS; Leite, IPR; Lyra, IM; Neres, JSDS; Pina, ETG; Pitanga, TN; Ribeiro-Filho, J; Santana, SS; Yahouédéhou, SCMA, 2020)	2.34
"Ticagrelor is a recommended P2Y"	( Ticagrelor Does Not Protect Against Endothelial Ischemia-Reperfusion Injury in Patients With Coronary Artery Disease. Ekström, M; Pernow, J; Saleh, N; Settergren, M; Sörensson, P; Verouhis, D, 2021)	3.51
"Ticagrelor is a successful purinergic drug directly targeting ADP-mediated P2Y"	( Ticagrelor: a cardiometabolic drug targeting erythrocyte-mediated purinergic signaling? Erlinge, D; Pernow, J; Wernly, B; Zhou, Z, 2021)	2.79
"Ticagrelor is a novel antiplatelet agent that is frequently used for secondary prevention in coronary artery disease and has emerging evidence in stroke after the recent results of SOCRATES and THALES trials. "	( Stroke Thrombolysis in Patients Taking Ticagrelor -Two Successful Cases and a Review of the Literature. English, S; Frankel, M; Landzberg, DR; Navalkele, D, 2021)	2.33
"Ticagrelor is a potent reversible P2Y12 inhibitor with proven superiority over clopidogrel. "	( A rare case of late-onset ticagrelor-induced sinus arrest. Aranganathan, P; Balasundaram, R; Boopathi, A; Rangan, A; Wilson, B, 2021)	2.36
"Ticagrelor is an antiplatelet agent which is extensively metabolized in an active metabolite: AR-C124910XX. "	( Validation of an HPLC-MS/MS Method for the Determination of Plasma Ticagrelor and Its Active Metabolite Useful for Research and Clinical Practice. Davani, S; Lagoutte-Renosi, J; Rabani, V; Royer, B, 2021)	2.3
"Ticagrelor is an effective antiplatelet that is unaffected by the CYP2C19 polymorphism."	( Short- and long-term cost-effectiveness analysis of CYP2C19 genotype-guided therapy, universal clopidogrel, versus universal ticagrelor in post-percutaneous coronary intervention patients in Qatar. Al-Badriyeh, D; AlMukdad, S; Arafa, S; Elewa, H, 2021)	1.55
"Ticagrelor is an adenosine diphosphate (ADP) receptor antagonist antithrombotic that can inhibit ADP-dependent platelet activation and aggregation."	( The effect of ticagrelor on microarterial thrombosis in an experimental model. Altun, S; Çetinbaş, A; Okur, Mİ; Özercan, İ; Öztan, M; Yıldız Altun, A, 2021)	1.7
"Ticagrelor is a first-line clinical drug for the treatment of acute coronary syndrome, but its oral bioavailability is relatively low. "	( Untargeted metabolomics reveals the mechanism of quercetin enhancing the bioavailability of ticagrelor. Sun, Y; Tang, Y; Wei, B; Wei, S; Xu, X; Zhang, W, 2021)	2.28
"Ticagrelor is a part of dual antiplatelet therapy (DAPT) which has proven benefits in patients with acute coronary syndrome especially in those undergoing percutaneous coronary intervention (PCI). "	( Severe diarrhoea due to use of P2Y12 inhibitor ticagrelor: a rarely reported adverse event. Elzouki, AN; Rashid, K; Rehman, HU; Waheed, MA, 2021)	2.32
"Ticagrelor is a novel P2Y12 antagonist, and little is known about its efficacy and safety in the endovascular treatment of aneurysms. "	( Ticagrelor versus Clopidogrel in the Dual Antiplatelet Regimen for Intracranial Stenting or Flow-Diverter Treatment for Unruptured Cerebral Aneurysms: A Single-Center Cohort Study. Agid, R; Hilario, A; Kortman, H; Kostynskyy, A; Krings, T; Nicholson, P; Ozaki, T; Park, KY; Pereira, VM, 2021)	3.51
"Ticagrelor is a potent oral platelet P2Y"	( Ticagrelor: clinical development and future potential. Parker, WAE; Sanderson, NC; Storey, RF, 2021)	2.79
"Ticagrelor is an oral antiplatelet drug that can reversibly bind to the platelet P2Y12 receptor. "	( A review of the effects of ticagrelor on adenosine concentration and its clinical significance. Akkaif, MA; Daud, NAA; Ibrahim, B; Ng, ML; Sha'aban, A; Sk Abdul Kader, MA, 2021)	2.36
"Ticagrelor is a P2Y12 receptor inhibitor, constituting the first-line treatment for STEMI and NSTEMI."	( Comparison of Ticagrelor Pharmacokinetics and Pharmacodynamics in STEMI and NSTEMI Patients (PINPOINT): protocol for a prospective, observational, single-centre study. Adamski, P; Buszko, K; Koziński, M; Krintus, M; Kubica, J; Marszałł, MP; Obońska, K; Ostrowska, M; Sikora, J; Sypniewska, G, 2017)	1.54
"Ticagrelor is a safe and effective agent for prevention of thromboembolic complications following flow diverter deployment when compared to clopidogrel. "	( A Multicenter Cohort Comparison Study of the Safety, Efficacy, and Cost of Ticagrelor Compared to Clopidogrel in Aneurysm Flow Diverter Procedures. Adeeb, N; Griessenauer, CJ; Gupta, R; Moore, JM; Ogilvy, CS; Patel, AS; Shallwani, H; Siddiqui, A; Thomas, AJ; Youn, R, 2017)	2.13
"Ticagrelor is an effective antiplatelet therapy among patients with atherosclerotic disease and, therefore, could be more effective than aspirin in preventing recurrent stroke and cardiovascular events among patients with embolic stroke of unknown source (ESUS), which includes patients with ipsilateral stenosis <50% and aortic arch atherosclerosis."	( Ticagrelor Versus Aspirin in Acute Embolic Stroke of Undetermined Source. Albers, GW; Amarenco, P; Denison, H; Easton, JD; Evans, SR; Held, P; Hill, MD; Johnston, SC; Jonasson, J; Kasner, SE; Ladenvall, P; Minematsu, K; Molina, CA; Wang, Y; Wong, KSL, 2017)	3.34
"Ticagrelor is a direct acting and reversibly binding P2Y12 antagonist approved for the prevention of thromboembolic events. "	( Effects of ticagrelor in a mouse model of ischemic stroke. Hara, H; Imai, T; Iwama, T; Shimazawa, M; Yamauchi, K, 2017)	2.29
"Ticagrelor is an antiplatelet agent that inhibits platelet activation via P2Y12 antagonism. "	( Impact of ticagrelor on P2Y1 and P2Y12 localization and on cholesterol levels in platelet plasma membrane. Davani, S; Meneveau, N; Montange, D; Rabani, V, 2018)	2.33
"Ticagrelor is a direct-acting P2Y12 inhibitor and, unlike clopidogrel and prasugrel, does not require metabolic activation."	( Effect of Chewing vs Swallowing Ticagrelor on Platelet Inhibition in Patients With ST-Segment Elevation Myocardial Infarction: A Randomized Clinical Trial. Abu-Much, A; Asher, E; Barbash, I; Beigel, R; Chernomordik, F; Elian, D; Fefer, P; Guetta, V; Katz, M; Matetzky, S; Mazin, I; Narodistky, M; Regev, E; Sabbag, A; Segev, A; Tal, S, 2017)	1.46
"Ticagrelor is a first drug of a new chemical class cyclopentyltriazolopyrimidines. "	( Ticagrelor in modern cardiology - an up-to-date review of most important aspects of ticagrelor pharmacotherapy. Danielak, D; Główka, F; Karaźniewicz-Łada, M, 2018)	3.37
"Ticagrelor is an orally administered, reversibly binding, direct-acting P2Y"	( Safety and Incidence of Cardiovascular Events in Chinese Patients with Acute Coronary Syndrome Treated with Ticagrelor: the 12-Month, Phase IV, Multicenter, Single-Arm DAYU Study. Gao, R; Han, Y; Leonsson-Zachrisson, M; Liu, H; Liu, L; Shen, L; Su, G; Wang, Y; Wang, Z; Wu, Y; Yuan, Z; Zhang, A; Zhang, H; Zheng, Y, 2018)	2.14
"Ticagrelor is an antiplatelet agent with low resistance rates but unknown efficacy and safety in neurovascular patients."	( Dual Antiplatelet Therapy Combining Aspirin and Ticagrelor for Intracranial Stenting Procedures: A Retrospective Single Center Study of 154 Consecutive Patients With Unruptured Aneurysms. Amelot, A; Angoulvant, D; Bibi, R; Gruel, Y; Herbreteau, D; Janot, K; Narata, AP, 2019)	1.49
"Ticagrelor is a reversible P2Y"	( Is ticagrelor worth its high cost and side-effects? Ennezat, PV; Guerbaai, RA; Le Jemtel, TH; Mahata, I; Maréchaux, S, 2019)	2.58
"Ticagrelor is a P2Y"	( Ticagrelor Use in Acute Myocardial Infarction: Insights From the National Cardiovascular Data Registry. Alam, M; Ballantyne, CM; Basra, SS; Bozkurt, B; Chiswell, K; Denktas, AE; Deswal, A; Jneid, H; Nambi, V; Peterson, ED; Simon, DN; Virani, SS; Wang, TY, 2018)	3.37
"Ticagrelor is a direct and reversible competitive antagonist of the P2Y12 receptor and inhibits platelet activation. "	( Lethal cerebral hemorrhage after ticagrelor intoxication: a specific antidote is urgently needed. Böhle, H; Fonrose, X; Francony, G; Jourdil, JF; Marlu, R; Stanke-Labesque, F; Willeman, T, 2018)	2.2
"Ticagrelor is a P2Y"	( Does Ticagrelor Improve Endothelial Function? Alexopoulos, D; Moulias, A; Xanthopoulou, I, 2019)	2.47
"Ticagrelor is a P2Y12 receptor antagonist with evidence of cardiovascular event reduction in patients with acute coronary syndromes and those with a previous myocardial infarction."	( Ticagrelor and the Prevention of Microvascular Complications in Diabetes Patients with Lower Extremity Arterial Disease; Rationale and Design of the Hema-Kinesis Trial. Chen, Q; Cho, DJ; Lee, ML; Najera, SD; Rosenson, RS, 2018)	2.64
"Ticagrelor is a state-of-the-art antiplatelet agent used for the treatment of patients with acute coronary syndromes (ACS). "	( Metabolism of ticagrelor in patients with acute coronary syndromes. Adamski, P; Barańska, M; Buszko, K; Gorog, DA; Kubica, J; Navarese, EP; Niezgoda, P; Ostrowska, M; Paciorek, P; Sikora, J, 2018)	2.28
" Ticagrelor is an anti-platelet agent that is indicated for prevention of thrombosis after acute coronary syndrome or intra-coronary artery stent implantation, but it increases the risk of bleeding. "	( In Vitro Reversal of the Anti-Aggregant Effect of Ticagrelor Using Untreated Platelets. Bhagirath, VC; Chan, NC; Dale, B; de Vries, TAC; Eikelboom, JW; Ginsberg, JS; Hirsh, J; Kruger, PC; Xu, K, 2018)	1.64
"Ticagrelor is an antiplatelet agent for adults with coronary artery disease. "	( Ticagrelor does not impact patient-reported pain in young adults with sickle cell disease: a multicentre, randomised phase IIb study. Abboud, MR; Amilon, C; Gottfridsson, C; Kanter, J; Kaya, B; Leonsson-Zachrisson, M; Nduba, V; Rensfeldt, M, 2019)	3.4
"Ticagrelor is an alternative not requiring platelet inhibition testing."	( Comparison of two preventive dual antiplatelet regimens for unruptured intracranial aneurysm embolization with flow diverter/disrupter: A matched-cohort study comparing clopidogrel with ticagrelor. Backchine, S; Foussier, C; Gawlitza, M; Litré, CF; Manceau, PF; Pierot, L; Soize, S, 2019)	1.43
"Ticagrelor is an orally administered platelet aggregation inhibitor with a cyclopentyl-triazolopyrimidine structure; it is a selective reversible P2Y12 receptor antagonist, which prevents P2Y12-mediated and ADP-mediated platelet activation and aggregation. "	( Analytical methodologies for the determination of ticagrelor. Hancu, G; Kelemen, H; Papp, LA, 2019)	2.21
"Ticagrelor is an oral P2Y"	( Antibody-Based Ticagrelor Reversal Agent in Healthy Volunteers. Arnold, SE; Bhatt, DL; Jennings, LK; Lee, JS; Mays, MC; Pollack, CV; Umstead, BR; Weitz, JI; Xu, S, 2019)	2.31
"Ticagrelor is an intriguing antiplatelet agent with a potentially beneficial impact on endothelial dysfunction and confers a mortality benefit beyond 1 month after acute coronary syndrome (ACS). "	( Ticagrelor Does Not Improve Endothelial Dysfunction in Stable Survivors of Acute Coronary Syndrome. Chang, K; Choi, IJ; Choo, EH; Chung, WS; Hwang, BH; Kim, CJ; Lee, JM; Lee, KY; Lim, S, 2019)	3.4
"Ticagrelor is a cornerstone of modern antithrombotic therapy alongside aspirin in patients with acute coronary syndrome and after percutaneous coronary intervention. "	( Premature Ticagrelor Discontinuation in Secondary Prevention of Atherosclerotic CVD: JACC Review Topic of the Week. Arora, S; Das, SR; Garg, SK; Gupta, A; Khalili, H; Kumbhani, DJ; Mayo, H; Pandey, A; Qamar, A; Shemisa, K; Vaduganathan, M, 2019)	2.36
"Ticagrelor is an oral, reversible, direct-acting P2Y"	( YINGLONG: A Multicenter, Prospective, Non-Interventional Study Evaluating the Safety and Tolerability of Ticagrelor in Chinese Patients with Acute Coronary Syndrome. Bai, L; Du, X; Ge, J; Leonsson-Zachrisson, M; Ma, CS; Ma, S; Su, X; Sun, J; Wang, X; Yang, P; Yu, Z; Zheng, Y, 2019)	2.17
"Ticagrelor is a reversibly binding oral P2Y(12) inhibitor, which belongs to a novel chemical class of antiplatelet agents named cyclopentyl-triazolo-pyrimidines. "	( Cost-effectiveness of ticagrelor in acute coronary syndromes. Henriksson, M; Janzon, M, 2013)	2.15
"Ticagrelor is a direct-acting, reversibly binding, oral P2Y12 platelet inhibitor that reduces thrombotic cardiovascular events in patients with acute coronary syndrome. "	( Effect of ticagrelor on pulmonary function in healthy elderly volunteers and asthma or chronic obstructive pulmonary disease patients. Butler, K; Maya, J; Teng, R, 2013)	2.23
"Ticagrelor is a reversible inhibitor of platelet-aggregation, and is used instead of clopidogrel in the treatment of acute coronary syndrome (ACS). "	( [Gastrointestinal bleeding after treatment with ticagrelor]. Hauge, J; Kragh, R; Poulsen, BK, 2013)	2.09
"Ticagrelor is a novel antiplatelet drug developed to reduce atherothrombosis. "	( Lifetime cost-effectiveness analysis of ticagrelor in patients with acute coronary syndromes based on the PLATO trial: a Singapore healthcare perspective. Chin, CT; Chua, TS; Matchar, DB; Mellstrom, C, 2013)	2.1
"Ticagrelor is a reversibly binding P2Y12 receptor antagonist for the prevention of atherothrombotic events in patients with acute coronary syndrome. "	( A pharmacokinetic interaction study of ticagrelor and digoxin in healthy volunteers. Butler, K; Teng, R, 2013)	2.1
"Ticagrelor is a new reversible ADP P2Y12 platelet receptor inhibitor with no known resistance."	( Safety and efficacy of ticagrelor for neuroendovascular procedures. A single center initial experience. Dixon, T; Freeman, WD; Hanel, RA; Johns, G; Miller, DA; Navarro, R; Nordeen, JD; Sapin, M; Taussky, P; Tawk, RG, 2014)	1.43
"Ticagrelor (Brilinta®) is a new oral reversible antiplatelet agent approved by the FDA in July 2011 based on the results of the PLATO (Platelet Inhibition and Patient Outcomes) trial. "	( Changes of ticagrelor formulary tiers in the USA: targeting private insurance providers away from government-funded plans. Dinicolantonio, JJ; Serebruany, VL, 2013)	2.22
"Ticagrelor is a P2Y12 receptor antagonist, with superior effects but also ensuing enhanced bleeding risk as compared to clopidogrel. "	( Comparison of a new ELISA-based with the flow cytometric assay for vasodilator-associated stimulated phosphoprotein phosphorylation to assess P2Y12 -inhibition after ticagrelor intake. Derhaschnig, U; Hobl, EL; Jilma, B; Jilma-Stohlawetz, P; Schoergenhofer, C; Schwameis, M, )	1.77
"Ticagrelor is a potent P2Y12 adenosine diphosphate receptor antagonist characterized by a rapid onset, consistent and reversible antiplatelet effect, and an acceptable safety profile compared with existing adenosine diphosphate receptor blockers. "	( Ticagrelor for acute coronary syndromes. Bansilal, S; Bonaca, MP; Sabatine, MS, 2013)	3.28
"Ticagrelor is a direct-acting P2Y12-adenosine diphosphate receptor blocker. "	( Ticagrelor increases adenosine plasma concentration in patients with an acute coronary syndrome. Bonello, L; Camoin-Jau, L; Condo, J; Dignat-George, F; Frere, C; Fromonot, J; Gariboldi, V; Guieu, R; Helal, O; Kipson, N; Laine, M; Mancini, J; Paganelli, F; Thuny, F, 2014)	3.29
"Ticagrelor (Brilique®) is a novel reversible platelet inhibitor at P2Y12 receptor used in patients with acute coronary syndrome and patients undergoing percutaneous coronary interventions. "	( Perioperative outcomes of cardiac surgery patients with ongoing ticagrelor therapy: boon and bane of a new drug. Bauer, M; Bräuer, A; Danner, BC; Hinz, J; Meyer, K; Mohite, PN; Popov, AF; Schöndube, FA; Schotola, H; Sossalla, S, 2014)	2.08
"Ticagrelor is a reversibly binding and selective P2Y12 -receptor antagonist approved for the prevention of atherothrombotic events in patients with acute coronary syndromes. "	( The effect of desmopressin on bleeding time and platelet aggregation in healthy volunteers administered ticagrelor. Butler, K; Mitchell, PD; Teng, R, 2014)	2.06
"Ticagrelor is a recently approved P2Y12 receptor antagonist that is subject to drug-drug interactions involving the hepatic cytochrome P450-3A4 enzyme system because of its metabolic elimination pathway."	( Improved ticagrelor antiplatelet effect on discontinuation of phenytoin. Nathan, S; Raissi, F; Sieg, A; Vahdat, K; Weeks, P, 2014)	1.54
"Ticagrelor is a potent, reversibly binding P2Y12 receptor-antagonist that has been shown to be superior to clopidogrel in patients with acute coronary syndromes for up to 1 year."	( Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial. Bhatt, DL; Bonaca, MP; Braunwald, E; Cohen, M; Held, P; Jensen, EC; Sabatine, MS; Steg, PG; Storey, RF, 2014)	1.34
"Ticagrelor is a reversibly binding P2Y12 receptor antagonist used clinically for the prevention of atherothrombotic events in patients with acute coronary syndromes (ACS). "	( Evaluation of the pharmacokinetic interaction between ticagrelor and venlafaxine, a cytochrome P-450 2D6 substrate, in healthy subjects. Hsia, J; Kujacic, M; Teng, R, 2014)	2.09
"Ticagrelor is a more potent platelet inhibitor, but data supporting concurrent use of ticagrelor and warfarin (dual antithrombotic therapy, DT) is limited."	( Concomitant use of warfarin and ticagrelor as an alternative to triple antithrombotic therapy after an acute coronary syndrome. Bico, B; Braun, OÖ; Chaudhry, U; Gustav Smith, J; Jovinge, S; Koul, S; Scherstén, F; Svensson, PJ; Tydén, P; van der Pals, J; Wagner, H, 2015)	1.42
"Ticagrelor is a direct-acting and reversible P2Y12-adenosine diphosphate (ADP) receptor blocker used as antiplatelet drug. "	( Identification of the major degradation pathways of ticagrelor. Akrout, W; Amrani, F; Bernard, M; Do, B; Henriet, T; Sadou Yayé, H; Secrétan, PH; Tilleul, P; Yagoubi, N, 2015)	2.11
"Ticagrelor is a direct-acting reversibly binding P2Y12 antagonist and is widely used as an antiplatelet therapy for the prevention of cardiovascular events in acute coronary syndrome patients. "	( Structural and functional characterization of a specific antidote for ticagrelor. Antonsson, T; Austin, M; Buchanan, A; Gennemark, P; Howells, G; Inghardt, T; Janefeldt, A; Keyes, F; Newton, P; Nylander, S; Öster, L; Pehrsson, S; Penney, M; Sandinge, AS; Sjögren, T; Spooner, J; Svensson, P; Vaughan, T, 2015)	2.09
"Ticagrelor is an oral platelet P2Y12 receptor antagonist which is recommended for patients suffering from myocardial infarction, both with and without persistent ST segment elevation. "	( Influence of Morphine on Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients with Acute Myocardial Infarction (IMPRESSION): study protocol for a randomized controlled trial. Adamski, P; Grześk, G; Koziński, M; Kubica, J; Laskowska, E; Obońska, E; Obońska, K; Ostrowska, M; Paciorek, P; Winiarski, P, 2015)	2.1
"Ticagrelor is an oral antiplatelet agent of the cyclopentyltriazolopyrimidine class and also acts through the P2Y12 receptor."	( Ticagrelor: Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Profile: An Update. Teng, R, 2015)	2.58
"Ticagrelor is a novel ADP receptor blocker that has shown greater, more rapid and more consistent platelet inhibition than clopidogrel."	( Ticagrelor: a safe and effective approach for overcoming clopidogrel resistance in patients with stent thrombosis? Duraj, L; Fedor, M; Galajda, P; Kovář, F; Kubisz, P; Mokáň, M; Samoš, M; Stančiaková, L; Staško, J, 2016)	2.6
"Ticagrelor is a novel direct-acting P2Y12 receptor antagonist used for preventing atherothrombotic events in patients with acute coronary syndromes (ACS). "	( Comparison of half- and standard-dose ticagrelor in Chinese patients with NSTE-ACS. Dong, XW; Dong, ZX; Guo, H; Kong, YH; Li, JQ; Li, Y; Liu, B; Pan, YJ; Shao, Q; Sheng, L; Shi, J; Sun, DH; Wang, DY; Xue, HJ; Xue, JY; Yang, HP; Zhang, L; Zhou, YY, 2016)	2.15
"Ticagrelor is a cost-effective strategy for the treatment of patients with acute coronary syndrome in Colombia."	( Cost-effectiveness analysis of ticagrelor compared to clopidogrel for the treatment of patients with acute coronary syndrome in Colombia. Atehortúa, S; Ceballos, M; Mejía, A; Mejía, ME; Ramírez, C; Saldarriaga, C; Senior, JM; Toro, JM, )	1.86
"Ticagrelor is a newer P2Y12 receptor antagonist with established clinical benefit."	( Spontaneous subdural hematoma and antiplatelet therapy: Does efficacy of Ticagrelor come with added risk? Hegde, AV; Javali, M; Mahale, R; Srinivasa, R; Suryanarayana Sharma, PM; Tekkatte Jagannatha, A, 2015)	1.37
"Ticagrelor is an orally administered antiplatelet agent used to reduce thrombotic events in patients with acute coronary syndromes. "	( Population pharmacokinetics of ticagrelor in patients with acute coronary syndromes. Husted, S; Li, J; Storey, RF; Tang, W; Teng, R, 2016)	2.16
"Ticagrelor is a direct acting on the P2Y12 receptor blocker, which provides faster and greater platelet inhibition than clopidogrel. "	( Design and Rationale of the APELOT Trial: A Randomized, Open-Label, Multicenter, Phase IV Study to Evaluate the Antiplatelet Effect of Different Loading Dose of Ticagrelor in Patients With Non-ST Acute Coronary Syndrome Undergoing Percutaneous Coronary In Ding, P; Han, W; Jin, ZG; Liu, HL; Liu, Y; Luo, JP; Ma, DX; Wei, YJ; Yang, SL; Zhang, J, 2016)	2.07
"Ticagrelor is a potent antiplatelet drug metabolized by cytochrome (CYP)3A. "	( Coadministration of ticagrelor and ritonavir: Toward prospective dose adjustment to maintain an optimal platelet inhibition using the PBPK approach. Daali, Y; Desmeules, JA; Fontana, P; Marsousi, N; Reny, JL; Rudaz, S; Samer, CF, 2016)	2.2
"Ticagrelor is an antagonist of the platelet P2Y"	( Studies of the interaction of ticagrelor with the P2Y Balduini, A; Becker, RC; Björquist, A; Cattaneo, M; Di Buduo, CA; Femia, EA; Nylander, S; Storey, RF, 2016)	2.17
"Ticagrelor seems to be an attractive option for patients with renal dysfunction, peripheral arterial disease, or following a brief P2Y12-receptor antagonist interruption, whereas clopidogrel may be advised in the presence of cost and availability issues."	( Long-Term P2Y12-Receptor Antagonists in Post-Myocardial Infarction Patients: Facing a New Trilemma? Alexopoulos, D; Lekakis, J; Moulias, A; Xanthopoulou, I, 2016)	1.16
"Ticagrelor is an oral P2Y12 antagonist that is used as a standard treatment in patients after acute myocardial infarction."	( Ticagrelor promotes atherosclerotic plaque stability in a mouse model of advanced atherosclerosis. Bea, F; Blessing, E; Katus, HA; Mogler, C; Preusch, MR; Rusnak, J; Sievers, P; Staudacher, I; Staudacher, K; Uhlmann, L, 2016)	2.6
"Ticagrelor is a potent antagonist of the P2Y"	( Inverse agonism at the P2Y12 receptor and ENT1 transporter blockade contribute to platelet inhibition by ticagrelor. Aungraheeta, R; Butler, M; Conibear, A; Kelly, E; Mumford, A; Mundell, SJ; Nylander, S, 2016)	2.09
"Ticagrelor is a direct-acting inhibitor of the adenosine diphosphate receptor P2Y12 that has a more rapid onset and offset than clopidogrel."	( Efficacy and safety of ticagrelor versus clopidogrel with different dosage in high-risk patients with acute coronary syndrome. Gao, Y; Guan, QG; Guo, L; Jia, DL; Li, YZ; Qi, GX; Sun, YX; Tian, W; Xin, YG; Xu, F; Yu, HJ; Zhang, HS; Zhang, XG; Zhang, YL, 2017)	1.49
"Ticagrelor is a direct-acting P2Y12 receptor antagonist. "	( No Effect of SLCO1B1 and CYP3A4/5 Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Ticagrelor in Healthy Chinese Male Subjects. Chen, X; Hu, X; Hu, Y; Li, H; Li, M; Tang, J; Wen, Z; Xiao, J; Zhang, D; Zhang, Y, 2017)	2.12
"Ticagrelor is a reversible and direct-acting oral antagonist of the adenosine diphosphate receptor P2Y12. "	( Ticagrelor induced systemic inflammatory response syndrome. Buser, PT; Haschke, M; Krisai, P; Mueller, C, 2017)	3.34
"Ticagrelor is an orally administered, direct, and reversible inhibitor of the P2Y"	( Long-Term Use of Ticagrelor in Patients with Coronary Artery Disease. Ariotti, S; Gargiulo, G; Valgimigli, M, 2017)	2.24
"Ticagrelor is a potent but more expensive alternative antiplatelet agent that is not affected by CYP2C19 polymorphism."	( Cost-effectiveness of cytochrome P450 2C19 *2 genotype-guided selection of clopidogrel or ticagrelor in Chinese patients with acute coronary syndrome. Lee, VWY; Liew, D; Wang, Y; Yan, BP, 2018)	1.42
"Ticagrelor is a direct acting P2Y12 inhibitor and, unlike clopidogrel and prasugrel, does not require metabolic activation."	( Chewing versus Swallowing Ticagrelor to Accelerate Platelet Inhibition in Acute Coronary Syndrome - the CHEERS study. For The PLATIS (Platelets and Thrombosis in Sheba) Study Group. Abu-Much, A; Asher, E; Barbash, I; Beigel, R; Berkovitch, A; Erez, A; Frydman, S; Katz, M; Kukuy, A; Matetzky, S; Mazin, I; Mazo, A; Narodistky, M; Regev, E; Sabbag, A; Segev, A, 2017)	1.48
"Ticagrelor is an effective antiplatelet therapy for patients with coronary atherosclerotic disease and might be more effective than aspirin in preventing recurrent stroke and cardiovascular events in patients with acute cerebral ischaemia of atherosclerotic origin. "	( Efficacy and safety of ticagrelor versus aspirin in acute stroke or transient ischaemic attack of atherosclerotic origin: a subgroup analysis of SOCRATES, a randomised, double-blind, controlled trial. Albers, GW; Amarenco, P; Denison, H; Easton, JD; Evans, SR; Held, P; Hill, MD; Johnston, SC; Jonasson, J; Kasner, SE; Ladenvall, P; Minematsu, K; Molina, CA; Wang, Y; Wong, KSL, 2017)	2.21
"Ticagrelor is an orally active ADP P2Y12 receptor antagonist in development by AstraZeneca plc for the reduction of recurrent ischemic events in patients with acute coronary syndromes (ACS). "	( Ticagrelor, a platelet aggregation inhibitor for the potential prevention and treatment of arterial thrombosis and acute coronary syndromes. Doggrell, SA, 2009)	3.24
"Ticagrelor is an oral reversible P2Y12 antagonist with greater platelet inhibition compared with clopidogrel."	( Emerging P2Y12 receptor antagonists: role in coronary artery disease. Blade, CL; Das, K; Das, P; Doby, JB; Mukherjee, D; Oliphant, CS, 2010)	1.08
"Ticagrelor is an oral, reversible, direct-acting inhibitor of the adenosine diphosphate receptor P2Y12 that has a more rapid onset and more pronounced platelet inhibition than clopidogrel."	( Ticagrelor versus clopidogrel in patients with acute coronary syndromes. Becker, RC; Budaj, A; Cannon, CP; Emanuelsson, H; Freij, A; Harrington, RA; Held, C; Horrow, J; Husted, S; James, S; Katus, H; Mahaffey, KW; Scirica, BM; Skene, A; Steg, PG; Storey, RF; Thorsén, M; Wallentin, L, 2009)	3.24
"Ticagrelor seems to be a better option than clopidogrel for patients with acute coronary syndromes for whom an early invasive strategy is planned."	( Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Ardissino, D; Becker, RC; Cannon, CP; Emanuelsson, H; Harrington, RA; Husted, S; James, S; Katus, H; Keltai, M; Khurmi, NS; Kontny, F; Lewis, BS; Steg, PG; Storey, RF; Wallentin, L; Wojdyla, D, 2010)	2.16
"Ticagrelor (AZD6140) is a new antiplatelet agent in clinical development for reduction of thrombotic events in patients with ACS."	( Pharmacokinetics, pharmacodynamics, safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteers. Butler, K; Teng, R, 2010)	1.3
"Ticagrelor is a more efficacious treatment for acute coronary syndromes than is clopidogrel, irrespective of CYP2C19 and ABCB1 polymorphisms. "	( Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Armstrong, M; Barratt, BJ; Becker, RC; Horrow, J; Husted, S; James, S; Katus, H; Shah, SH; Steg, PG; Storey, RF; Wallentin, L, 2010)	2.02
"Ticagrelor is an orally administered, antiplatelet agent that inhibits the prothrombotic effects of ADP on the platelet by antagonizing the P2Y(12) receptor. "	( In vitro evaluation of potential drug-drug interactions with ticagrelor: cytochrome P450 reaction phenotyping, inhibition, induction, and differential kinetics. Andersson, TB; Grimm, SW; Zhou, D, 2011)	2.05
"Ticagrelor is a novel, reversibly binding, oral, direct-acting P2Y(12)-receptor antagonist. "	( Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial. Asenblad, N; Bassand, JP; Becker, RC; Cannon, CP; Claeys, MJ; Harrington, RA; Held, C; Horrow, J; Husted, S; James, SK; Mahaffey, KW; Nicolau, JC; Scirica, BM; Storey, RF; Vintila, M; Wallentin, L; Ycas, J, 2011)	3.25
"Ticagrelor is a drug in a new chemical class that reversibly binds the P2Y12 receptor and noncompetitively blocks adenosine diphosphate-induced platelet activation."	( Ticagrelor: a novel reversible oral antiplatelet agent. Clark, SM; Nawarskas, JJ, )	2.3
"Ticagrelor is a direct-acting and reversible inhibitor of the P2Y(12) receptor with potentially more pleiotropic effects."	( [Myocardial infarction: Role of new antiplatelet agents]. Bellemain, A; Collet, JP; Ecollan, P; Montalescot, G; Silvain, J, 2011)	1.09
"Ticagrelor is a reversibly binding and selective oral P2Y(12) antagonist, developed for the prevention of atherothrombotic events in patients with acute coronary syndromes. "	( Disposition and metabolism of ticagrelor, a novel P2Y12 receptor antagonist, in mice, rats, and marmosets. Grimm, SW; Landqvist, C; Li, Y, 2011)	2.1
"Ticagrelor is an oral, reversible blocker of the P2Y12 adenosine receptor. "	( [Ticagrelor: a novel antiplatelet agent for patients with acute coronary syndrome]. Hinneburg, I, 2011)	2.72
"Ticagrelor is an antiplatelet drug belonging to a different chemical class than clopidogrel."	( Ticagrelor. Acute coronary syndromes: nothing new. , 2011)	2.53
"Ticagrelor is a direct-acting, oral, reversibly binding P2Y(12) receptor antagonist. "	( Evaluating the risk-benefit profile of the direct-acting P2Y(12) inhibitor ticagrelor in acute coronary syndromes. Husted, S, 2011)	2.04
"Ticagrelor (Brilinta™) is an antithrombotic agent that reversibly binds to P2Y(12) receptors and inhibits adenosine diphosphate-induced platelet aggregation. "	( Pharmacokinetics and tolerability of single and multiple doses of ticagrelor in healthy Chinese subjects: an open-label, sequential, two-cohort, single-centre study. Butler, K; Li, H; Teng, R; Yang, L; Yang, Z, 2012)	2.06
"Ticagrelor is a new oral antagonist of the platelet P2Y₁₂ receptor that offers several potential advantages compared to clopidogrel including faster and more effective inhibition of platelet aggregation. "	( Ticagrelor in ST-elevation myocardial infarction. Niccoli, G; Sgueglia, GA; Tarantini, G, 2012)	3.26
"Ticagrelor is a nonthienopyridine antiplatelet agent and is the first reversible oral antagonist of the P2Y(12) receptors."	( Ticagrelor: oral reversible P2Y(12) receptor antagonist for the management of acute coronary syndromes. Cheng, JW, 2012)	2.54
"Ticagrelor is a new, direct acting, reversibly binding P2Y12 receptor antagonist with more potent inhibition of platelets than clopidogrel and which does not require metabolic activation. "	( Lessons from platelet inhibition and patient outcomes. Held, C, 2012)	1.82
"Ticagrelor is a direct-acting, oral, reversibly binding P2Y(12) receptor antagonist. "	( Antiplatelet therapy in acute coronary syndromes: ticagrelor. Husted, S, 2012)	2.07
"Ticagrelor is a promising P2Y(12) receptor antagonist with characteristics that offer advantages for patients beyond those currently demonstrated by other P2Y(12) receptor antagonists. "	( Review of ticagrelor in the management of acute coronary syndromes. Burgess, S; Juergens, CP; Mallard, TA, 2012)	2.21
"Ticagrelor is a novel, non-thienopyridine ADP inhibitor that reversibly blocks the P2Y(12) receptor, preventing platelet activation and aggregation. "	( Safety profile and bleeding risk of ticagrelor compared with clopidogrel. Lincoff, AM; May, CH, 2012)	2.1
"Ticagrelor is a new antiplatelet agent that was pitted against clopidogrel in the Platelet Inhibition and Patient Outcomes (PLATO) trial. "	( Angiotensin receptor blockers worsen renal function and dyspnea on ticagrelor: a potential ticagrelor-angiotensin receptor blocker interaction? DiNicolantonio, JJ; Serebruany, VL, 2012)	2.06
"Ticagrelor is a novel antiplatelet agent which has a faster onset of action, produces high level of platelet inhibition with minimal inter patient variability."	( Ticagrelor: molecular discovery to clinical evidence: ticagrelor: a novel antiplatelet agent. Sinha, N, )	2.3
"Ticagrelor is a potent oral inhibitor of platelet activity."	( [Medication of the month. Ticagrelor (Brilique): potent oral antagonist of platelet activity]. Lancellotti, P, 2012)	1.4
"Ticagrelor is a P2Y(12) receptor antagonist that showed superior clinical benefit versus clopidogrel in a phase III trial (PLATO [Platelet Inhibition and Patient Outcomes]). "	( Ticagrelor enhances adenosine-induced coronary vasodilatory responses in humans. Brandrup-Wognsen, G; Emanuelsson, H; Gan, LM; Jonasson, J; Nylander, S; van Giezen, JJ; Wittfeldt, A, 2013)	3.28

Excerpt	Reference	Relevance
"Ticagrelor has a bactericidal effect in vitro, and clinical studies suggest a beneficial effect in infections. "	( Ticagrelor and Infection Risk in Patients with Coronary Artery Disease. Alcalá, L; Bruña, V; Devesa, C; Fernández-Avilés, F; Juárez, M; Martínez-Sellés, M; Muñoz, P; Sousa-Casasnovas, I; Vicent, L, )	3.02
"Ticagrelor has a Class I recommendation for use following percutaneous coronary intervention (PCI) in acute coronary syndrome (ACS). "	( Comparison of ticagrelor with clopidogrel on quality of life in patients with acute coronary syndrome. Jo, S; Jo, YS; Kim, SJ; Moon, H; Park, K, 2021)	2.42
"Ticagrelor has a higher risk of dyspnea than clopidogrel, which was not observed in patients using prasugrel."	( The risk of dyspnea in patients treated with third-generation P2Y Li, O; Xu, W; Zhang, B; Zhang, N, 2020)	2
"Ticagrelor has a reducing effect on thrombosis in the microarterial tuck model."	( The effect of ticagrelor on microarterial thrombosis in an experimental model. Altun, S; Çetinbaş, A; Okur, Mİ; Özercan, İ; Öztan, M; Yıldız Altun, A, 2021)	1.7
"Ticagrelor has an improved safety and efficacy profile in patients with acute coronary syndrome; however, data regarding stroke prevention remain controversial."	( Network Meta-Analysis of Ticagrelor for Stroke Prevention in Patients at High Risk for Cardiovascular or Cerebrovascular Events. Bálint, A; El Alaoui El Abdallaoui, O; Komócsi, A; Kupó, P; Tornyos, D, 2021)	1.65
"Ticagrelor has a similar efficacy and safety profile in men and women."	( The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trial. Bach, RG; Becker, RC; Budaj, A; Heras, M; Himmelmann, A; Horrow, J; Husted, S; James, SK; Katus, HA; Lassila, R; Morais, J; Nicolau, JC; Steg, PG; Storey, RF; Wallentin, L; Wojdyla, D, 2014)	1.47
"Ticagrelor has a faster onset of action and provides greater inhibition of platelet aggregation than clopidogrel."	( Ticagrelor: a review of its use in adults with acute coronary syndromes. Dhillon, S, 2015)	2.58
"Ticagrelor has a greater antiplatelet efficacy than clopidogrel but may be accompanied by an increased risk of bleeding. "	( Low-dose ticagrelor yields an antiplatelet efficacy similar to that of standard-dose ticagrelor in healthy subjects: an open-label randomized controlled trial. Cai, Q; Chen, L; Gao, L; Gu, Y; Li, P; Liu, J; Ma, L; Qin, Y; Wang, Z; Yang, Y; Zhao, X, 2016)	2.29
"Ticagrelor has an important role as an antiplatelet agent in the settings of acute coronary syndrome and percutaneous coronary intervention and once accepted will be in widespread use."	( Ticagrelor for the treatment of arterial thrombosis. Gurbel, PA; Kereiakes, DJ; Tantry, US, 2010)	3.25
"As ticagrelor has been shown to significantly decrease circulating levels of several pro-inflammatory cytokines in patients after acute myocardial infarction with ST-elevation (STEMI), we sought to investigate a potential suppressive effect of ticagrelor over prasugrel on cardiac magnetic resonance (CMR) T1 and T2 values in remote myocardium."	( Effect of ticagrelor and prasugrel on remote myocardial inflammation in patients with acute myocardial infarction with ST-elevation: a CMR T1 and T2 mapping study. Demirkiran, A; El Messaoudi, S; Everaars, H; Hoeven, NWV; Konijnenberg, LSF; Nijveldt, R; Riksen, NP; Rodwell, L; Royen, NV; van Leeuwen, MAH; van Rossum, AC; Zugwitz, D, 2023)	1.83
"Ticagrelor has been used across ACS types and in different management strategies in real world settings in India. "	( Therapeutic experience of ticagrelor in Indian patients with acute coronary syndrome: A non-interventional, prospective, and observational study. Bansal, S; Dalal, J; Kahali, D; Mullasari, A; Sawhney, JPS, )	1.87
"Ticagrelor has been shown to provide greater absolute reduction in ischemic risk following acute coronary syndrome (ACS) in those with versus without IRF."	( Impact of renal function on clinical outcomes after PCI in ACS and stable CAD patients treated with ticagrelor: a prespecified analysis of the GLOBAL LEADERS randomized clinical trial. Anderson, R; Angiolillo, DJ; Capodanno, D; Chichareon, P; Curzen, N; Gao, C; Garg, S; Gori, T; Hamm, C; Hara, H; Haude, M; Kawashima, H; Klimczak-Tomaniak, D; Kochman, J; Kogame, N; Modolo, R; Montalescot, G; Ono, M; Onuma, Y; Rademaker-Havinga, T; Serruys, PW; Storey, RF; Takahashi, K; Tomaniak, M; Valgimigli, M; Vranckx, P; Wang, R; Windecker, S, 2020)	1.5
"Ticagrelor has been shown to reduce the risk of pneumonia and improve lung function, but the findings across studies were inconsistent. "	( Risk of infections in patients treated with ticagrelor vs. clopidogrel: a systematic review and meta-analysis. Cheung, BMY; Fei, Y; Feng, Q; Li, HL; Tsoi, MF, 2021)	2.33
"Ticagrelor has been a popular alternative antiplatelet agent for such patients."	( Utility of P2Y Bohan, CO; Dalal, S; Goren, O; Grassi, DM; Griessenauer, CJ; Hendrix, P; Islak, C; Schirmer, CM; Weiner, G; Wirtz, MM, 2020)	1.28
"Ticagrelor has been shown to offer potential outcome benefits in acute coronary syndromes and for the long-term cardiovascular prevention, reducing mortality and the recurrence of ischemic events. "	( Ticagrelor as compared to conventional antiplatelet agents in coronary artery disease: A comprehensive meta-analysis of 15 randomized trials. De Luca, G; Dudek, D; Kedhi, E; Savonitto, S; Verdoia, M, 2021)	3.51
"Ticagrelor has been reported to decrease cardiovascular mortality compared with clopidogrel. "	( Ticagrelor protects against AngII-induced endothelial dysfunction by alleviating endoplasmic reticulum stress. Han, X; Han, Y; Li, M; Li, Y; Wang, X; Zhang, Y; Zhao, S, 2018)	3.37
"Ticagrelor has been acknowledged as a new oral antagonist of P2Y12-adenosine diphosphate receptor, as a strategy with more rapid onset as well as more significant platelet inhibition function in acute coronary syndrome (ACS) patients. "	( Compared efficacy of clopidogrel and ticagrelor in treating acute coronary syndrome: a meta-analysis. Cui, XR; Jia, M; Li, RB; Wang, D; Yang, XH; Zhang, JD, 2018)	2.2
"Ticagrelor has been reported to increase plasma adenosine levels, which might have a protective effect on the microcirculation."	( Evaluation of Microvascular Injury in Revascularized Patients With ST-Segment-Elevation Myocardial Infarction Treated With Ticagrelor Versus Prasugrel. de Waard, GA; Diletti, R; Escaned, J; Everaars, H; Janssens, GN; Lemkes, JS; Nap, A; Nijveldt, R; Piek, JJ; Riksen, NP; Ten Cate, TJF; Valgimigli, M; van de Ven, PM; van der Hoeven, NW; van Leeuwen, MAH; van Mieghem, NM; van Rossum, AC; van Royen, N; von Birgelen, C, 2019)	1.44
"Ticagrelor has been widely accepted in clinical practice for treatment of acute myocardial infarction (AMI), however its clinical safety and efficacy have not been revealed sufficiently in Asian populations."	( One-year clinical outcomes of ticagrelor compared with clopidogrel after percutaneous coronary intervention in patients with acute myocardial infarction: From Korean Health Insurance Review and Assessment Data. Ahn, CM; Choi, D; Hong, MK; Hong, SJ; Jang, Y; Kim, BK; Kim, C; Kim, DS; Kim, JS; Ko, YG; Lee, H; Oh, SK; Park, J; Shin, DH, 2019)	2.25
"Ticagrelor has been promoted to reduce the rate of definite stent thrombosis compared to clopidogrel from the The Platelet Inhibition and Patient Outcomes (PLATO) trial. "	( Challenging ticagrelor's claimed reduction in the rate of definite stent thrombosis versus clopidogrel: insights from the FDA reports. Biondi-Zoccai, G; Dinicolantonio, JJ, 2013)	2.21
"Ticagrelor has been shown in vitro to be a weak inhibitor of cytochrome P-450 (CYP) 2D6, a clinically important enzyme for the metabolism of many drugs."	( Evaluation of the pharmacokinetic interaction between ticagrelor and venlafaxine, a cytochrome P-450 2D6 substrate, in healthy subjects. Hsia, J; Kujacic, M; Teng, R, 2014)	1.37
"Ticagrelor has been shown to improve outcomes in patients with ACS. "	( Angiographic and electrocardiographic parameters of myocardial reperfusion in angioplasty of patients with ST elevation acute myocardial infarction loaded with ticagrelor or clopidogrel (MICAMI-TICLO trial). Guarda, E; Lindefjeld, DS; Martínez, A; Méndez, M; Mestas, M; Pérez, O; Valdebenito, M; Veas, N; Winter, JL; Zuanic, K, )	1.77
"Ticagrelor and prasugrel have shown superiority over clopidogrel. "	( High on-treatment platelet reactivity with ticagrelor versus prasugrel: a systematic review and meta-analysis. Bauters, C; Hamon, M; Lemesle, G; Schurtz, G, 2015)	2.12
"Ticagrelor has been shown to have antiplatelet effects superior to those of clopidogrel, with subsequent reduced clinical ischemic events."	( Effect of Modifying Antiplatelet Treatment to Ticagrelor in High-Risk Coronary Patients With Low Response to Clopidogrel (MATTIS). Arbel, Y; Lev, EI; Mosseri, M; Musallam, A; Orvin, K; Perl, L; Roguin, A, 2016)	1.41
"Ticagrelor has been demonstrated to provide a more rapid and powerful inhibition of platelet aggregation compared with clopidogrel in coronary artery disease (CAD) patients. "	( One-quarter standard-dose ticagrelor better than standard-dose clopidogrel in Chinese patients with stable coronary artery disease: A randomized, single-blind, crossover clinical study. Dong, X; Han, Y; He, M; Li, M; Li, Y; Liu, B; Lu, S; Pan, Y; Shi, J; Sun, D; Zhao, S; Zheng, W, 2016)	2.18
"Ticagrelor has shown greater, more rapid and more consistent platelet inhibition than clopidogrel. "	( Randomised trial to compare a protective effect of Clopidogrel Versus TIcagrelor on coronary Microvascular injury in ST-segment Elevation myocardial infarction (CV-TIME trial). Baek, YS; Kim, DH; Kwan, J; Kwon, SW; Lee, MJ; Park, KS; Park, SD; Shin, SH; Woo, SI, 2016)	2.11
"Ticagrelor has been endorsed by guidelines as the P2Y"	( A randomised study for optimising crossover from ticagrelor to clopidogrel in patients with acute coronary syndrome. The CAPITAL OPTI-CROSS Study. Bernick, J; Chong, AY; Dick, A; Froeschl, M; Glover, C; Hibbert, B; Labinaz, M; Le May, MR; Lugomirski, P; Marquis, JF; Maze, R; Pourdjabbar, A; Ramirez, FD; Simard, T; So, DY; Wells, G, 2017)	2.15
"Ticagrelor has been associated with dyspnea and bradyarrhythmias, both attributed to increased adenosine exposure."	( Successful Reversal of Bradycardia and Dyspnea With Aminophylline After Ticagrelor Load. Chung, BB; Minner, SA; Shah, AP; Simone, P, 2018)	1.43
"Ticagrelor has been put forward for approval to the European Medical Agency (EMEA) and the Food and Drug Administration (FDA) as an investigational oral antiplatelet treatment for the reduction of major adverse cardiac events in patients with acute coronary syndrome."	( Ticagrelor. Davies, SL, 2010)	2.52
"Ticagrelor has shown a significant ischemic benefit and an increase in non-surgical bleeding over clopidogrel in the large phase 3 Platelet Inhibition and Patient Outcomes trial."	( Emerging oral antiplatelet therapies for acute coronary syndromes. Pollack, CV, 2010)	1.08
"Ticagrelor has been shown to be superior to clopidogrel in patients presenting with acute myocardial infarction who undergo early invasive treatment. "	( The use of ticagrelor in a patient at increased risk of stent thrombosis resistant to multiple thienopyridines. Chauhan, A; More, RS; Morgan, KP, 2011)	2.2
"Ticagrelor has been authorised in the European Union for patients with acute coronary syndromes, in combination with aspirin."	( Ticagrelor. Acute coronary syndromes: nothing new. , 2011)	2.53
"Ticagrelor has been compared to clopidogrel in the PLATelet inhibition and patient Outcomes (PLATO) trial in a broad population of patients with acute coronary syndrome showing a reduction of the 12-month risk of death from vascular causes, myocardial infarction and stroke without increasing the overall risk of major bleeding."	( Ticagrelor in ST-elevation myocardial infarction. Niccoli, G; Sgueglia, GA; Tarantini, G, 2012)	2.54
"Ticagrelor has been shown to inhibit cell uptake of adenosine and enhance adenosine-mediated hyperemia responses in a dog model."	( Ticagrelor enhances adenosine-induced coronary vasodilatory responses in humans. Brandrup-Wognsen, G; Emanuelsson, H; Gan, LM; Jonasson, J; Nylander, S; van Giezen, JJ; Wittfeldt, A, 2013)	2.55

Excerpt	Reference	Relevance
"The ticagrelor group had lower incidence of all-cause death and cardiac death compared with the clopidogrel group, and the difference was significant (P < .05)."	( A Comparative Study on Ticagrelor and Clopidogrel in Patients With Acute Coronary Syndrome Treated With Primary Percutaneous Coronary Intervention. Jia, S; Wu, H, 2023)	1.7
"Ticagrelor reached a lower plasma concentration in morphine group (MD = -481.8 ng/ml, 95% CI = -841.2 to -122.4 ng/ml, p < 0.01) with a higher vomiting rate (odds = 5.3, 95% CI = 2.5-11.1, p < 0.01)."	( Effect of morphine use on oral P2Y12 platelet inhibitors in acute myocardial infarction: Meta-analysis. Ghafghazi, S; Khan, A; Vaidya, GN, )	0.85
"Ticagrelor reduced all-cause mortality by a small margin compared with rest of treatments."	( Comparative Efficacy and Safety of Prasugrel, Ticagrelor, and Standard-Dose and High-Dose Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention: A Network Meta-analysis. Grewal, N; Khosla, S; Singh, M; Singh, S, )	1.11
"Ticagrelor can lower the resting heart rate of patients and cause bradyarrhythmias in the 12th month after PCI."	( Ticagrelor vs. clopidogrel in non-ST-elevation acute coronary syndromes. Dong, C; Liu, X; Ren, C; Ren, Q; Zhang, X, 2016)	3.32
"Ticagrelor exhibited lower platelet reactivity than clopidogrel by all assays irrespective of 2C19 genotype or metabolizer status (P<0.01)."	( First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET/OFFSET and RESPOND genotype studies. Armstrong, M; Bliden, KP; Butler, K; Gurbel, PA; Storey, RF; Tantry, US; Wei, C, 2010)	1.3
"Ticagrelor is known to increase adenosine concentrations by inhibiting red blood cell reuptake, but the potency of this effect may be too low to fully explain the adenosine related effects. "	( Ticagrelor induces adenosine triphosphate release from human red blood cells. Albinsson, S; Erlinge, D; Kudira, R; Ohman, J; Olde, B, 2012)	3.26

Excerpt	Reference	Relevance
"Ticagrelor treatment was associated with increased CFR in this high-risk population. "	( Ticagrelor Treatment is Associated With Increased Coronary Flow Reserve in Survivors of Myocardial Infarction. Erlinge, D; Gan, LM; Omerovic, E; Rylance, R; Svedlund, S; Torngren, K, 2023)	3.8
"Ticagrelor treatment resulted in significantly lower PRU [10 (7-39) vs. "	( Increased platelet inhibition after switching from prasugrel to low-dose ticagrelor in Japanese patients with prior myocardial infarction. Fujimoto, Y; Kitahara, H; Kobayashi, Y; Nakayama, T; Saito, Y; Tateishi, K, 2020)	2.23
"Ticagrelor treatment in diabetic mice lowered urinary albumin excretion, it prevented diabetes-induced mesangial matrix expansion, podocyte effacement, and glomerular endothelial cell injury, which includes loss of endothelial fenestrations, ICAM-1 expression, and PECAM expression."	( Platelet inhibition by ticagrelor is protective against diabetic nephropathy in mice. Butter, LM; Claessen, N; Florquin, S; Larsen, PW; Roelofs, JJTH; Uil, M, 2020)	1.59
"Ticagrelor treatment was associated with a marked reduction in tumor cell-platelet aggregates in the lungs at 10, 30 and 60 min post-intravenous inoculation."	( Ticagrelor inhibits platelet-tumor cell interactions and metastasis in human and murine breast cancer. Bezuhly, M; Brien, C; Gareau, AJ; Gebremeskel, S; Johnston, B; Liwski, RS, 2018)	2.64
"Ticagrelor pretreatment versus ticagrelor given in the catheterization laboratory in patients with ST-segment-elevation myocardial infarction undergoing primary PCI did not improve the composite end point of all-cause mortality or MI or stent thrombosis or its individual components at 30 days."	( No Benefit of Ticagrelor Pretreatment Compared With Treatment During Percutaneous Coronary Intervention in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. Alfredsson, J; Erlinge, D; Götberg, M; James, S; Jensen, J; Koul, S; Lagerqvist, B; Omerovic, E; Persson, J; Redfors, B; Smith, JG; Venetsanos, D, 2018)	2.28
"Ticagrelor treatment for 20 weeks attenuated atherosclerotic lesion progression in the aortic arch compared with control (p < 0.05). "	( Ticagrelor, a P2Y12 antagonist, attenuates vascular dysfunction and inhibits atherogenesis in apolipoprotein-E-deficient mice. Fukuda, D; Ganbaatar, B; Higashikuni, Y; Hirata, Y; Nishimoto, S; Salim, HM; Sata, M; Soeki, T; Tanaka, K; Yagi, S, 2018)	3.37
"Ticagrelor treatment caused fewer major adverse cardiovascular events (MACEs) and more episodes of minor bleeding than the other two treatments."	( DAPT Plus Cilostazol is Better Than Traditional DAPT or Aspirin Plus Ticagrelor as Elective PCI for Intermediate-to-Highly Complex Cases: Prospective, Randomized, PRU-Based Study in Taiwan. Chang, CC; Chen, SM; Chen, YC; Cheng, SM; Chuang, CL; Lin, FY; Lin, RH; Lin, YW; Sheu, JS; Tsai, CS, 2019)	1.47
"Ticagrelor treated patients were significantly more likely to stop/switch therapy as compared to prasugrel (15.9% vs."	( Incidence, predictors, and prognosis of premature discontinuation or switch of prasugrel or ticagrelor: the ATLANTIS - SWITCH study. Hengstenberg, C; Kolesnik, E; Prüller, F; Siller-Matula, JM; von Lewinski, D; Wallner, M; Winter, MP, 2019)	1.46
"Ticagrelor treats HPR more effectively compared to high dose clopidogrel therapy."	( Ticagrelor versus high dose clopidogrel in ST-segment elevation myocardial infarction patients with high platelet reactivity post fibrinolysis. Akinosoglou, K; Alexopoulos, D; Barampoutis, N; Hahalis, G; Karvounis, H; Koniari, I; Panagiotidis, T; Patsilinakos, S; Perperis, A; Xanthopoulou, I; Ziakas, A, 2015)	2.58
"Ticagrelor treated patients have overall lower PR than patients on prasugrel, independent of DM status or insulin treatment."	( Diabetes mellitus and platelet reactivity in patients under prasugrel or ticagrelor treatment: an observational study. Alexopoulos, D; Pentara, I; Perperis, A; Stavrou, K; Vlassopoulou, N; Vogiatzi, C; Xanthopoulou, I, 2015)	1.37
"All ticagrelor treatments improved left ventricular ejection fraction, acute (69.5%±1.6%), chronic (69.2%±1.0%), and acute+chronic (76.3%±1.2%), whereas clopidogrel had no effect (37.4%±3.7%)."	( Ticagrelor protects the heart against reperfusion injury and improves remodeling after myocardial infarction. Birnbaum, GD; Birnbaum, Y; Nanhwan, MK; Nylander, S; Perez-Polo, JR; Ye, Y, 2015)	2.34
"Ticagrelor treatment has the side effect of increased incidence of dyspnea. "	( Design and rationale of TROCADERO: A TRial Of Caffeine to Alleviate DyspnEa Related to ticagrelOr. Braun, OÖ; Christersson, C; Grove, EL; Halvorsen, S; James, SK; Lindholm, D; Storey, RF; Varenhorst, C, 2015)	2.08
"Ticagrelor treatment could provide a marginally favorable effect at the expense of an increased risk of dyspnea in real-life situations. "	( Efficacy and safety of ticagrelor versus clopidogrel in acute coronary syndrome in Taiwan: A multicenter retrospective pilot study. Chao, TH; Chen, IC; Chen, Y; Cheng, CL; Fang, CC; Lee, CH; Li, YH; Lin, CC; Lin, CY; Yu, CL, 2016)	2.19
"Ticagrelor treatment at the time of heart rhythm device procedures does not seem to be associated with an increased risk of significant bleeding complications. "	( [Safety of device implantation under antipatelet therapy with ticagrelor: About 20 cases]. Akret, C; Amara, W; Cheggour, S; Dompnier, A; Galuscan, G; M'Zoughi, S; Naccache, S, 2016)	2.12
"Ticagrelor treatment was well tolerated in DISPERSE-2, and discontinuation rates were comparable to those observed for clopidogrel."	( Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist. Husted, S; van Giezen, JJ, 2009)	2.52
"Treatment with ticagrelor was associated with a 29% lower risk of developing OA compared to treatment with clopidogrel over 5 years of follow-up. "	( Reduction in Osteoarthritis Risk After Treatment With Ticagrelor Compared to Clopidogrel: A Propensity Score-Matching Analysis. Ahuja, N; Baker, MC; Robinson, WH; Rohatgi, N; Weng, Y, 2020)	1.16
"Treatment with ticagrelor was not associated with a lower risk for the primary end point (adjusted odds ratio [aOR], 1.20; 95% CI, 0.87-1.61;"	( Ticagrelor is Not Superior to Clopidogrel in Patients With Acute Coronary Syndromes Undergoing PCI: A Report from Swedish Coronary Angiography and Angioplasty Registry. Albertsson, P; Angerås, O; Dworeck, C; Haraldsson, I; Hirlekar, G; Ioanes, D; Myredal, A; Odenstedt, J; Omerovic, E; Petursson, P; Råmunddal, T; Redfors, B; Völz, S, 2020)	2.34
"Treatment with ticagrelor was not associated with a reduced risk of gram-negative infections (HR, 0.48; 95% CI, 0.21 to 1.06; p = 0.07)."	( Effect of Ticagrelor on Reducing the Risk of Gram-Positive Infections in Patients With Acute Coronary Syndrome. Banai, S; Hershkoviz, R; Isakov, O; Lupu, L; Shepshelovich, D, 2020)	1.3
"Treatment with ticagrelor was associated with a significantly lower 1-year risk of SAB, sepsis, and pneumonia compared with clopidogrel."	( Ticagrelor and the risk of Staphylococcus aureus bacteraemia and other infections. Andersen, PS; Bruun, NE; Bundgaard, H; Butt, JH; Fosbøl, EL; Gerds, TA; Gislason, GH; Havers-Borgersen, E; Iversen, K; Køber, L; Larsen, AR; Olesen, JB; Petersen, A; Skov, RL; Torp-Pedersen, C; Østergaard, L, 2022)	2.52
"Treatment with ticagrelor also increases the expression of several actors of the endoplasmic reticulum (ER) stress pathways, suggesting activation of the unfolded protein response (UPR)."	( Inhibiting P2Y12 in Macrophages Induces Endoplasmic Reticulum Stress and Promotes an Anti-Tumoral Phenotype. Gerwins, P; Heindryckx, F; Kopsida, M; Pavlović, N, 2020)	0.9
"Pretreatment with ticagrelor before coronary anatomy is known as a widely adopted strategy."	( Downstream or upstream administration of P2Y12 receptor blockers in non-ST elevated acute coronary syndromes: study protocol for a randomized controlled trial. Andò, G; Angiolillo, DJ; Caporale, R; Castiglioni, B; Cernetti, C; Cirillo, P; De Cesare, N; Favero, L; Ferlini, M; Ferri, L; Gasparetto, V; Gregori, D; Guiducci, V; La Manna, A; Limbruno, U; Lupi, A; Marchese, A; Martinato, M; Mauro, C; Mojoli, M; Musumeci, G; Penzo, C; Pierini, S; Ricci, R; Rigattieri, S; Ronco, F; Roncon, L; Russo, A; Saia, F; Santarelli, A; Sganzerla, P; Tarantini, G; Tarantino, F; Trabattoni, D; Varbella, F, 2020)	0.88
"Treatment with ticagrelor on discharge was associated with improved survival rates during 4 years of follow-up."	( Risk definition and outcomes with the application of the PEGASUS-TIMI 54 trial inclusion criteria to a "real world" STEMI population: results from the Italian "CARDIO-STEMI SANREMO" registry. Boasi, V; Cannarile, P; Cattunar, S; Gomez, L; Mascelli, G; Perri, D; Pingelli, N; Sanchez, F; Tacchi, C; Vercellino, M, 2021)	0.96
"Treatment with ticagrelor seems independently associated with less in-hospital moderate and severe bleeding events compared to clopidogrel."	( Clopidogrel vs. prasugrel vs. ticagrelor in patients with acute myocardial infarction complicated by cardiogenic shock: a pooled IABP-SHOCK II and CULPRIT-SHOCK trial sub-analysis. Clemmensen, P; Desch, S; Dudek, D; Feistritzer, HJ; Freund, A; Fuernau, G; Geisler, T; Haller, P; Hausleiter, J; Huber, K; Kleeberger, J; Massberg, S; Montalescot, G; Neumer, A; Noc, M; Orban, M; Ouarrak, T; Schneider, S; Thiele, H; Zeymer, U, 2021)	1.25
"Treatment with ticagrelor monotherapy did not significantly affect ischemic stroke (risk ratio, 0.88 [95% CI, 0.77–1.00]; P=0.05)."	( Network Meta-Analysis of Ticagrelor for Stroke Prevention in Patients at High Risk for Cardiovascular or Cerebrovascular Events. Bálint, A; El Alaoui El Abdallaoui, O; Komócsi, A; Kupó, P; Tornyos, D, 2021)	1.26
"The treatment of ticagrelor combined with tirofiban significantly attenuated inflammation response and improved the prognosis of UA patients."	( Comparison of the effect of ticagrelor combined with tirofiban versus clopidogrel combined with tirofiban on inflammation response and prognosis of patients with unstable angina pectoris in long term follow-up. Deng, L; Jia, HZ; Li, MC; Zhu, W, 2021)	1.24
"Treatment with ticagrelor as compared with clopidogrel in patients with MI was associated with lower risk for the composite of death, MI or stroke and a higher bleeding risk across all strata of eGFR. "	( Outcomes in patients treated with ticagrelor versus clopidogrel after acute myocardial infarction stratified by renal function. Carrero, JJ; Edfors, R; Evans, M; James, SK; Jernberg, T; Lagerqvist, B; Renlund, H; Sahlén, A; Spaak, J; Szummer, K; Varenhorst, C, 2018)	1.11
"Treatment with ticagrelor appears to yield greater net benefit for patients when the probability of ACS >8%. "	( Optimising antiplatelet utilisation in the acute care setting: a novel threshold for medical intervention in suspected acute coronary syndromes. Body, R; Jarman, H; Morris, N; Moss, P; Reynard, C, 2019)	0.87
"Treatment with ticagrelor with or without aspirin reduced high-shear BV by 5%, in both cases, while aspirin monotherapy increased high-shear BV by 3.4% (p < 0.0001)."	( Ticagrelor improves blood viscosity-dependent microcirculatory flow in patients with lower extremity arterial disease: the Hema-kinesis clinical trial. Chen, Q; Cho, DJ; Krishnan, P; Lee, ML; Najera, SD; Rosenson, RS, 2019)	2.3
"Oral treatment with ticagrelor protected photoreceptors in the ABCA4-/- mouse, which is consistent with enhanced lysosomal function. "	( Oral Delivery of the P2Y12 Receptor Antagonist Ticagrelor Prevents Loss of Photoreceptors in an ABCA4-/- Mouse Model of Retinal Degeneration. Campagno, KE; Carlsson, LG; Cenaj, A; Laties, AM; Lu, W; Mitchell, CH; Tso, HY, 2019)	1.09
"Treatment with ticagrelor improves peripheral endothelial function compared to no ADP blocker, clopidogrel, or prasugrel treatment."	( Ticagrelor improves peripheral arterial function in patients with a previous acute coronary syndrome. Erlinge, D; Larsson, J; Ohman, J; Salmi, H; Torngren, K, 2013)	2.19
"Treatment with Ticagrelor was associated to an incremental cost of 1,228 Euros per year, an increase in 0.1652 life years gained, and 0.1365 years adjusted by quality of life, as compared to Clopidogrel. "	( [Long-term cost-effectiveness of ticagrelor versus clopidogrel in acute coronary syndrome in Spain]. Mateo-Carrasco, H; Molina-Cuadrado, E; Nieto-Guindo, P; Rodríguez-Gómez, P, 2014)	1.04
"Treatment with ticagrelor versus clopidogrel reduced the occurrence of definite stent thrombosis (HR 0.58, 95% CI 0.37 to 0.89, p=0.013)."	( Safety and efficacy of ticagrelor and clopidogrel in primary percutaneous coronary intervention. Abtan, J; Angiolillo, DJ; Ardissino, D; Gabriel Steg, P; Harrington, RA; Hellkamp, A; Himmelmann, A; Husted, S; James, SK; Katus, HA; Meier, B; Schulte, PJ; Storey, RF; Velders, MA; Wallentin, L, 2016)	1.08
"Treatment with ticagrelor among nonresponders resulted in a >10%, >30%, and >50% decrease in platelet aggregation from baseline in 100%, 75%, and 13% of patients, respectively."	( Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. Antonino, MJ; Bliden, KP; Butler, K; Eikelboom, JW; Gurbel, PA; Henderson, D; Husted, S; Kereiakes, DJ; Nielsen, T; Patel, DV; Rasmussen, L; Sabe-Affaki, G; Storey, RF; Tantry, US; Teng, R; Wei, C, 2010)	1.08
"Treatment with ticagrelor 180 mg/day was effective in reducing the platelet reactivity."	( Resistance to high-maintenance dose of prasugrel treated by ticagrelor: a case report. Alexopoulos, D; Goudas, P; Kassimis, G; Stavrou, EF; Xanthopoulou, I, 2013)	0.97
"Treatment with ticagrelor was associated with increased health-care costs of €362 and a QALY gain of 0.13 compared with generic clopidogrel, yielding a cost per QALY gained with ticagrelor of €2753."	( Cost-effectiveness of treating acute coronary syndrome patients with ticagrelor for 12 months: results from the PLATO study. Hauch, O; Henriksson, M; Janzon, M; Nikolic, E; Wallentin, L, 2013)	0.96

Excerpt	Reference	Relevance
" Ticagrelor was well tolerated, with no serious or dose-related adverse events or notable changes in laboratory values observed."	( Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y(12) receptor antagonist, in healthy subjects. Butler, K; Teng, R, 2010)	1.49
" Ticagrelor was well tolerated in both groups, and no adverse events were reported."	( Pharmacokinetics, pharmacodynamics, and safety of ticagrelor in volunteers with mild hepatic impairment. Butler, K; Teng, R, 2011)	1.53
" Ticagrelor was well tolerated in both groups with few adverse events."	( Pharmacokinetics, pharmacodynamics, and safety of ticagrelor in volunteers with severe renal impairment. Butler, K; Teng, R, 2012)	1.54
" Other common adverse effects of ticagrelor such as dyspnea and ventricular pauses appear to be mild and self-limited."	( Safety profile and bleeding risk of ticagrelor compared with clopidogrel. Lincoff, AM; May, CH, 2012)	0.94
" No patient experienced any adverse effects in the postoperative period related to the use of ticagrelor."	( Safety and efficacy of ticagrelor for neuroendovascular procedures. A single center initial experience. Dixon, T; Freeman, WD; Hanel, RA; Johns, G; Miller, DA; Navarro, R; Nordeen, JD; Sapin, M; Taussky, P; Tawk, RG, 2014)	0.93
" All of our patients showed immediate platelet inhibition after a loading dose of 180 mg of ticagrelor, with no adverse effects."	( Safety and efficacy of ticagrelor for neuroendovascular procedures. A single center initial experience. Dixon, T; Freeman, WD; Hanel, RA; Johns, G; Miller, DA; Navarro, R; Nordeen, JD; Sapin, M; Taussky, P; Tawk, RG, 2014)	0.93
" However, the comparative risks of gastrointestinal (GI) adverse events during DAPT are not clear."	( Gastrointestinal adverse events after dual antiplatelet therapy: clopidogrel is safer than ticagrelor, but prasugrel data are lacking or inconclusive. Can, MM; Dinicolantonio, JJ; Kuliczkowski, W; Pershukov, IV; Serebruany, VL, 2013)	0.61
"The study stopping criteria were met when 3 of the 6 volunteers receiving ticagrelor 1,260 mg experienced moderate gastrointestinal adverse events (AE); none were observed with placebo."	( Safety, tolerability, pharmacokinetics and pharmacodynamics of high single-ascending doses of ticagrelor in healthy volunteers. Butler, K; Teng, R, 2013)	0.84
" We analysed adverse events (AEs) consistent with either pulmonary infection or sepsis, and subsequent mortality, in 18,421 PLATO patients treated with ticagrelor or clopidogrel."	( Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO study. Åsenblad, N; Becker, RC; Cannon, CP; Held, C; Husted, SE; James, SK; Siegbahn, A; Steg, PG; Storey, RF; Varenhorst, C; Wallentin, L; Ycas, J, 2014)	0.84
" However, in addition to bleeding, distinctive adverse effects of this new chemical entity have not been reported with the thienopyridine P2Y12 -receptor inhibitors."	( Ticagrelor: pharmacokinetics, pharmacodynamics, clinical efficacy, and safety. Dobesh, PP; Oestreich, JH, 2014)	1.85
"NSTE-ACS management with DAPT and DES is probably safe and effective in class II G6PD-deficient patients."	( Antiplatelet and invasive treatment in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency and acute coronary syndrome. The safety of aspirin. Kafkas, NV; Liakos, CI; Mouzarou, AG, 2015)	0.42
"73 m(2) pre-specified for analysis of the effect of ticagrelor on the primary efficacy composite of cardiovascular death, MI, or stroke (major adverse cardiovascular events, MACE) and the primary safety endpoint of TIMI major bleeding."	( Efficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in relation to renal function: insights from the PEGASUS-TIMI 54 trial. Ardissino, D; Aylward, P; Bhatt, DL; Bonaca, MP; Braunwald, E; Cohen, M; Corbalan, R; Dellborg, M; Goudev, AR; Held, P; Im, K; Isaza, D; Jensen, EC; Kontny, F; Kuder, J; Magnani, G; Medina, F; Parkhomenko, A; Sabatine, MS; Steg, G; Storey, RF, 2016)	1
" An understanding of stroke mechanisms and causes is important to deliver safe and efficacious treatments for early stroke prevention."	( Efficacy and safety of ticagrelor versus aspirin in acute stroke or transient ischaemic attack of atherosclerotic origin: a subgroup analysis of SOCRATES, a randomised, double-blind, controlled trial. Albers, GW; Amarenco, P; Denison, H; Easton, JD; Evans, SR; Held, P; Hill, MD; Johnston, SC; Jonasson, J; Kasner, SE; Ladenvall, P; Minematsu, K; Molina, CA; Wang, Y; Wong, KSL, 2017)	0.77
" Outcomes were evaluated for major adverse cardiovascular events (MACE) and bleeding at 1 year."	( Comparative Effectiveness and Safety Analysis of Dual Antiplatelet Therapies Within an Integrated Delivery System. Boyd, A; Chambers, A; Chanas, T; Coons, JC; Eckardt, J; Ensor, CR; Iasella, CJ; Lemon, LS; Lyons, J; Merkel, A; Rihtarchik, L; Smith, R; Wang, N; Williams, K, 2017)	0.46
"Thromboembolic and hemorrhagic complications are among the most feared adverse events in the endovascular treatment of aneurysms, and this is particularly the case for flow diverter devices."	( A Multicenter Cohort Comparison Study of the Safety, Efficacy, and Cost of Ticagrelor Compared to Clopidogrel in Aneurysm Flow Diverter Procedures. Adeeb, N; Griessenauer, CJ; Gupta, R; Moore, JM; Ogilvy, CS; Patel, AS; Shallwani, H; Siddiqui, A; Thomas, AJ; Youn, R, 2017)	0.69
"Ticagrelor is a safe and effective agent for prevention of thromboembolic complications following flow diverter deployment when compared to clopidogrel."	( A Multicenter Cohort Comparison Study of the Safety, Efficacy, and Cost of Ticagrelor Compared to Clopidogrel in Aneurysm Flow Diverter Procedures. Adeeb, N; Griessenauer, CJ; Gupta, R; Moore, JM; Ogilvy, CS; Patel, AS; Shallwani, H; Siddiqui, A; Thomas, AJ; Youn, R, 2017)	2.13
" The aim of this study was to analyse the safety profile of these drugs using data from spontaneous reporting of suspected adverse reactions (ADRs)."	( Safety of Antiplatelet Agents: Analysis of 'Real-World' Data from the Italian National Pharmacovigilance Network. Benfatto, G; Drago, F; Gozzo, L; Longo, L; Mansueto, S; Navarria, A; Pani, L; Salomone, S; Sottosanti, L, 2017)	0.46
"The US Food and Drug Administration Adverse Event Reporting System (FAERS) is a global passive surveillance database that relies on voluntary reporting by health care professionals and consumers as well as required mandatory reporting by pharmaceutical manufacturers."	( Filing Sources after Oral P2Y12 Platelet Inhibitors to the Food and Drug Administration Adverse Event Reporting System (FAERS). Cabrera-Fuentes, HA; Cherepanov, V; Kim, MH; Litvinov, O; Marciniak, TA; Serebruany, VL, )	0.13
"From the FAERS database we extracted and examined adverse event cases coreported with oral P2Y12 platelet inhibitors."	( Filing Sources after Oral P2Y12 Platelet Inhibitors to the Food and Drug Administration Adverse Event Reporting System (FAERS). Cabrera-Fuentes, HA; Cherepanov, V; Kim, MH; Litvinov, O; Marciniak, TA; Serebruany, VL, )	0.13
"Overall, 2015 annual adverse events were more commonly coreported with clopidogrel (n = 13,234) with known source filers (n = 12,818, or 96."	( Filing Sources after Oral P2Y12 Platelet Inhibitors to the Food and Drug Administration Adverse Event Reporting System (FAERS). Cabrera-Fuentes, HA; Cherepanov, V; Kim, MH; Litvinov, O; Marciniak, TA; Serebruany, VL, )	0.13
" Patients filed most adverse events for clopidogrel and prasugrel, while physicians originated most ticagrelor complaints."	( Filing Sources after Oral P2Y12 Platelet Inhibitors to the Food and Drug Administration Adverse Event Reporting System (FAERS). Cabrera-Fuentes, HA; Cherepanov, V; Kim, MH; Litvinov, O; Marciniak, TA; Serebruany, VL, )	0.35
" Safety was evaluated via PLATO-defined bleeding events, adverse events (AEs), serious AEs, and laboratory measurements."	( Safety and Incidence of Cardiovascular Events in Chinese Patients with Acute Coronary Syndrome Treated with Ticagrelor: the 12-Month, Phase IV, Multicenter, Single-Arm DAYU Study. Gao, R; Han, Y; Leonsson-Zachrisson, M; Liu, H; Liu, L; Shen, L; Su, G; Wang, Y; Wang, Z; Wu, Y; Yuan, Z; Zhang, A; Zhang, H; Zheng, Y, 2018)	0.69
" Major adverse cardiac and cerebrovascular events (MACCE) [death, myocardial infarction (MI), stroke, and unplanned reintervention] and thrombolysis in myocardial infarction (TIMI) bleeding (major/minor) were registered during hospitalization and follow-up."	( Safety and Efficacy in Prasugrel- Versus Ticagrelor-Treated Patients With ST-Elevation Myocardial Infarction. Dannenberg, L; Dimitroulis, D; Golabkesh, M; Helten, C; Jung, C; Kelm, M; Knoop, B; Naguib, D; Pöhl, M; Polzin, A; Zeus, T, 2018)	0.75
" We analyzed the occurrence of major adverse cardiovascular events and periprocedural myocardial infarction."	( Efficacy and Safety of Loading Doses With P2Y12-Receptor Antagonists in Patients Without Dual Antiplatelet Therapy Undergoing Elective Coronary Intervention. Abellán-Huerta, J; Jurado-Román, A; López-Lluva, MT; Lozano-Ruiz Poveda, F; Piqueras-Flores, J; Sánchez-Pérez, I, 2019)	0.51
" At the end of follow-up, major adverse cardiovascular event rate was not different between groups."	( Efficacy and Safety of Loading Doses With P2Y12-Receptor Antagonists in Patients Without Dual Antiplatelet Therapy Undergoing Elective Coronary Intervention. Abellán-Huerta, J; Jurado-Román, A; López-Lluva, MT; Lozano-Ruiz Poveda, F; Piqueras-Flores, J; Sánchez-Pérez, I, 2019)	0.51
" Secondary outcomes were adverse bleeding events (safety outcome)."	( Efficacy and safety of alternative oral administrations of P2Y12-receptor inhibitors: Systematic review and meta-analysis. Bilotta, F; Campo, G; Parodi, G; Pavasini, R; Serenelli, M; Tonet, E; Vitali, F, 2019)	0.51
" Compared with nonsmokers within the first year of follow-up, the reductions of stroke and major adverse cardiovascular event rate were 18% ( P=0."	( Effectiveness and Safety of Platelet ADP -P2Y12 Receptor Inhibitors Influenced by Smoking Status: A Systematic Review and Meta-Analysis. Chen, S; Cui, Y; Gong, Y; Hu, K; Jiang, J; Liu, Z; Mu, G; Wang, Z; Xiang, Q; Xie, Q; Zhou, S, 2019)	0.51
" Primary outcomes were the incidence of adverse events (AEs), in particular, PLATelet inhibition and patient Outcomes (PLATO)-defined bleeding AEs, and other serious AEs during the 1-year follow-up."	( YINGLONG: A Multicenter, Prospective, Non-Interventional Study Evaluating the Safety and Tolerability of Ticagrelor in Chinese Patients with Acute Coronary Syndrome. Bai, L; Du, X; Ge, J; Leonsson-Zachrisson, M; Ma, CS; Ma, S; Su, X; Sun, J; Wang, X; Yang, P; Yu, Z; Zheng, Y, 2019)	0.73
"In PEGASUS-TIMI 54, ticagrelor significantly reduced the risk of the composite of major adverse cardiovascular (CV) events by 15-16% in stable patients with a prior myocardial infarction (MI) 1-3 years earlier."	( Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUS-TIMI 54. Ardissino, D; Bengtsson, O; Bhatt, DL; Bonaca, MP; Braunwald, E; Budaj, A; Cohen, M; Dellborg, M; Hamm, C; Himmelmann, A; Im, KA; Johanson, P; Kamensky, G; Kiss, RG; Kontny, F; Lopez-Sendon, J; Montalescot, G; Oude Ophuis, T; Sabatine, MS; Spinar, J; Steg, PG; Storey, RF; Van de Werf, F, 2019)	1.14
" This practice, especially in complex PCI, could be affected by a higher rate of peri-procedural adverse events."	( Safe and Effective Management of Antiplatelet Therapy in a Clopidogrel-Naive Patient Undergoing "Ad Hoc" Complex Coronary Intervention: A Case Report. Colombo, A; Marchese, A; Resta, F; Tito, A, 2020)	0.56
" The primary efficacy endpoint was major adverse cardiovascular events (MACE) defined by each study, and the safety endpoint was TIMI non-CABG major bleeding."	( Efficacy and Safety of Potent Oral P2Y Han, Y; Jiang, Z; Li, Y; Li, Z; Ma, S; Song, H; Yu, P, 2020)	0.56
" However, an increased risk of ticagrelor-related adverse events prompted the evaluation of low-dose regimens."	( Efficacy and safety of different ticagrelor regimens versus clopidogrel in patients with coronary artery disease: a retrospective multicenter study (SUPERIOR). Cang, H; He, M; Li, J; Li, Y; Liu, G; Mu, H; Shi, J; Sun, D; Wang, J; Wang, W; Xu, M; Zhang, C; Zhang, H; Zhang, Z; Zhao, C; Zhao, S, 2021)	1.19
" The primary endpoint was major adverse cardiovascular events (MACE), including cardiovascular (CV) death, all-cause death, myocardial infarction (MI), stent thrombosis and stroke."	( Efficacy and safety of clopidogrel versus prasugrel and ticagrelor for coronary artery disease treatment in patients with CYP2C19 LoF alleles: a systemic review and meta-analysis. Gwak, HS; Lee, N; Seong, JM; Yoon, HY, 2020)	0.8
"Ticagrelor is a safe and effective SAPT for the prevention of TEE after FD."	( Safety and efficacy of ticagrelor as single antiplatelet therapy in prevention of thromboembolic complications associated with the Pipeline Embolization Device (PED): multicenter experience. Elbassiouny, A; English, SW; Hegazy, A; Khedr, E; Mohammaden, MH; Shoyb, A; Stapleton, CJ, 2020)	2.31
" The endpoints were major adverse cardiac events (MACEs), death, stroke, myocardial infarction (MI), stent thrombosis, and bleeding events."	( Efficacy and Safety of Ticagrelor Compared to Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention: A Meta-Analysis. Li, D; Li, X; Shen, S; Wu, H; Xiang, X, 2020)	0.87
" The primary endpoint for efficacy was the rate of major adverse cardiac events (MACEs)."	( Efficacy and safety of low dose ticagrelor in patients with acute coronary syndrome: a systematic review and meta-analysis. Chen, Q; Li, D; Lu, C; Wang, C; Wang, S; Wang, Y; Wang, Z; Xu, T; Xuan, H; Zhang, H; Zhang, Y, 2020)	0.84
" The aim of this study is to investigate the efficacy and safety of switching from ticagrelor to clopidogrel in AMI patients with no adverse event during the first month after the index PCI with newer-generation DES."	( A prospective, multicentre, randomised, open-label trial to compare the efficacy and safety of clopidogrel versus ticagrelor in stabilised patients with acute myocardial infarction after percutaneous coronary intervention: rationale and design of the TALO Ahn, Y; Chang, K; Choo, EH; Hwang, BH; Jeon, DS; Jeong, MH; Kim, CJ; Kim, HY; Kim, MC; Park, CS; Park, MW; Seung, KB; Yoo, KD, 2021)	1.06
"TALOS-AMI is a multicentre, randomised, open-label study enrolling 2,590 AMI patients with no adverse events during the first month after the index PCI."	( A prospective, multicentre, randomised, open-label trial to compare the efficacy and safety of clopidogrel versus ticagrelor in stabilised patients with acute myocardial infarction after percutaneous coronary intervention: rationale and design of the TALO Ahn, Y; Chang, K; Choo, EH; Hwang, BH; Jeon, DS; Jeong, MH; Kim, CJ; Kim, HY; Kim, MC; Park, CS; Park, MW; Seung, KB; Yoo, KD, 2021)	0.83
"The antiplatelet agents ticagrelor and eptifibatide were safe in DSS colitis mice, suggesting their potential in humans suffering from ulcerative colitis, and supporting future safety studies."	( Antiplatelet agents'-ticagrelol and eptifibatide-safety in experimental colitis in mice. Brcerevic, IA; Cikota, BM; Doder, RB; Magic, ZM; Majstorovic, IJ; Manojlovic, NS; Obradovic, SD; Perisic, NJ; Petrovic, MD; Petrovic, SS; Rancic, NK; Tarabar, DK; Vasiljevska, MM, 2020)	0.87
" Random-effects model was used to calculate an unadjusted odds ratio (OR) for major adverse cardiovascular and cerbrovascular events (MACCE) and its components."	( Meta-Analysis Comparing the Safety and Efficacy of Prasugrel and Ticagrelor in Acute Coronary Syndrome. Ali, Z; Fischman, DL; Khan, S; Mamas, MA; Rafiq, A; Sabouret, P; Sadiq, U; Ullah, W, 2020)	0.8
" Major adverse cardiovascular and cerebrovascular events (MACCEs) and bleeding events according to ticagrelor or clopidogrel use were compared."	( Efficacy and Safety of Ticagrelor and Clopidogrel in Patients with Stable Coronary Artery Disease Undergoing Percutaneous Coronary Intervention. Gao, R; Guo, T; Li, J; Li, Y; Qiao, S; Qiu, H; Tang, Y; Wang, Y; Xu, B; Yan, L; Yang, Y; Zheng, J, 2021)	1.15
" On the other hand, the difference between ticagrelor and clopidogrel for net adverse clinical events was significant (4."	( Efficacy and Safety of Ticagrelor and Clopidogrel in Patients with Stable Coronary Artery Disease Undergoing Percutaneous Coronary Intervention. Gao, R; Guo, T; Li, J; Li, Y; Qiao, S; Qiu, H; Tang, Y; Wang, Y; Xu, B; Yan, L; Yang, Y; Zheng, J, 2021)	1.19
" To the best of our knowledge this is the first thrombotic coronary side effect ever reported."	( Coronary Plaque Erosion after Abemaciclib Treatment Onset: An Unknown Side Effect? Alfonso, F; Alvarado-Casas, T; Rivero, F; Salamanca, J; Vera, A, 2021)	0.62
"It is safe and feasible of low-dose ticagrelor in patients with STEMI."	( Safety and feasibility of low-dose ticagrelor in patients with ST-segment elevation myocardial infarction. Fu, Y; Hao, G; Jiang, Y; Wang, Q; Wang, Y; Zheng, S; Zhi, W; Zhou, J, 2021)	1.17
" The incidence of major adverse cardiac events (MACE), bleeding events were compared between the two groups within 6 months of follow-up."	( Safety and feasibility of low-dose ticagrelor in patients with ST-segment elevation myocardial infarction. Fu, Y; Hao, G; Jiang, Y; Wang, Q; Wang, Y; Zheng, S; Zhi, W; Zhou, J, 2021)	0.9
"It is safe and feasible of low-dose ticagrelor for patients with STEMI based on the monitoring of PAR."	( Safety and feasibility of low-dose ticagrelor in patients with ST-segment elevation myocardial infarction. Fu, Y; Hao, G; Jiang, Y; Wang, Q; Wang, Y; Zheng, S; Zhi, W; Zhou, J, 2021)	1.17
"Prasugrel/ticagrelor, compared to clopidogrel, reduces risk of major adverse cardiovascular event (MACE) in Hong Kong ACS population."	( Efficacy and safety comparing prasugrel/ticagrelor and clopidogrel in Hong Kong post-acute coronary syndrome patients-A 10-year cohort study. Lam, ASM; Lee, VWY; Yan, BPY, 2021)	1.29
" The primary effectiveness endpoint was a major adverse cardiovascular event (MACE), and the primary safety endpoint was a major bleeding event."	( Comparison of effectiveness and safety between ticagrelor and clopidogrel in patients with acute coronary syndrome and on dialysis in Taiwan. Hsieh, KP; Hwang, SJ; Li, YS; Wang, SH; Yang, YH, 2022)	0.98
" However, like most other drugs, it can lead to undesired and adverse effects such as dyspnoea, easy bruising and gastrointestinal bleeding."	( Severe diarrhoea due to use of P2Y12 inhibitor ticagrelor: a rarely reported adverse event. Elzouki, AN; Rashid, K; Rehman, HU; Waheed, MA, 2021)	0.88
" The primary endpoint was net adverse clinical event, defined as the primary efficacy endpoint of death, myocardial infarction, or cerebrovascular accident and the primary safety endpoint of any bleeding event."	( Safety and Efficacy of Triple Therapy With Ticagrelor or Prasugrel Versus Clopidogrel After Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction. Flahive, J; Fraielli, K; Gill, K; Servati, N, 2021)	0.88
"This small cohort study suggests, in patients with ST-elevation myocardial infarction undergoing percutaneous coronary intervention, the net adverse clinical event rate does not differ between clopidogrel and potent P2Y12 inhibitors in the setting of triple antithrombotic therapy."	( Safety and Efficacy of Triple Therapy With Ticagrelor or Prasugrel Versus Clopidogrel After Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction. Flahive, J; Fraielli, K; Gill, K; Servati, N, 2021)	0.88
" The Safe and Timely Antithrombotic Removal - Ticagrelor (STAR-T) Trial is a multi-center, double-blind, randomized, controlled trial enrolling patients who require cardiothoracic surgery on cardiopulmonary bypass (CPB) within 48 hours of last ticagrelor dose."	( Rationale and design of the safe and timely antithrombotic removal - ticagrelor (STAR-T) trial: A prospective, multi-center, double-blind, randomized controlled trial evaluating reductions in postoperative bleeding with intraoperative removal of ticagrelo Cutlip, DE; Deliargyris, EN; Doros, G; Gibson, CM; Kroger, H; Lee, VT; Mack, MJ; Ohman, EM; Schneider, DJ; Sellke, FW; Thourani, VH, 2022)	1.21
"In the TWILIGHT trial, ticagrelor monotherapy after a short course of dual antiplatelet therapy (DAPT) was shown to be a safe bleeding avoidance strategy in high-risk patients undergoing percutaneous coronary intervention (PCI) with drug-eluting stents (DES)."	( Safety and efficacy of ticagrelor monotherapy according to drug-eluting stent type: the TWILIGHT-STENT study. Angiolillo, DJ; Baber, U; Briguori, C; Camaj, A; Cao, D; Cohen, D; Collier, T; Dangas, G; Dudek, D; Escaned, J; Gibson, CM; Gil, R; Giustino, G; Goel, R; Han, YL; Huber, K; Kastrati, A; Kaul, U; Kornowski, R; Krucoff, MW; Kunadian, V; Mehran, R; Mehta, S; Moliterno, DJ; Nicolas, J; Ohman, EM; Oldroyd, KG; Pocock, S; Sardella, G; Sartori, S; Sharma, S; Shlofmitz, R; Steg, PG; Weisz, G; Witzenbichler, B; Zhang, Z, 2022)	1.34
"To establish the safety and efficacy of different dual antiplatelet therapy (DAPT) combinations in patients with acute coronary syndrome (ACS) according to their baseline ischaemic and bleeding risk estimated with a machine learning derived model [machine learning-based prediction of adverse events following an acute coronary syndrome (PRAISE) score]."	( Safety and efficacy of different P2Y12 inhibitors in patients with acute coronary syndromes stratified by the PRAISE risk score: a multicentre study. Abu-Assi, E; Bruno, F; Cerrato, E; Chieffo, A; Conrotto, F; D'Ascenzo, F; De Ferrari, GM; De Filippo, O; Dominguez-Rodriguez, A; Elia, E; Gallone, G; Henriques, JPS; Iannaccone, M; Kinnaird, T; Leonardi, S; Liebetrau, C; Manzano-Fernández, S; Omedè, P; Patti, G; Piroli, F; Raposeiras-Roubin, S; Wańha, W, 2022)	0.72
" Major adverse cardiovascular events and bleeding events were assessed by using Mantel-Haenszel-pooled risk ratio and 95% con- fidence interval."	( Efficacy and Safety of Ticagrelor in East Asian Patients with Acute Coronary Syndrome: A Meta-Analysis of Randomized Controlled Trials. Lin, J; Qin, Q; Xie, C; Zhu, J, 2022)	1.03
" The effectiveness outcome was major adverse cardiovascular events (MACE) defined as a composite of recurrent myocardial infarction, repeat revascularization, stroke, or cardiovascular death at 12 months."	( Effectiveness and safety of P2Y12 inhibitors in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention: a nationwide registry-based study. Bhatt, DL; Butt, JH; Christensen, MK; Fosbøl, EL; Gislason, G; Godtfredsen, SJ; Jørgensen, SH; Kragholm, KH; Køber, L; Leutscher, P; Pareek, M; Sessa, M; Torp-Pedersen, C, 2022)	0.72
" Effectiveness endpoints were evaluated by the major adverse cardiovascular events, encompassing all-cause death, non-fatal myocardial infarction, and clinically driven revascularization."	( Comparative Effectiveness and Safety of Ticagrelor Versus Clopidogrel for Elderly Chinese Patients Undergoing Percutaneous Coronary Intervention: A Single-Center Retrospective Cohort Study. Chen, Y; Gao, H; Han, P; Li, C; Lian, K; Liang, Y; Liu, Y; Tan, Z; Tao, F; Wang, Q; Wang, Z; Xu, S; Yang, L; Zhang, A; Zhang, Y; Zhao, S; Zhu, B, 2022)	0.99
"Ticagrelor was associated with a lower incidence of major adverse cardiovascular events than clopidogrel at 12 months in elderly Chinese patients with coronary artery disease, without a significant increase of Bleeding Academic Research Consortium bleeding events."	( Comparative Effectiveness and Safety of Ticagrelor Versus Clopidogrel for Elderly Chinese Patients Undergoing Percutaneous Coronary Intervention: A Single-Center Retrospective Cohort Study. Chen, Y; Gao, H; Han, P; Li, C; Lian, K; Liang, Y; Liu, Y; Tan, Z; Tao, F; Wang, Q; Wang, Z; Xu, S; Yang, L; Zhang, A; Zhang, Y; Zhao, S; Zhu, B, 2022)	2.43
"The first 3 months after percutaneous coronary intervention (PCI) in patients with acute coronary syndrome (ACS) is a high-risk period for adverse events, including ischemic and bleeding events, which decrease greatly with time."	( Efficacy and Safety of Clopidogrel Versus Ticagrelor for Stabilized Patients With Acute Coronary Syndromes After Percutaneous Coronary Intervention: Results From a Real-World Registry in China. Li, X; Lin, Y; Peng, W; Zhang, Y, 2023)	1.17
" Major adverse cardiovascular and cerebrovascular events (MACCE) were considered the primary end point, and major bleeding was considered the secondary end point."	( Efficacy and Safety of Clopidogrel Versus Ticagrelor for Stabilized Patients With Acute Coronary Syndromes After Percutaneous Coronary Intervention: Results From a Real-World Registry in China. Li, X; Lin, Y; Peng, W; Zhang, Y, 2023)	1.17
" There was no significant difference between the two groups regarding hemorrhagic adverse effects."	( A randomized pilot study of the efficacy and safety of loading ticagrelor in acute ischemic stroke. Aref, HM; El-Khawas, H; Elbassiouny, A; Roushdy, TM; Shokri, HM; Zeinhom, MG, 2023)	1.15
" The adverse events and the hemorrhage events 30 days after the operation were observed and recorded."	( Safety of Bivalirudin Combined with Ticagrelor in the Emergency PCI in Patients with Acute ST-Segment Elevation Myocardial Infarction. Chen, YX; Li, P; Liang, XW; Liao, W; Liu, M; Wang, ZD; Xie, WC; Zhu, XZ, )	0.41
"Immature or reticulated platelets are associated with impaired efficacy of antiplatelet drugs and adverse events in cardiovascular patients."	( Immature Platelet Fraction Predicts Adverse Events in Patients With Acute Coronary Syndrome: the ISAR-REACT 5 Reticulated Platelet Substudy. Anetsberger, A; Angiolillo, DJ; Bernlochner, I; Bongiovanni, D; Fegers-Wustrow, I; Gosetti, R; Holdenrieder, S; Kastrati, A; Laugwitz, KL; Mayer, K; Schreiner, N; Schunkert, H; Schüpke, S; Sibbing, D; von Scheidt, M, 2023)	0.91
"Independently from drug treatment, IPF was associated with the primary end point and therefore is a promising biomarker for the prediction of adverse cardiovascular events in patients with acute coronary syndrome treated with prasugrel or ticagrelor."	( Immature Platelet Fraction Predicts Adverse Events in Patients With Acute Coronary Syndrome: the ISAR-REACT 5 Reticulated Platelet Substudy. Anetsberger, A; Angiolillo, DJ; Bernlochner, I; Bongiovanni, D; Fegers-Wustrow, I; Gosetti, R; Holdenrieder, S; Kastrati, A; Laugwitz, KL; Mayer, K; Schreiner, N; Schunkert, H; Schüpke, S; Sibbing, D; von Scheidt, M, 2023)	1.09
" The primary comprehensive endpoint was a major adverse cardiovascular event (MACE) composite of cardiovascular death, stroke, or myocardial infarction, while the secondary endpoints were cardiovascular death, all-cause stroke, ischemic stroke, myocardial infarction, and all-cause death."	( Prophylactic Efficacy and Safety of Antithrombotic Regimens in Patients with Stable Atherosclerotic Cardiovascular Disease (S-ASCVD): A Bayesian Network Meta-Regression Analysis. Chen, X; Jiang, L; Liu, C; Su, J; Zheng, N; Zhong, J, 2023)	0.91
" Our meta-analysis aimed to demonstrate whether intensified antithrombotic regimens with ticagrelor plus aspirin have more beneficial effects and fewer adverse events compared to those of clopidogrel plus aspirin in East Asian patients with ACS undergoing PCI."	( Safety and Efficacy of Ticagrelor versus Clopidogrel in East Asian Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention Treated with Dual Antiplatelet Therapy: A Meta-Analysis of Randomized Controlled Trials. He, X; Li, J; Ma, S; Qiu, M; Qu, X; Wang, Q; Wang, X; Wu, C; Zhang, L, 2023)	1.44
" The primary endpoint was bleeding events, and the secondary endpoints were major adverse cardiovascular and cerebrovascular events (MACCEs, including cardiovascular death, nonfatal myocardial infarction [MI], and stroke), all-cause death, and definite/probable/possible stent thrombosis."	( Safety and Efficacy of Ticagrelor versus Clopidogrel in East Asian Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention Treated with Dual Antiplatelet Therapy: A Meta-Analysis of Randomized Controlled Trials. He, X; Li, J; Ma, S; Qiu, M; Qu, X; Wang, Q; Wang, X; Wu, C; Zhang, L, 2023)	1.22
" The primary outcomes were major adverse cardiovascular and cerebrovascular events (MACCE), defined as a composite of death, myocardial infarction, and stroke occurring from 12 months after discharge to follow-up visit."	( Efficacy and Safety of Prolonged Dual Antiplatelet Therapy after Percutaneous Coronary Intervention in Acute Coronary Syndrome Patients. Han, J; Lin, B; Lin, Y; Shi, X; Wang, Y; Yan, J; Zhang, R; Zhang, Y, 2023)	0.91
" Outcomes included major adverse cardiovascular events, all cause death, major bleeding and myocardial infarction."	( Comparison efficacy and safety of different antiplatelet or anticoagulation drugs in chronic coronary syndromes patients: A Bayesian network meta-analysis. Liu, C; Ma, L, 2023)	0.91
" In head-to-head comparison, no significant difference was observed between all antithrombotic treatment strategies with respect to primary endpoint of major adverse cardiovascular events."	( Comparison efficacy and safety of different antiplatelet or anticoagulation drugs in chronic coronary syndromes patients: A Bayesian network meta-analysis. Liu, C; Ma, L, 2023)	0.91

Excerpt	Reference	Relevance
" The mean terminal-phase half-life (t(1/2)) was approximately 7-8."	( Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y(12) receptor antagonist, in healthy subjects. Butler, K; Teng, R, 2010)	0.58
"This report is the first to demonstrate the superior pharmacodynamic effect of ticagrelor compared with clopidogrel irrespective of CYP2C19 genotype."	( First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET/OFFSET and RESPOND genotype studies. Armstrong, M; Bliden, KP; Butler, K; Gurbel, PA; Storey, RF; Tantry, US; Wei, C, 2010)	0.8
" This has led to the development of other P2Y12 receptor inhibitors, such as prasugrel and ticagrelor, with different pharmacokinetic characteristics that influence their pharmacodynamics."	( Beyond efficacy: pharmacokinetic differences between clopidogrel, prasugrel and ticagrelor. Cohen Arazi, H; Di Girolamo, G; Giorgi, MA; Gonzalez, CD, 2011)	0.82
" However, the pharmacokinetic advantages of both prasugrel and ticagrelor allow clinicians to center patient management by selecting the best drug for the appropriate subject."	( Beyond efficacy: pharmacokinetic differences between clopidogrel, prasugrel and ticagrelor. Cohen Arazi, H; Di Girolamo, G; Giorgi, MA; Gonzalez, CD, 2011)	0.84
" Pharmacokinetic parameters were evaluated on cycle day 21, and endogenous hormones assayed on cycle days 1, 7, 14 and 21."	( Effect of ticagrelor on the pharmacokinetics of ethinyl oestradiol and levonorgestrel in healthy volunteers. Butler, K; Teng, R, 2011)	0.77
" Ticagrelor and AR-C124910XX (a major pharmacologically active metabolite) plasma concentrations were quantified for pharmacokinetic analysis."	( Lack of significant food effect on the pharmacokinetics of ticagrelor in healthy volunteers. Butler, K; Mitchell, PD; Teng, R, 2012)	1.53
" The objectives of this study were to assess the pharmacokinetic parameters of ticagrelor and its active metabolite AR-C124910XX, and the safety and tolerability of ticagrelor in healthy Chinese subjects, following single and multiple oral doses of ticagrelor."	( Pharmacokinetics and tolerability of single and multiple doses of ticagrelor in healthy Chinese subjects: an open-label, sequential, two-cohort, single-centre study. Butler, K; Li, H; Teng, R; Yang, L; Yang, Z, 2012)	0.84
" On days 1 and 10 of both dosing schedules, blood samples for pharmacokinetic analyses were collected for 72 hours."	( Pharmacokinetics and tolerability of single and multiple doses of ticagrelor in healthy Chinese subjects: an open-label, sequential, two-cohort, single-centre study. Butler, K; Li, H; Teng, R; Yang, L; Yang, Z, 2012)	0.62
"Following single and multiple doses at both dose levels, ticagrelor was rapidly absorbed (median time [t(max)] to reach maximum plasma concentration [C(max)] 2 hours) with a mean elimination half-life (t(1/2;)) of 10."	( Pharmacokinetics and tolerability of single and multiple doses of ticagrelor in healthy Chinese subjects: an open-label, sequential, two-cohort, single-centre study. Butler, K; Li, H; Teng, R; Yang, L; Yang, Z, 2012)	0.86
" Mean terminal elimination half-life was slightly longer in women vs."	( Effect of age and gender on pharmacokinetics and pharmacodynamics of a single ticagrelor dose in healthy individuals. Butler, K; Mitchell, P; Teng, R, 2012)	0.61
" The recently approved oral antiplatelet agent ticagrelor has the potential to overcome some of the limitations of current therapy due to its unique pharmacokinetic and pharmacodynamic profiles."	( Pharmacokinetic, pharmacodynamic and pharmacogenetic profile of the oral antiplatelet agent ticagrelor. Teng, R, 2012)	0.86
" In the ONSET-OFFSET study (parallel group trial) and the RESPOND study (crossover trial), the pharmacodynamic effects of ticagrelor were compared with clopidogrel in patients with coronary artery disease (CAD)."	( Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET-OFFSET and RESPOND studies. Bliden, K; Butler, K; Gurbel, PA; Husted, SE; Høimark, L; Storey, RF; Tantry, US; Teng, R; Wei, C, 2012)	0.85
" Expression of the 3435T/T genetic variant encoding the MDR1 gene for the P-glycoprotein efflux transporter results in a significantly reduced maximum drug concentration and area under the plasma concentration-time curve as intestinal absorption of clopidogrel is reduced; and the expression of the mutant *2 allele of CYP2C19 results in similar pharmacokinetic effects as the two cytochrome P450 (CYP)-mediated steps required for the production of the active metabolite of clopidogrel are impaired."	( Comparative pharmacokinetics and pharmacodynamics of platelet adenosine diphosphate receptor antagonists and their clinical implications. Ferro, A; Floyd, CN; Passacquale, G, 2012)	0.38
"As ticagrelor, clopidogrel and cangrelor therapies may be used in the same clinical setting, their potential pharmacodynamic interactions are of interest."	( Evaluation of ticagrelor pharmacodynamic interactions with reversibly binding or non-reversibly binding P2Y(12) antagonists in an ex-vivo canine model. Emanuelsson, BM; Ravnefjord, A; van Giezen, JJ; Weilitz, J, 2012)	1.36
" No pharmacodynamic interaction occurred between ticagrelor and cangrelor."	( Evaluation of ticagrelor pharmacodynamic interactions with reversibly binding or non-reversibly binding P2Y(12) antagonists in an ex-vivo canine model. Emanuelsson, BM; Ravnefjord, A; van Giezen, JJ; Weilitz, J, 2012)	0.99
"The extent of the pharmacodynamic drug-drug interactions observed between clopidogrel and cangrelor or ticagrelor apparently depends on the level of receptor occupancy when clopidogrel is administered."	( Evaluation of ticagrelor pharmacodynamic interactions with reversibly binding or non-reversibly binding P2Y(12) antagonists in an ex-vivo canine model. Emanuelsson, BM; Ravnefjord, A; van Giezen, JJ; Weilitz, J, 2012)	0.95
" Ticagrelor and AR-C124910XX plasma concentrations were quantified for pharmacokinetic analysis (n = 14); inhibition of platelet aggregation (IPA) was also assessed (n = 14)."	( Effect of rifampicin on the pharmacokinetics and pharmacodynamics of ticagrelor in healthy subjects. Butler, K; Mitchell, P; Teng, R, 2013)	1.53
" At steady-state ticagrelor (50 mg bid, or 200 mg bid), concomitant aspirin (300 mg qd) had no effect on mean maximum plasma concentration (Cmax), median time to Cmax (tmax), or mean area under the plasma concentration-time curve for the dosing interval (AUC0-τ) for ticagrelor and its primary metabolite, AR-C124910XX."	( Evaluation of the pharmacokinetics and pharmacodynamics of ticagrelor co-administered with aspirin in healthy volunteers. Butler, K; Maya, J; Teng, R, 2013)	0.97
" Plasma concentrations of tolbutamide, 4-hydroxytolbutamide, ticagrelor, and AR-C124910XX were determined for pharmacokinetic analyses."	( Evaluation of the pharmacokinetic interaction between ticagrelor and tolbutamide, a cytochrome P450 2C9 substrate, in healthy volunteers. Butler, K; Mitchell, P; Teng, R, 2013)	0.88
"Ticagrelor had no effect on tolbutamide or 4-hydroxytolbutamide pharmacokinetic parameters."	( Evaluation of the pharmacokinetic interaction between ticagrelor and tolbutamide, a cytochrome P450 2C9 substrate, in healthy volunteers. Butler, K; Mitchell, P; Teng, R, 2013)	2.08
" Pharmacokinetic parameters of digoxin and ticagrelor were evaluated following co-administration of ticagrelor 400 mg qd or placebo on days 1-16, and digoxin (0."	( A pharmacokinetic interaction study of ticagrelor and digoxin in healthy volunteers. Butler, K; Teng, R, 2013)	0.92
" The objective of the present study was to evaluate the pharmacokinetic profile after different subcutaneous (s."	( Evaluation of systemic exposure of nanoparticle suspensions subcutaneously administered to mice regarding stabilization, volume, location, concentration and size. Palmer, M; Sigfridsson, K, 2014)	0.4
"The goal of this study was to evaluate the pharmacodynamic effects of switching patients from ticagrelor to prasugrel."	( Pharmacodynamic evaluation of switching from ticagrelor to prasugrel in patients with stable coronary artery disease: Results of the SWAP-2 Study (Switching Anti Platelet-2). Angiolillo, DJ; Curzen, N; Effron, MB; Gurbel, P; Jakubowski, JA; Li, W; Lipkin, F; Trenk, D; Vaitkus, P; Zettler, M, 2014)	0.88
" Pharmacodynamic assessments were defined according to P2Y12 reaction unit (PRU) (P2Y12 assay) and platelet reactivity index (vasodilator-stimulated phosphoprotein phosphorylation assay) at baseline (before and after the run-in phase) and 2, 4, 24, and 48 h and 7 days after randomization."	( Pharmacodynamic evaluation of switching from ticagrelor to prasugrel in patients with stable coronary artery disease: Results of the SWAP-2 Study (Switching Anti Platelet-2). Angiolillo, DJ; Curzen, N; Effron, MB; Gurbel, P; Jakubowski, JA; Li, W; Lipkin, F; Trenk, D; Vaitkus, P; Zettler, M, 2014)	0.66
"In patients referred for PPCI, ticagrelor bolus following clopidogrel resulted in more rapid and profound platelet inhibition, demonstrating a positive pharmacodynamic interaction."	( A comparative pharmacodynamic study of ticagrelor versus clopidogrel and ticagrelor in patients undergoing primary percutaneous coronary intervention: the CAPITAL RELOAD study. Blondeau, M; Dick, A; Froeschl, M; Glover, C; Hibbert, B; Labinaz, M; Le May, MR; Marquis, JF; Maze, R; Moudgil, R; Pourdjabbar, A; Ramirez, FD; Simard, T; So, DY, 2014)	0.96
"This study sought to determine pharmacodynamic effects during transition from intravenous cangrelor to oral ticagrelor and from oral ticagrelor to intravenous cangrelor."	( Pharmacodynamic effects during the transition between cangrelor and ticagrelor. Agarwal, Z; Gogo, P; Keating, FK; Schneider, DJ; Seecheran, N, 2014)	0.85
" Pharmacodynamic effects (light transmission platelet aggregation in response to 20 and 5 μmol/l adenosine diphosphate, VerifyNow, P2Y12 assay (Accumetrics, San Diego, California), vasodilator-stimulated phosphoprotein index, and flow cytometry) were assessed during and after the cangrelor infusion."	( Pharmacodynamic effects during the transition between cangrelor and ticagrelor. Agarwal, Z; Gogo, P; Keating, FK; Schneider, DJ; Seecheran, N, 2014)	0.64
"Ticagrelor given before or during infusion of cangrelor did not attenuate the pharmacodynamic effects of cangrelor."	( Pharmacodynamic effects during the transition between cangrelor and ticagrelor. Agarwal, Z; Gogo, P; Keating, FK; Schneider, DJ; Seecheran, N, 2014)	2.08
" This study assessed the potential pharmacokinetic drug-drug interaction between ticagrelor and cyclosporine."	( Pharmacokinetic interaction study of ticagrelor and cyclosporine in healthy volunteers. Hsia, J; Kujacic, M; Teng, R, 2014)	0.9
" Plasma concentrations of ticagrelor and its active metabolite (AR-C124910XX) and blood concentrations of cyclosporine were analyzed, and pharmacokinetic parameters were calculated."	( Pharmacokinetic interaction study of ticagrelor and cyclosporine in healthy volunteers. Hsia, J; Kujacic, M; Teng, R, 2014)	0.98
"Co-administration of cyclosporine with ticagrelor increased exposure to ticagrelor and its active metabolite and had no effect on cyclosporine pharmacokinetic parameters."	( Pharmacokinetic interaction study of ticagrelor and cyclosporine in healthy volunteers. Hsia, J; Kujacic, M; Teng, R, 2014)	0.94
" The impact of venlafaxine on ticagrelor pharmacokinetic parameters was also investigated."	( Evaluation of the pharmacokinetic interaction between ticagrelor and venlafaxine, a cytochrome P-450 2D6 substrate, in healthy subjects. Hsia, J; Kujacic, M; Teng, R, 2014)	0.94
" Plasma concentrations of ticagrelor, venlafaxine, and their metabolites (AR-C124910XX and O-desmethylvenlafaxine [ODV], respectively) were quantified for pharmacokinetic analyses."	( Evaluation of the pharmacokinetic interaction between ticagrelor and venlafaxine, a cytochrome P-450 2D6 substrate, in healthy subjects. Hsia, J; Kujacic, M; Teng, R, 2014)	0.95
" Venlafaxine Cmax was increased by 22% in the presence of ticagrelor (121."	( Evaluation of the pharmacokinetic interaction between ticagrelor and venlafaxine, a cytochrome P-450 2D6 substrate, in healthy subjects. Hsia, J; Kujacic, M; Teng, R, 2014)	0.9
" In pharmacodynamic studies, ticagrelor demonstrated faster onset and more potent inhibition of platelet aggregation than clopidogrel."	( Ticagrelor: pharmacokinetics, pharmacodynamics, clinical efficacy, and safety. Dobesh, PP; Oestreich, JH, 2014)	2.14
"The objective was to compare the pharmacodynamic (PD) and pharmacokinetic (PK) effects of ticagrelor with clopidogrel among subjects of Hispanic ethnicity, as the PD and PK effects of antiplatelet agents among Hispanics are not specifically known."	( A randomised trial of the pharmacodynamic and pharmacokinetic effects of ticagrelor compared with clopidogrel in Hispanic patients with stable coronary artery disease. Angiolillo, DJ; Caplan, R; Carlson, G; Clavijo, L; Maya, J; Price, MJ; Teng, R, 2015)	0.87
" The aim of this study was to evaluate the pharmacodynamic profile of 5 different anti-platelet treatments in the acute phase of STEMI in patients undergoing primary PCI."	( A pharmacodynamic comparison of 5 anti-platelet protocols in patients with ST-elevation myocardial infarction undergoing primary PCI. Andell, P; Björnsson, S; Erlinge, D; Götberg, M; Harnek, J; Koul, S; Martinsson, A; Norström, E; Scherstén, F; Smith, JG, 2014)	0.4
" We describe the unique pharmacokinetic and pharmacodynamic properties of this drug and the extensive data obtained by preclinical and Phase II and III clinical studies."	( Pharmacokinetics and pharmacodynamics of ticagrelor when treating non-ST elevation acute coronary syndromes. Aspromonte, N; Caldarola, P; Chiatto, M; Iacoviello, M; Monitillo, F; Valle, R, 2015)	0.68
" In light of new data, this review provides an update on the pharmacokinetic, pharmacodynamic and pharmacogenetic profiles of ticagrelor in different study populations."	( Ticagrelor: Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Profile: An Update. Teng, R, 2015)	2.07
"The aim of this study was to assess the impact of ticagrelor dosing regimens on pharmacodynamic (PD) profiles in patients on maintenance ticagrelor therapy."	( Pharmacodynamic Effects of Ticagrelor Dosing Regimens in Patients on Maintenance Ticagrelor Therapy: Results From a Prospective, Randomized, Double-Blind Investigation. Angiolillo, DJ; Bass, TA; Bhatti, M; Cho, JR; DeGroat, C; Dunn, EC; Ferrante, E; Franchi, F; Guzman, LA; Muniz-Lozano, A; Rollini, F; Suryadevara, S; Zenni, MM, 2015)	0.97
" (Impact of Ticagrelor Re-Load Pharmacodynamic Profiles; NCT01731041)."	( Pharmacodynamic Effects of Ticagrelor Dosing Regimens in Patients on Maintenance Ticagrelor Therapy: Results From a Prospective, Randomized, Double-Blind Investigation. Angiolillo, DJ; Bass, TA; Bhatti, M; Cho, JR; DeGroat, C; Dunn, EC; Ferrante, E; Franchi, F; Guzman, LA; Muniz-Lozano, A; Rollini, F; Suryadevara, S; Zenni, MM, 2015)	1.09
"The objective of this study was to assess the pharmacokinetic and pharmacodynamic behavior of ticagrelor administered either as crushed (in the semi-upright sitting position) or as integral (in the supine position) tablets in ST-segment elevation myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention (PCI)."	( Crushed Versus Integral Tablets of Ticagrelor in ST-Segment Elevation Myocardial Infarction Patients: A Randomized Pharmacokinetic/Pharmacodynamic Study. Alexopoulos, D; Barampoutis, N; Davlouros, P; Gkizas, V; Hahalis, G; Koutsogiannis, N; Nylander, S; Parodi, G; Tsigkas, G; Vogiatzi, C; Xanthopoulou, I, 2016)	0.93
" In this study, we compared the pharmacodynamic efficacy of prasugrel and ticagrelor in East Asian patients with acute coronary syndrome (ACS)."	( A pharmacodynamic study of the optimal P2Y12 inhibitor regimen for East Asian patients with acute coronary syndrome. Ahn, MS; Ahn, SG; Kang, YS; Kim, JY; Lee, JH; Lee, JW; Lee, SH; Park, B; Park, SW; Yoo, BS; Yoon, J; Youn, YJ, 2015)	0.65
"The goal of this study was to assess the pharmacokinetic (PK) and pharmacodynamic (PD) profiles of escalating ticagrelor loading dose (LD) regimens in primary percutaneous coronary intervention (PPCI)."	( Impact of Escalating Loading Dose Regimens of Ticagrelor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: Results of a Prospective Randomized Pharmacokinetic and Pharmacodynamic Investigati Angiolillo, DJ; Bass, TA; Bhatti, M; Carraway, E; Cho, JR; DeGroat, C; Dunn, EC; Ferrante, E; Franchi, F; Guzman, LA; Nanavati, A; Rollini, F; Suryadevara, S; Zenni, MM, 2015)	0.89
" Pharmacodynamic assessments were conducted using three assays (vasodilator-stimulated phosphoprotein, VerifyNow P2Y12, and light transmittance aggregometry, LTA) at baseline, 30 min, 2, 24 h, and 1 week."	( A head-to-head pharmacodynamic comparison of prasugrel vs. ticagrelor after switching from clopidogrel in patients with coronary artery disease: results of a prospective randomized study. Angiolillo, DJ; Bass, TA; Bhatti, M; Cho, JR; DeGroat, C; Dunn, EC; Ferrante, E; Franchi, F; Guzman, LA; Muniz-Lozano, A; Rollini, F; Singh, K; Wilson, RE; Zenni, MM, 2016)	0.68
"This study sought to assess the pharmacodynamic (PD) effects of switching to ticagrelor patients who were treated with prasugrel after undergoing percutaneous coronary intervention in the setting of an acute coronary syndrome."	( Pharmacodynamic Effects of Switching From Prasugrel to Ticagrelor: Results of the Prospective, Randomized SWAP-3 Study. Aggarwal, N; Angiolillo, DJ; Antoun, P; Bass, TA; Been, L; Cho, JR; Durairaj, A; Faz, GT; Franchi, F; Guzman, LA; Hu, J; Kureti, M; Park, Y; Rollini, F; Suryadevara, S; Thano, E; Zenni, MM, 2016)	0.91
"The aim of the study was to assess ticagrelor's effects on inhibition of platelet aggregation (IPA), P2Y12 reaction units (PRU, measure of platelet P2Y12 receptor blockade), pharmacokinetic (PK) parameters and safety in Chinese patients with stable coronary artery disease (CAD)."	( Pharmacodynamics, pharmacokinetics, and safety of ticagrelor in Chinese patients with stable coronary artery disease. Carlson, GF; Guo, J; Li, H; Teng, R, 2016)	0.96
" 90 mg twice daily) in ticagrelor Cmax (616 [37] vs."	( Pharmacodynamics, pharmacokinetics, and safety of ticagrelor in Chinese patients with stable coronary artery disease. Carlson, GF; Guo, J; Li, H; Teng, R, 2016)	1
" However, the mean pharmacodynamic differences between 45 and 60 mg doses were small."	( Pharmacodynamics, pharmacokinetics, and safety of ticagrelor in Chinese patients with stable coronary artery disease. Carlson, GF; Guo, J; Li, H; Teng, R, 2016)	0.69
" Data from two studies in patients with acute coronary syndromes with large amounts of pharmacokinetic (PK) data (phase IIb DISPERSE-2 study (n = 609)); phase III PLATO PK substudy (n = 6,381)), along with non-linear mixed effects modeling software, were used to develop population PK models for ticagrelor and its metabolite, AR-C124910XX, and to evaluate the impact of demographic and clinical factors on the PK of ticagrelor and AR-C124910XX."	( Population pharmacokinetics of ticagrelor in patients with acute coronary syndromes. Husted, S; Li, J; Storey, RF; Tang, W; Teng, R, 2016)	0.9
"To complete a systematic review evaluating the currently available evidence regarding the pharmacokinetic and pharmacodynamic activity of orally administered clopidogrel, prasugrel and ticagrelor during the acute phase of a myocardial infarction in relation to mechanical reperfusion with primary percutaneous coronary angioplasty."	( Pharmacokinetics and pharmacodynamics of oral P2Y12 inhibitors during the acute phase of a myocardial infarction: A systematic review. Cotton, JM; Cox, AR; Khan, N, 2016)	0.63
"Twelve papers were included in our final analysis; seven relating to pharmacodynamic studies, one to a pharmacokinetic study and four to pharmacokinetic/pharmacodynamic studies."	( Pharmacokinetics and pharmacodynamics of oral P2Y12 inhibitors during the acute phase of a myocardial infarction: A systematic review. Cotton, JM; Cox, AR; Khan, N, 2016)	0.43
" However, the dynamic interaction of ticagrelor, the ticagrelor active metabolite (TAM), and MEDI2452, makes pharmacokinetic (PK) analysis nontrivial and mathematical modeling becomes essential to unravel the complex behavior of this system."	( Unraveling the pharmacokinetic interaction of ticagrelor and MEDI2452 (Ticagrelor antidote) by mathematical modeling. Almquist, J; Gennemark, P; Goodman, J; Janefeldt, A; Madalli, S; Maqbool, S; Nylander, S; Pehrsson, S; Penney, M; Sandinge, AS, 2016)	0.97
" Whether these findings may be attributed to differences in the pharmacodynamic profiles of these drugs in DM patients remains poorly explored and represented the aim of this study."	( Pharmacodynamic Comparison of Prasugrel Versus Ticagrelor in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The OPTIMUS (Optimizing Antiplatelet Therapy in Diabetes Mellitus)-4 Study. Aggarwal, N; Angiolillo, DJ; Bass, TA; Been, L; Cho, JR; Duarte, VE; Durairaj, A; Franchi, F; Hu, J; Kureti, M; Rollini, F; Zenni, MM, 2016)	0.69
"In this prospective, randomized, double-blind, double-dummy, crossover pharmacodynamic study, aspirin-treated DM patients (n=50) with coronary artery disease were randomly assigned to receive prasugrel (60 mg loading dose [LD]/10 mg maintenance dose once daily) or ticagrelor (180 mg LD/90 mg maintenance dose twice daily) for 1 week."	( Pharmacodynamic Comparison of Prasugrel Versus Ticagrelor in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The OPTIMUS (Optimizing Antiplatelet Therapy in Diabetes Mellitus)-4 Study. Aggarwal, N; Angiolillo, DJ; Bass, TA; Been, L; Cho, JR; Duarte, VE; Durairaj, A; Franchi, F; Hu, J; Kureti, M; Rollini, F; Zenni, MM, 2016)	0.87
" Pharmacodynamic assessments measured by vasodilator-stimulated phosphoprotein, light transmittance aggregometry, and Multiplate were similar between prasugrel and ticagrelor at each time point, including at 1 week."	( Pharmacodynamic Comparison of Prasugrel Versus Ticagrelor in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The OPTIMUS (Optimizing Antiplatelet Therapy in Diabetes Mellitus)-4 Study. Aggarwal, N; Angiolillo, DJ; Bass, TA; Been, L; Cho, JR; Duarte, VE; Durairaj, A; Franchi, F; Hu, J; Kureti, M; Rollini, F; Zenni, MM, 2016)	0.89
" Inhibition in platelet aggregation (IPA) was assessed and the area under the time-effect curve (AUEC) for the IPA was calculated as pharmacodynamic parameters."	( No Effect of SLCO1B1 and CYP3A4/5 Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Ticagrelor in Healthy Chinese Male Subjects. Chen, X; Hu, X; Hu, Y; Li, H; Li, M; Tang, J; Wen, Z; Xiao, J; Zhang, D; Zhang, Y, 2017)	0.67
" Thus, we designed a pharmacokinetic and pharmacodynamic study setting the feasibility of platelet inhibition with a loading dose of ticagrelor given as crushed tablets sublingually compared with two other ticagrelor loading dose administration strategies: integral tablet given orally and crushed tablet given orally in patients with unstable angina."	( Crushed sublingual versus oral ticagrelor administration strategies in patients with unstable angina. A pharmacokinetic/pharmacodynamic study. Alexopoulos, D; Barańska, M; Buszko, K; Fabiszak, T; Jilma, B; Kubica, J; Marszałł, MP; Niezgoda, P; Siemińska, E; Sikora, A; Sikora, J; Siller-Matula, JM, 2017)	0.94
" This is coherent with the emergence of an uninhibited subpopulation of reticulated platelets during treatment with aspirin plus thienopyridine, explained by the short pharmacokinetic half-lives of these drugs."	( Newly Formed Reticulated Platelets Undermine Pharmacokinetically Short-Lived Antiplatelet Therapies. Armstrong, PC; Chan, MV; Ferreira, PM; Hayman, MA; Hoefer, T; Knowles, RB; Tucker, AT; Warner, TD, 2017)	0.46
"In this single-center, prospective, randomized pharmacodynamic study, 52 ESRD patients on HD were prescribed clopidogrel (300mg loading dose [LD], then 75mg daily), standard-dose ticagrelor (180mg LD, then 90mg twice daily), or low-dose ticagrelor (90mg LD, then 90mg daily) for 14days."	( The pharmacodynamics of low and standard doses of ticagrelor in patients with end stage renal disease on hemodialysis. Ihm, CG; Jeong, KH; Kim, JB; Kim, JS; Kim, KS; Kim, W; Kim, WS; Lee, TW; Woo, JS, 2017)	0.9
" This post hoc analysis investigated the pharmacodynamic effects of ticagrelor versus clopidogrel loading dose (LD) in troponin-negative acute coronary syndrome patients with or without DM undergoing percutaneous coronary intervention in the Ad Hoc PCI study."	( Impact of Diabetes Mellitus on the Pharmacodynamic Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Acute Coronary Syndrome Patients Undergoing Ad Hoc Percutaneous Coronary Intervention. Angiolillo, DJ; Carlson, GF; Dangas, G; Franchi, F; Khan, ND; Mehran, R; Raveendran, G; Rollini, F; Sweeny, JM; Teng, R; Waksman, R; Zhao, Y, 2017)	0.93
"The long-term pharmacodynamic effects of Ticagrelor versus Clopidogrel in patients undergoing early percutaneous coronary intervention (PCI) after fibrinolytic therapy is unknown."	( Long-term pharmacodynamic effects of Ticagrelor versus Clopidogrel in fibrinolytic-treated STEMI patients undergoing early PCI. Bagai, A; Booker, J; Cantor, WJ; Cheema, AN; Crawford, JJ; Dehghani, P; Goodman, SG; Harenberg, S; Kelly, S; Lavi, S; Lavoie, A; Mehta, SR; Pon, Q; Yang, A; Zimmermann, RH, 2018)	1.02
" Log-transformed pharmacokinetic parameters of ticagrelor and AR-C124910XX obtained from the trials were compared by the mean of two one-sided t-test."	( Effects of food and gender on pharmacokinetics of ticagrelor and its main active metabolite AR-C124910XX in healthy Chinese subjects . Ding, L; Feng, W; Liu, D; Liu, F; Shi, X; Sun, L; Wang, Y, 2018)	0.99
"Platelet function data were integrated with plasma concentration data of ticagrelor and its active metabolite AR-C1249010XX in a population pharmacokinetic (PK) and pharmacodynamic (PD) model, based on two clinical studies."	( Pharmacokinetic-pharmacodynamic modelling of platelet response to ticagrelor in stable coronary artery disease and prior myocardial infarction patients. Amilon, C; Angiolillo, DJ; Åstrand, M; Bonaca, MP; Gurbel, PA; Hamrén, B; Himmelmann, A; Röshammar, D; Storey, RF, 2019)	0.98
" Clopidogrel has long been the gold standard but has major pharmacological limitations such as a slow onset and long duration of effect, as well as weak platelet inhibition with high inter-individual pharmacokinetic and pharmacodynamic variability."	( Pharmacokinetics and Pharmacodynamics of Approved and Investigational P2Y12 Receptor Antagonists. Dingemanse, J; Schilling, U; Ufer, M, 2020)	0.56
" Plasma samples were collected for pharmacokinetic analysis."	( Effect of tea polyphenols on the oral and intravenous pharmacokinetics of ticagrelor in rats and its in vitro metabolism. Cai, WM; Liu, SB; Sun, H; Tang, ZJ; Wang, ZT; Xue, Y; Zhang, Z, 2020)	0.79
" A preliminary pharmacokinetic study in rats was conducted and could be used to monitor plasma ticagrelor levels in humans."	( Rapid fluorometric determination of ticagrelor in tablets and rat plasma: Application to pharmacokinetics study. Belal, F; Elmansi, H; Zayed, S, 2020)	1.05
" The aim of this review was to discuss the rationale and summarize the current pharmacodynamic and clinical outcomes-based evidence from reduced MD of ticagrelor in patients with coronary artery disease (CAD)."	( Pharmacodynamic and clinical efficacy of reduced ticagrelor maintenance doses in patients with coronary artery disease. Adamski, P; Kubica, J; Navarese, EP; Ostrowska, M, 2021)	1.07
" The pre-determined inclusion criteria were: (1) randomized or observational trials; (2) presentation of clinical or pharmacodynamic results; (3) evaluation of any ticagrelor MD below 90 mg BID in patients with CAD."	( Pharmacodynamic and clinical efficacy of reduced ticagrelor maintenance doses in patients with coronary artery disease. Adamski, P; Kubica, J; Navarese, EP; Ostrowska, M, 2021)	1.07
" The method was then successfully applied for pharmacokinetic study of ticagrelor, its two metabolites and four major constituents of TPs in rat plasma after oral administration of ticagrelor and tea polyphenol extracts."	( A Validated LC-MS/MS Method for the Simultaneous Determination of Ticagrelor, Its Two Metabolites and Major Constituents of Tea Polyphenols in Rat Plasma and Its Application in a Pharmacokinetic Study. Cai, W; Liu, S; Tian, X; Wang, Z; Xue, Y, 2021)	1.09
" How CKD status affects the pharmacodynamic (PD) and pharmacokinetic (PK) profiles of different ticagrelor maintenance dose regimens in patients with DM is unknown."	( Impact of chronic kidney disease on the pharmacodynamic and pharmacokinetic effects of ticagrelor in patients with diabetes mellitus and coronary artery disease. Abou Jaoude, P; Angiolillo, DJ; Bass, TA; Been, L; Briceno, M; Franchi, F; Jia, S; Lee, CH; Maaliki, N; Pineda, AM; Rivas, A; Rollini, F; Soffer, D; Suryadevara, S; Zenni, MM; Zhou, X, 2022)	1.16
" Human PK and pharmacodynamic data from sequential dose cohorts were used to initially define and then refine model parameters."	( Population pharmacokinetic-pharmacodynamic modeling of PB2452, a monoclonal antibody fragment being developed as a ticagrelor reversal agent, in healthy volunteers. Arnold, SE; Bhatt, DL; Kathman, SJ; Lee, JS; Wheeler, JJ, 2022)	0.93
"This investigation was a substudy analysis conducted in selected cohorts of patients with stable atherosclerotic disease enrolled from a larger prospective, open-label, parallel-group pharmacodynamic (PD) study."	( Platelet P2Y12 inhibiting therapy in adjunct to vascular dose of rivaroxaban or aspirin: a pharmacodynamic study of dual pathway inhibition vs. dual antiplatelet therapy. Angiolillo, DJ; Bass, TA; Been, L; Franchi, F; Galli, M; Geisler, T; Jaoude, PA; Jennings, LK; Jia, S; Lee, CH; Maaliki, N; Pineda, AM; Rivas, A; Rollini, F; Soffer, D; Suryadevara, S; Zenni, MM; Zhou, X, 2022)	0.72

Excerpt	Reference	Relevance
" This study assessed whether high-dose aspirin: a) provides additional anti-platelet efficacy, assessed in vivo and ex vivo, when combined with P2Y12 inhibition; and/or b) has a negative effect on vascular function."	( High-dose aspirin in dogs increases vascular resistance with limited additional anti-platelet effect when combined with potent P2Y12 inhibition. Björkman, JA; Forsberg, GB; Hansson, GI; Nylander, S; von Bahr, H; Warner, TD; Zachrisson, H, 2013)	0.39
"The risk and benefit of GP-IIb/IIIa Inhibition (GPI) in combination with recent antiplatelet regimens in acute coronary syndromes (ACS) remain unassessed."	( Safety and efficacy of IIb/IIIa inhibitors in combination with highly active oral antiplatelet regimens in acute coronary syndromes: A meta-analysis of pivotal trials. Agueznai, M; Ardouin, P; Beygui, F; Blanchart, K; Collet, JP; Lemaître, A; Milliez, P; Montalescot, G; Roule, V; Sabatier, R, 2017)	0.46
" In conclusion, cangrelor in combination with ticagrelor results in consistent and strong P2Y12 inhibition during and after infusion and cangrelor may bridge the gap until oral P2Y12 inhibitors achieve effect in real-world STEMI patients undergoing primary PCI."	( Cangrelor in combination with ticagrelor provides consistent and potent P2Y12-inhibition during and after primary percutaneous coronary intervention in real-world patients with ST-segment-elevation myocardial infarction. Andell, P; Erlinge, D; Götberg, M; James, S; Koul, S; Mohammad, MA; Scherstén, F, 2017)	1
" This study aimed to investigate the influences of dual-dose clopidogrel, clopidogrel combined with tongxinluo, and ticagrelor on the platelet activity and MACE events of patients with CYP2C19*2 gene function deficiency and poor clopidogrel response after PCI."	( Effects of Dual-Dose Clopidogrel, Clopidogrel Combined with Tongxinluo Capsule, and Ticagrelor on Patients with Coronary Heart Disease and CYP2C19*2 Gene Mutation After Percutaneous Coronary Interventions (PCI). Chen, S; Geng, Y; Gu, J; Hao, Q; Qi, P; Wang, H; Wang, L; Zhang, Y, 2017)	0.89
"The present case demonstrates that a potential drug-drug interaction (DDI) may lead to a life-threatening drug adverse reaction especially in special subjects."	( Ticagrelor-induced life-threatening bleeding via the cyclosporine-mediated drug interaction: A case report. Cui, M; Gu, Z; Liu, X; Shen, L; Zhang, C, 2017)	1.9
" Three months later, he was noted to have elevated creatine kinase (CK), thought to be related to a potential drug-drug interaction between ticagrelor and atorvastatin."	( Elevated Creatine Kinase due to Potential Drug Interaction With Ticagrelor and Atorvastatin. Beavers, JC, 2019)	0.95
"A probable drug-drug interaction occurred with concomitant ticagrelor and atorvastatin."	( Elevated Creatine Kinase due to Potential Drug Interaction With Ticagrelor and Atorvastatin. Beavers, JC, 2019)	1
" We studied the effect of high-dose atorvastatin combined with ticagrelor loading on endothelial dysfunction in a model of forearm vascular ischemia-reperfusion (IR) injury."	( Atorvastatin combined with ticagrelor prevent ischemia-reperfusion induced vascular endothelial dysfunction in healthy young males - A randomized, placebo-controlled, double-blinded study. Kerbel, T; Litschauer, B; Weisshaar, S; Wolzt, M, 2018)	1.02
"Chronic atorvastatin treatment combined with ticagrelor loading prevents against endothelial dysfunction after acute forearm ischemia."	( Atorvastatin combined with ticagrelor prevent ischemia-reperfusion induced vascular endothelial dysfunction in healthy young males - A randomized, placebo-controlled, double-blinded study. Kerbel, T; Litschauer, B; Weisshaar, S; Wolzt, M, 2018)	1.04
"This study aimed to investigate the effect of ticagrelor combined with omeprazole on patients with acute myocardial infarction (AMI) undergoing primary percutaneous coronary intervention (PCI)."	( Effects (MACE and bleeding events) of ticagrelor combined with omeprazole on patients with acute myocardial infarction undergoing primary PCI. Hou, Y; Liu, F; Su, S; Wang, Z; Wu, F; Zhang, F; Zhang, L; Zhao, L, )	0.66
" The objective of this study is to investigate the efficacy and safety of ticagrelor combined with a lower dose of aspirin (50 mg) than that recommended by guidelines (75-100 mg)."	( Combined with ticagrelor, 50 mg aspirin daily can reduce bleeding events without increasing ischemic risk compared with 75-100 mg aspirin daily in coronary artery disease patients: insights from the TIFU (Ticagrelor in Fuwai Hospital) study. Chen, R; Chen, Y; Li, J; Liu, C; Sheng, Z; Song, L; Tan, Y; Yan, H; Zhao, H; Zhou, J; Zhou, P, 2020)	1.15
"This study aims to explore the clinical efficacy of ticagrelor combined with aspirin in patients with coronary heart disease angina pectoris and the effects on N terminal pro B type natriuretic peptide (NT-ProBNP) and creatine kinase-MB (CK-MB) levels."	( Clinical efficacy of ticagrelor combined with aspirin in patients with coronary heart disease angina pectoris and its effects on NT-ProBNP and CK-MB levels. Chen, LL; Lu, WL; Tang, DD; Wang, JP; Wang, W; Yan, SR; Zhao, LH, 2020)	1.13
"Ticagrelor combined with aspirin has definite therapeutic effect on patients with coronary heart disease angina pectoris, with low prevalence of adverse reactions."	( Clinical efficacy of ticagrelor combined with aspirin in patients with coronary heart disease angina pectoris and its effects on NT-ProBNP and CK-MB levels. Chen, LL; Lu, WL; Tang, DD; Wang, JP; Wang, W; Yan, SR; Zhao, LH, 2020)	2.32
"Coronary endarterectomy (CE) combined with coronary artery bypass grafting (CABG) can be the only option for complete revascularization in some patients with diffuse coronary artery disease."	( Comparison of dual antiplatelet therapies after coronary endarterectomy combined with coronary artery bypass grafting: a cohort study. Feng, W; Song, Y; Tiemuerniyazi, X; Xu, F; Yan, H, 2020)	0.56
"This study evaluated the cardioprotective effects of NXT alone and in combination with ticagrelor (TIC) and atorvastatin (ATO)."	( Protective effects of Naoxintong capsule alone and in combination with ticagrelor and atorvastatin in rats with Qi deficiency and blood stasis syndrome. He, Y; Li, PB; Lin, QW; Liu, H; Su, WW; Wang, YG; Wu, H; Yan, ZH; Yao, HL; Zhang, WJ, 2020)	1.01
"To investigate the effect of ticagrelor combined with tirofiban versus clopidogrel combined with tirofiban on inflammation response and prognosis of patients with unstable angina pectoris (UA)."	( Comparison of the effect of ticagrelor combined with tirofiban versus clopidogrel combined with tirofiban on inflammation response and prognosis of patients with unstable angina pectoris in long term follow-up. Deng, L; Jia, HZ; Li, MC; Zhu, W, 2021)	1.21
"To explore the clinical efficacy of tirofiban combined with ticagrelor and aspirin in acute myocardial infarction treatment by percutaneous coronary intervention and its effect on patients' cardiac function."	( The Clinical Efficacy of Tirofiban Combined with Ticagrelor and Aspirin in Treating Acute Myocardial Infarction by Percutaneous Coronary Intervention and Its Effect on Patients' Cardiac Function. Li, F; Peng, R, 2022)	1.22
" On the basis of conventional treatment, patients were separated into a joint group (tirofiban combined with ticagrelor and aspirin) comprising 55 cases and a control group (conventional ticagrelor and aspirin dual treatment) involving 47 cases."	( The Clinical Efficacy of Tirofiban Combined with Ticagrelor and Aspirin in Treating Acute Myocardial Infarction by Percutaneous Coronary Intervention and Its Effect on Patients' Cardiac Function. Li, F; Peng, R, 2022)	1.19
" The aim of our study was to investigate if the Syk inhibitor fostamatinib could be repurposed as an antiplatelet drug, either alone or in combination with conventional antiplatelet therapy."	( Antithrombotic Effects of Fostamatinib in Combination with Conventional Antiplatelet Drugs. Alenazy, FO; Harbi, MH; Nicolson, PLR; Smith, CW; Thomas, MR; Tiwari, A; Watson, SP, 2022)	0.72
"The present study aimed to investigate the application safety of bivalirudin combined with ticagrelor in the emergency percutaneous coronary intervention (PCI) in patients with ST-segment elevation myocardial infarction (STEMI)."	( Safety of Bivalirudin Combined with Ticagrelor in the Emergency PCI in Patients with Acute ST-Segment Elevation Myocardial Infarction. Chen, YX; Li, P; Liang, XW; Liao, W; Liu, M; Wang, ZD; Xie, WC; Zhu, XZ, )	0.63
"Compared with unfractionated heparin combined with ticagrelor in patients with STEMI undergoing emergency PCI treatment, bivalirudin combined with ticagrelor could significantly reduce the occurrence of mild hemorrhage events, and it would not increase the incidence of MACE during the 30 days of follow-up."	( Safety of Bivalirudin Combined with Ticagrelor in the Emergency PCI in Patients with Acute ST-Segment Elevation Myocardial Infarction. Chen, YX; Li, P; Liang, XW; Liao, W; Liu, M; Wang, ZD; Xie, WC; Zhu, XZ, )	0.66

Excerpt	Reference	Relevance
"To compare the bioavailability and safety profile of crushed ticagrelor tablets suspended in water and administered orally or via nasogastric tube, with that of whole tablets administered orally."	( An open-label, randomized bioavailability study with alternative methods of administration of crushed ticagrelor tablets in healthy volunteers. Carlson, G; Hsia, J; Teng, R, 2015)	0.87
"A one-compartment model with population mean PK parameters of firstorder absorption rate constant (0."	( Population pharmacokinetics of ticagrelor in patients with acute coronary syndromes. Husted, S; Li, J; Storey, RF; Tang, W; Teng, R, 2016)	0.72
"Cell membrane permeability is an important determinant for oral absorption and bioavailability of a drug molecule."	( Highly predictive and interpretable models for PAMPA permeability. Jadhav, A; Kerns, E; Nguyen, K; Shah, P; Sun, H; Xu, X; Yan, Z; Yu, KR, 2017)	0.46
"Data from available studies suggest that the presence of ST-elevation myocardial infarction (STEMI) may be associated with delayed and attenuated ticagrelor bioavailability and effect compared with non-ST-elevation myocardial infarction (NSTEMI)."	( Comparison of bioavailability and antiplatelet action of ticagrelor in patients with ST-elevation myocardial infarction and non-ST-elevation myocardial infarction: A prospective, observational, single-centre study. Adamska, U; Adamski, P; Buszko, K; Gorog, DA; Kubica, A; Kubica, J; Laskowska, E; Marszałł, MP; Navarese, EP; Ostrowska, M; Paciorek, P; Rość, D; Sikora, A; Sikora, J; Skibińska, N; Sobczak, P; Umińska, JM, 2017)	0.9
" Impaired bioavailability of ticagrelor and AR-C124910XX seen in STEMI subjects was associated with diminished platelet inhibition in this group, which was most pronounced during the initial hours of treatment."	( Comparison of bioavailability and antiplatelet action of ticagrelor in patients with ST-elevation myocardial infarction and non-ST-elevation myocardial infarction: A prospective, observational, single-centre study. Adamska, U; Adamski, P; Buszko, K; Gorog, DA; Kubica, A; Kubica, J; Laskowska, E; Marszałł, MP; Navarese, EP; Ostrowska, M; Paciorek, P; Rość, D; Sikora, A; Sikora, J; Skibińska, N; Sobczak, P; Umińska, JM, 2017)	0.99
" This reduced and delayed ticagrelor bioavailability was associated with weaker antiplatelet effect in STEMI."	( Comparison of bioavailability and antiplatelet action of ticagrelor in patients with ST-elevation myocardial infarction and non-ST-elevation myocardial infarction: A prospective, observational, single-centre study. Adamska, U; Adamski, P; Buszko, K; Gorog, DA; Kubica, A; Kubica, J; Laskowska, E; Marszałł, MP; Navarese, EP; Ostrowska, M; Paciorek, P; Rość, D; Sikora, A; Sikora, J; Skibińska, N; Sobczak, P; Umińska, JM, 2017)	1
"The aim of this study is to improve the bioavailability of ticagrelor, BCS class 4 drug, using solid dispersion technique, and to evaluate the potential of ticagrelor loaded-solid dispersion, as a new formulation."	( A novel composition of ticagrelor by solid dispersion technique for increasing solubility and intestinal permeability. Bang, KH; Cho, CW; Huh, HW; Kim, SJ; Lee, HJ; Lee, HK; Na, YG; Wang, M, 2019)	1.07
"Ticagrelor (TCG) is used to inhibit platelet aggregation in patients with acute coronary syndrome, but its poor solubility and low bioavailability limit its in vivo efficacy."	( Strategic approach to developing a self-microemulsifying drug delivery system to enhance antiplatelet activity and bioavailability of ticagrelor. Bang, KH; Byeon, JJ; Cho, CW; Huh, HW; Jeon, SH; Kim, SJ; Lee, HJ; Lee, HK; Na, YG; Son, GH; Wang, M, 2019)	2.16
"These results suggest that the developed TCG-SM could be successfully used as an efficient method to achieve the enhanced antiplatelet activity and bioavailability of TCG."	( Strategic approach to developing a self-microemulsifying drug delivery system to enhance antiplatelet activity and bioavailability of ticagrelor. Bang, KH; Byeon, JJ; Cho, CW; Huh, HW; Jeon, SH; Kim, SJ; Lee, HJ; Lee, HK; Na, YG; Son, GH; Wang, M, 2019)	0.72
" Similar bioavailability of ticagrelor (and AR-C124910XX) was demonstrated for all comparisons tested."	( Development Strategy and Relative Bioavailability of a Pediatric Tablet Formulation of Ticagrelor. Berggren, AR; Johanson, P; Karlsson, C; Niazi, M; Wissmar, J, 2019)	1.03
"Similar bioavailability of a new pediatric dispersible tablet formulation of ticagrelor for use across a wide age range of pediatric patients was demonstrated compared with other oral ticagrelor formulations."	( Development Strategy and Relative Bioavailability of a Pediatric Tablet Formulation of Ticagrelor. Berggren, AR; Johanson, P; Karlsson, C; Niazi, M; Wissmar, J, 2019)	0.97
"The aim of this study was to solidify a ticagrelor loaded self-microemulsifying drug delivery system (TCG-SM) with enhanced dissolution and bioavailability of ticagrelor (TCG) for developing TCG-SM granules and tablets."	( Statistical approach for solidifying ticagrelor loaded self-microemulsifying drug delivery system with enhanced dissolution and oral bioavailability. Bang, KH; Byeon, JJ; Cho, CW; Han, MG; Huh, HW; Kim, MK; Lee, HK; Na, YG; Wang, M, 2019)	1.05
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51
"In this study, we developed ticagrelor-dispersed nanosuspension (TCG-NSP) to enhance the dissolution and oral bioavailability of ticagrelor (TCG) through a statistical design approach."	( Development and evaluation of TPGS/PVA-based nanosuspension for enhancing dissolution and oral bioavailability of ticagrelor. Baek, JS; Byeon, JJ; Cho, CW; Han, MG; Kim, MK; Lee, HK; Na, YG; Pham, TMA, 2020)	1.06
" We highlighted a mechanism triggered mainly by the increased extracellular bioavailability of adenosine, which activates A2B and A3 receptors on the endothelium."	( Ticagrelor Prevents Endothelial Cell Apoptosis through the Adenosine Signalling Pathway in the Early Stages of Hypoxia. Brassart-Pasco, S; Djerada, Z; Feliu, C; Millart, H; Nguyen, P; Oszust, F; Peyret, H; Poitevin, G, 2020)	2
"Ticagrelor (TGR), being an antiplatelet agent, belongs to BCS class IV drug with low solubility and permeability that undergoes first-pass metabolism, leading to reduced bioavailability of 36%."	( Formulation and In Vivo Evaluation of Ticagrelor Self-nanoemulsifying Drug Delivery Systems. Aparna, A; Bhikshapathi, DVRN; Kumar, YS, 2021)	2.34
" In vivo bioavailability studies of optimized SNEDDS are performed in Wistar rats."	( Formulation and In Vivo Evaluation of Ticagrelor Self-nanoemulsifying Drug Delivery Systems. Aparna, A; Bhikshapathi, DVRN; Kumar, YS, 2021)	0.89
"Ticagrelor is a first-line clinical drug for the treatment of acute coronary syndrome, but its oral bioavailability is relatively low."	( Untargeted metabolomics reveals the mechanism of quercetin enhancing the bioavailability of ticagrelor. Sun, Y; Tang, Y; Wei, B; Wei, S; Xu, X; Zhang, W, 2021)	2.28
"Unlike fentanyl, lignocaine does not impair the bioavailability or delay the antiplatelet effect of ticagrelor."	( Effects of lignocaine vs. opioids on antiplatelet activity of ticagrelor: the LOCAL trial. Duffy, SJ; Duong, T; Fernando, H; Huynh, K; Meikle, PJ; Myles, PS; Nehme, Z; Noonan, J; Peter, K; Shaw, J; Smith, K; Stub, D, 2021)	1.08
"Ticagrelor (TG), an antiplatelet drug is employed to treat patients with acute coronary syndrome, but its inadequate oral bioavailability due to poor solubility and low permeability restricts its effectiveness."	( pH-Responsive Nanocomposite Based Hydrogels for the Controlled Delivery of Ticagrelor; In Vitro and In Vivo Approaches. Alqahtani, F; Alshehri, S; Erum, A; Imran, I; Majeed, A; Noorani, B; Rasool, MF; Shahid, N; Shoaib, QU; Tulain, UR; Zaman, M, 2021)	2.29
"This contemporary work was aimed to design a novel pH-sensitive nanocomposite hydrogel (NCH) formulation incorporating thiolated chitosan (TCH) based nanoparticles (NPs) of Ticagrelor (TG), to enhance its oral bioavailability for effectively inhibiting platelet aggregation."	( pH-Responsive Nanocomposite Based Hydrogels for the Controlled Delivery of Ticagrelor; In Vitro and In Vivo Approaches. Alqahtani, F; Alshehri, S; Erum, A; Imran, I; Majeed, A; Noorani, B; Rasool, MF; Shahid, N; Shoaib, QU; Tulain, UR; Zaman, M, 2021)	1.05
" The NCHs were evaluated by various physicochemical techniques and the selected formulation was subjected to in vivo bioavailability studies, confirming enhancement of bioavailability as indicated by prolonged half-life and multifold increase in area under the curve (AUC) as compared to pure TG."	( pH-Responsive Nanocomposite Based Hydrogels for the Controlled Delivery of Ticagrelor; In Vitro and In Vivo Approaches. Alqahtani, F; Alshehri, S; Erum, A; Imran, I; Majeed, A; Noorani, B; Rasool, MF; Shahid, N; Shoaib, QU; Tulain, UR; Zaman, M, 2021)	0.85
" However, pharmacological use of endogenous ligands for these receptors is limited by their lack of specificity (PACAP binds with high affinity to VPAC1, VPAC2 and PAC1 receptors while VIP recognizes both VPAC1 and VPAC2 receptors), their poor oral bioavailability (VIP and PACAP are 27- to 38-amino acid peptides) and their short half-life."	( Drug Repositioning For Allosteric Modulation of VIP and PACAP Receptors. Langer, I; Latek, D, 2021)	0.62
" In pharmacokinetic study, compared with raw TCG, the bioavailability of HL-NLC and S-HL-NLC was increased by 293% and 323%, respectively."	( Development of a long-acting tablet with ticagrelor high-loaded nanostructured lipid carriers. Bai, HW; Cho, CW; Han, SC; Jeon, WJ; Jin, M; Jung, M; Kang, KU; Kim, H; Lee, H; Lee, HK; Suh, H; Won, JH; Yoo, H, 2023)	1.18

Excerpt	Relevance	Reference
" AZD6140 (100 and 200 mg bid, 400 mg qd) rapidly and nearly completely inhibited ADP-induced platelet aggregation after initial dosing (day 1) and at day 28."	( Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Emanuelsson, H; Heptinstall, S; Husted, S; Peters, G; Sandset, PM; Wickens, M, 2006)	0.33
" Despite the unambiguous clinical benefit associated with clopidogrel, accumulating experience with this drug has also led to identification of some of its drawbacks, which are related to inadequate platelet inhibition with standard dosage regimens as well as to its irreversible antiplatelet effects."	( ADP receptor antagonism: what's in the pipeline? Angiolillo, DJ, 2007)	0.34
" It is quickly absorbed and exhibits a rapid antiplatelet effect, with higher and more consistent levels of inhibition of platelet aggregation (IPA) being maintained across the dosing interval than with clopidogrel."	( Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist. Husted, S; van Giezen, JJ, 2009)	1.8
" Optimal dosing strategy as determined by ticagrelor's pharmacokinetic and pharmacodynamic profile is a loading dose of 180 mg followed by 90 mg by mouth twice daily."	( Efficacy and safety of ticagrelor: a reversible P2Y12 receptor antagonist. Anderson, SD; Epstein, BJ; Shah, NK; Yim, J, 2010)	0.94
"This study assesses the optimal dosing schedule for ticagrelor in healthy volunteers and compares the degree of IPA with clopidogrel."	( Pharmacokinetics, pharmacodynamics, safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteers. Butler, K; Teng, R, 2010)	0.83
"Multiple dosing provided predictable pharmacokinetics of ticagrelor and its metabolite over the dose range of 50-600 mg once daily and 50-300 mg twice daily with C(max) and AUC(0,t) increasing approximately dose-proportionally."	( Pharmacokinetics, pharmacodynamics, safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteers. Butler, K; Teng, R, 2010)	0.83
" However, different degrees of resistance to clopidogrel have been the subject of many recent studies that led to higher dosing regimens of clopidogrel."	( A new era for antiplatelet therapy in patients with acute coronary syndrome. Abu-Fadel, MS; Dib, C; Hanna, EB, 2010)	0.36
" Based on these data, no ticagrelor dosage adjustment is needed in patients with mild hepatic impairment."	( Pharmacokinetics, pharmacodynamics, and safety of ticagrelor in volunteers with mild hepatic impairment. Butler, K; Teng, R, 2011)	0.93
" The present article reviews data on the clinical impact of enhanced P2Y12 inhibition with either higher clopidogrel dosing or new oral antiplatelet agents, including prasugrel and ticagrelor, in the setting of STEMI, focusing on results in the setting of primary PCI."	( Clinical impact of enhanced inhibition of P2Y12-mediated platelet aggregation in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention. Capranzano, P; Dangas, G; Mehran, R; Stone, GW; Tamburino, C, 2010)	0.55
"In the recent PLATO trial, the daily aspirin dosages in the USA were split between 81 and 325 mg while the vast majority of dosing outside of the USA was 75 or 100 mg."	( Aspirin dose and ticagrelor benefit in PLATO: fact or fiction? Serebruany, VL, 2010)	0.7
" After completion of this phase, additional subjects (n = 14) were recruited into the ticagrelor 180 mg group, and received ticagrelor 180 mg under the same dosing schedule."	( Pharmacokinetics and tolerability of single and multiple doses of ticagrelor in healthy Chinese subjects: an open-label, sequential, two-cohort, single-centre study. Butler, K; Li, H; Teng, R; Yang, L; Yang, Z, 2012)	0.84
" Steady-state concentrations of ticagrelor and AR-C124910XX were rapidly established with both dosing regimens."	( Pharmacokinetics and tolerability of single and multiple doses of ticagrelor in healthy Chinese subjects: an open-label, sequential, two-cohort, single-centre study. Butler, K; Li, H; Teng, R; Yang, L; Yang, Z, 2012)	0.9
" Whether this is worth both the risk of non-compliance with twice-a-day dosing in real-life patients lacking the same motivation as their trial-volunteer counterparts, and the 2000-fold difference in incremental cost, is the remaining matter for debate."	( Quantitative comparison of clopidogrel 600 mg, prasugrel and ticagrelor, against clopidogrel 300 mg on major adverse cardiovascular events and bleeding in coronary stenting: synthesis of CURRENT-OASIS-7, TRITON-TIMI-38 and PLATO. Davies, JE; Francis, DP; Nijjer, SS, 2012)	0.62
" In RESPOND, ticagrelor mean C(max) and AUC(8) following 2-week dosing were comparable between clopidogrel responders (724 ng/mL and 3983 ng · h/mL, respectively) and non-responders (764 ng/mL and 3986 ng · h/mL, respectively)."	( Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET-OFFSET and RESPOND studies. Bliden, K; Butler, K; Gurbel, PA; Husted, SE; Høimark, L; Storey, RF; Tantry, US; Teng, R; Wei, C, 2012)	1.01
" The compound design was based on modifications of ticagrelor and its major metabolite (33) in order to ameliorate their pharmacokinetic properties and dosing profile."	( Synthesis and biological evaluation of ticagrelor derivatives as novel antiplatelet agents. Kong, L; Liu, J; Sun, H; Yao, H; Zhang, H; Zhang, L, 2012)	0.9
" However, the reversible binding of ticagrelor to the P2Y(12) receptor requires a twice-daily dosing regimen."	( Comparative pharmacokinetics and pharmacodynamics of platelet adenosine diphosphate receptor antagonists and their clinical implications. Ferro, A; Floyd, CN; Passacquale, G, 2012)	0.65
"Six male dogs all received 7 different dosing regimens separated by 1-5week washout periods: cangrelor (1μg/kg/min, intravenous infusion); ticagrelor (0."	( Evaluation of ticagrelor pharmacodynamic interactions with reversibly binding or non-reversibly binding P2Y(12) antagonists in an ex-vivo canine model. Emanuelsson, BM; Ravnefjord, A; van Giezen, JJ; Weilitz, J, 2012)	0.94
" With clopidogrel dosed 3hours after ticagrelor, IPA was reduced after washout of ticagrelor to 38% at 24hrs vs."	( Evaluation of ticagrelor pharmacodynamic interactions with reversibly binding or non-reversibly binding P2Y(12) antagonists in an ex-vivo canine model. Emanuelsson, BM; Ravnefjord, A; van Giezen, JJ; Weilitz, J, 2012)	1.01
" The comparator was standard dosage of clopidogrel."	( Comparing newer oral anti-platelets prasugrel and ticagrelor in reduction of ischemic events-evidence from a network meta-analysis. Chatterjee, S; Frankel, R; Ghose, A; Guha, G; Mukherjee, D; Sharma, A, 2013)	0.64
" At steady-state ticagrelor (50 mg bid, or 200 mg bid), concomitant aspirin (300 mg qd) had no effect on mean maximum plasma concentration (Cmax), median time to Cmax (tmax), or mean area under the plasma concentration-time curve for the dosing interval (AUC0-τ) for ticagrelor and its primary metabolite, AR-C124910XX."	( Evaluation of the pharmacokinetics and pharmacodynamics of ticagrelor co-administered with aspirin in healthy volunteers. Butler, K; Maya, J; Teng, R, 2013)	0.97
" Tolbutamide had no effect on the Cmax, area under the concentration curve over the 2-hour dosing interval (AUC0-τ), t1/2 or tmax of either ticagrelor or AR-C124910XX."	( Evaluation of the pharmacokinetic interaction between ticagrelor and tolbutamide, a cytochrome P450 2C9 substrate, in healthy volunteers. Butler, K; Mitchell, P; Teng, R, 2013)	0.84
" Moreover, inappropriate statin dosing restrictions (underdosing of simvastatin and lovastatin) were deliberately utilized in PLATO, potentially contributing to the beneficial effect of ticagrelor."	( Exploring the ticagrelor-statin interplay in the PLATO trial. Dinicolantonio, JJ; Serebruany, VL, 2013)	0.94
" For the oral dose, ticagrelor tablets were crushed using a mortar and pestle and transferred to a dosing cup."	( Evaluation of crushed ticagrelor tablet doses: recovery following crushing and naso-gastric tube passage ex vivo. Crean, B; Crosby, A; Finnie, C, 2013)	1.03
" Future studies are required to test the effect of crushed dosing on pharmacokinetic and pharmacodynamic parameters."	( Evaluation of crushed ticagrelor tablet doses: recovery following crushing and naso-gastric tube passage ex vivo. Crean, B; Crosby, A; Finnie, C, 2013)	0.7
" A review of data regarding aspirin use for secondary prevention of events in ACS demonstrated that low aspirin doses (75 to 160 mg/day) are consistently favored for short- and long-term use because of the lack of a dose-response relationship between increasing aspirin dose and improved efficacy, and a higher incidence of gastrointestinal bleeding with increasing aspirin dose."	( Aspirin, clopidogrel, and ticagrelor in acute coronary syndromes. Berger, JS, 2013)	0.69
" In contrast, on an oral dosage basis (mg/kg), prasugrel showed more potent platelet inhibition compared to ticagrelor on ex vivo aggregation and VASP phosphorylation assays in monkeys."	( Comparison of antiplatelet effects of prasugrel and ticagrelor in cynomolgus monkeys by an ELISA-based VASP phosphorylation assay and platelet aggregation. Jakubowski, JA; Mizuno, M; Ohno, K; Sugidachi, A; Tomizawa, A, 2013)	0.85
" Dans certaines situations de risque par contre, une adaption du dosage est conseillée pour minimiser les effets secondaires négatifs: Chez les patients de plus de 75 ans, et/ou d'un poids corporel de moins de 60 kg, une réduction du dosage de prasugrel est conseillée en raison d'un risque élevé d'hémorragie."	( [Thrombocyte aggregation inhibitors: what are the risks?]. Curkovic, I; Egbring, M; Kullak-Ublick, GA, 2013)	0.39
" In this situation, a number of alternatives to conventional dosing of clopidogrel have been investigated, including increasing the dosage of clopidogrel, switching from clopidogrel to either prasugrel or ticagrelor, or adding cilostazol to clopidogrel therapy."	( Treatment options for patients with poor clopidogrel response. Nawarskas, JJ; Roberts, DI, )	0.32
" A clear dose-response was obtained after spiking whole blood with increasing amounts of PRP."	( Reversal strategy in antagonizing the P2Y12 -inhibitor ticagrelor. Derhaschnig, U; Firbas, C; Hobl, EL; Jilma, B; Schoergenhofer, C; Schwameis, M, 2013)	0.64
"Clinicians may need to switch between more potent P2Y12 inhibitors because of adverse effects or switch to the use of a once-daily dosing regimen due to compliance issues."	( Pharmacodynamic evaluation of switching from ticagrelor to prasugrel in patients with stable coronary artery disease: Results of the SWAP-2 Study (Switching Anti Platelet-2). Angiolillo, DJ; Curzen, N; Effron, MB; Gurbel, P; Jakubowski, JA; Li, W; Lipkin, F; Trenk, D; Vaitkus, P; Zettler, M, 2014)	0.66
" Bleeding times were >= 60 minutes in more Japanese than Caucasians with multiple dosing of 100 mg and 300 mg ticagrelor Adverse events were similar between groups (mild-to-moderate intensity)."	( Pharmacokinetics, pharmacodynamics, and tolerability of single and multiple doses of ticagrelor in Japanese and Caucasian volunteers. Butler, K; Teng, R, 2014)	0.84
"Twice daily dosing is often perceived as inferior to once daily dosing due to a higher likelihood of missing a dose."	( Projected inhibition of platelet aggregation with ticagrelor twice daily vs. clopidogrel once daily based on patient adherence data (the TWICE project). Claeys, MJ; Legrand, V; Van de Werf, F; Vandendriessche, E; Vrijens, B, 2014)	0.65
"Drug dosing histories of 5014 patients prescribed cardiovascular medications (primarily antihypertensive medicines) were extracted from an electronically compiled dosing history database."	( Projected inhibition of platelet aggregation with ticagrelor twice daily vs. clopidogrel once daily based on patient adherence data (the TWICE project). Claeys, MJ; Legrand, V; Van de Werf, F; Vandendriessche, E; Vrijens, B, 2014)	0.65
" This modelling and simulation study suggests a therapeutic benefit of ticagrelor over clopidogrel when taking into account the most common dosing omissions."	( Projected inhibition of platelet aggregation with ticagrelor twice daily vs. clopidogrel once daily based on patient adherence data (the TWICE project). Claeys, MJ; Legrand, V; Van de Werf, F; Vandendriessche, E; Vrijens, B, 2014)	0.89
" At the end of the dosing interval on day 28, mean final-extent IPA was 10."	( Pharmacodynamics, pharmacokinetics and safety of ticagrelor in Asian patients with stable coronary artery disease. Emanuelsson, H; Hiasa, Y; Teng, R, 2014)	0.66
" Coagulation biomarkers in shed blood were assessed at 3 h after monotherapy with the medicines under study, at 3 h after triple therapy dosing and at steady state trough conditions."	( Antithrombotic triple therapy and coagulation activation at the site of thrombus formation: a randomized trial in healthy subjects. Eichinger, S; Gouya, G; Kapiotis, S; Kyrle, PA; Litschauer, B; Mayer, P; Smerda, L; Weisshaar, S; Wolzt, M, 2014)	0.4
" In a double blind, placebo-controlled crossover trial in healthy volunteers, a single oral dosage of 180 mg ticagrelor reduced platelet-monocyte complex (PMC) formation."	( Differential effects of platelets and platelet inhibition by ticagrelor on TLR2- and TLR4-mediated inflammatory responses. de Groot, PG; de Mast, Q; Dinarello, CA; Fijnheer, R; Gasem, MH; Gomes, ME; Joosten, LA; Netea, MG; Riksen, N; Rongen, G; Tacke, S; Tunjungputri, RN; van de Veerdonk, FL; van den Berg, TN; van der Ven, AJ, 2015)	0.87
"The aim of this study was to assess the impact of ticagrelor dosing regimens on pharmacodynamic (PD) profiles in patients on maintenance ticagrelor therapy."	( Pharmacodynamic Effects of Ticagrelor Dosing Regimens in Patients on Maintenance Ticagrelor Therapy: Results From a Prospective, Randomized, Double-Blind Investigation. Angiolillo, DJ; Bass, TA; Bhatti, M; Cho, JR; DeGroat, C; Dunn, EC; Ferrante, E; Franchi, F; Guzman, LA; Muniz-Lozano, A; Rollini, F; Suryadevara, S; Zenni, MM, 2015)	0.97
"Many patients on maintenance P2Y12-inhibiting therapies may require coronary revascularization procedures, raising a common clinical question with regard to the dosing regimen of the P2Y12-inhibiting agent to be used."	( Pharmacodynamic Effects of Ticagrelor Dosing Regimens in Patients on Maintenance Ticagrelor Therapy: Results From a Prospective, Randomized, Double-Blind Investigation. Angiolillo, DJ; Bass, TA; Bhatti, M; Cho, JR; DeGroat, C; Dunn, EC; Ferrante, E; Franchi, F; Guzman, LA; Muniz-Lozano, A; Rollini, F; Suryadevara, S; Zenni, MM, 2015)	0.71
"This was a prospective, randomized, double-blind, placebo-controlled study assessing the PD effects of 2 dosing regimens of ticagrelor in patients on standard aspirin and ticagrelor maintenance therapy."	( Pharmacodynamic Effects of Ticagrelor Dosing Regimens in Patients on Maintenance Ticagrelor Therapy: Results From a Prospective, Randomized, Double-Blind Investigation. Angiolillo, DJ; Bass, TA; Bhatti, M; Cho, JR; DeGroat, C; Dunn, EC; Ferrante, E; Franchi, F; Guzman, LA; Muniz-Lozano, A; Rollini, F; Suryadevara, S; Zenni, MM, 2015)	0.92
" We sought to evaluate platelet reactivity during loading and maintenance dosing of ticagrelor versus clopidogrel, and the pharmacokinetic profile of ticagrelor and its metabolite AR-C124910XX, in black patients with stable CAD taking low-dose aspirin (acetylsalicylic acid)."	( Ticagrelor Versus Clopidogrel in Black Patients With Stable Coronary Artery Disease: Prospective, Randomized, Open-Label, Multiple-Dose, Crossover Pilot Study. Angiolillo, DJ; Caplan, RJ; Carlson, GF; Ferdinand, KC; Maya, J; Teng, R; Waksman, R, 2015)	2.08
" In mice dosed to complete P2Y12 inhibition, boosting coagulation by administration of rhFVIIa or rhFII within 90s after bleeding initiation can partly reverse ticagrelor-enhanced bleeding."	( Boosting the coagulation restores haemostasis in ticagrelor-treated mice. Hansson, K; Nelander, K; Nylander, S; Pehrsson, S, 2016)	0.89
" Newer P2Y12 antagonists with faster onset and greater inhibition of platelet activity have improved cardiovascular outcomes but have created uncertainty with the appropriate dosing when switching between agents."	( In-stent thrombosis when switching ticagrelor to clopidogrel after percutaneous coronary intervention. Brice, AE; Haynick, M; Hernandez, GA; Mendoza, CE; Sanchez, M, 2017)	0.73
"The optimal dosing of novel oral P2Y12 receptor platelet inhibitors such as prasugrel or ticagrelor is unclear and especially challenging in East Asians."	( A Prospective, Randomized, Open-Label, Blinded, Endpoint Study Exploring Platelet Response to Half-Dose Prasugrel and Ticagrelor in Patients with the Acute Coronary Syndrome: HOPE-TAILOR Study. Bang, J; Jin, C; Kim, MH; Serebruany, V, )	0.56
" Simulation for dosage regimen was performed based on the final PK-PD model."	( Population pharmacokinetics and pharmacodynamics of ticagrelor and AR-C124910XX in Chinese healthy male subjects. Liu, S; Shi, X; Sun, Z; Tian, X; Xue, L; Zhang, X; Zhu, Z, 2018)	0.73
" Simulation results indicated that a lower dosage regimen of 30 mg maintenance dose (MD) could produce an anticipated anti-platelet response in comparison to the routine clinical dosage regimen (180 mg loading dose (LD), 90 mg MD)."	( Population pharmacokinetics and pharmacodynamics of ticagrelor and AR-C124910XX in Chinese healthy male subjects. Liu, S; Shi, X; Sun, Z; Tian, X; Xue, L; Zhang, X; Zhu, Z, 2018)	0.73
"Our study developed a population PK-PD model for ticagrelor and further simulation for dosage regimen was performed based on the final model."	( Population pharmacokinetics and pharmacodynamics of ticagrelor and AR-C124910XX in Chinese healthy male subjects. Liu, S; Shi, X; Sun, Z; Tian, X; Xue, L; Zhang, X; Zhu, Z, 2018)	0.99
"This was a prospective, randomized, open-label study conducted in patients on maintenance dosing (MD) of aspirin (81 mg/d) and clopidogrel (75 mg/d)."	( Pharmacodynamic Effects of Switching From Ticagrelor to Clopidogrel in Patients With Coronary Artery Disease: Results of the SWAP-4 Study. Agarwal, M; Angiolillo, DJ; Bass, TA; Been, L; Briceno, M; Franchi, F; Kureti, M; Moon, JY; Nagaraju, D; Nawaz, A; Rivas Rios, J; Rivas, A; Rollini, F; Shaikh, Z; Soffer, D; Suryadevara, S; Wali, M; Zenni, MM, 2018)	0.75
" In the PEGASUS-TIMI 54 platelet function substudy, PK and platelet function were assessed during maintenance dosing in 180 prior MI patients receiving placebo, ticagrelor 60 mg or ticagrelor 90 mg twice daily."	( Pharmacokinetic-pharmacodynamic modelling of platelet response to ticagrelor in stable coronary artery disease and prior myocardial infarction patients. Amilon, C; Angiolillo, DJ; Åstrand, M; Bonaca, MP; Gurbel, PA; Hamrén, B; Himmelmann, A; Röshammar, D; Storey, RF, 2019)	0.95
" Oral dosing with vehicle, ticagrelor (300mg/kg/d), aspirin (20mg/kg/d), their combination or prasugrel (15mg/kg/d) started 7days after infarction."	( Ticagrelor Improves Remodeling, Reduces Apoptosis, Inflammation and Fibrosis and Increases the Number of Progenitor Stem Cells After Myocardial Infarction in a Rat Model of Ischemia Reperfusion. Birnbaum, Y; Chen, H; Nylander, S; Sampaio, LC; Tran, D; Ye, Y, 2019)	2.25
" Recent studies have provided important information to guide choice and dosing of antiplatelet agents as well as the length of treatment."	( Evolving Approaches to Antithrombotics in Stroke Prevention and Treatment. Amireh, A; Javalkar, V; Kelley, RE; Kuybu, O, 2020)	0.56
" Of which, there were 2 cases which changed the dosage of clopidogrel to 75 mg BID, 14 cases who changed clopidogrel to ticagrelor."	( Effects of individualized antiplatelet therapy based on CYP2C19 genotype and platelet function on the prognosis of patients after PCI. Gao, M; Hou, YL; Jia, XM; Ma, LP; Ren, MY; Wang, JR; Zhang, M; Zhang, P; Zhang, Y, 2020)	0.77
" A decreased MACCE rate was also observed in patients administered the double dosage of clopidogrel, but the bleeding risk was increased compared with the control group."	( Efficacy and safety of ticagrelor versus clopidogrel with different dosages in acute coronary syndrome patients with high GRACE and CRUSADE scores. Lan, Y; Xiao, P; Xie, F, )	0.44
" The study was conducted to validate whether vasodilatorstimulated phosphoprotein (VASP)-guided ticagrelor dosing individual therapy may result in more effective platelet inhibition and better clinical outcomes."	( Modified ticagrelor loading doses according to the vasodilator-stimulated phosphoprotein phosphorylation index improve the clinical outcome in ST-elevation myocardial infarction patients with high on-treatment platelet reactivity. Gao, Y; Kang, S; Li, X; Liu, Y; Liu, Z; Wang, X, 2023)	1.55
" Up to 2 additional boluses of ticagrelor (every additional dosing was 90 mg) were prescribed after the first LD, and the VASP index was assessed 2 hours after each administration until a VASP index < 50% was obtained or up to 3 dosages (360 mg)."	( Modified ticagrelor loading doses according to the vasodilator-stimulated phosphoprotein phosphorylation index improve the clinical outcome in ST-elevation myocardial infarction patients with high on-treatment platelet reactivity. Gao, Y; Kang, S; Li, X; Liu, Y; Liu, Z; Wang, X, 2023)	1.61
"The incremental ticagrelor dosing strategy decreases the rate of MACE after PCI without increasing major and minor bleeding."	( Modified ticagrelor loading doses according to the vasodilator-stimulated phosphoprotein phosphorylation index improve the clinical outcome in ST-elevation myocardial infarction patients with high on-treatment platelet reactivity. Gao, Y; Kang, S; Li, X; Liu, Y; Liu, Z; Wang, X, 2023)	1.67
" To better understand this apparent paradox, we measured ARS gene expression and score in volunteers to determine aspirin dose-response and ticagrelor relationships with ARS score and separately in patients to assess whether ARS is associated with incident bleeding."	( An antiplatelet response gene expression signature is associated with bleeding. Friede, KA; Gales, J; Ginsburg, GS; Kraus, WE; Myers, RA; Ortel, TL; Shah, SH; Voora, D; Zhbannikov, I, 2023)	1.11
"A fixed dose of ticagrelor, without adjusting the dosing regimen other than covariates of FOOD/WT/SEX, could be used in patients with acute coronary syndromes, and the standard regimen could be used in Chinese patients from the perspective of exposure."	( Integrated Pharmacokinetics/Pharmacodynamics Model and Simulation of the Ticagrelor Effect on Patients with Acute Coronary Syndrome. Cui, Y; Guo, L; Guo, N; Huang, J; Huang, Y; Jiang, J; Li, J; Liu, Y; Liu, Z; Mu, G; Song, H; Wang, Z; Xiang, Q; Xie, Q; Yang, G; Yuan, D; Zhang, H; Zhou, S, 2023)	1.48
"The objective of the study was to fabricate tailored extended-release tablets of blood thinner Ticagrelor as once-daily dosing using additive manufacturing for better compliance in heart failure therapy."	( Facile fabrication of an extended-release tablet of Ticagrelor using three dimensional printing technology. Akrami, M; Asadi, M; Haririan, I; Panahi, Z; Rastpeiman, S, 2024)	1.91

Role	Description
platelet aggregation inhibitor	A drug or agent which antagonizes or impairs any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.
P2Y12 receptor antagonist	An antagonist at the P2Y12 receptor
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
triazolopyrimidines
organofluorine compound	An organofluorine compound is a compound containing at least one carbon-fluorine bond.
aryl sulfide	Any organic sulfide in which the sulfur is attached to at least one aromatic group.
secondary amino compound	A compound formally derived from ammonia by replacing two hydrogen atoms by organyl groups.
hydroxyether	Any ether carrying a hydroxy group at unspecified position.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Spike glycoprotein	Severe acute respiratory syndrome-related coronavirus	Potency	7.0795	0.0096	10.5250	35.4813	AID1479145
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
P2Y purinoceptor 13	Homo sapiens (human)	IC50 (µMol)	1.3980	1.3980	1.3980	1.3980	AID1896871
P2Y purinoceptor 12	Homo sapiens (human)	IC50 (µMol)	1.1028	0.0004	1.0489	10.0000	AID1298772; AID1462749; AID1684289; AID1850679; AID1881430
P2Y purinoceptor 12	Homo sapiens (human)	Ki	0.0080	0.0020	2.8220	9.8300	AID309606; AID703441
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
biological_process	P2Y purinoceptor 13	Homo sapiens (human)
G protein-coupled purinergic nucleotide receptor signaling pathway	P2Y purinoceptor 13	Homo sapiens (human)
cellular response to organic cyclic compound	P2Y purinoceptor 13	Homo sapiens (human)
G protein-coupled receptor signaling pathway	P2Y purinoceptor 13	Homo sapiens (human)
G protein-coupled adenosine receptor signaling pathway	P2Y purinoceptor 12	Homo sapiens (human)
monoatomic ion transport	P2Y purinoceptor 12	Homo sapiens (human)
substrate-dependent cell migration, cell extension	P2Y purinoceptor 12	Homo sapiens (human)
G protein-coupled receptor signaling pathway	P2Y purinoceptor 12	Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway	P2Y purinoceptor 12	Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathway	P2Y purinoceptor 12	Homo sapiens (human)
hemostasis	P2Y purinoceptor 12	Homo sapiens (human)
calcium-mediated signaling	P2Y purinoceptor 12	Homo sapiens (human)
cerebral cortex radial glia-guided migration	P2Y purinoceptor 12	Homo sapiens (human)
cell projection organization	P2Y purinoceptor 12	Homo sapiens (human)
lamellipodium assembly	P2Y purinoceptor 12	Homo sapiens (human)
platelet activation	P2Y purinoceptor 12	Homo sapiens (human)
positive regulation of integrin activation by cell surface receptor linked signal transduction	P2Y purinoceptor 12	Homo sapiens (human)
positive regulation of cell adhesion mediated by integrin	P2Y purinoceptor 12	Homo sapiens (human)
G protein-coupled purinergic nucleotide receptor signaling pathway	P2Y purinoceptor 12	Homo sapiens (human)
positive regulation of monoatomic ion transport	P2Y purinoceptor 12	Homo sapiens (human)
response to axon injury	P2Y purinoceptor 12	Homo sapiens (human)
regulation of chemotaxis	P2Y purinoceptor 12	Homo sapiens (human)
positive regulation of chemotaxis	P2Y purinoceptor 12	Homo sapiens (human)
establishment of localization in cell	P2Y purinoceptor 12	Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	P2Y purinoceptor 12	Homo sapiens (human)
platelet aggregation	P2Y purinoceptor 12	Homo sapiens (human)
cellular response to ATP	P2Y purinoceptor 12	Homo sapiens (human)
visual system development	P2Y purinoceptor 12	Homo sapiens (human)
positive regulation of ruffle assembly	P2Y purinoceptor 12	Homo sapiens (human)
regulation of microglial cell migration	P2Y purinoceptor 12	Homo sapiens (human)
positive regulation of microglial cell migration	P2Y purinoceptor 12	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
protein binding	P2Y purinoceptor 13	Homo sapiens (human)
G protein-coupled purinergic nucleotide receptor activity	P2Y purinoceptor 13	Homo sapiens (human)
G protein-coupled adenosine receptor activity	P2Y purinoceptor 12	Homo sapiens (human)
G protein-coupled ADP receptor activity	P2Y purinoceptor 12	Homo sapiens (human)
guanyl-nucleotide exchange factor activity	P2Y purinoceptor 12	Homo sapiens (human)
G protein-coupled purinergic nucleotide receptor activity	P2Y purinoceptor 12	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
virion membrane	Spike glycoprotein	Severe acute respiratory syndrome-related coronavirus
endoplasmic reticulum	P2Y purinoceptor 13	Homo sapiens (human)
plasma membrane	P2Y purinoceptor 13	Homo sapiens (human)
plasma membrane	P2Y purinoceptor 12	Homo sapiens (human)
cell surface	P2Y purinoceptor 12	Homo sapiens (human)
membrane	P2Y purinoceptor 12	Homo sapiens (human)
cell projection membrane	P2Y purinoceptor 12	Homo sapiens (human)
cell body membrane	P2Y purinoceptor 12	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Assay ID	Title	Year	Journal	Article
AID1347159	Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347160	Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508591	NCATS Rat Liver Microsome Stability Profiling	2020	Scientific reports, 11-26, Volume: 10, Issue:1	Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1645848	NCATS Kinetic Aqueous Solubility Profiling	2019	Bioorganic & medicinal chemistry, 07-15, Volume: 27, Issue:14	Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.
AID1508612	NCATS Parallel Artificial Membrane Permeability Assay (PAMPA) Profiling	2017	Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3	Highly predictive and interpretable models for PAMPA permeability.
AID1881417	Antiplatelet activity against ADP-induced human platelet in platelet rich plasma assessed as inhibition of platelet aggregation preincubated for 2 mins followed by ADP stimulation and measured for 5 mins by aggregometry	2021	RSC medicinal chemistry, Aug-18, Volume: 12, Issue:8	Synthesis and biological evaluation of
AID1061841	Antagonist activity at P2Y12 receptor in human platelet-rich plasma assessed as inhibition of ADP-induced platelet aggregation incubated for 5 mins prior to ADP-challenge by light transmission-based assay	2014	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1	Synthesis and biological evaluation of cyclopentyl-triazolol-pyrimidine (CPTP) based P2Y12 antagonists.
AID309606	Displacement of [125I] labeled ligand from human P2Y12 receptor in human platelets	2007	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 17, Issue:21	From ATP to AZD6140: the discovery of an orally active reversible P2Y12 receptor antagonist for the prevention of thrombosis.
AID1881421	Toxicity in mouse assessed as bleeding time at 5 mg/kg, po administered via gavage measured after 1 hr by bleeding tail test (Rvb = 5.2 mins)	2021	RSC medicinal chemistry, Aug-18, Volume: 12, Issue:8	Synthesis and biological evaluation of
AID1061817	Inhibition of ADP-induced platelet aggregation in Sprague-Dawley rat assessed as blood loss volume at 2.5 mg/kg, po administered 2 hrs prior to transection measured for 30 mins (Rvb = < 0.5 ml)	2014	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1	Synthesis and biological evaluation of cyclopentyl-triazolol-pyrimidine (CPTP) based P2Y12 antagonists.
AID1684332	Toxicity in Sprague-Dawley rat model of tail-snip bleeding assessed as bleeding time at 10 mg/kg, po administered via gavage as single dose measured within 2 hrs post tail snip (Rvb = 17.69 min)	2020	Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24	Switching a Xanthine Oxidase Inhibitor to a Dual-Target Antagonist of P2Y
AID1186077	Permeability across human Caco2 cells	2014	Journal of medicinal chemistry, Sep-11, Volume: 57, Issue:17	N-[6-(4-butanoyl-5-methyl-1H-pyrazol-1-yl)pyridazin-3-yl]-5-chloro-1-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]-1H-indole-3-carboxamide (SAR216471), a novel intravenous and oral, reversible, and directly acting P2Y12 antagonist.
AID1061829	AUC in dog at 1 mg/kg, po	2014	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1	Synthesis and biological evaluation of cyclopentyl-triazolol-pyrimidine (CPTP) based P2Y12 antagonists.
AID1881430	Inhibition of P2Y12 receptor in human platelet assessed as reduction in ADP-induced VASP phosphorylation by flow cytometry	2021	RSC medicinal chemistry, Aug-18, Volume: 12, Issue:8	Synthesis and biological evaluation of
AID1061840	Antagonist activity at P2Y12 receptor in rat platelet-rich plasma assessed as inhibition of ADP-induced platelet aggregation incubated for 5 mins prior to ADP-challenge by light transmission-based assay	2014	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1	Synthesis and biological evaluation of cyclopentyl-triazolol-pyrimidine (CPTP) based P2Y12 antagonists.
AID766347	In vivo antithrombotic activity in Beagle dog modified Folts model assessed as increase in blood flow administered as bolus infusion measured after 30 mins	2013	Journal of medicinal chemistry, Sep-12, Volume: 56, Issue:17	Lead optimization of ethyl 6-aminonicotinate acyl sulfonamides as antagonists of the P2Y12 receptor. separation of the antithrombotic effect and bleeding for candidate drug AZD1283.
AID1061837	Apparent volume of distribution during terminal phase in rat at 10 mg/kg, po	2014	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1	Synthesis and biological evaluation of cyclopentyl-triazolol-pyrimidine (CPTP) based P2Y12 antagonists.
AID1737158	Inhibition of collagen-induced platelet aggregation in human platelet preincubated for 5 mins followed by collagen-stimulation and measured after 6 mins by lumi-aggregometric method
AID703442	Inhibition of ADP-stimulated platelet aggregation in human platelet rich plasma by 96-well format based turbidimetric method	2012	Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20	Identification of high-affinity P2Y₁₂ antagonists based on a phenylpyrazole glutamic acid piperazine backbone.
AID1737160	Selectivity index, ratio of IC50 for inhibition of TRAP6-induced platelet aggregation in human platelet to IC50 for inhibition of collagen-induced platelet aggregation in human platelet
AID1061831	Half life in dog at 1 mg/kg, po	2014	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1	Synthesis and biological evaluation of cyclopentyl-triazolol-pyrimidine (CPTP) based P2Y12 antagonists.
AID1737159	Inhibition of TRAP6-induced platelet aggregation in human platelet preincubated for 5 mins followed by TRAP6-stimulation and measured after 6 mins by lumi-aggregometric method
AID1684289	Antagonist activity at P2Y12 in human whole blood assessed as suppression of ADP-induced decrease in PGE1-induced VASP phosphorylation measured after 10 mins by immunostaining based flow cytometric analysis	2020	Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24	Switching a Xanthine Oxidase Inhibitor to a Dual-Target Antagonist of P2Y
AID1881422	Toxicity in mouse assessed as blood loss at 5 mg/kg, po administered via gavage measured after 1 hr by bleeding tail test (Rvb = 34.92 uL)	2021	RSC medicinal chemistry, Aug-18, Volume: 12, Issue:8	Synthesis and biological evaluation of
AID1061832	Apparent volume of distribution during terminal phase in dog at 1 mg/kg, po	2014	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1	Synthesis and biological evaluation of cyclopentyl-triazolol-pyrimidine (CPTP) based P2Y12 antagonists.
AID1061830	Cmax in dog at 1 mg/kg, po	2014	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1	Synthesis and biological evaluation of cyclopentyl-triazolol-pyrimidine (CPTP) based P2Y12 antagonists.
AID1684329	Antithrombotic activity in FeCl3-induced Sprague-Dawley rat model of arterial thrombosis assessed as reduction in thrombus weight at 10 mg/kg, po qd administered as single dose for 7 days and measured 2 hrs post last dose	2020	Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24	Switching a Xanthine Oxidase Inhibitor to a Dual-Target Antagonist of P2Y
AID309614	Volume of distribution at steady state in dog at 1 mg/kg, iv	2007	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 17, Issue:21	From ATP to AZD6140: the discovery of an orally active reversible P2Y12 receptor antagonist for the prevention of thrombosis.
AID1186087	Ex vivo inhibition of platelet aggregation in po dosed Sprague-Dawley rat after 2 hrs	2014	Journal of medicinal chemistry, Sep-11, Volume: 57, Issue:17	N-[6-(4-butanoyl-5-methyl-1H-pyrazol-1-yl)pyridazin-3-yl]-5-chloro-1-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]-1H-indole-3-carboxamide (SAR216471), a novel intravenous and oral, reversible, and directly acting P2Y12 antagonist.
AID1684333	Toxicity in Sprague-Dawley rat model of tail snip bleeding assessed as bleeding weight at 10 mg/kg, po administered via gavage as single dose measured within 2 hrs post tail snip(Rvb = 0.08 g)	2020	Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24	Switching a Xanthine Oxidase Inhibitor to a Dual-Target Antagonist of P2Y
AID1881416	Antiplatelet activity against ADP-induced human platelet in platelet rich plasma assessed as inhibition of platelet aggregation at 3 uM preincubated for 2 mins followed by ADP stimulation and measured for 5 mins by aggregometry relative to control	2021	RSC medicinal chemistry, Aug-18, Volume: 12, Issue:8	Synthesis and biological evaluation of
AID1881415	Antiplatelet activity against ADP-induced human platelet in platelet rich plasma assessed as inhibition of platelet aggregation at 10 uM preincubated for 2 mins followed by ADP stimulation and measured for 5 mins by aggregometry relative to control	2021	RSC medicinal chemistry, Aug-18, Volume: 12, Issue:8	Synthesis and biological evaluation of
AID309615	Half life in dog at 1 mg/kg, iv	2007	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 17, Issue:21	From ATP to AZD6140: the discovery of an orally active reversible P2Y12 receptor antagonist for the prevention of thrombosis.
AID1462749	Inhibition of P2Y12 in human platelet rich plasma assessed as reduction in ADP-induced platelet aggregation pre-incubated before ADP addition and measured after 10 mins by Bruker spectrophotometry	2017	Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20	Facile alkylation of 4-nitrobenzotriazole and its platelet aggregation inhibitory activity.
AID309612	Metabolic stability in human hepatocytes in presence of NADPH relative to dextromethorphan	2007	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 17, Issue:21	From ATP to AZD6140: the discovery of an orally active reversible P2Y12 receptor antagonist for the prevention of thrombosis.
AID309609	Half life in rat at 3 mg/kg, iv	2007	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 17, Issue:21	From ATP to AZD6140: the discovery of an orally active reversible P2Y12 receptor antagonist for the prevention of thrombosis.
AID1298772	Antagonist activity at P2Y12 receptor (unknown origin)	2016	Bioorganic & medicinal chemistry letters, 06-15, Volume: 26, Issue:12	State of affairs: Design and structure-activity relationships of reversible P2Y12 receptor antagonists.
AID1684336	Agonist activity at P2Y12 in human whole blood assessed as decrease in PGE1-induced VASP phosphorylation at 4 to 10 uM measured after 10 mins in absence of ADP by immunostaining based flow cytometric analysis	2020	Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24	Switching a Xanthine Oxidase Inhibitor to a Dual-Target Antagonist of P2Y
AID1061838	Apparent oral clearance in rat at 10 mg/kg	2014	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1	Synthesis and biological evaluation of cyclopentyl-triazolol-pyrimidine (CPTP) based P2Y12 antagonists.
AID1743130	Antibacterial activity against methicillin-resistant Staphylococcus aureus BAA-1556 by broth microdilution method	2020	European journal of medicinal chemistry, Dec-15, Volume: 208	Synthesis of ticagrelor analogues belonging to 1,2,3-triazolo[4,5-d]pyrimidines and study of their antiplatelet and antibacterial activity.
AID1881420	Antiplatelet activity against ADP-induced platelet aggregation in mouse assessed as inhibition of platelet aggregation at 5 mg/kg, po measured after 1 hr by turbidimetric method relative to control	2021	RSC medicinal chemistry, Aug-18, Volume: 12, Issue:8	Synthesis and biological evaluation of
AID1061822	Inhibition of ADP-induced platelet aggregation in Sprague-Dawley rat assessed as bleeding time at 2.5 mg/kg, po after 2 hrs (Rvb = 9.4 mins)	2014	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1	Synthesis and biological evaluation of cyclopentyl-triazolol-pyrimidine (CPTP) based P2Y12 antagonists.
AID1684291	Inhibition of bovine xanthine oxidase assessed as reduction in uric acid formation at 10 uM using xanthine as substrate preincubated for 15 mins followed by substrate addition measured at 30 sec interval for upto 2 mins by spectrophotometric analysis rela	2020	Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24	Switching a Xanthine Oxidase Inhibitor to a Dual-Target Antagonist of P2Y
AID1896871	Antagonist activity at human P2Y13R expressed in HEK293 cells assessed as inhibition of 2MeSADP-induced cAMP production preincubated for 0.5 hrs followed by 2MeSADP stimulation by cAMP-glo assay	2022	Journal of medicinal chemistry, 12-08, Volume: 65, Issue:23	Discovery of a Series of 5-Amide-1
AID1222793	Dissociation constant, pKa of the compound	2013	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5	Which metabolites circulate?
AID309611	Metabolic stability in human hepatocytes in presence of UDPGA relative to zileuton	2007	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 17, Issue:21	From ATP to AZD6140: the discovery of an orally active reversible P2Y12 receptor antagonist for the prevention of thrombosis.
AID1881419	Antiplatelet activity against ADP-induced platelet aggregation in mouse assessed as inhibition of platelet aggregation at 2.5 mg/kg, iv measured after 1 hr by turbidimetric method relative to control	2021	RSC medicinal chemistry, Aug-18, Volume: 12, Issue:8	Synthesis and biological evaluation of
AID1186076	Antagonist activity at P2Y12 receptor in Sprague-Dawley rat platelet rich plasma assessed as inhibition of ADP-induced aggregation	2014	Journal of medicinal chemistry, Sep-11, Volume: 57, Issue:17	N-[6-(4-butanoyl-5-methyl-1H-pyrazol-1-yl)pyridazin-3-yl]-5-chloro-1-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]-1H-indole-3-carboxamide (SAR216471), a novel intravenous and oral, reversible, and directly acting P2Y12 antagonist.
AID1462750	Binding affinity to P2Y12 in human platelets assessed as blocking of ADP-induced inhibition of PGE1-stimulated VASP phosphorylation by measuring remaining VASP phosphorylation level at 200 uM by CY-QUANT VASP/P2Y12 ELISA method	2017	Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20	Facile alkylation of 4-nitrobenzotriazole and its platelet aggregation inhibitory activity.
AID309610	Oral bioavailability in rat at 3 to 10 mg/kg	2007	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 17, Issue:21	From ATP to AZD6140: the discovery of an orally active reversible P2Y12 receptor antagonist for the prevention of thrombosis.
AID1061835	Cmax in rat at 10 mg/kg, po	2014	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1	Synthesis and biological evaluation of cyclopentyl-triazolol-pyrimidine (CPTP) based P2Y12 antagonists.
AID766345	Therapeutic index, ratio of ED50 for antithrombotic activity in Beagle dog modified Folts model to dose required to increase in bleeding time by 3.5 fold in Beagle dog modified Folts model	2013	Journal of medicinal chemistry, Sep-12, Volume: 56, Issue:17	Lead optimization of ethyl 6-aminonicotinate acyl sulfonamides as antagonists of the P2Y12 receptor. separation of the antithrombotic effect and bleeding for candidate drug AZD1283.
AID309607	Plasma clearance in rat at 3 mg/kg, iv	2007	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 17, Issue:21	From ATP to AZD6140: the discovery of an orally active reversible P2Y12 receptor antagonist for the prevention of thrombosis.
AID703441	Displacement of [33P]2-MeS-ADP from human recombinant P2Y12 receptor expressed in CHO cell membranes by scintillation counting method	2012	Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20	Identification of high-affinity P2Y₁₂ antagonists based on a phenylpyrazole glutamic acid piperazine backbone.
AID1186078	Metabolic stability in human liver microsomes assessed as compound metabolism after 20 mins incubation in presence of 1 mM NADPH	2014	Journal of medicinal chemistry, Sep-11, Volume: 57, Issue:17	N-[6-(4-butanoyl-5-methyl-1H-pyrazol-1-yl)pyridazin-3-yl]-5-chloro-1-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]-1H-indole-3-carboxamide (SAR216471), a novel intravenous and oral, reversible, and directly acting P2Y12 antagonist.
AID1743129	Antiplatelet activity in human platelet-rich plasma assessed as inhibition of ADP-induced platelet aggregation at 1.8 uM preincubated for 10 mins followed by ADP addition and measured for 10 mins by light transmission aggregometry relative to control	2020	European journal of medicinal chemistry, Dec-15, Volume: 208	Synthesis of ticagrelor analogues belonging to 1,2,3-triazolo[4,5-d]pyrimidines and study of their antiplatelet and antibacterial activity.
AID1684287	Antiplatelet activity in rabbit platelet-rich plasma assessed as inhibition of ADP-induced platelet aggregation preincubated for 5 mins followed by ADP addition measured every 1 min for up to 6 mins by microplate reader analysis	2020	Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24	Switching a Xanthine Oxidase Inhibitor to a Dual-Target Antagonist of P2Y
AID1850679	Inhibition of P2Y12 (unknown origin)	2022	Bioorganic & medicinal chemistry letters, 09-01, Volume: 71	Strategies for targeting the P2Y
AID309616	Oral bioavailability in dog at 1 mg/kg	2007	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 17, Issue:21	From ATP to AZD6140: the discovery of an orally active reversible P2Y12 receptor antagonist for the prevention of thrombosis.
AID1061834	AUC in rat at 10 mg/kg, po	2014	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1	Synthesis and biological evaluation of cyclopentyl-triazolol-pyrimidine (CPTP) based P2Y12 antagonists.
AID309613	Plasma clearance in dog at 1 mg/kg, iv	2007	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 17, Issue:21	From ATP to AZD6140: the discovery of an orally active reversible P2Y12 receptor antagonist for the prevention of thrombosis.
AID661901	Antiplatelet activity in Sprague-Dawley rat assessed as ex-vivo inhibition of ADP-induced platelet aggregation at 5 mg/kg, po at 0.5 hrs by Born's method relative to vehicle-treated control	2012	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 22, Issue:11	Synthesis and biological evaluation of ticagrelor derivatives as novel antiplatelet agents.
AID1061836	Half life in rat at 10 mg/kg, po	2014	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1	Synthesis and biological evaluation of cyclopentyl-triazolol-pyrimidine (CPTP) based P2Y12 antagonists.
AID1061825	Inhibition of ADP-induced platelet aggregation in Sprague-Dawley rat plasma at 2.5 mg/kg, po treated 2.5 hrs prior to ADP-challenge measured after 2 mins by light transmission-based assay	2014	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1	Synthesis and biological evaluation of cyclopentyl-triazolol-pyrimidine (CPTP) based P2Y12 antagonists.
AID309608	Volume of distribution at steady state in rat at 3 mg/kg, iv	2007	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 17, Issue:21	From ATP to AZD6140: the discovery of an orally active reversible P2Y12 receptor antagonist for the prevention of thrombosis.
AID1061833	Apparent oral clearance in dog at 1 mg/kg	2014	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1	Synthesis and biological evaluation of cyclopentyl-triazolol-pyrimidine (CPTP) based P2Y12 antagonists.
AID1346320	Human P2Y12 receptor (P2Y receptors)	2014	Journal of thrombosis and haemostasis : JTH, Nov, Volume: 12, Issue:11	Competitive mode and site of interaction of ticagrelor at the human platelet P2Y12 -receptor.
AID1345166	Human Equilibrative nucleoside transporter 1 (SLC29 family)	2014	Journal of cardiovascular pharmacology and therapeutics, Mar, Volume: 19, Issue:2	Characterization of the adenosine pharmacology of ticagrelor reveals therapeutically relevant inhibition of equilibrative nucleoside transporter 1.
AID1346320	Human P2Y12 receptor (P2Y receptors)	2012	Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20	Identification of high-affinity P2Y₁₂ antagonists based on a phenylpyrazole glutamic acid piperazine backbone.
AID1346320	Human P2Y12 receptor (P2Y receptors)	2007	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 17, Issue:21	From ATP to AZD6140: the discovery of an orally active reversible P2Y12 receptor antagonist for the prevention of thrombosis.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	49 (2.08)	29.6817
2010's	1420 (60.22)	24.3611
2020's	889 (37.70)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	594 (24.49%)	5.53%
Reviews	440 (18.14%)	6.00%
Case Studies	122 (5.03%)	4.05%
Observational	126 (5.20%)	0.25%
Other	1,143 (47.13%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (400)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Mechanistic Study in Patients With Non-Dialysis Chronic Kidney Disease to Investigate Altered Platelet Response to Antiplatelet Therapy (CKD-Platelet Study) [NCT03649711]	Phase 3	76 participants (Actual)	Interventional	2018-11-01	Completed
A 30 Day International, Randomized, Parallel-group, Double-blind, Placebo-controlled Phase IV Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for PCI. [NCT01347580]	Phase 4	1,875 participants (Actual)	Interventional	2011-09-30	Completed
Efficacy and Safety of Sequential Monotherapy of Ticagrelor and Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention With Acute Coronary Syndrome [NCT04937699]	Phase 4	2,690 participants (Anticipated)	Interventional	2023-03-28	Recruiting
A Phase 2B, Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy of Bentracimab (PB2452) in Reversing Ticagrelor in Subjects Aged 50 to 80 Years Old [NCT04122170]	Phase 2	205 participants (Actual)	Interventional	2019-09-24	Completed
A Phase I, Single Centre, Open Study to Assess the Pharmacokinetics of Oral AZD6140 After Single Dose in Healthy Japanese Male Volunteers [NCT01588626]	Phase 1	12 participants (Actual)	Interventional	2012-05-31	Completed
Can Very Low Dose Rivaroxaban in Addition to Dual Antiplatelet Therapy (DAPT) Improve Thrombotic Status in Acute Coronray Syndrome (ACS) ACS [NCT03775746]	Phase 4	150 participants (Anticipated)	Interventional	2019-01-08	Recruiting
A Randomised, Double-Blind, Parallel-Group, Multicentre, Phase III Study to Evaluate the Effect of Ticagrelor Versus Placebo in Reducing the Rate of Vaso-Occlusive Crises in Paediatric Patients With Sickle Cell Disease (HESTIA3) [NCT03615924]	Phase 3	193 participants (Actual)	Interventional	2018-09-26	Terminated(stopped due to Recommendation from an independent data monitoring committee (DMC) and accepted by AstraZeneca.)
A Phase 2A, Randomized, Double-blind, Placebo-controlled, Single Dose, Sequential Group Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PB2452 With Ticagrelor Pretreatment in Older and Elderly Subjects and With High-D [NCT03928353]	Phase 2	23 participants (Actual)	Interventional	2019-04-16	Completed
A Randomized, Single Center Trial to Assess the Endothelial Function With Ticagrelor Monotherapy Compared to Aspirin Monotherapy in Patients With History of Acute Coronary Syndrome [NCT03881943]	Phase 4	200 participants (Actual)	Interventional	2017-01-31	Completed
Comparison of TIcagrelor and Clopidogrel in Patients With Coronary Artery diseaSe and Type 2 Diabetes Mellitus (TICS-DM): a Randomized Pharmacodynamic Study [NCT02457130]	Phase 4	30 participants (Anticipated)	Interventional	2015-04-30	Recruiting
A Sequential, Open Label Study to Compare the Pharmacokinetics, Safety and Tolerability of Ticagrelor and Venlafaxine Given Concomitantly in Healthy Subjects Aged 18 to 45 Years [NCT01350921]	Phase 1	22 participants (Actual)	Interventional	2011-05-31	Completed
Reducing Micro Vascular Dysfunction In Revascularized ST-elevation Myocardial Infarction Patients by Off-target Properties of Ticagrelor [NCT02422888]	Phase 4	110 participants (Actual)	Interventional	2015-05-31	Active, not recruiting
Ticagrelor in Comparison to Prasugrel for Inhibition of Platelet Reactivity, in Patients With Acute Coronary Syndrome (ACS) Presenting Resistance to the Usual Clopidogrel Dose After PCI [NCT01360437]	Phase 3	44 participants (Actual)	Interventional	2011-05-31	Completed
Impact of Genetic Variation in CES1 on Antiplatelet Therapy [NCT03161678]	Phase 4	89 participants (Actual)	Interventional	2017-08-22	Completed
Registry of Patients Admitted by Acute Coronary Syndrome to University Hospital of Vigo [NCT03664388]		8,000 participants (Anticipated)	Observational	2016-02-01	Recruiting
Comparison of the Effects of Ticagrelor Versus Clopidogrel on Endothelial Dysfunction and Vascular Inflammation in Patients With Prior Non-ST-segment Acute Coronary Syndrome [NCT02379676]	Phase 4	38 participants (Anticipated)	Interventional	2015-01-31	Recruiting
Pharmacodynamic Comparison of Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-function Genotype: a Validation Study in Patients With Stable Coronary Artery Disease [NCT03489863]	Phase 4	14 participants (Actual)	Interventional	2018-05-30	Completed
The Optimal Strategy of Switching From Clopidogrel to Ticagrelor in Patients With Complexity of Coronary Artery Disease [NCT03577652]		108 participants (Actual)	Interventional	2017-07-10	Completed
Switching From Ticagrelor to Prasugrel in Patients With Acute Coronary Syndrome-a Stepped Wedge Cluster Randomized Evaluation in the SWEDEHEART-registry [NCT05183178]	Phase 4	16,000 participants (Anticipated)	Interventional	2022-02-01	Recruiting
[NCT02037412]	Phase 4	148 participants (Actual)	Interventional	2014-01-31	Terminated(stopped due to The patient registration was not successful.)
Effects of TIcaGREloR on Circulating Microparticles and Micro-RNAs in Patients With Non ST Elevation Acute Coronary Syndromes [NCT02071966]	Phase 4	55 participants (Anticipated)	Interventional	2012-11-30	Terminated(stopped due to slow enrollment)
The Effect of Ticagrelor and Apixaban With or Without Acetylsalicylic Acid on Markers of Coagulation Activation at the Site of Thrombus Formation in Vivo in Healthy Male Subjects and in an ex Vivo Perfusion Chamber Model at High and Low Shear Rate [NCT02080858]	Phase 1	40 participants (Actual)	Interventional	2014-05-31	Completed
The Effect of Clopidogrel and Ticagrelor With and Without Acetylsalicylic Acid (ASA) on Hemostatic System Activation at the Site of Plug Formation in Vivo in Man [NCT02120092]	Phase 2	89 participants (Actual)	Interventional	2010-10-31	Completed
Tailored Versus Coventional AntiPlaTelet Strategy Intended After OPTIMIZEd Drug [NCT05418556]	Phase 4	3,944 participants (Anticipated)	Interventional	2022-10-21	Recruiting
Study of Clopidogrel and Ticagrelor Anti-Platelet Treatment Using an Individualized Strategy Based on Genotyping in Chinese ACS Patients [NCT02048228]	Phase 2/Phase 3	200 participants (Anticipated)	Interventional	2014-10-31	Not yet recruiting
Optimal Dose of Ticagrelor（90 mg qd）and Double Standard-dose Clopidogrel on Platelet Aggregation in Clopidogrel Resistance's Patients With Coronary Heart Disease [NCT03614832]	Phase 4	100 participants (Anticipated)	Interventional	2018-05-01	Recruiting
The Early De-escalation Strategy With Ticagrelor 60 mg or 45 mg on Platelet Reactivity and Clinical Outcomes in Korean Patients With Acute Myocardial Infarction [NCT05210595]	Phase 4	120 participants (Anticipated)	Interventional	2022-01-01	Recruiting
[NCT02032290]	Phase 4	88 participants (Anticipated)	Interventional	2014-02-28	Not yet recruiting
The Impact of Aspirin Dose Modification on the Innate Immune Response - Will Lower Dose Aspirin Therapy Reduce the Response to Endotoxin [NCT03869268]	Phase 4	72 participants (Actual)	Interventional	2019-04-24	Completed
Ticagrelor and Aspirin for the Prevention of Cardiovascular Events After Coronary Artery Bypass Surgery (CABG) [NCT01373411]	Phase 4	70 participants (Actual)	Interventional	2011-09-30	Completed
a Single Centre Open Pilot Study to Explore if the Efficacy of PLAtelet Aggregation Inhibition by Ticagrelor Mediated P2Y12 Blockade Dependent Upon Endogenous Endothelial Nitric OXide? [NCT02169596]	Phase 4	74 participants (Actual)	Interventional	2015-06-30	Completed
Ticagrelol Versus Aspirin in Ischemic Stroke [NCT03884530]	Phase 3	169 participants (Actual)	Interventional	2019-05-01	Completed
Clopidogrel With Aspirin in High-risk Patients With Acute Non-disabling Cerebrovascular Events II [NCT04078737]	Phase 3	6,412 participants (Actual)	Interventional	2019-09-23	Completed
An Open-label Study Evaluating the Acute Efficacy of Treatment With Ticagrelor Versus Clopidogrel on Myocardial Tissue-level Perfusion Assessed by TMPFC and MRI in Patients With High-risk NSTE-ACS Undergoing Early PCI（EARLY-MYO II） [NCT02201667]	Phase 4	444 participants (Anticipated)	Interventional	2014-08-31	Not yet recruiting
Peripheral Endothelial Function Assessment of Patients on Ticagrelor vs. Clopidogrel Who Have Undergone Percutaneous Coronary Intervention - a Randomised, Crossover Study. [NCT02469740]	Phase 4	61 participants (Actual)	Interventional	2015-07-31	Completed
Prospective, Randomized Trial of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome - Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment (ISAR-REACT) 5 [NCT01944800]	Phase 4	4,018 participants (Actual)	Interventional	2013-09-15	Completed
The Effects of Crushed Ticagrelor Versus Eptifibatide Bolus +Clopidogrel in Troponin-Negative ACS Patients Undergoing Coronary Intervention [NCT02925923]	Phase 2	100 participants (Actual)	Interventional	2016-11-01	Completed
A comParison on Platelet Resistance With Ticagrelor or Standard-Dose Clopidogrel Study Among SeVerE Chronic Kidney Disease/ End-Stage-Renal-Disease Patients With Recent Acute Coronary Syndrome. [NCT02459288]	Phase 4	80 participants (Anticipated)	Interventional	2014-01-31	Recruiting
"High on Treatment Platelet Reactivity in the Intensive Care Unit" [NCT02285751]	Phase 2	200 participants (Anticipated)	Interventional	2012-11-30	Recruiting
Impact of Renal Function on Ticagrelor-Induced Antiplatelet Effects in Coronary Artery Disease Patients [NCT02323971]		80 participants (Anticipated)	Observational	2014-12-31	Recruiting
A Single Centre, Cross-over, Single Dose, Two Period, Randomized, Open Label Bioequivalence Study of Anplag® 90mg (Ticagrelor) Tablet With Brilinta® 90 mg (Ticagrelor) Tablet in Healthy Adult Male Pakistani Subjects Under Fasting Condition [NCT04941196]	Phase 1	30 participants (Actual)	Interventional	2020-10-16	Completed
[NCT02032303]	Phase 4	88 participants (Anticipated)	Interventional	2014-02-28	Not yet recruiting
Evaluation of the Safety and Efficacy of an Edoxaban-based Compared to a Vitamin K Antagonist-based Antithrombotic Regimen in Subjects With Atrial Fibrillation Following Successful Percutaneous Coronary Intervention (PCI) With Stent Placement. [NCT02866175]	Phase 3	1,506 participants (Actual)	Interventional	2017-02-24	Completed
[NCT02817789]	Phase 3	50 participants (Actual)	Interventional	2016-05-09	Completed
Study of Two Regimens of TicagrElor Compared to Clopidogrel in Patients Undergoing ELective Percutaneous Coronary Intervention [NCT02327624]	Phase 4	180 participants (Actual)	Interventional	2015-06-30	Completed
Effects of P2Y12 Receptor Inhibitors on Central and Peripheral Chemoreceptors' Sensitivity [NCT05080478]		50 participants (Anticipated)	Observational	2018-11-01	Recruiting
A Single Center Phase II Assessor-Blinded RaNdomised Active Controlled Parallel-Group Trial to COmpare Ticagrelor Versus Clopidogrel on the REduction of ArteriaL STiffness and Wave Reflections in Patients With CoronarY Artery Disease. [NCT02071212]	Phase 2	120 participants (Actual)	Interventional	2014-02-28	Completed
Comparison of Ticagrelor and Clopidogrel on Reperfusion in Patients With AMI Undergoing PPCI Evaluated by SPECT [NCT02233790]	Phase 4	600 participants (Anticipated)	Interventional	2014-12-31	Not yet recruiting
The Laboratory AntiPlatelet Efficacy and Clinical Outcome Registry [NCT02264912]		2,016 participants (Actual)	Observational [Patient Registry]	2008-07-31	Completed
Real-TICA Real Life Long-term Adherence to Ticagrelor After PCI for Acute Coronary Syndromes. Evaluation of Antiplatelet Therapy After 12 Months in Patients Undergoing PCI and Treated With Ticagrelor During the Acute Phase of an ACS. [NCT02265068]		700 participants (Actual)	Observational	2014-08-31	Completed
Ticagrelor Plus Aspirin vs Clopidogrel Plus Aspirin in Mild Non-cardioembolic Ischemic Stroke: A Randomized, Active Comparator Arm, Outcome Assessor Blind, Controlled, Feasibility Study [NCT04738097]	Phase 3	90 participants (Actual)	Interventional	2021-08-08	Completed
Dual Antithrombotic Therapy With Dabigatran and Ticagrelor in Patients With Acute Coronary Syndrome and Non-valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention (ADONIS-PCI) [NCT04695106]	Phase 4	2,230 participants (Anticipated)	Interventional	2021-10-25	Recruiting
Differential Effect of Ticagrelor vs Prasugrel or Clopidogrel Loading on Fractional Flow Reserve [NCT02108808]	Phase 4	76 participants (Actual)	Interventional	2014-04-30	Completed
Randomized Evaluation of Short-term DUal Anti Platelet Therapy in Patients With Acute Coronary Syndrome Treated With the COMBO Dual-therapy stEnt [NCT02118870]	Phase 4	1,500 participants (Actual)	Interventional	2014-06-10	Completed
Comparison of The Influence of Ticagrelor And Clopidogrel on Inflammatory Biomarkers And Vascular Endothelial Function For Patients With ST-Segment Elevation Myocardial Infarction Receiving Emergency Percutaneous Coronary Intervention [NCT02123004]	Phase 4	350 participants (Anticipated)	Interventional	2014-04-30	Not yet recruiting
A Randomized, Open-Label, Parallel, Multi-Center, Phase IV Study to Assess the Effect of Ticagrelor vs Clopidogrel on Adenosine-Induced Myocardial Blood Flow in Peripheral Artery Disease (PAD)Patients [NCT02121288]	Phase 4	0 participants (Actual)	Interventional	2014-12-31	Withdrawn
PANDDA Study: Pharmacokinetics of Antiplatelet Drugs in Diabetic pAtients [NCT02302508]	Phase 4	0 participants (Actual)	Interventional	2019-09-01	Withdrawn(stopped due to Funding)
Tailoring P2Y12 Inhibiting Therapy in Patients Requiring Oral Anticoagulation After Undergoing Percutaneous Coronary Intervention:The Switching Anti-Platelet and Anti-Coagulant Therapy (SWAP-AC) - 2 Study [NCT04483583]	Phase 4	80 participants (Anticipated)	Interventional	2020-12-08	Recruiting
Combined Effect of Diabetes and cyp2c19 Polymorphism on Clopidogrel VS Ticagrelor Antiplatelet Activity in Patients of Anterior ST Elevation Myocardial Infarction Undergoing Primary PCI [NCT03613857]		1,022 participants (Actual)	Observational [Patient Registry]	2017-04-15	Completed
Platelet Reactivity in Patients With End Stage Renal Disease Receiving Clopidogrel Compared With Ticagrelor [NCT02163954]	Phase 3	16 participants (Actual)	Interventional	2013-01-31	Completed
Anti-platelet Therapy in the Primary Prevention of Cardiovascular Disease in Patients With Chronic Obstructive Pulmonary Disease [NCT03487406]	Phase 2	120 participants (Actual)	Interventional	2015-09-30	Completed
A Randomized Non-inferiority Study of Low-dose and Standard-dose Ticagrelor After Intervention for Acute Coronary Syndrome [NCT04255602]	Phase 4	2,120 participants (Anticipated)	Interventional	2020-02-19	Recruiting
A Randomized, Open-label, Single Dose, Crossover Study to Evaluate Pharmacokinetic Profiles and Safety/Tolerability of CKD-357 in Healthy Volunteers [NCT03671941]	Phase 1	31 participants (Actual)	Interventional	2018-05-25	Completed
Stent-Assisted Coiling Followed by Ticagrelor Monotherapy Instead of Dual Antiplatelet Therapy in Endovascular Treatment of Unruptured Intracranial Aneurysm (SAC-TIDE) ---a Pilot Study [NCT06015477]		180 participants (Anticipated)	Interventional	2023-09-01	Not yet recruiting
A Randomized, Open Label, Pilot Study to Assess the Pharmacodynamics Using Vefiynow and VASP Assay; and Pharmacokinetics of Ticagrelor vs Clopidogrel in Patients Undergoing PCI With History of Fibrinolysis in 24-48 Hours [NCT02048085]	Phase 4	0 participants (Actual)	Interventional	2014-01-02	Withdrawn(stopped due to unable to get study up and enrolling)
CYP2C19 Genotype-GUided Dual Antiplatelet theRapy in pAtieNts Treated With New Generation Drug Eluting stEnts (the GUARANTEE Study) [NCT03783351]		4,009 participants (Anticipated)	Interventional	2019-05-27	Recruiting
ST-segment Elevation Myocardial infArction Treated With a Polymer-free Sirolimus-based nanocarrieR Eluting Stent and a P2Y12 Inhibitor-based Aspirin-free Single Antiplatelet Strategy Versus Conventional Dual AntiPlatelet Therapy [NCT05785897]		350 participants (Anticipated)	Interventional	2024-06-01	Not yet recruiting
A Prospective Randomized Double Blind Study to Evaluate the Effect of Ticagrelor on Endothelial Function [NCT02261922]	Phase 4	20 participants (Anticipated)	Interventional	2014-10-31	Recruiting
A Randomized, Open-label, Parallel Group, Multicenter Phase IV Study to Assess Safety and Efficacy of Ticagrelor Versus Clopidogrel in Asian/KOREAn Patients With Acute Coronary Syndromes Intended for Invasive Management:TICAKOREA Trial [NCT02094963]	Phase 4	800 participants (Actual)	Interventional	2014-07-05	Completed
Assessment of Loading With the P2Y12 Inhibitor Ticagrelor or Clopidogrel to Halt Ischemic Events in Patients Undergoing Elective Coronary Stenting: The ALPHEUS Study [NCT02617290]	Phase 3	1,900 participants (Actual)	Interventional	2017-01-09	Completed
Comparison of 1-month Versus 12-month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents Guided by Either Intravascular Ultrasound or Angiography in Patients With Acute Coronary Syndrome: The Prospective, Multicenter, Randomized, Placebo- [NCT03971500]		3,710 participants (Actual)	Interventional	2019-08-20	Active, not recruiting
A Randomized, Double-blind, Placebo Controlled, Crossover, Single Centre Phase I Study to Assess the Effect of Ticagrelor on Adenosine-induced Coronary Blood Flow Velocity in Healthy Male Subjects [NCT01226602]	Phase 1	39 participants (Actual)	Interventional	2010-12-31	Completed
Assessment of Platelet REACtivity After Transcatheter Aortic Valve Implantation [NCT02224066]	Phase 4	65 participants (Actual)	Interventional	2016-01-31	Completed
Comparison of Analgesia With Fentanyl and Morphine on Platelet Inhibition After Pre-hospital Ticagrelor Administration in Patients With ST-segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention [NCT02531165]		38 participants (Actual)	Interventional	2015-09-30	Completed
High PlatElet Inhibition With TicAgrelor to Improve Left Ventricular RemodeLING in Patients With ST-segment ElevAtion Myocardial Infarction: the HEALING-AMI Trial. [NCT02224534]	Phase 4	326 participants (Anticipated)	Interventional	2014-10-31	Recruiting
Study on the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SHR2285 Tablets Combined With Aspirin, Clopidogrel or Ticagrelor in Healthy Subjects [NCT04945616]	Phase 1	52 participants (Actual)	Interventional	2021-07-13	Completed
Effect of Ticagrelor on Adenosine-Induced Coronary Flow Reserve in Patients With Microvascular Angina [NCT02284048]	Phase 4	140 participants (Anticipated)	Interventional	2014-11-30	Not yet recruiting
Ticagrelor and Clopidogrel on Platelet Effects in Chinese Patients With Stable Coronary Artery Disease: a Randomized, Single-blind, Crossover Clinical Study [NCT04001894]	Phase 4	50 participants (Actual)	Interventional	2019-07-02	Completed
Ticagrelor Versus Clopidogrel in Ischemic Stroke. a Randomized Double-blinded Controlled Trial [NCT05553613]	Phase 3	900 participants (Actual)	Interventional	2022-10-01	Completed
Phase III, Randomized, International, Multicenter, Open Label, With Blinded Adjudication of Outcomes, Non-Inferiority Clinical Trial to Explore the Safety and Efficacy of Ticagrelor Compared With Clopidogrel in Patients With Acute Coronary Syndrome With S [NCT02298088]	Phase 3	3,799 participants (Actual)	Interventional	2015-08-31	Completed
Ticagrelor or Prasugrel Versus Clopidogrel in Elderly Patients With an Acute Coronary Syndrome and a High Bleeding Risk: Optimization of Antiplatelet Treatment in High-risk Elderly [NCT02317198]	Phase 4	1,011 participants (Actual)	Interventional	2013-06-30	Active, not recruiting
High On-treatment Platelet Reactivity to Adenosine Diphosphate Identified by Multiple Platelet Function Assay Guide to Modify Anti-platelet Strategy in Patients Undergoing Percutaneous Coronary Intervention [NCT02699008]		477 participants (Actual)	Interventional	2014-01-31	Completed
A Randomised, Double-Blind, Placebo-Controlled, International, Multicentre, Phase III Study to Investigate the Efficacy and Safety of Ticagrelor and ASA Compared With ASA in the Prevention of Stroke and Death in Patients With Acute Ischaemic Stroke or Tra [NCT03354429]	Phase 3	11,016 participants (Actual)	Interventional	2018-01-22	Completed
Hunting for the Off-Target Properties of Ticagrelor on Endothelial Function and Other Circulating Biomarkers in Humans [NCT02587260]	Phase 4	54 participants (Actual)	Interventional	2015-12-17	Completed
Incidence and Models of Ticagrelor Discontinuation in Patients With Acute Coronary Syndrome [NCT03129867]		480 participants (Actual)	Observational	2017-01-01	Completed
Low Dose EPInephrine to Improve Platelet Reactivity in TICagrelor-treated Subjects: A Proof of Concept Study in Healthy Volunteers (EPITIC) [NCT03441412]	Phase 1	10 participants (Actual)	Interventional	2018-02-28	Completed
A Prospective, Randomised, Open-labeled, Parallel Group Study to Assess the Efficacy and Safety of Low Dose Ticagrelor Compared With Standard Dose Ticagrelor in Patients With Unstable Angina Pectoris After Drug Eluting Stent Implantation [NCT03620760]	Phase 4	2,036 participants (Anticipated)	Interventional	2018-08-07	Recruiting
Dual Antiplatelet Therapy in Patients With Clopidogrel Resistance Following Off-Pump Coronary Artery Bypass: Prospective, Randomized Controlled Trial [NCT05166538]	Phase 4	204 participants (Anticipated)	Interventional	2022-02-01	Not yet recruiting
Impact of Chronic Kidney Disease on the Pharmacodynamic and Pharmacokinetic Effects of Ticagrelor in Patients With Diabetes Mellitus and Coronary Artery Disease [NCT02539160]	Phase 4	101 participants (Actual)	Interventional	2016-02-29	Completed
A Randomized, Pharmacodynamic Comparison of Low Dose Ticagrelor (60mg Bid) to Low Dose Prasugrel (5mg od) in Patients With Prior Myocardial Infarction [NCT03387826]	Phase 4	20 participants (Actual)	Interventional	2018-01-11	Completed
Comparison Between Ticagrelor and Clopidogrel Effect on Endothelial, Platelet and Inflammation Parameters in Patients With Stable Coronary Artery Disease and Chronic Obstructive Pulmonary Disease Undergoing PCI [NCT02519608]	Phase 2	44 participants (Actual)	Interventional	2015-09-30	Completed
TicagRelor Or Clopidogrel in Severe and Terminal Chronic Kidney Disease Patients Undergoing PERcutaneous Coronary Intervention for an Acute Coronary Syndrome. [NCT03357874]	Phase 3	514 participants (Anticipated)	Interventional	2018-10-28	Recruiting
Comparison of Clopidogrel and Ticagrelor on Microvascular Dysfunction in Acute Coronary Syndrome Patients: The Index of MIcrocirculatory Resistance After PCI in STEMI Patients (TIME Study) [NCT02026219]	Phase 4	76 participants (Actual)	Interventional	2013-10-31	Completed
Effects of Different Doses of Ticagrelor and Standard-dose Clopidogrel on Platelet Aggregation and Endothelial Function in Diabetic Patients With Stable Coronary Artery Disease [NCT02889549]	Phase 2/Phase 3	60 participants (Anticipated)	Interventional	2016-08-31	Recruiting
Multivariate Analysis of Platelet Reactivity Variety in Patients With Coronary Heart Disease After PCI [NCT02888652]		1,500 participants (Actual)	Observational [Patient Registry]	2015-09-30	Completed
COmparison of the Pharmacodynamics and Pharmacokinetics of Ticagrelor Versus Clopidogrel in Patients With Chronic Kidney Disease and Non-ST-Elevation Acute Coronary Syndromes(OPT-CKD Trial) [NCT02578537]	Phase 4	60 participants (Anticipated)	Interventional	2015-10-31	Recruiting
KF2019#1-tutkimus: Verihiutaleiden estäjän Vaikutus kolesterolilääkkeeseen [NCT05373277]	Phase 1	10 participants (Anticipated)	Interventional	2022-05-11	Recruiting
Ticagrelor Versus Clopidogrel for Platelet Inhibition in Patients Undergoing Neurovascular Stenting for Intracranial Aneurysm [NCT02675205]	Phase 3	100 participants (Actual)	Interventional	2015-12-31	Completed
Safety and Effectiveness of Ticagrelor in Patients Undergoing Carotid Stenting [NCT04091074]	Phase 1	26 participants (Anticipated)	Interventional	2022-01-01	Not yet recruiting
A Prospective Randomized Controlled Clinical Trial of Comparing ticagreLor Versus clopidogrEl on mIcrocirculation in Patients With Acute cOronary Syndrome Study [NCT02618733]		120 participants (Actual)	Interventional	2014-12-31	Completed
A Randomised, Double-Blind, Outpatient, Crossover Study of the Anti-platelet Effects of Ticagrelor Compared With Clopidogrel in Patients With Stable Coronary Artery Disease Previously Identified as Clopidogrel Non-responders or Responders [RESPOND] [NCT00642811]	Phase 2	98 participants (Actual)	Interventional	2008-05-31	Completed
An Open-label, Randomised, 3-period, 3-treatment, Crossover, Single-centre, Single-dose, Bioavailability Study With Alternative Methods of Administration of Crushed Ticagrelor Tablets, 90 mg, Compared to Whole Ticagrelor Tablets, 90 mg, in Healthy Volunte [NCT01887626]	Phase 1	36 participants (Actual)	Interventional	2013-07-31	Completed
Ticagrelor Versus Clopidogrel for Coronary Microvascular Dysfunction in Patients With Acute Myocardial Infarction: A Retrospective Study Based on the Angiography-derived Index of Microcirculatory Resistance [NCT05978726]		325 participants (Actual)	Observational	2017-07-01	Completed
Chinese People's Liberation Army General Hospital [NCT02798874]		240 participants (Anticipated)	Interventional	2016-05-31	Enrolling by invitation
Ticagrelor Versus Clopidogrel in Myocardial Salvage in Patients With ST-elevation Myocardial Infarction (STEMI) Undergoing Primary Percutaneous Coronary Intervention: A Magnetic Resonance Imaging Study (TIGER Study) [NCT02792712]	Phase 4	200 participants (Anticipated)	Interventional	2016-01-31	Recruiting
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PB2452 (Bentracimab) With and Without Ticagrelor Pretreatment in Chinese Healthy Volunteer [NCT05162131]	Phase 1	40 participants (Anticipated)	Interventional	2021-12-25	Recruiting
A Randomized, Open-label Study to Compare the Platelet Inhibition With VerifyNow Assay of Ticagrelor Versus Clopidogrel in Troponin Negative Acute Coronary Syndrome Subjects Undergoing Ad Hoc Percutaneous Coronary Intervention [NCT01603082]	Phase 4	343 participants (Actual)	Interventional	2012-07-31	Completed
TIcagrelor in Rotational Atherectomy to Reduce TROPonin Enhancement: the TIRATROP Study, a Randomized Controlled Trial [NCT02505399]	Phase 4	180 participants (Actual)	Interventional	2015-11-30	Completed
Single Antiplatelet Treatment With Ticagrelor or Aspirin After Transcatheter Aortic Valve Implantation: Multicenter Randomized Clinical Trial [NCT05283356]	Phase 4	1,206 participants (Anticipated)	Interventional	2022-01-21	Recruiting
Aspirin Plus Ticagrelor for 1 Month Followed by 5 Months Ticagrelor Monotherapy Versus Aspirin Plus Ticagrelor for 12 Months in Acute Coronary Syndrome Patients With Drug-coated Balloon: a Multicentre, Randomized, Non-inferiority Trial [NCT04971356]		1,948 participants (Actual)	Interventional	2021-11-01	Active, not recruiting
Pharmacodynamic Effect of Loading And Maintenance Doses Of Clopidogrel Versus Half Doses of Ticagrelor In Healthy Subjects [NCT02086903]	Phase 3	12 participants (Actual)	Interventional	2014-02-28	Completed
Dual Antiplatelet Therapy to Inhibit Coronary Atherosclerosis and Myocardial Injury in Patients With Necrotic High-Risk Coronary Plaque Disease [NCT02110303]	Phase 2/Phase 3	220 participants (Actual)	Interventional	2015-03-31	Completed
Half-dose Ticagrelor Overcomes High-dose Clopidogrel in Acute Coronary Syndrome Patients With High On-Clopidogrel Platelet Reactivity [NCT03062462]	Phase 2/Phase 3	80 participants (Anticipated)	Interventional	2017-02-10	Recruiting
Does Ticagrelor Inhibit Growth of Small Abdominal Aortic Aneurysms? A Randomised Controlled Trial (TicAAA) [NCT02070653]	Phase 2	145 participants (Actual)	Interventional	2014-03-31	Completed
A Randomised, Open-label, Parallel Group, Multi-center Study Using OCT to Comparing the Efficacy and Safety of Ticagrelor With Clopidogrel in the Prevention of Subclinical Thrombus in Patients After Drug-eluting Stent Implantation [NCT02140801]	Phase 4	352 participants (Actual)	Interventional	2014-05-01	Completed
A Multicenter Trial to Assess the MIcrovascular Integrity and Left Ventricular Function Recovery After Clopidogrel or TicagrelOr Administration, in Patients With STEMI Treated With Thrombolysis - The 'MIRTOS' Study [NCT02429271]	Phase 3	336 participants (Actual)	Interventional	2015-08-31	Completed
Safety and Efficacy of Ticagrelor Single Antiplatelet Therapy in Patients With High Risk of Bleeding After Drug-coated Balloons for Coronary Small Vessel Disease: A Prospective, Randomized, Open-label, Blinded-endpoint Evaluation, Single-center Study [NCT06088433]	Phase 4	292 participants (Anticipated)	Interventional	2023-11-15	Not yet recruiting
A Randomized Controlled Trial of Patients Undergoing Percutaneous Coronary Intervention Who Receive Ticagrelor and Fentanyl [NCT03476369]	Phase 4	80 participants (Anticipated)	Interventional	2018-04-18	Recruiting
Study to Investigate the Effects of AZD6140 in Patients With Renal Impairment and in Healthy Volunteers [NCT00733265]	Phase 1	24 participants (Anticipated)	Interventional	2007-02-28	Completed
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia [NCT02735707]	Phase 3	10,000 participants (Anticipated)	Interventional	2016-04-11	Recruiting
A Randomized, Open-label, Active-controlled, Parallel-group Study to Investigate the Platelet Inhibition of Ticagrelor Versus Clopidogrel in Patients With Stable Coronary Artery Disease and Type 2 Diabetes Mellitus After Recent Elective Percutaneous Coron [NCT02748330]	Phase 4	40 participants (Actual)	Interventional	2016-06-30	Completed
Post-operative Treatment of Diabetic Peripheral Arterial Disease Guided by Platelet Reactivity Unit [NCT02762864]		200 participants (Anticipated)	Interventional	2016-05-31	Enrolling by invitation
Comparison of Prasugrel and Ticagrelor in the Treatment of Acute Myocardial Infarction [NCT02808767]	Phase 4	1,226 participants (Actual)	Interventional	2013-01-31	Completed
30-d Rand, Eval-blind, Controlled, Multi-centre, Parallel, ph III Study to Evaluate Effect of a Low Maint Dose Ticagrelor Regimen vs Standard Dose Clopidogrel on Coronary Flow Reserve in DM Patients With Impaired Microvascular Function Without Prior MI or [NCT04069234]	Phase 3	0 participants (Actual)	Interventional	2019-09-15	Withdrawn(stopped due to Sponsor decided to stop the study due to commercial reasons.)
Safety and Efficacy of Century Clot-Guided Prophylactic Rivaroxaban Therapy for Post ST-Segment Elevation Myocardial Infarction Complicating Left Ventricular Thrombus Compared With Conventional Antiplatelet Therapy [NCT06013020]	Phase 4	374 participants (Anticipated)	Interventional	2023-08-28	Recruiting
Differential EFfects of Dual antIplatelet and Dual aNtithrombotic thErapy on Hemostasis in Chronic Coronary Syndrome Patients: Define CCS Study, a Prospective Randomized Crossover Clinical Trial. [NCT05116995]	Phase 4	30 participants (Anticipated)	Interventional	2021-11-01	Recruiting
DEVELOPMENT OF PROGNOSTIC PLATELET RNA BIOMARKERS TO TAILOR ANTIPLATELET THERAPY [NCT05278637]	Early Phase 1	135 participants (Actual)	Interventional	2013-11-01	Completed
Prasugrel Or Ticagrelor In ST-Elevation Myocardial Infarction Patients With Diabetes Mellitus [NCT01531114]	Phase 3	50 participants (Actual)	Interventional	2013-05-31	Completed
The Effect of Ticagrelor on 15-Epi-Lipoxin A4 and Inflammation [NCT02626169]	Phase 4	0 participants (Actual)	Interventional	2015-12-31	Withdrawn(stopped due to Pharmaceutical company sponsor withdrew support prior to enrollment of subjects.)
The Effect of Ticagrelor on the Inflammatory Response to Human Endotoxemia [NCT02612480]		40 participants (Actual)	Interventional	2015-10-31	Completed
Pharmacokinetic/Pharmacodynamic Effects of add-on Antiplatelet Therapy With Parenteral Cangrelor as Compared to Standard Dual Antiplatelet Treatment in Patients With ST-elevation Myocardial Infarction Complicated by Out-of-hospital Cardiac Arrest and Trea [NCT03273075]	Phase 4	60 participants (Anticipated)	Interventional	2017-09-30	Recruiting
Prevention of Cerebral Ischaemia in Stent Treatment for Carotid Artery Stenosis - A Randomised Multi-centre Phase II Trial Comparing Ticagrelor Versus Clopidogrel With Outcome Assessment on MRI (PRECISE-MRI) [NCT02677545]	Phase 2	210 participants (Actual)	Interventional	2016-12-31	Completed
A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multinational Trial, to Assess the Prevention of Thrombotic Events With Ticagrelor Compared to Placebo on a Background of Acetyl Salicylic Acid (ASA) Therapy in Patients With History of Myoca [NCT01225562]	Phase 3	21,379 participants (Actual)	Interventional	2010-10-31	Completed
A Randomized, Pharmacodynamic Comparison of Low Dose Ticagrelor to Clopidogrel in Patients With Prior Myocardial Infarction [NCT02663713]	Phase 4	20 participants (Actual)	Interventional	2017-01-31	Completed
Ticagrelor in Remote Ischemic Preconditioning Study [NCT04174261]	Phase 4	245 participants (Actual)	Interventional	2017-01-29	Completed
Rapid P2Y12 Receptor Inhibition Attenuates Inflammatory Cell Infiltration in Thrombus Aspirated From the Infarct-related Artery in STEMI Patients: A Prospective Randomized Trial of Ticagrelor Versus Clopidogrel [NCT02639143]	Phase 4	50 participants (Actual)	Interventional	2015-12-31	Completed
A Randomized Controlled sTudy of Low Dose vs Standard Dose of tIcaGrelor on Platelet Function After intErvention for Acute Coronary syndRome in Diabetes Mellitus Patients [NCT04307511]	Phase 4	40 participants (Anticipated)	Interventional	2020-04-20	Recruiting
SMart Angioplasty Research Team: Comparison Between P2Y12 Inhibitor MonotHerapy and Dual Antiplatelet Therapy in Patients UndergOing Implantation of Coronary BiorEsorbable Scaffold II: (SMART-CHOICE II) Trial [NCT03119012]	Phase 4	1,520 participants (Anticipated)	Interventional	2017-04-19	Suspended(stopped due to cannot use bioabsorbable scaffold)
Safety and Efficacy of Ticagrelor With Low-dose Aspirin Versus Regular Aspirin in Patients With Acute Coronary Syndrome at High-risk for Ischemia After Percutaneous Coronary Intervention: A Prospective, Randomized, Open-label, Blinded-endpoint Evaluation, [NCT04240834]	Phase 3	1,220 participants (Anticipated)	Interventional	2020-02-29	Not yet recruiting
LOwer Maintenance Dose TICagrelor in Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention [NCT04060914]	Phase 4	225 participants (Anticipated)	Interventional	2019-08-30	Not yet recruiting
A Randomized Controlled Trial on the Switch From Ticagrelor to Clopidogrel in Acute Coronary Syndrome Patients After Percutaneous Coronary Intervention--OPTImal Management of Antithrombotic Agents: OPTIMA-5 [NCT04116931]	Phase 4	80 participants (Anticipated)	Interventional	2020-06-22	Recruiting
A Randomized, Open-label, Pharmacodynamic and Pharmacokinetic Trial Assessing the Effect of Lowering Ticagrelor Maintenance Dose Early After Myocardial Infarction on Platelet Inhibition (ELECTRA Pilot Study). [NCT03251859]	Phase 3	52 participants (Actual)	Interventional	2017-08-11	Completed
Paclitaxel-Coated Balloon Versus Zotarolimus-Eluting Stent for Treatment of De Novo Coronary Artery Lesions: an Open-label, Multicenter, Randomized, Non-inferiority Trial [NCT05209412]		370 participants (Anticipated)	Interventional	2022-02-01	Recruiting
Single-center, Prospective, Controlled Study of the Safety and Efficacy of Aspirin and Clopidogrel in Ischemic Cardiovascular and Cerebrovascular Patients Complications With CAA [NCT04654026]		43 participants (Anticipated)	Observational	2021-02-20	Not yet recruiting
One Month Dual Antiplatelet Therapy With Ticagrelor in Coronary Artery Bypass Graft Patients [NCT05997693]	Phase 3	700 participants (Anticipated)	Interventional	2024-01-31	Not yet recruiting
The Effect of an Acute Dose of Ticagrelor or Clopidogrel and of Treatment for 14 Days on Ischemia-reperfusion Induced Endothelial Dysfunction of the Forearm Vasculature in Healthy Male Subjects. [NCT02580149]	Phase 4	24 participants (Actual)	Interventional	2015-10-31	Completed
A Multi-centre Randomised, Double-blind, Double-dummy Parallel Group Study of the Onset and Offset of Antiplatelet Effects of Ticagrelor Compared With Clopidogrel and Placebo With Aspirin as Background Therapy in Patients With Stable Coronary Artery Disea [NCT00528411]	Phase 2	123 participants (Actual)	Interventional	2007-10-31	Completed
A Randomised, Double-blind, Two-way Crossover Study to Determine the Effects of Co-administration of AZD6140 and Nordette® (Combination of Levonorgestrel and Ethinyl Estradiol) After Multiple Oral Doses in Healthy Female Volunteers [NCT00685906]	Phase 1	24 participants (Anticipated)	Interventional	2008-04-30	Completed
Efficacy and Safety of Early Versus Late Loading Dose of Ticagrelol in Patients With ST Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention [NCT04267224]		800 participants (Anticipated)	Observational	2020-03-01	Not yet recruiting
Personalization of Long-Term Antiplatelet Therapy Using a Novel Combined Demographic/Pharmacogenomic Strategy - The RAPID EXTEND Randomized Study [NCT03729401]	Phase 4	390 participants (Anticipated)	Interventional	2019-08-22	Suspended(stopped due to Testing supplies unavailable.)
Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis - Coronary Intervention With Next Generation Drug-Eluting Stent Platforms and Abbreviated Dual Antiplatelet Therapy (HOST-IDEA) Trial [NCT02601157]	Phase 4	2,173 participants (Actual)	Interventional	2016-01-18	Completed
The Success of Opening Single CTO Lesions to Improve Myocardial Viability Study (SOS-comedy) [NCT02767401]	Phase 4	200 participants (Actual)	Interventional	2015-09-15	Completed
Platelet Sub-study of the TWILIGHT Trial [NCT04001374]		40 participants (Actual)	Observational	2015-06-28	Completed
REACTIC-TAVI Trial: Platelet REACtivity According to TICagrelor Dose After Transcatheter AorticValve Implantation. A Pilot Study. [NCT04331145]	Phase 4	40 participants (Actual)	Interventional	2020-06-23	Completed
Comparison of Ticagrelor Pharmacokinetics and Pharmacodynamics in ST-elevation Myocardial Infarction and Non-ST-elevation Myocardial Infarction Patients [NCT02602444]		73 participants (Actual)	Observational	2015-10-31	Completed
Optical Coherence Tomography-Guided PCI With Single-Antiplatelet Therapy [NCT04766437]	Phase 2	75 participants (Actual)	Interventional	2021-02-19	Completed
Effect of Pretreatment With Ticagrelor on Residual Thrombus After Percutaneous Coronary Intervention (PCI) in Patients Presenting With Acute Coronary Syndrome in Comparison With Delayed Treatment at the Time of PCI: an Optical Coherence Tomography Study [NCT01916902]	Phase 4	0 participants (Actual)	Interventional	2014-02-28	Withdrawn(stopped due to Despite a large number of patients screened, very few met eligibility guidelines.)
The Safety and Efficacy of Ticagrelor for Coronary Stenting Post Thrombolysis (SETFAST) Trial. [NCT01930591]	Phase 3	140 participants (Actual)	Interventional	2014-05-31	Completed
Plaque Erosion: A New in Vivo Diagnosis and Paradigm Shift in the Treatment of Patients With Acute Coronary Syndrome [NCT02041650]	Phase 4	250 participants (Anticipated)	Interventional	2014-08-31	Completed
Reassessment of Anti-Platelet Therapy Using InDividualized Strategies - Modifying Acute CoroNary Syndrome Algorithms Based on Genetic and Demographic Evaluation: The RAPID-MANAGE Study [NCT02044146]	Phase 2/Phase 3	120 participants (Actual)	Interventional	2014-09-30	Completed
OraL Crushed and dIspersed Ticagrelor 180mg Compared to Whole Tablets of eQUal Dose in STEMI Patients unDergoing Primary PCI: a Pharmacokinetic/Pharmacodynamic Study [NCT02046486]	Phase 4	20 participants (Anticipated)	Interventional	2014-01-31	Completed
An Open-label, Randomized, Prospective Study Exploring Half Dose of Prasugrel and Ticagrelor in Platelet Response After Acute Coronary Syndromes [NCT02944123]	Phase 3	120 participants (Actual)	Interventional	2016-09-30	Completed
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Effect of Atorvastatin Treatment for 14 Days in Combination With an Acute Dose of Ticagrelor on Ischemia Reperfusion Induced Endothelial Dysfunction of the Forearm Vasculat [NCT02910778]	Phase 4	32 participants (Actual)	Interventional	2016-10-31	Completed
A Randomised, Double-blind, Parallel Group, Phase 3, Efficacy and Safety Study of Ticagrelor Compared With Clopidogrel for Prevention of Vascular Events in Patients With Non-ST or ST Elevation Acute Coronary Syndromes (ACS) [PLATO- a Study of PLATelet Inh [NCT00391872]	Phase 3	18,624 participants (Actual)	Interventional	2006-10-31	Completed
A Single Dose, Open-label, One Sequence, 2-period, Crossover Study to Characterize the Pharmacokinetics and Pharmacodynamics of Ticagrelor and Prasugrel in Healthy Male Adult Subjects [NCT01876797]	Phase 1	12 participants (Actual)	Interventional	2013-07-31	Completed
XANTHIPPE: Examining the Effect of Ticagrelor on Platelet Activation, Platelet-Leukocyte Aggregates, and Acute Lung Injury in Pneumonia [NCT01883869]	Phase 1	60 participants (Actual)	Interventional	2013-06-30	Completed
ComPArison of the Effect of Ticagrelor Versus Clopidogrel on Myocardial Blood Flow (MBF) and Reserve (MBFR) Measured With Positron Emission TomograpHy (PET) in Patients With Coronary Artery Disease (CAD): The PATH Study [NCT01894789]	Phase 2/Phase 3	36 participants (Actual)	Interventional	2013-03-31	Completed
Comparison of Clopidogrel Versus Ticagrelor Therapy for Atherosclerotic Plaque Inflammation: Serial FDG PET/CT Imaging Study of Carotid Artery and Ascending Aorta [NCT01905566]	Phase 4	50 participants (Actual)	Interventional	2013-09-30	Completed
A Randomized Controlled sTudy of Low Dose vs Standard tIcaGrelor on Platelet Function After intErvention for Acute Coronary syndRome in Senior Patients [NCT04307485]	Phase 4	40 participants (Anticipated)	Interventional	2020-03-10	Recruiting
3 Months Versus 12 Months Dual Antiplatelet Therapy After Second Generation Sirolimus Stent Implantation in ST-elevation Myocardial Infarction(BULK-STEMI) [NCT04570345]	Phase 4	1,002 participants (Anticipated)	Interventional	2021-01-01	Recruiting
Randomized, Placebo-controlled, Single Blind, Trial to Determine the Safety and Efficacy of Ticagrelor for Maintaining Patency of Arterio-Venous Fistulae Created for Hemodialysis [NCT02335099]	Phase 1/Phase 2	54 participants (Actual)	Interventional	2014-12-31	Completed
Pharmacodynamic Assessment of Ticagrelor vs High Dose Clopidogrel in Patients With ST Elevation Myocardial Infarction Exhibiting High Platelet Reactivity Post Fibrinolysis [NCT01950416]	Phase 4	56 participants (Actual)	Interventional	2013-03-31	Completed
Intensified Antiplatelet Therapy in Post-PCI Patients With High On-treatment Platelet Reactivity: the OPTIMA-2 Trial [NCT01955200]	Phase 4	1,724 participants (Actual)	Interventional	2013-10-05	Completed
Differential Effect of Ticagrelor Versus Prasugrel Maintenance Dose on Endothelial Function of Peripheral Vessels in Patients With Coronary Artery Disease [NCT01957540]	Phase 4	22 participants (Actual)	Interventional	2014-06-30	Completed
Platelet Reactivity After Ticagrelor Loading Dose Versus Clopidogrel Loading Dose and Reloading With Ticagrelor, in Patients With ST-elevation Myocardial Infarction (STEMI) Undergoing Primary Percutaneous Coronary Intervention (PCI). [NCT01961856]	Phase 3	74 participants (Actual)	Interventional	2013-09-30	Completed
Genotype Guided Versus Conventional Approach in Selection of Oral P2Y12 Receptor Blocker in Chinese Patients Suffering From Acute Coronary Syndrome [NCT01994941]	Phase 4	133 participants (Actual)	Interventional	2013-08-31	Completed
The Effect of Ticagrelor on the Adenosine System [NCT01996735]	Phase 4	14 participants (Actual)	Interventional	2013-04-30	Completed
[NCT02012140]	Phase 4	200 participants (Anticipated)	Interventional	2014-01-31	Not yet recruiting
A Prospective, Multicenter, Randomized, Open-label Trial to Compare Efficacy and Safety of Clopidogrel vs Ticagrelor in Stabilized Patients With Acute Myocardial Infarction After Percutaneous Coronary Intervention; TicAgrelor Versus CLOpidogrel in Stabili [NCT02018055]	Phase 4	2,590 participants (Actual)	Interventional	2014-02-14	Completed
Ticagrelor Versus Clopidogrel in Large Vessel Ischemic Stroke, a Randomized Controlled Trial [NCT06120725]	Phase 3	580 participants (Actual)	Interventional	2021-09-01	Completed
Cangrelor Versus Ticagrelor In Patients With Acute Myocardial Infarction Complicated With Initial Cardiogenic Shock [NCT03551964]	Phase 4	550 participants (Anticipated)	Interventional	2018-08-01	Recruiting
Pragmatic Randomized Controlled Trial Comparing Treatment Effectiveness of Guideline Indicated Anti-platelet Therapy for Acute Coronary Syndrome in Patients With Chronic Kidney Disease [NCT03150667]	Phase 4	220 participants (Anticipated)	Interventional	2017-04-10	Recruiting
Pharmacodynamic Evaluation of Antiplatelet Effect of Swallowing Versus Chewing Ticagrelor in Patients With Acute Coronary Syndrome [NCT04567290]	Phase 4	50 participants (Anticipated)	Interventional	2020-10-07	Recruiting
TIcaGrEloR and ABSORB Bioresorbable Vascular Scaffold Implantation for Recovery of Vascular Function After Successful Chronic Total Occlusion Recanalization [NCT02211066]	Phase 4	59 participants (Actual)	Interventional	2014-10-31	Completed
Inflammation and Thrombosis in Patients With Severe Aortic Stenosis After Transcatheter Aortic Valve Replacement (TAVR) [NCT02486367]	Phase 4	60 participants (Actual)	Interventional	2015-06-30	Completed
An Open Label, Two Arms, Randomized Controlled Pilot Study Comparing the Arachidonic Acid-induced Platelet Aggregation Rate in Patients With Stable Coronary Artery Disease Treated With Ticagrelor Monotherapy or Ticagrelor and Asprin [NCT02219412]	Phase 4	70 participants (Actual)	Interventional	2014-08-31	Completed
Τicagrelor Versus Prasugrel in Diabetic Patients: a Pharmacodynamic Study [NCT01642940]	Phase 4	30 participants (Actual)	Interventional	2012-06-30	Completed
Drug-eluting Stenting Versus Medical Treatment Alone for Patients With Extracranial Vertebral Artery Stenosis: The VISTA Trial [NCT05885932]		472 participants (Anticipated)	Interventional	2023-08-25	Recruiting
The Risk of Major Bleeding With Novel Anti-platelets: A Comparison of Ticagrelor With Clopidogrel in a Real World Population of 5000 Patients Treated for Acute Coronary Syndrome [NCT02484924]		5,225 participants (Actual)	Observational	2010-06-30	Completed
A Two-Cohort, Open-Label, Single and Multiple Dose Pharmacokinetic Study of 90 mg and 180 mg Doses of AZD6140 in Healthy Chinese Volunteers Living in China [NCT00721448]	Phase 1	24 participants (Anticipated)	Interventional	2008-06-30	Completed
A Randomised, Double-Blind, Two-Period Crossover Study to Assess the Effect of AZD6140 on Uric Acid Levels in Healthy Male Volunteers [NCT00738842]	Phase 1	24 participants (Actual)	Interventional	2008-05-31	Completed
A Study of Platelet Function Test in the Application of Prevention of Ischemic Events After Stent Placement in Intracranial Aneurysms [NCT03989557]	Phase 4	314 participants (Actual)	Interventional	2019-07-01	Completed
The Effect of Intravenous Cangrelor and Oral Ticagrelor on Platelets, the Microcirculation and Myocardial Damage in Patients Admitted With STEMI Treated by Primary Percutaneous Coronary Intervention: A Randomized Controlled Pilot Trial [NCT02733341]	Phase 4	100 participants (Actual)	Interventional	2016-07-21	Completed
A Phase 2a Single Dose Study to Evaluate the Effect of BMS-986141 Added on to Aspirin or Ticagrelor or the Combination, on Thrombus Formation in an Ex Vivo Thrombosis Chamber Model in Patients With Stable Coronary Artery Disease and Healthy Participants [NCT05093790]	Phase 2	58 participants (Actual)	Interventional	2022-03-25	Completed
A Randomised, Double-Blind, Parallel Group, Asian, Multicenter Study, to Assess Pharmacokinetic and Pharmacodynamic Profile of 2 Doses of Ticagrelor on Top of Low Dose Acetyl Salicylic Acid (ASA) Therapy on Platelet Aggregation in Japanese and Asian Patie [NCT01118325]	Phase 2	146 participants (Actual)	Interventional	2010-04-30	Completed
Chewing Versus Traditional Oral Administration of Ticagrelor in ST-elevation Myocardial Infarction Patients - A Platelet Reactivity Study [NCT02725099]	Phase 4	50 participants (Actual)	Interventional	2016-05-31	Completed
Optimizing Timing of Coronary Artery Bypass Surgery in Patients Presenting With Acute Coronary Syndrome and Treated With Second Generation ADP Receptor Antagonist [NCT02627521]	Phase 4	260 participants (Anticipated)	Interventional	2015-07-31	Recruiting
The Effects of loW Dose tIcagrelor on Platelet Function Testing in Patients With Stable Coronary arTery Disease: TWIST Trial [NCT04206176]	Phase 1/Phase 2	25 participants (Actual)	Interventional	2019-10-01	Completed
The Application of Ticagrelor Combined With Low Molecular Weight Heparin During PCI [NCT02658838]	Phase 4	300 participants (Anticipated)	Interventional	2015-04-30	Active, not recruiting
Prasugrel Or Ticagrelor De-escalation in Non-ST-elevation Acute Coronary Syndrome [NCT05779059]	Phase 3	50 participants (Anticipated)	Interventional	2023-04-01	Not yet recruiting
Impact of Morphine Treatment on Platelet Inhibition in Acute Myocardial Infarction [NCT02627950]	Phase 4	138 participants (Actual)	Interventional	2015-12-31	Completed
Evaluation of Safety and Efficacy of Two Ticagrelor-based De-escalation Antiplatelet Strategies in Acute Coronary Syndrome: the Randomized, Multicenter, Double-blind ELECTRA RCT Study [NCT04718025]	Phase 3	4,500 participants (Anticipated)	Interventional	2022-02-07	Recruiting
Influence of METHoxyflurane on ANtiplatelet Effect of Ticagrelor in Patients With Unstable Angina Pectoris - METHANE Study [NCT04442919]	Phase 4	75 participants (Anticipated)	Interventional	2020-06-01	Recruiting
Dual Antiplatelet Therapy With Ticagrelor and Acetylsalicylic Acid (ASA) vs. ASA Only After Isolated Coronary Artery Bypass Grafting in Patient With Acute Coronary Syndrome [NCT03560310]	Phase 4	2,200 participants (Anticipated)	Interventional	2018-06-29	Recruiting
Effect of Ticagrelor on Endothelial Function [NCT01805596]	Phase 3	45 participants (Anticipated)	Interventional	2013-04-30	Completed
The Impact of Administration Strategy of Ticagrelor on Its Pharmacokinetics and Pharmacodynamics in Patients With Unstable Angina Pectoris - a Randomized, Single-center, Open-label Pilot Study [NCT02612116]	Phase 4	49 participants (Actual)	Interventional	2015-09-30	Completed
Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis (CAPTIVA) [NCT05047172]	Phase 3	1,683 participants (Anticipated)	Interventional	2022-08-02	Recruiting
MULTIcentric Study About RESistance to CLOpidogrel in Dual Antiplatelet Therapy for Carotid Stenting [NCT05566301]		1,140 participants (Anticipated)	Observational	2021-09-02	Recruiting
ANTIPLATELET TREATMENT IN ACUTE CORONARY SYNDROMES. SAFETY AND EFFICACY OF ANTIPLATELET SWITCHING Safety and Efficacy of Ticagrelor vs Clopidogrel in Patients With Acute Coronary Syndrome [NCT04630288]		1,900 participants (Actual)	Observational	2019-07-02	Active, not recruiting
Evaluation the Effect of Ticagrelor and Clopidogrel in Stable Coronary Syndrome A Randomized Clinical Trial [NCT05858918]		476 participants (Actual)	Interventional	2022-10-01	Completed
Overcoming High On-Treatment Platelet Reactivity (HPR) During Prasugrel Therapy [NCT01869309]	Phase 4	400 participants (Anticipated)	Interventional	2014-01-31	Recruiting
RE-DUAL PCI Real Life Registry Dual Therapy With Dabigatran/Ticagrelor Versus Dual Therapy With Dabigatran/Clopidogrel in ACS Patients With Indication for NOAC Undergoing PCI [NCT04688723]	Phase 4	1,000 participants (Anticipated)	Interventional	2020-12-23	Recruiting
Platelet Function Evaluation in Patients With Acute Coronary Syndromes on Potent P2Y12 Inhibitor Monotherapy Versus Dual Antiplatelet Therapy With Aspirin and a Potent P2Y12 Inhibitor [NCT05767723]	Phase 4	48 participants (Anticipated)	Interventional	2023-02-06	Recruiting
Effects of Ticagrelor Versus Prasugrel on Coronary Microcirculation in Patients Undergoing Elective Percutaneous Coronary Intervention: Results of the PROtecting MICROcirculation During Coronary Angioplasty (PROMICRO)-3 Randomised Study [NCT05643586]	Phase 4	50 participants (Actual)	Interventional	2017-12-01	Completed
Ticagrelor Monotherapy After Coronary Stenting in Patients With Acute Myocardial Infarction - A Prospective Single-centre, Single-arm Phase II Study [NCT05149560]	Phase 2	200 participants (Anticipated)	Interventional	2021-12-04	Recruiting
Cangrelor Administration Following Ticagrelor Loading vs Ticagrelor Loading Alone in ST Segment Elevation Myocardial Infarction Patients: A Randomized, Pharmacodynamic Study [NCT02943369]	Phase 4	30 participants (Actual)	Interventional	2017-07-28	Completed
Differences in the Pharmacokinetic and Pharmacodynamic Profile of Ticagrelor and Its Active Metabolite AR-C124900XX Between Patients With Unstable Angina Pectoris Treated With Crushed Ticagrelor and a Combination of Morphine and Metoclopramide or Morphine [NCT02939235]	Phase 4	32 participants (Actual)	Interventional	2016-07-31	Completed
A Randomised, Double-blind, Double-dummy, Parallel Group, International (Asian), Multicenter, Phase 3 Study to Assess Safety and Efficacy of AZD6140 on Top of Low Dose Acetyl Salicylic Acid (ASA) Versus Clopidogrel on Top of Low Dose ASA in Asian/Japanese [NCT01294462]	Phase 3	801 participants (Actual)	Interventional	2011-02-28	Completed
Comparison of Circadian Variability of Platelet Inhibition in Patients With Myocardial Infarction Treated With Prasugrel and Ticagrelor [NCT03454841]		73 participants (Actual)	Observational	2018-02-26	Completed
The Effect of Early Administration of Dapagliflozin in ST Elevation Myocardial Infarction Patients Presenting With Left Ventricular Systolic Dysfunction [NCT05045274]		300 participants (Anticipated)	Interventional	2021-12-31	Not yet recruiting
The Impact of Genotype on Pharmacokinetics and Antiplatelet Effects of Ticagrelor in Healthy Chinese [NCT03092076]	Phase 1	51 participants (Actual)	Interventional	2015-05-20	Completed
[NCT03016611]	Phase 4	100 participants (Anticipated)	Interventional	2017-02-28	Not yet recruiting
Study of the Effect of Ticagrelor and Clopidogrel on the Immune Response of Healthy Volunteers [NCT01846559]	Phase 4	30 participants (Actual)	Interventional	2013-04-30	Completed
Prospective, Randomized, Open Label Trial of 6 Months vs. 12 Months Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation In ST-elevation Myocardial Infarction [NCT01459627]	Phase 4	1,100 participants (Anticipated)	Interventional	2011-12-31	Completed
Standard Versus Low Dose Maintenance Ticagrelor After Primary Percutaneous Intervention for STEMI in Diabetic Patients: a Randomized Controlled Trial [NCT05831462]	Phase 1/Phase 2	400 participants (Anticipated)	Interventional	2023-06-01	Not yet recruiting
Switching From Standard of Care Dual Antiplatelet Treatment (DAPT) Regimens With Aspirin Plus a P2Y12 Inhibitor to Dual Pathway Inhibition (DPI) With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease: The Switching Anti-P [NCT04006288]	Phase 4	90 participants (Actual)	Interventional	2019-09-06	Completed
Effect of Antiplatelet Therapies in Patients With Depression and Coronary Disease [NCT05821062]		400 participants (Anticipated)	Observational	2022-04-14	Recruiting
CLOpidogrel Versus TIcagreLor for Antiplatelet Maintenance in DIAbetic Patients Treated With Percutaneous Coronary Intervention: Results of the CLOTILDIA Study [NCT02742987]	Phase 4	42 participants (Actual)	Interventional	2014-03-31	Completed
Differences in the Pharmacokinetic and Pharmacodynamic Profile of Ticagrelor and Its Active Metabolite AR-C124900XX Between Patients With Unstable Angina Pectoris Treated With Crushed Ticagrelor and a Combination of Morphine and Naloxone or Morphine Alone [NCT02939248]	Phase 4	30 participants (Actual)	Interventional	2016-10-31	Completed
Single Versus Dual Antiplatelet Therapy in Patients With Incomplete Revascularization After Coronary Artery Bypass Graft Surgery [NCT03789916]	Phase 3	800 participants (Anticipated)	Interventional	2019-01-02	Recruiting
Ticagrelor Compared to Clopidogrel in Acute Coronary Syndromes - the TC4 Comparative Effectiveness Study [NCT04057300]	Phase 4	1,038 participants (Actual)	Interventional	2018-10-01	Completed
A Randomised, Double Blind, Parallel Group, Multicentre, Phase III Study to Evaluate the Effect of Ticagrelor Versus Placebo in Reducing the Number of Vaso-Occlusive Crises in Paediatric Patients Aged 6 Months to <18 Years With Sickle Cell Disease (HESTIA [NCT04293172]	Phase 3	0 participants (Actual)	Interventional	2020-06-30	Withdrawn(stopped due to Study halted prematurely, prior to enrolment of first patient.)
A Dose Blocked-randomized, Double-blind, Active and Placebo Controlled, Single and Multiple Dosing, Dose-escalation Clinical Trial to Investigate the Safety, Tolerability, Pharmacokinetic/Pharmacodynamic Characteristics and Food Effect [NCT01526577]	Phase 1	113 participants (Actual)	Interventional	2012-03-31	Completed
An Open Label, Single Centre, Randomised, Phase IV, Pharmacokinetic, Pharmacodynamic, and Safety Study to Evaluate Single and Multiple Doses of 45, 60, and 90 mg of Ticagrelor in Chinese Patients With Stable Coronary Heart Disease [NCT02064985]	Phase 4	61 participants (Actual)	Interventional	2014-02-28	Completed
The Safety of Ticagrelor Monotherapy After Primary Percutaneous Coronary Intervention for ST-elevation Myocardial Infarction and the Effect on Intramyocardial Haemorrhage [NCT05986968]		200 participants (Anticipated)	Interventional	2023-07-06	Recruiting
Comparison of Therapy With TICAGRELOR, Prasugrel and High Clopidogrel Dose in PCI Patients With High on Treatment Platelet Reactivity and Genotype Variation [NCT01543932]	Phase 3	81 participants (Actual)	Interventional	2012-07-31	Completed
Efficacy, Safety and Tolerability of PrasugrEl 5mg or TIcagrelor 60mg in COmplex and Higher-Risk Indicated PCI/PatieNts: The Prospective, Randomized, Open-labeled, Blinded Endpoint (PROBE), Multi-center E5TION Trial [NCT04734353]	Phase 4	492 participants (Anticipated)	Interventional	2020-01-15	Recruiting
Rapid Activity of Platelet Inhibitor Drugs Study (RAPID 2) [NCT01805570]	Phase 4	50 participants (Actual)	Interventional	2012-11-30	Completed
A Prospective, Multi-center, Optical Coherence Tomography Guided Reperfusion Strategy in Patients With STEMI (EROSION II) [NCT03062826]		347 participants (Actual)	Observational	2017-01-11	Active, not recruiting
Standard (180mg) Versus Double (360mg) Loading Dose of Ticagrelor in Patients With ST-elevation Myocardial Infarction (STEMI), Undergoing Primary Percutaneous Coronary Intervention (PCI): a Multi-center Randomized Parallel Pharmacodynamic Study. [NCT01575795]	Phase 4	83 participants (Actual)	Interventional	2012-04-30	Completed
[NCT02487732]	Phase 4	60 participants (Actual)	Interventional	2015-07-31	Completed
Platelet Aggregation and Adenosine Levels Among Patients With Stable Chronic Coronary Artery Disease Taking Ticagrelor or Prasugrel [NCT05247385]	Phase 4	87 participants (Actual)	Interventional	2017-03-20	Completed
THE CAPITAL PCI AF Study: The Safety and Efficacy of Rivaroxaban and Ticagrelor for Patients With Atrial Fibrillation After Percutaneous Coronary Intervention [NCT03331484]	Phase 3	40 participants (Actual)	Interventional	2018-11-01	Active, not recruiting
A Pharmacodynamic Study Comparing Prasugrel Versus Ticagrelor in Patients With Coronary Artery Disease Undergoing PCI With CYP2C19 Loss-of-function Genotypes: A Feasibility Study With Point-of-care Pharmacodynamic and Genetic Testing [NCT02065479]	Phase 4	65 participants (Actual)	Interventional	2014-03-31	Completed
Impact of CYP2C19 Genotype-guided Clopidogrel and Ticagrelor Treatment on Platelet Function Test and Metabolomics Profile Among Coronary Artery Disease (CAD) Patients Undergoing Percutaneous Coronary Intervention (PCI) [NCT05516784]	Phase 4	80 participants (Actual)	Interventional	2019-09-01	Completed
A Study of the Transition From Cangrelor to Ticagrelor, and Ticagrelor to Cangrelor in Patients With Coronary Artery Disease [NCT01766466]	Phase 2	12 participants (Actual)	Interventional	2013-01-31	Completed
Normalizing Platelet Reactivity After Treatment With Ticagrelor [NCT02201394]	Phase 4	20 participants (Actual)	Interventional	2014-07-31	Completed
Sampling P2Y12 Receptor Inhibition With Prasugrel and Ticagrelor in Patients Submitted to Thrombolysis After Loading Dose of Clopidogrel [NCT02215993]	Phase 4	50 participants (Actual)	Interventional	2013-07-31	Completed
Differential Effect of Ticagrelor Versus Prasugrel on the Adenosine-induced Coronary Vasodilatory Responses in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. [NCT01642966]	Phase 4	56 participants (Actual)	Interventional	2012-09-30	Completed
A Single-Center,Open-Label,Randomized,3-Treatment,3-Period Cross-Over Study to Investigate the Potential Effect of Cyclosporine on the Pharmacokinetics, Safety, and Tolerability of Ticagrelor and the Effect of Ticagrelor on the Pharmacokinetics, Safety, a [NCT01504906]	Phase 1	20 participants (Actual)	Interventional	2012-01-31	Completed
Rapid Activity of Platelet Inhibitor Drugs Study [NCT01510171]	Phase 4	50 participants (Actual)	Interventional	2012-01-31	Completed
Ticagrelor in Clopidogrel Resistant Patients Undergoing Chronic Hemodialysis [NCT01511471]	Phase 3	20 participants (Actual)	Interventional	2012-01-31	Completed
Effect of Modifying Anti-platelet Treatment to Ticagrelor in Patients With Diabetes and Low Response to Clopidogrel [NCT01643031]	Phase 4	500 participants (Anticipated)	Interventional	2012-08-31	Not yet recruiting
A Randomised Mechanistic Study Comparing the Effects of Different Anti-platelet Combinations (Ticagrelor vs. Placebo/ Clopidogrel) With Aspirin in Patients Presenting With Anterior STEMI Treated With Primary PCI [NCT03145194]	Phase 2	140 participants (Anticipated)	Interventional	2017-01-30	Recruiting
Reassessment of Anti-Platelet Therapy Using InDividualized Strategies -Ticagrelor in Patients With Acute Coronary Syndromes Treated by Coronary Artery Bypass Graft Surgery - A Pharmacodynamic and Clinical Study to Decrease Bleeding Risks and Ischemic Comp [NCT02668562]		143 participants (Actual)	Interventional	2016-02-29	Completed
Ticagrelor vs. Tirofiban, Comparison of Anti-platelet Effects in Patients With Non-ST Elevation Acute Coronary Syndrome(TE-CLOT Trial : Ticagrelor's Effect for CLOT Prevention) ; A Single Center, Open-label Randomized Controlled Study [NCT01660373]	Phase 3	100 participants (Anticipated)	Interventional	2012-08-31	Recruiting
Comparative Efficacy of Ticagrelor Versus Aspirin on Blood Viscosity in Peripheral Artery Disease (PAD) Patients With Type 2 Diabetes (T2D) [NCT02325466]	Phase 3	70 participants (Actual)	Interventional	2015-04-30	Completed
Effects of Clopidogrel vs Prasugel vs Ticagrelor on Endothelial Function, Inflammatory and Oxidative Stress Parameters and Platelet Function in Patients Undergoing Coronary Artery Stenting. A Randomised, Prospective Study. [NCT01700322]	Phase 4	126 participants (Actual)	Interventional	2012-08-31	Completed
Smart Angioplasty Research Team: Safety of 6-month Duration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndromes (SMART-DATE) [NCT01701453]		2,712 participants (Actual)	Interventional	2012-08-31	Active, not recruiting
A Single Center, Randomized, Open Label, Multiple Dose, Crossover Study of the Antiplatelet Effects of Ticagrelor Versus Clopidogrel in American Indian Patients With Stable Coronary Artery Disease [NCT01706510]	Phase 4	28 participants (Actual)	Interventional	2012-12-31	Completed
Effects of Ticagrelor and Intracoronary Morphine on Myocardial Salvage in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention [NCT01738100]	Phase 2	100 participants (Anticipated)	Interventional	2012-09-30	Recruiting
On-treatment PLAtelet Reactivity-guided Therapy Modification FOR ST-segment Elevation Myocardial Infarction (PLATFORM) [NCT01739556]	Phase 3	242 participants (Actual)	Interventional	2015-06-30	Terminated(stopped due to An interim analysis showed that there is no difference in the primary endpoint, given the small number of events in the groups examined.)
A Open Label, Randomized, Crossover and Potential Parallel, Single Dose Study of Ticagrelor 180 mg and Acetylsalicylic Acid (ASA) in Healthy Volunteers Followed by Autologous in Vivo Platelet Transfusion to Determine the Effects of Platelet Supplementatio [NCT01744288]	Phase 1	258 participants (Actual)	Interventional	2012-12-31	Completed
A Randomized, Parallel Group, Double-Blind Study of Ticagrelor Compared With Aspirin for Prevention of Vascular Events in Patients Undergoing Coronary Artery Bypass Graft Operation TiCAB- Ticagrelor in CABG [NCT01755520]	Phase 3	1,893 participants (Actual)	Interventional	2013-04-24	Terminated(stopped due to DSMB Interim Analyses)
Safety and P2Y12 Receptor Inhibition Effects of Ticagrelor and Clopidogrel in Vietnamese Patients With Coronary Heart Disease: A Randomized, Open Label, Crossover Study [NCT01757262]	Phase 3	0 participants (Actual)	Interventional	2013-01-31	Withdrawn
A REAl-life Study on Short-term Dual Antiplatelet Treatment in Patients With Ischemic Stroke or Transient Ischemic Attack [NCT05476081]		1,067 participants (Anticipated)	Observational [Patient Registry]	2021-02-03	Recruiting
A Prospective, Randomized, Controlled, Analyst-blinded, Parallel Group Study to Investigate the Effect of Antithrombotic Triple Therapy With Ticagrelor and Acetylsalicylic Acid in Combination With Dabigatran or Rivaroxaban or Phenprocoumon on Markers of C [NCT01812200]	Phase 4	60 participants (Actual)	Interventional	2012-10-31	Completed
The Effect of Ticagrelor on Acute Coronary Syndrome Patients With Clopidogrel Resistance Undergoing Percutaneous Coronary Intervention [NCT01812330]	Phase 3	180 participants (Anticipated)	Interventional	2013-01-31	Recruiting
Bedside Testing of the CYP2C19 Gene to Asses Effectiveness of Clopidogrel in Coronary Artery Disease Patients Treated With Percutaneous Coronary Intervention : Individualized Antiplatelet Drugs Treatment to Improve Prognosis [NCT01823185]	Phase 4	1,500 participants (Anticipated)	Interventional	2013-03-31	Recruiting
Comparison of Ticagrelor Versus Clopidogrel on Residual Thrombus Burden During Percutaneous Coronary Intervention: an Optical Coherence Tomography Study [NCT01826175]	Phase 4	0 participants (Actual)	Interventional	2013-05-31	Withdrawn(stopped due to Study terminated mutually by sponsor & PI due to no enrollment)
The ACS Ethnicity Platelet Function Study [NCT01829659]		4 participants (Actual)	Observational	2013-05-31	Completed
Relationship of Dose of Ticagrelor and Anti-inflammatory Effect in Patients With End Stage Renal Disease on Hemodialysis: PIANO-6 Randomized Crossover Study [NCT02406911]	Phase 3	25 participants (Anticipated)	Interventional	2015-02-28	Recruiting
Pharmacodynamic Effects of Ticagrelor and Eptifibatide Bolus-Only Versus Ticagrelor and Eptifibatide Bolus Plus Abbreviated Infusion in Patients Undergoing Percutaneous Coronary Intervention [NCT01919723]	Phase 2	70 participants (Actual)	Interventional	2014-02-28	Completed
Tailored Antiplatelet Initiation to Lesson Outcomes Due to Decreased Clopidogrel Response After Percutaneous Coronary Intervention (TAILOR-PCI) [NCT01742117]	Phase 4	5,276 participants (Actual)	Interventional	2013-05-31	Completed
Impact of Ticagrelor Re-load on Pharmacodynamic Profiles in Patients on Maintenance Ticagrelor Therapy [NCT01731041]		60 participants (Actual)	Interventional	2013-01-31	Completed
A head-to Head Comparison of the Pharmacodynamic Effects of Prasugrel Compared With Ticagrelor in Patients With Coronary Artery Disease [NCT01852175]		110 participants (Actual)	Interventional	2012-01-31	Completed
A Prospective, Randomized, Open-Label, Multicenter Study Assessing Efficacy and Safety of Ticagrelor De-escalation Strategy in East Asian Acute Myocardial Infarction With Coronary Intervention: EASTYLE Trial [NCT04755387]	Phase 4	2,000 participants (Anticipated)	Interventional	2021-02-15	Recruiting
A U.S. Post-Approval Study of the PROMUS Element™ Plus Everolimus-Eluting Platinum Chromium Coronary Stent System [NCT01589978]	Phase 4	2,681 participants (Actual)	Interventional	2012-05-31	Completed
Antiplatelet Therapy Effect on Platelet Extracellular Vesicles in Acute Myocardial Infarction [NCT02931045]	Phase 4	60 participants (Actual)	Interventional	2017-12-30	Completed
Randomized, Crossover Study of the Antithrombotic Effects of Ticagrelor Plus Aspirin Versus Clopidogrel Plus Aspirin When Administered With Bivalirudin [NCT01642238]	Phase 4	15 participants (Actual)	Interventional	2012-07-31	Completed
Pharmacodynamic Evaluation of Switching From Ticagrelor to Clopidogrel in Patients With Coronary Artery Disease [NCT02287909]	Phase 4	87 participants (Actual)	Interventional	2014-12-31	Completed
A Phase IV, Randomised, Multi-Centre, Open Label Study, Comparing Ticagrelor Versus Clopidogrel in Non-ST Elevation Acute Coronary Syndrome (NSTE-ACS) Patients Undergoing Percutaneous Coronary Intervention (PCI) With Bivalirudin [NCT02052635]	Phase 4	34 participants (Actual)	Interventional	2014-09-30	Terminated(stopped due to Patient recruitment challenges, low enrolment, and a forecasted inability to complete the study in an acceptable timeframe)
Comparative Study of the Antithrombotic Effects of Ticagrelor and Clopidogrel in Type 2 Diabetic Patients [NCT01823510]	Phase 4	20 participants (Actual)	Interventional	2013-07-31	Completed
Tailoring Bleeding Reduction Approaches in Patients Undergoing Percutaneous Coronary Interventions: Comparative Pharmacodynamic Effects of Potent P2Y12 Inhibitor Monotherapy Versus Dual Antiplatelet Therapy De-escalation [NCT05681702]	Phase 4	90 participants (Anticipated)	Interventional	2023-02-15	Recruiting
Replication of the ISAR-REACT 5 Antiplatelet Trial in Healthcare Claims Data [NCT05086081]		28,389 participants (Actual)	Observational	2020-10-10	Completed
Replication of the PLATO Antiplatelet Trial in Healthcare Claims Data [NCT04237935]		27,960 participants (Actual)	Observational	2019-09-22	Completed
Ticagrelor in Comparison to Prasugrel for Early Inhibition of Platelet Reactivity in Patients With ST-elevation Myocardial Infarction (STEMI), Undergoing Primary Percutaneous Coronary Intervention (PCI) [NCT01463163]	Phase 4	50 participants (Actual)	Interventional	2011-10-31	Completed
Platelet Inhibition With Ticagrelor 60 mg Versus Ticagrelor 90 mg Twice Daily in Elderly Patients With Acute Coronary Syndrome (ACS) [NCT04739384]	Phase 3	50 participants (Actual)	Interventional	2021-04-01	Completed
A Randomized Comparison of Platelet Inhibition Using a Low Maintenance Dose Ticagrelor Regimen Versus Standard Dose Clopidogrel in Diabetes Mellitus Patients Without Prior Major Cardiovascular Events Undergoing Elective Percutaneous Coronary Intervention: [NCT03437044]	Phase 4	40 participants (Actual)	Interventional	2018-03-14	Completed
Efficacy and Safety of Different Ticagrelor Regimens Versus Clopidogrel in Patients With Coronary Artery Disease: a Retrospective Multicenter Study (SUPERIOR) [NCT03381742]	Phase 2/Phase 3	3,043 participants (Actual)	Interventional	2017-12-13	Completed
A Multi-centre, Phase I, Open-label, Single-dose Study to Investigate Pharmacokinetics (PK) of Ticagrelor in Infants and Toddlers, Aged 0 to Less Than 24 Months, With Sickle Cell Disease (HESTIA4) [NCT03492931]	Phase 1	21 participants (Actual)	Interventional	2018-03-28	Completed
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MEDI2452 (PB2452) With and Without Ticagrelor Pretreatment in Healthy Volunteers [NCT03492385]	Phase 1	64 participants (Actual)	Interventional	2018-04-03	Completed
Prospective, Randomized Study of the Platelet Inhibitory Efficacy of Ticagrelor Versus Prasugrel in Clopidogrel Low Responders After Percutaneous Coronary Intervention [NCT01456364]	Phase 4	70 participants (Anticipated)	Interventional	2011-09-30	Recruiting
The Impact of Ticagrelor on Coronary Atherosclerotic Lipid Pool and Inflammation Assessed by Near-Infrared Spectroscopy [NCT02282332]	Phase 4	30 participants (Actual)	Interventional	2014-06-30	Completed
A Pharmacodynamic Evaluation of Switching From Ticagrelor to Prasugrel in Subjects With Stable Coronary Artery Disease: 2nd Switching Antiplatelet Agents [NCT01587651]	Phase 4	110 participants (Actual)	Interventional	2012-03-31	Completed
Comparison of Prasugrel vs. Ticagrelor on Myocardial Injury in Revascularized ST Elevation Acute Myocardial Infarction Patients [NCT03435133]		61 participants (Actual)	Interventional	2015-11-23	Completed
24-month Ticagrelor-based Dual-antiplatelet Therapy Versus Clopidogrel-based Dual-antiplatelet theRapy aftEr 12 Months of DrUg-eluting Stent Implantation in High isChEmic Risk Patients: P-REDUCE Trial [NCT04989257]		3,488 participants (Anticipated)	Interventional	2021-08-31	Not yet recruiting
A Multinational, Randomised, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Ticagrelor Twice Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Stroke in Patients With Type 2 Diabetes Mellitus (THEMIS - Effect of Ti [NCT01991795]	Phase 3	19,271 participants (Actual)	Interventional	2014-02-10	Completed
In Vitro Pharmacodynamic Effects of Cangrelor on Platelet P2Y12 Receptor Mediated Signaling in Ticagrelor Treated Patients [NCT02081443]		60 participants (Actual)	Interventional	2014-04-30	Completed
Single-center, Double-blind (ACT-246475), Open-label (Clopidogrel, Prasugrel, and Ticagrelor), Placebo-controlled, Randomized, Two-way Crossover Study to Investigate the Pharmacodynamics, Safety, and Tolerability of a Single Oral Dose of Clopidogrel or, P [NCT03430661]	Phase 1	77 participants (Actual)	Interventional	2018-01-24	Completed
A Multicenter, Single Arm, Open Label, Phase IV Study to Evaluate Safety and to Describe the Incidence of Major Cardiovascular Events of Ticagrelor in Chinese Patients With Acute Coronary Syndrome(ACS) [NCT01870921]	Phase 4	2,004 participants (Actual)	Interventional	2013-06-26	Completed
Ticagrelor Antiplatelet Therapy to Reduce Graft Events and Thrombosis (TARGET Trial): Does Ticagrelor Improve Graft Patency After Coronary Bypass? [NCT02053909]	Phase 4	250 participants (Actual)	Interventional	2014-09-30	Completed
Effect of Upstream Treatment With High Intensity Statin on the Outcomes of ST Segment Elevation Myocardial Infarction Patients Treated With Primary Percutaneous Coronary Intervention [NCT04754789]	Phase 3	160 participants (Anticipated)	Interventional	2021-02-20	Not yet recruiting
Individualizing Dual Antiplatelet Therapy After Percutaneous Coronary Intervention - The IDEAL-PCI Registry [NCT01515345]	Phase 3	1,008 participants (Actual)	Interventional	2011-07-31	Completed
Clopidogrel or Ticagrelor in Acute Coronary Syndrome Patients Treated With Newer-Generation Drug-Eluting Stents: CHANGE DAPT [NCT03197298]		2,062 participants (Actual)	Observational [Patient Registry]	2012-12-21	Completed
Testing P2Y12 Platelet Inhibitors Generics Beyond Bioequivalence: A Parallel Single-blinded Randomized Trial [NCT05474053]	Phase 3	29 participants (Actual)	Interventional	2021-11-13	Completed
Comparison of Coronary Artery Bypass Graft Surgery Related Bleeding Complications in Patients Treated With Ticagrelor or Clopidogrel [NCT04431349]		1,097 participants (Actual)	Observational	2016-01-01	Completed
Evaluation of Platelet Aggregation and Adenosine Levels in Patients With Coronary Artery Disease and Chronic Kidney Dysfunction Taking Dual Antiplatelet Therapy With Aspirin and Clopidogrel or Ticagrelor [NCT03039205]	Phase 2	90 participants (Actual)	Interventional	2017-11-07	Completed
An Open-label, Randomised, Four-period, Four-treatment, Crossover, Single-centre, Single-dose Study to Assess the Bioavailability of Ticagrelor Orodispersible Tablets, Compared to Ticagrelor Immediate-release Tablets in Healthy Subjects [NCT02400333]	Phase 1	100 participants (Actual)	Interventional	2015-06-30	Completed
Reducing Inflammation in Ischemic Stroke With Colchicine, and Ticagrelor in High-risk Patients-extended Treatment in Ischemic Stroke [NCT05476991]	Phase 3	2,800 participants (Anticipated)	Interventional	2023-05-17	Recruiting
Escalated Single Platelet Inhibition for One Month Plus Direct Oral Anticoagulation in Patients With Atrial Fibrillation and acUte coRonary Syndrome Undergoing percutaneoUS Coronary Intervention [NCT04981041]	Phase 4	2,334 participants (Anticipated)	Interventional	2021-12-16	Recruiting
[NCT02494895]	Phase 4	3,056 participants (Anticipated)	Interventional	2015-08-01	Recruiting
Chewed Versus Integral Pill of Ticagrelor in All Patients Undergoing Percutaneous Coronary intervention--a Platelet Reactivity and Patient Outcomes Study. [NCT03708588]	Phase 4	112 participants (Actual)	Interventional	2018-09-19	Completed
A Phase II Multicentre, Randomised, Double-Blind, Controlled, Parallel-Group Study to Evaluate the Walking Time Effect of Long-Term Ticagrelor in Comparison to Long-Term Aspirin Administration in Ambulatory Patients With Peripheral Artery Disease Undergoi [NCT02227368]	Phase 2	40 participants (Actual)	Interventional	2014-10-20	Terminated
Non-interventional Prospective Data Collection on Persistence and Adherence on Ticagrelor in ACS Adult Patients in Serbia [NCT03444012]		269 participants (Actual)	Observational	2018-03-05	Completed
The Use of BRILInta to Optimize ANTiplatelet Therapy (BRILIANT) Registry: The BRILIANT KOREA Registry [NCT02521038]		2,000 participants (Anticipated)	Observational [Patient Registry]	2015-07-31	Recruiting
Adjunctive Vorapaxar Therapy in Patients With Prior Myocardial Infarction Treated With New Generation P2Y12 Receptor Inhibitors Prasugrel and Ticagrelor (VORA-PRATIC): A Prospective, Randomized, Pharmacodynamic Study [NCT02545933]	Phase 4	130 participants (Actual)	Interventional	2016-02-29	Completed
A Randomized, Double-Blind, Double-Dummy, Active-controlled, Parallel-group, Multicenter Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Subjects With Acute Coronary Syndrom [NCT02293395]	Phase 2	3,037 participants (Actual)	Interventional	2015-04-20	Completed
Establishing the Microcirculatory Effects of Ticagrelor on Tissue Perfusion in Critical Limb Ischemia [NCT02230527]	Phase 2/Phase 3	46 participants (Actual)	Interventional	2014-10-31	Terminated(stopped due to Lack of enrollment)
A Multicenter, Single Arm, Open Label, Phase IV Study to Evaluate Safety and to Describe the Cumulative Incidence of Major Cardiovascular Events of Ticagrelor in Taiwanese Patients With Non ST-segment Elevation Myocardial Infarction [NCT02406248]	Phase 4	108 participants (Actual)	Interventional	2015-04-23	Completed
Switch to Ticagrelor in Critical Limb Ischemia Anti-platelet Study [NCT02091921]	Phase 1/Phase 2	53 participants (Actual)	Interventional	2014-02-16	Completed
Ticagrelor Administered as Standard Tablet or orodispersiblE foRmulation [NCT03822377]	Phase 3	130 participants (Actual)	Interventional	2019-06-27	Completed
Investigation of Drug-drug Interaction of Dabigatran and Ticagrelor Under Steady State Conditions in Healthy Male Subjects [NCT01734772]	Phase 1	48 participants (Actual)	Interventional	2012-11-30	Completed
Randomized Trial of Ticagrelor for Severe Community Acquired Pneumonia [NCT01998399]	Phase 2	25 participants (Actual)	Interventional	2014-08-31	Terminated(stopped due to poor enrollment, unable to meet recruitment goals)
Safety of Ticagrelor Plus Warfarin Versus Clopidogrel+Aspirin+Warfarin in Patients With Persistent or Permanent Atrial Fibrillation and Undergoing PCI-S: A Randomized, Open, Controlled, Parallel Group, Multi-center Trial [NCT02206815]	Phase 4	296 participants (Actual)	Interventional	2014-09-19	Completed
Safety and Efficacy of Drug-Coated Balloon Angioplasty for the Treatment of Chronic Total Occlusions [NCT04744571]		200 participants (Anticipated)	Interventional	2021-02-28	Enrolling by invitation
Mojito Study (Mashed Or Just Integral Pill of TicagrelOr ? ) [NCT01992523]	Phase 3	82 participants (Actual)	Interventional	2013-11-30	Completed
Randomized Trial of Different Loading Dose of Ticagrelor for Antiplatelet Effect in Patients With Non -ST-segment Elevation ACS Undergoing Percutaneous Coronary Intervention [NCT01962428]	Phase 4	250 participants (Actual)	Interventional	2014-06-30	Completed
Effect of the Peripheral Opioid Receptor Antagonist Methylnaltrexone on the Pharmacokinetic and Pharmacodynamic Profiles of Ticagrelor in Patients Receiving Morphine: a Prospective, Randomized Placebo-controlled Trial [NCT02403830]	Phase 4	30 participants (Actual)	Interventional	2015-08-31	Completed
Pharmacokinetics and Pharmacodynamics of Platelet P2Y12 Inhibitors in Patients Undergoing Percutaneous Coronary Intervention (PCI) for Acute Myocardial Infarction: A Pilot Study [NCT02376283]	Phase 4	87 participants (Actual)	Interventional	2015-03-09	Completed
A Prospective, Randomised, Open-labeled, Parallel Group Study to Assess the Effect of Optimized Antiplatelet Therapy on the Prognosis of ACS Patients With Non-predominant Coronary Artery Disease After PCI [NCT04338919]		2,020 participants (Anticipated)	Interventional	2020-04-14	Recruiting
Ticagrelor in Methotrexate-Resistant Rheumatoid Arthritis [NCT02874092]	Phase 4	9 participants (Actual)	Interventional	2016-11-15	Completed
Efficacy and Safety of Ticagrelor Combined With ASA Versus ASA Alone in Preventing Stroke and Death in Patients With Acute Ischemic Stroke or Transient Ischemic Attack: a Randomized, Double-blind, Placebo-controlled, International Multicenter Phase III Cl [NCT04962451]	Phase 4	13,000 participants (Actual)	Interventional	2017-09-01	Completed
Determine the Safety/Efficacy of Ticagrelor in Post-transplant Patients With Hepatic Artery Thrombosis (HAT) [NCT04946929]	Phase 3	50 participants (Anticipated)	Interventional	2021-07-31	Not yet recruiting
A Randomized, Double-Blind, Placebo-Controlled Trial Investigating The Effect Of Ticagrelor On Saphenous Vein Graft Patency In Patients Undergoing Coronary Artery Bypass Grafting Surgery (The POPular CABG Study) [NCT02352402]	Phase 3	487 participants (Anticipated)	Interventional	2015-03-31	Active, not recruiting
A Single-center, Prospective,Randomized Study of Antiplatelet Effects of Ticagrelor Versus Clopidogrel in Patients With Dual Anti-platelet Therapy After Coronary Artery Bypass Grafting [NCT02330640]	Phase 4	137 participants (Actual)	Interventional	2016-01-31	Completed
Pivotal Study of the AggreGuide A-100 Adenosine Diphosphate (ADP) Assay to Evaluate the Detection of Platelet Dysfunction Due to P2Y12 Antiplatelet Drugs [NCT03111420]		280 participants (Actual)	Interventional	2017-01-09	Completed
Ticagrelor Versus High-dose Clopidogrel in Patients With High Platelet Reactivity on Clopidogrel After Percutaneous Coronary Intervention: The PL-PLATELET Randomized Trial [NCT03078465]	Phase 3	0 participants (Actual)	Interventional	2017-06-20	Withdrawn(stopped due to Competitive studies were conducted at the same time, and enrollment was suspended.)
Reassessment of Long-Term Dual Anti-Platelet Therapy Using InDividualized Strategies - Using a Novel Combined Demographic and Pharmacogenomic Strategy: The RAPID EXTEND Pilot Study [NCT03224923]	Phase 4	5 participants (Actual)	Interventional	2017-08-18	Terminated(stopped due to Competing study to be started in November 2018)
Antiplatelet Therapy in Elderly Patients Undergoing Percutaneous Coronary Intervention [NCT04999293]		1,505 participants (Actual)	Observational	2021-07-20	Completed
Cangrelor vs. Ticagrelor for Early Platelet Inhibition in ST-elevation Myocardial Infarction [NCT03182855]	Phase 4	80 participants (Anticipated)	Interventional	2018-09-01	Not yet recruiting
Safety and Efficacy of Low-Dose Ticagrelor in Chinese Patients With Non-ST-Elevation Acute Coronary Syndrome: A Randomized Clinical Trial [NCT02415803]	Phase 3	75 participants (Anticipated)	Interventional	2014-12-31	Recruiting
Dose Adaptation to Offset the Pharmacokinetic Interaction Between Ticagrelor and Ritonavir in Healthy Volunteers by Population-based PK Modeling (Simcyp®) [NCT02435563]	Phase 2	22 participants (Actual)	Interventional	2014-08-31	Completed
A Single Dose, Randomized, Open-Label, Parallel Group Study Comparing the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Ticagrelor in Hemodialysis Patients to Subjects With Normal Renal Function [NCT02022748]	Phase 1	27 participants (Actual)	Interventional	2013-12-29	Completed
Investigation of Anti-platelet Drug Single Dose Exposure on Platelet mRNA Splicing in Healthy Subjects [NCT04088123]		0 participants (Actual)	Observational	2020-04-01	Withdrawn(stopped due to Inability to commence enrollment at institution, terminated on 9/23/20)
The Relationship Between Genotype and Platelet Reactivity in Patients Treated With Ticagrelor Versus Clopidogrel: PIANO Genotype Study [NCT02394145]	Phase 3	20 participants (Anticipated)	Interventional	2009-09-30	Recruiting
Effect of Continue vs. Stop P2Y12 Inhibitor on Bleeding in Patient Receiving Dual-antiplatelet Therapy Undergoing Dental Procedure. [NCT03103685]	Phase 4	428 participants (Anticipated)	Interventional	2017-05-01	Not yet recruiting
Reversal of the Anti-platelet Effects of Ticagrelor in Healthy Persons and Patients With Coronary Artery Disease [NCT02383771]	Phase 4	64 participants (Actual)	Interventional	2015-03-31	Completed
Ndividualized and Combined Effects of Diabetes and Smoking on the Antiplatelet Activity of Ticagrelor in Acute Myocardial Infarction Patients Undergoing Primary PCI [NCT05911659]		60 participants (Anticipated)	Observational [Patient Registry]	2023-05-01	Recruiting
Evaluation of the Effects and Plasma Concentration of the Potent Platelet Inhibitor Ticagrelor, After Crushed and Non-crushed Intake, After Semi-urgent Coronary Bypass and in Patients After Cardiac Arrest. [NCT02341729]	Phase 4	40 participants (Actual)	Interventional	2015-03-31	Completed
Comparison of Prasugrel and Ticagrelor Antiplatelet Effects in Korean Patients Presenting With ST-segment Elevation Myocardial Infarction [NCT02075125]	Phase 3	39 participants (Actual)	Interventional	2014-01-31	Terminated(stopped due to Enrolling participants has halted prematurely and will not resume)
EndoTic - Endothelium and Ticagrelor: Pharmacological Effects Beyond Antiplatelet Therapy [NCT02244710]		109 participants (Actual)	Interventional	2015-03-31	Completed
Multicenter, Open-label, Randomised, Pharmacokinetic (PK) and Pharmacodynamic (PD) Dose-ranging Phase II Study of Ticagrelor Followed by a Double-blind, Randomised, Parallel-group, Placebo-controlled 4 Weeks Extension Phase in Paediatric Patients With Sic [NCT02214121]	Phase 2	46 participants (Actual)	Interventional	2014-09-11	Completed
A Pharmacodynamic Comparison of Prasugrel vs. Ticagrelor in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease [NCT01852214]		50 participants (Actual)	Interventional	2013-02-28	Completed
An Open-label, Randomized, Three-period, Three-treatment, Crossover, Single-centre, Single-dose Study to Assess the Bioequivalence Between Ticagrelor Orodispersible Tablets and Ticagrelor Immediate-release Tablets in Healthy Japanese Subjects. [NCT02436577]	Phase 1	51 participants (Actual)	Interventional	2015-06-30	Completed
A Randomized, Double-blind, Parallel Group, Multicentre Phase IIIb Study to Compare Ticagrelor With Clopidogrel Treatment on the Risk of Cardiovascular Death, Myocardial Infarction and Ischemic Stroke in Patients With Established Peripheral Artery Disease [NCT01732822]	Phase 3	13,885 participants (Actual)	Interventional	2012-12-04	Completed
SYNergy Stent® System Implantation With Mandatory Intra-VascularUltra-Sound Guidance to Examine the Safety of Cessation of Dual Anti-Platelet Therapy in High Bleeding Risk Patients at One Month [NCT03606642]	Phase 2	50 participants (Actual)	Interventional	2018-11-19	Active, not recruiting
"The Value of Screening for High on Treatment Platelet Reactivity in Patients Undergoing Lower Extremity Arterial Endovascular Interventions" [NCT04007055]	Phase 3	296 participants (Anticipated)	Interventional	2019-08-09	Recruiting
GLOBAL LEADERS: A Clinical Study Comparing Two Forms of Anti-platelet Therapy After Stent Implantation [NCT01813435]	Phase 3	15,991 participants (Actual)	Interventional	2013-07-01	Completed
Efficacy and Safety of Individualized P2Y12 Receptor Antagonists Treatment Based on Agregometry Versus Fixed Dose Regimen in Patients After Acute Myocardial Infarction [NCT04369534]	Phase 4	120 participants (Actual)	Interventional	2015-12-01	Completed
Pharmacodynamic Effects of Different Ticagrelor Maintenance Dosing Regimens With and Without Aspirin in Patients With Diabetes Mellitus: The OPTIMUS (Optimizing Antiplatelet Therapy in Diabetes Mellitus)-7 Study [NCT04484259]	Phase 4	63 participants (Anticipated)	Interventional	2021-03-31	Recruiting
Pharmacodynamic Profiles of Ticagrelor in Patients With ST Elevation Myocardial Infarction: A Randomized Comparison of Different Loading Dosage Regimens [NCT01898442]	Phase 2	52 participants (Actual)	Interventional	2013-09-30	Completed
Platelet Aggregation During Pharmacological Shift From Clopidogrel to Ticagrelor in Patients With Acute Coronary Syndrome [NCT01795820]		50 participants (Actual)	Interventional	2012-11-30	Completed
A Prospective Multi-center Open-label Controlled Trial of Comparison 3 vs 12 Months of Dual Anti-Platelet Therapy After Implantation of Firehawk Sirolimus Target- Eluting Stent in Patients With Stable Coronary Artery Disease [NCT03008083]	Phase 4	2,446 participants (Anticipated)	Interventional	2019-01-10	Recruiting
Ticagrelor Therapy for RefrACTORy Migraine Study Pilot (TRACTOR) [NCT02518464]	Phase 4	40 participants (Actual)	Interventional	2015-10-31	Completed
Reversal of the Antiplatelet Effects of Ticagrelor in Combination With Aspirin, Using Normal Platelets [NCT03005704]		10 participants (Anticipated)	Interventional	2017-01-31	Recruiting
Investigation of Pharmacodynamic Effects of Dabigatran and Ticagrelor (Part 1 and 2, Open, Non-randomised, 2 Parallel Groups) and Assessment of Ticagrelor Interaction Potential With Dabigatran (Part 3, Open, Randomised, Two-period Cross-over) in Healthy M [NCT01595854]	Phase 1	36 participants (Actual)	Interventional	2012-05-31	Completed
"Evaluation of Antiplatelet Effects and Safety of Intraoperative Administration of Ticagrelor Versus Clopidogrel in Patients Undergoing One-stop Hybrid Coronary Revascularization" [NCT02513004]	Phase 4	60 participants (Anticipated)	Interventional	2015-06-30	Recruiting
A Randomized, Open-label, Active-Controlled and Blinded-Endpoint Trial Comparing the Antiplatelet Effects of Ticagrelor Plus Aspirin Versus Clopidogrel Plus Aspirin in Chinese Patients With High-risk Transient Ischemic Attack or Minor Stroke. [NCT02506140]	Phase 2/Phase 3	675 participants (Actual)	Interventional	2015-08-31	Completed
Safety and Efficacy of Low-dose Ticagrelor in Chinese Patients With Stable Coronary Artery Disease: a Randomized, Single-blind, Crossover Clinical Trial [NCT02514642]	Phase 4	30 participants (Anticipated)	Interventional	2015-07-31	Recruiting
Comparison of Low-Dose, Standard-Dose Ticagrelor and Clopidogrel for Inhibition of Platelet Reactivity in Patients With Acute Coronary Syndromes; Pharmacodynamics and Pharmacokinetics Study [NCT02319941]	Phase 2	65 participants (Actual)	Interventional	2015-05-20	Completed
A Prospective, Multicentre, Randomized, Open Label, Blinded Endpoint, Phase 3 Trial to Assess the Safety and Efficacy of Prophylactic TicagrelOr With Acetylsalicylic Acid Versus CLopidogrel With Acetylsalicylic Acid in the Development of Cerebrovascular E [NCT02989558]	Phase 3	90 participants (Actual)	Interventional	2016-12-31	Completed
A Phase 1, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD3366 in Healthy Men and Women of Non-Childbearing Potential Following: Part A: Single Ascending Dose Administrati [NCT04588727]	Phase 1	103 participants (Actual)	Interventional	2020-10-15	Completed
An Open-label, Randomized, Controlled, Multicenter Study to Evaluate DUAL Antithrombotic Therapy With Rivaroxaban Plus Ticagrelor vs. Rivaroxaban Plus Clopidogrel in Patients With Atrial Fibrillation and Acute Coronary Syndrome [NCT04023630]	Phase 4	4,000 participants (Anticipated)	Interventional	2019-10-01	Not yet recruiting
Evaluation of Ticagrelor Pharmacokinetics in Patients With Non-ST Elevation Myocardial Infarction After a 180 mg Ticagrelor Loading Dose [NCT02292277]		63 participants (Actual)	Observational	2014-10-31	Completed
Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention [NCT02270242]	Phase 4	9,006 participants (Actual)	Interventional	2015-07-31	Completed
A Randomised, Double-blind, Double-dummy, Parallel-group, Multicenter, Phase IIb Study to Evaluate the Effect of Ticagrelor Versus Placebo in Reducing the Number of Days With Pain in Young Adults With Sickle Cell Disease [NCT02482298]	Phase 2	87 participants (Actual)	Interventional	2015-07-09	Completed
A Prospective Randomised, Open Label, Blinded Endpoint (PROBE) Study to Evaluate DUAL Antithrombotic Therapy With Dabigatran Etexilate (110mg and 150mg b.i.d.) Plus Clopidogrel or Ticagrelor vs. Triple Therapy Strategy With Warfarin (INR 2.0 - 3.0) Plus C [NCT02164864]	Phase 3	2,725 participants (Actual)	Interventional	2014-07-22	Completed
Low-dose of Ticagrelor and Standard-dose Clopidogrel on Platelet Effects in Chinese Patients With Stable Coronary Artery Disease: a Randomized, Single-blind, Crossover Clinical Study [NCT03679091]	Phase 4	36 participants (Actual)	Interventional	2018-08-29	Completed
An Open-label, Randomized, 4-period, 4-treatment, Cross-over, Single-center, Single-dose Study to Assess the Relative Bioavailability of Ticagrelor in Different Formulations in Healthy Adult Subjects [NCT03126695]	Phase 1	44 participants (Actual)	Interventional	2017-05-12	Completed
Comparative Effectiveness and Safety Analysis of Low-dose and Standard-dose Ticagrelor in Chinese Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention [NCT03381755]	Phase 4	200 participants (Anticipated)	Interventional	2018-01-01	Recruiting
A Randomized, Open-Label, Multiple Dose, Crossover, Multiple Center Study of the Antiplatelet Effects of Ticagrelor Versus Clopidogrel in Hispanic Patients With Stable Coronary Artery Disease [NCT01523366]	Phase 4	53 participants (Actual)	Interventional	2012-04-30	Completed
A Multicentre, Open-label, Randomized, 6-week, Phase IV Study of the Onset and Maintenance of the Antiplatelet Effect of Ticagrelor Compared With Clopidogrel With Aspirin as Background Therapy in Chinese Patients With Non-ST or ST Elevation Acute Coronary [NCT01864005]	Phase 4	60 participants (Actual)	Interventional	2013-05-31	Completed
Compare the Efficacy of Different Antiplatelet Therapy Strategy After Coronary Artery Bypass Graft Surgery [NCT02201771]	Phase 4	500 participants (Actual)	Interventional	2014-07-31	Completed
An Open-label, Randomized, Controlled, Multicenter Study Exploring Two Treatment Strategies of Rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy in Subjects With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention [NCT01830543]	Phase 3	2,124 participants (Actual)	Interventional	2013-05-10	Completed
Pharmacodynamic Outcomes in Patients With Coronary Artery Disease Undergoing Percutaneous Coronary Intervention Treated With an Individualized Treatment STRATEGY [NCT05773989]	Phase 4	88 participants (Anticipated)	Interventional	2023-07-01	Not yet recruiting
A Randomised, Double-Blind, Multinational Study to Prevent Major Vascular Events With Ticagrelor Compared to Aspirin (ASA) in Patients With Acute Ischaemic Stroke or TIA. [NCT01994720]	Phase 3	13,307 participants (Actual)	Interventional	2014-01-07	Completed
Pharmacodynamic Evaluation of Switching From Prasugrel to Ticagrelor: The SWAP (SWitching Anti Platelet)-3 Study [NCT02016170]		82 participants (Actual)	Interventional	2014-03-31	Completed
TIPRIS: Ticagrelor vs. Prasugrel Effects on Infarct Size: A Head to Head Comparison With Prasugrel [NCT02507323]	Phase 2	0 participants (Actual)	Interventional	2016-02-29	Withdrawn(stopped due to collaborator withdrew the study)
Effect of Haemodialysis on the Efficacy of Antiplatelet Agents [NCT03330223]		60 participants (Anticipated)	Observational	2017-11-10	Recruiting
The Success of Opening Concurrent Chronic Total Occlusion leSion to Improve Cardiac Function Trial in Patients With Multi-vessel Disease (SOS-moral): Study Protocol of a Prospective Multicenter Study [NCT03372785]		240 participants (Anticipated)	Observational [Patient Registry]	2018-04-10	Enrolling by invitation
A Multicenter, Adaptive, Randomized Controlled Platform Trial of the Safety and Efficacy of Antithrombotic and Additional Strategies in Hospitalized Adults With COVID-19 [NCT04505774]	Phase 4	880 participants (Actual)	Interventional	2020-09-04	Active, not recruiting
Role of Innate and Adaptive Immunity After Acute Myocardial Infarction BATTLE-AMI Study (B And T Types of Lymphocytes Evaluation in Acute Myocardial Infarction) [NCT02428374]	Phase 4	300 participants (Anticipated)	Interventional	2015-05-31	Recruiting
Impact of Ticagrelor and Aspirin Versus Clopidogrel and Aspirin in Patients With Claudication and Peripheral Arterial Disease (PAD): Thrombus Burden Assessed by Optical Coherence Tomography [NCT02407314]	Phase 4	26 participants (Actual)	Interventional	2015-06-30	Terminated(stopped due to AZ discontinued study)
Sub Lingual Versus Traditional Oral Administration of Ticagrelor in Acute Coronary Syndrome [NCT02402400]	Phase 4	50 participants (Actual)	Interventional	2015-07-31	Completed
An Open Label, Randomized Study to Determine the Rate of Cardiovascular Events at 1 yr for Patients With Elevated Troponins Post Major Non-cardiac Surgery and the Impact of Ticagrelor vs Aspirin on the Occurrence of Cardiovascular Events [NCT02291419]	Phase 4	6 participants (Actual)	Interventional	2015-07-31	Terminated(stopped due to Enrollment expectations were not met)
Comparison of Antiplatelet Therapy With Clopidogrel and Ticagrelor in Patients After Cardiac Arrest Treated With Therapeutic Hypothermia [NCT02224274]	Phase 4	57 participants (Actual)	Interventional	2014-08-31	Completed
A Single Center, Randomized, Open Label, Crossover Study With Ticagrelor and Prasugrel to Evaluate Ticagrelor Mechanism of Action in Inhibiting Juvenile Platelet ADP Response [NCT03027934]	Phase 4	0 participants (Actual)	Interventional	2017-08-28	Withdrawn(stopped due to Study population difficult to recruit)
A Randomized, Double-blind Study Evaluating the Influence of Morphine on Pharmacokinetics and Pharmacodynamics of Ticagrelor and Its Active Metabolite (AR-C124910XX) in Patients With ST-segment Elevation Myocardial Infarction and Non-ST-segment Elevation [NCT02217878]	Phase 4	74 participants (Actual)	Interventional	2014-08-31	Completed
A Randomized, Open-Label, Multiple Dose, Crossover, Multiple Center Study of the Antiplatelet Effects of Ticagrelor Versus Clopidogrel in African American Patients With Stable Coronary Artery Disease [NCT01523392]	Phase 4	50 participants (Actual)	Interventional	2012-03-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00391872 (16) [back to overview]	Participants With Any Event From the Composite of All-cause Mortality, MI, and Stroke
NCT00391872 (16) [back to overview]	Participants With Major or Minor Bleeding
NCT00391872 (16) [back to overview]	Participants With Non-CABG (Coronary Artery Bypass Graft) Related Major Bleeding
NCT00391872 (16) [back to overview]	Participants With Stroke
NCT00391872 (16) [back to overview]	Participants With Ventricular Pauses of Greater Than or Equal to 3 Seconds in Patients Monitored by Holter 24 Hour ECG Recorders for 1 Week at 1 Month Following Randomization
NCT00391872 (16) [back to overview]	Participants With Ventricular Pauses of Greater Than or Equal to 3 Seconds in Patients Monitored by Holter 24-hour ECG Recorders for 1 Week Following Randomization
NCT00391872 (16) [back to overview]	Participants With MI Event
NCT00391872 (16) [back to overview]	Participants With Any Event From the Composite of Death From Vascular Causes, MI (Including Silent), Stroke, Recurrent Ischemia, Transient Ischemic Attack (TIA) and Other Arterial Thrombotic Events.
NCT00391872 (16) [back to overview]	Participants With Non-procedural Major Bleeding
NCT00391872 (16) [back to overview]	Participants With Death From Vascular Causes
NCT00391872 (16) [back to overview]	Participants With Any Event From the Composite of Death From Vascular Causes, MI, and Stroke for the Subgroup of Patients With Intent for Invasive Management at Randomization
NCT00391872 (16) [back to overview]	Participants With Any Event From the Composite of Death From Vascular Causes, Myocardial Infarction (MI), and Stroke
NCT00391872 (16) [back to overview]	Participants With Death From Any Cause
NCT00391872 (16) [back to overview]	Participants With Coronary Artery Bypass Graft (CABG) Major Fatal/Life-threatening Bleeding
NCT00391872 (16) [back to overview]	Participants With Coronary Artery Bypass Graft (CABG) Major Bleeding
NCT00391872 (16) [back to overview]	Participants With Any Major Bleeding Event
NCT00528411 (45) [back to overview]	Cardiopulmonary Parameters at Baseline: Mean Forced Expiratory Flow Between 25% and 75% of the FVC (FEF25-75)
NCT00528411 (45) [back to overview]	Cardiopulmonary Parameters at Baseline: Functional Residual Capacity (FRC)
NCT00528411 (45) [back to overview]	Cardiopulmonary Parameters at Baseline: Forced Vital Capacity (FVC)
NCT00528411 (45) [back to overview]	Cardiopulmonary Parameters at Baseline: Forced Expiratory Volume in 1 Second (FEV1)
NCT00528411 (45) [back to overview]	Cardiopulmonary Parameters at Baseline: Ejection Fraction (EF)
NCT00528411 (45) [back to overview]	Cardiopulmonary Parameters at Baseline: Blood Oxygen Saturation Measured by Pulse Oximetry (SpO2)
NCT00528411 (45) [back to overview]	Final Extent IPA Induced by 20 µM ADP at 8 Hours After Last Dose
NCT00528411 (45) [back to overview]	Slope of Extent IPA Offset Curve 4 to 72 Hours After Last Dose of Study Drug
NCT00528411 (45) [back to overview]	Cardiopulmonary Parameters Post 6-week Treatment: RR
NCT00528411 (45) [back to overview]	Cardiopulmonary Parameters Post 6-week Treatment: RV
NCT00528411 (45) [back to overview]	Cardiopulmonary Parameters Post 6-week Treatment: SpO2
NCT00528411 (45) [back to overview]	Cardiopulmonary Parameters Post 6-week Treatment: TLC
NCT00528411 (45) [back to overview]	Cardiopulmonary Parameters Post 6-week Treatment: VE
NCT00528411 (45) [back to overview]	Cardiopulmonary Parameters Post 6-week Treatment: VT
NCT00528411 (45) [back to overview]	Final Extent IPA Induced by 20 µM ADP at 8 Hours After First Dose
NCT00528411 (45) [back to overview]	Final Extent IPA Induced by 20 µM ADP at 0.5 Hours After First Dose
NCT00528411 (45) [back to overview]	Final Extent IPA Induced by 20 µM ADP at 1 Hour After First Dose
NCT00528411 (45) [back to overview]	Final Extent IPA Induced by 20 µM ADP at 120 Hours - Day 5 After Last Dose
NCT00528411 (45) [back to overview]	Final Extent IPA Induced by 20 µM ADP at 168 Hours - Day 7 After Last Dose
NCT00528411 (45) [back to overview]	Final Extent IPA Induced by 20 µM ADP at 2 Hours After Last Dose
NCT00528411 (45) [back to overview]	Final Extent IPA Induced by 20 µM ADP at 24 Hours After First Dose
NCT00528411 (45) [back to overview]	Final Extent IPA Induced by 20 µM ADP at 24 Hours After Last Dose
NCT00528411 (45) [back to overview]	Final Extent IPA Induced by 20 µM ADP at 240 Hours - Day 10 After Last Dose
NCT00528411 (45) [back to overview]	Final Extent IPA Induced by 20 µM ADP at 0 Hour Before Last Dose
NCT00528411 (45) [back to overview]	Final Extent IPA Induced by 20 µM ADP at 4 Hours After Last Dose
NCT00528411 (45) [back to overview]	Final Extent IPA Induced by 20 µM ADP at 48 Hours After Last Dose
NCT00528411 (45) [back to overview]	Final Extent IPA Induced by 20 µM ADP at 72 Hours After Last Dose
NCT00528411 (45) [back to overview]	Final Extent IPA Induced by 20 µM ADP at 4 Hours After First Dose
NCT00528411 (45) [back to overview]	Final Extent Inhibition of Platelet Aggregation (IPA) Induced by 20 µM Adenosine Diphosphate (ADP) at 2 Hours After First Dose
NCT00528411 (45) [back to overview]	Cardiopulmonary Parameters at Baseline: Single Breath Diffusing Capacity for the Lungs Using Carbon Monoxide (DLCOSB)
NCT00528411 (45) [back to overview]	Cardiopulmonary Parameters at Baseline: Respiratory Rate (RR)
NCT00528411 (45) [back to overview]	Cardiopulmonary Parameters at Baseline: Residual Volume (RV)
NCT00528411 (45) [back to overview]	Cardiopulmonary Parameters at Baseline: Ratio of Forced Expiratory Volume in 1 Second Over Forced Vital Capacity (FEV1/FVC Ratio)
NCT00528411 (45) [back to overview]	Cardiopulmonary Parameters at Baseline: N-terminal Pro-brain Natriuretic Peptide (NT-proBNP)
NCT00528411 (45) [back to overview]	Cardiopulmonary Parameters at Baseline: Minute Ventilation (VE)
NCT00528411 (45) [back to overview]	Cardiopulmonary Parameters at Baseline: Tidal Volume (VT)
NCT00528411 (45) [back to overview]	Cardiopulmonary Parameters at Baseline: Total Lung Capacity (TLC)
NCT00528411 (45) [back to overview]	Cardiopulmonary Parameters at Post 6-week Treatment: FEV1
NCT00528411 (45) [back to overview]	Cardiopulmonary Parameters at Post 6-week Treatment: FEV1/FVC Ratio
NCT00528411 (45) [back to overview]	Cardiopulmonary Parameters at Post 6-week Treatment: FVC
NCT00528411 (45) [back to overview]	Cardiopulmonary Parameters Post 6-week Treatment: DLCOSB
NCT00528411 (45) [back to overview]	Cardiopulmonary Parameters Post 6-week Treatment: EF
NCT00528411 (45) [back to overview]	Cardiopulmonary Parameters Post 6-week Treatment: FEF25-75
NCT00528411 (45) [back to overview]	Cardiopulmonary Parameters Post 6-week Treatment: FRC
NCT00528411 (45) [back to overview]	Cardiopulmonary Parameters Post 6-week Treatment: NT-proBNP
NCT00642811 (6) [back to overview]	Clopidogrel Responders Final Extent IPA Post Switching Treatment - Comparing Ticagrelor to Ticagrelor Versus Ticagrelor to Clopidogrel on Day 15
NCT00642811 (6) [back to overview]	Clopidogrel Responders Final Extent IPA Post Switching Treatment - Comparing Ticagrelor to Ticagrelor Versus Ticagrelor to Clopidogrel on Day 28
NCT00642811 (6) [back to overview]	Proportion of Clopidogrel Non-responders Who Responded to Clopidogrel or Ticagrelor. - Comparing Ticag. (Day 28 of Clop. to Ticag., and Day 14 of Ticag. to Clop.) Versus Clop. (Day 14 of Clop. to Ticag., and Day 28 of Ticag. to Clop.
NCT00642811 (6) [back to overview]	Clopidogrel Responders Final Extent IPA Post Switching Treatment - Comparing Clopidogrel to Clopidogrel Versus Clopidogrel to Ticagrelor on Day 15
NCT00642811 (6) [back to overview]	Proportion of Clopidogrel Non-responders Who Responded to Clopidogrel or Ticagrelor. - Comparing Ticag. (Day 28 of Clop. to Ticag., and Day 14 of Ticag. to Clop.) Versus Clop. (Day 14 of Clop. to Ticag., and Day 28 of Ticag. to Clop.)
NCT00642811 (6) [back to overview]	Clopidogrel Responders Final Extent IPA Post Switching Treatment - Comparing Clopidogrel to Clopidogrel Versus Clopidogrel to Ticagrelor on Day 28
NCT01118325 (11) [back to overview]	IPA Final Extent at 12 Hours Post Dose on Week 4 in Japanese Patients
NCT01118325 (11) [back to overview]	AR-C124910XX (AUC0-tau) at Week 4
NCT01118325 (11) [back to overview]	AR-C124910XX (Cmax) at Week 4
NCT01118325 (11) [back to overview]	AR-C124910XX (Tmax) at Week 4
NCT01118325 (11) [back to overview]	AZD6140 (AUC0-tau) at Week 4
NCT01118325 (11) [back to overview]	AZD6140 (Cmax) at Week 4
NCT01118325 (11) [back to overview]	AZD6140 (Tmax) at Week 4
NCT01118325 (11) [back to overview]	Inhibition of Platelet Aggregation(IPA) Final Extent at 2 Hours Post Dose on Week 4 in Japanese Patients
NCT01118325 (11) [back to overview]	IPA Final Extent at 24 Hours Post Dose on Week 4 in Japanese Patients
NCT01118325 (11) [back to overview]	IPA Final Extent at 4 Hours Post Dose on Week 4 in Japanese Patients
NCT01118325 (11) [back to overview]	IPA Final Extent at 8 Hours Post Dose on Week 4 in Japanese Patients
NCT01225562 (4) [back to overview]	Kaplan-Meier Estimate of the Percentage of Patients Who Experienced Cardiovascular Death (CV Death) Within 3 Years From Randomization
NCT01225562 (4) [back to overview]	Kaplan-Meier Estimate of the Percentage of Patients Who Died From Any Cause Within 3 Years From Randomization
NCT01225562 (4) [back to overview]	Kaplan-Meier Estimate of the Percentage of Patients Who Experienced a TIMI Major Bleeding Within 3 Years From First Dose of Study Drug Units: Percentage of Patients
NCT01225562 (4) [back to overview]	Kaplan-Meier Estimate of the Percentage of Patients Who Experienced Cardiovascular Death (CV Death), Myocardial Infarction (MI) or Stroke Within 3 Years From Randomization
NCT01294462 (4) [back to overview]	Major Adverse Cardiac Events (MACE)
NCT01294462 (4) [back to overview]	Composite of All-cause Mortality, MI or Stroke
NCT01294462 (4) [back to overview]	Major Bleeding
NCT01294462 (4) [back to overview]	Major and Minor Bleeding
NCT01347580 (12) [back to overview]	Major Bleeds Within 48 Hours
NCT01347580 (12) [back to overview]	Major Bleeds After 48 Hours
NCT01347580 (12) [back to overview]	Definite Stent Thrombosis
NCT01347580 (12) [back to overview]	2nd Composite Clinical Endpoint
NCT01347580 (12) [back to overview]	1st Composite Clinical Endpoint
NCT01347580 (12) [back to overview]	Minor and Major Bleeds After 48 Hours
NCT01347580 (12) [back to overview]	Minor and Major Bleedings Within 48 Hours
NCT01347580 (12) [back to overview]	TIMI Flow Grade 3 Post -PCI
NCT01347580 (12) [back to overview]	Thrombotic Bail-out With GPIIb/IIIa Inhibitors at Initial PCI
NCT01347580 (12) [back to overview]	Thrombolysis In Myocardial Infarction (TIMI) Flow Grade 3 of MI Culprit Vessel at Initial Angiography (Co-primary Endpoint)
NCT01347580 (12) [back to overview]	ST-segment Elevation Resolution Pre PCI ≥70% (Co-primary Endpoint)
NCT01347580 (12) [back to overview]	ST Segment Elevation Resolution Post-PCI >= 70%
NCT01515345 (3) [back to overview]	Any Bleeding Event
NCT01515345 (3) [back to overview]	Probable Stent Thrombosis
NCT01515345 (3) [back to overview]	Definite Stent Thrombosis
NCT01523366 (5) [back to overview]	Ticagrelor Plasma Concentrations After the Loading and Maintenance Doses
NCT01523366 (5) [back to overview]	Inhibition of the P2Y12 Receptor as Measured by PRU From VerifyNow™ at 2 and 8 Hours on Day 7 After Multiple Doses and at End of Dosing Interval on Day 8
NCT01523366 (5) [back to overview]	Inhibition of the P2Y12 Receptor as Measured by PRU From VerifyNow™ at 0.5 and 8 Hours After Loading Dose
NCT01523366 (5) [back to overview]	AR-C124910XX (an Active Metabolite of Ticagrelor) Plasma Concentrations After the Loading and Maintenance Doses
NCT01523366 (5) [back to overview]	Inhibition of the P2Y12 Receptor as Measured by P2Y12 Reactions Units (PRU) From VerifyNow™ (a Platelet Function Test Developed by Accumetrics) at 2 Hours After Loading Dose
NCT01523392 (5) [back to overview]	Inhibition of the P2Y12 Receptor as Measured by Platelet Reaction Unit (PRU) From VerifyNow™ (a Platelet Function Test Developed by Accumetrics) at 2 Hours After Loading Dose
NCT01523392 (5) [back to overview]	Inhibition of the P2Y12 Receptor as Measured by PRU From VerifyNow™ at 2 Hours and 8 Hours on Day 7 After Multiple Doses and at End of Dosing Interval on Day 8
NCT01523392 (5) [back to overview]	Inhibition of the P2Y12 Receptor as Measured by PRU From VerifyNow™ at 0.5 Hour and 8 Hours After Loading Dose
NCT01523392 (5) [back to overview]	AR-C124910XX (an Active Metabolite of Ticagrelor) Plasma Concentrations After the Loading and Maintenance Doses
NCT01523392 (5) [back to overview]	Ticagrelor Plasma Concentrations After the Loading and Maintenance Doses
NCT01526577 (1) [back to overview]	Pharmacodynamic Measurement
NCT01587651 (6) [back to overview]	P2Y12 Reaction Units
NCT01587651 (6) [back to overview]	P2Y12 Reaction Units
NCT01587651 (6) [back to overview]	Percentage of Subjects With High On-treatment Platelet Reactivity
NCT01587651 (6) [back to overview]	Platelet Reactivity Index
NCT01587651 (6) [back to overview]	PRU Percent Inhibition (Calculated)
NCT01587651 (6) [back to overview]	PRU Percent Inhibition (Device-reported)
NCT01589978 (21) [back to overview]	All Death or Myocardial Infarction Rate
NCT01589978 (21) [back to overview]	All Death Rate
NCT01589978 (21) [back to overview]	ARC ST Rate in PLATINUM-like Population.
NCT01589978 (21) [back to overview]	Cardiac Death or Myocardial Infarction (MI) Rate
NCT01589978 (21) [back to overview]	Cardiac Death or Myocardial Infarction Rate in PLATINUM-like Patients
NCT01589978 (21) [back to overview]	Cardiac Death Rate
NCT01589978 (21) [back to overview]	Definite + Probable Stent Thrombosis (ST) Rate Based on Academic Research Consortium (ARC) Definition in All Patients
NCT01589978 (21) [back to overview]	Major Adverse Cardiac Event Rate (MACE)
NCT01589978 (21) [back to overview]	Myocardial Infarction (MI) Rate
NCT01589978 (21) [back to overview]	Non-cardiac Death Rate
NCT01589978 (21) [back to overview]	Rate of Cardiac Death Events Related to the PROMUS Element Stent
NCT01589978 (21) [back to overview]	Rate of Cardiac Death or Myocardial Infarction Events Related to the PROMUS Element Stent
NCT01589978 (21) [back to overview]	Rate of Longitudinal Stent Deformation
NCT01589978 (21) [back to overview]	Rate of Major Adverse Cardiac Events Related to the PROMUS Element Stent
NCT01589978 (21) [back to overview]	Rate of Myocardial Infarction (MI) Events Related to the PROMUS Element Stent
NCT01589978 (21) [back to overview]	Rate of Target Vessel Failure (TVF) Related to the PROMUS Element Stent
NCT01589978 (21) [back to overview]	Rate of Target Vessel Revascularization (TVR) Events Related to the PROMUS Element Stent
NCT01589978 (21) [back to overview]	Target Vessel Failure (TVF) Rate
NCT01589978 (21) [back to overview]	Target Vessel Failure (TVF) Rate in PLATINUM-like Medically Treated Diabetic Patients
NCT01589978 (21) [back to overview]	Target Vessel Revascularization (TVR) Rate
NCT01589978 (21) [back to overview]	Definite + Probable Stent Thrombosis (ST) Rate Based on Academic Research Consortium (ARC) Definition in PLATINUM-like Patients
NCT01595854 (3) [back to overview]	Number of Participants With Drug Related Adverse Events
NCT01595854 (3) [back to overview]	Total Dabigatran: Maximum Measured Concentration (Cmax)
NCT01595854 (3) [back to overview]	Total Dabigatran (Dabi): Area Under the Curve 0 to Infinity (AUC0-∞)
NCT01603082 (2) [back to overview]	Inhibition of the P2Y12 Receptor at 0.5 Hours, End of PCI, and 8 Hours After Loading Doses of Ticagrelor and Clopidogrel as Measured by PRU From VerifyNow™
NCT01603082 (2) [back to overview]	Inhibition of the P2Y12 Receptor at 2 Hours After Loading Doses of Ticagrelor and Clopidogrel as Measured by P2Y12 Reaction Units (PRU) From VerifyNow™
NCT01642238 (8) [back to overview]	Platelet-thrombus Formation in an ex Vivo Model of Thrombosis
NCT01642238 (8) [back to overview]	Platelet Reactivity
NCT01642238 (8) [back to overview]	Blood Thrombogenicity
NCT01642238 (8) [back to overview]	Platelet Reactivity
NCT01642238 (8) [back to overview]	Platelet-thrombus Formation in an ex Vivo Model of Thrombosis
NCT01642238 (8) [back to overview]	Platelet Reactivity
NCT01642238 (8) [back to overview]	Blood Thrombogenicity
NCT01642238 (8) [back to overview]	Blood Thrombogenicity
NCT01731041 (2) [back to overview]	Platelet Reactivity Index (PRI) by Vasodilator-stimulated Phosphoprotein (VASP)
NCT01731041 (2) [back to overview]	P2Y12 Reaction Units (PRU) Determined by VerifyNow P2Y12
NCT01732822 (24) [back to overview]	MI
NCT01732822 (24) [back to overview]	Any Revascularisation (Coronary, Peripheral [Limb, Mesenteric, Renal, Carotid and Other])
NCT01732822 (24) [back to overview]	Composite of Cardiovascular (CV) Death/MI/Ischemic Stroke
NCT01732822 (24) [back to overview]	Composite of CV Death, MI, and All-cause Stroke (Ischemic or Hemorrhagic)
NCT01732822 (24) [back to overview]	Composite of CV Death, MI, Ischemic Stroke, and ALI
NCT01732822 (24) [back to overview]	CV Death
NCT01732822 (24) [back to overview]	CV-related Hospitalization
NCT01732822 (24) [back to overview]	All-cause Mortality
NCT01732822 (24) [back to overview]	Major Amputation Caused by PAD
NCT01732822 (24) [back to overview]	Net Clinical Benefit (Composite of All-cause Mortality/MI/Ischemic Stroke/ALI/Major Amputation/Fatal Bleeding/Intracranial Bleeding)
NCT01732822 (24) [back to overview]	Net Clinical Benefit (Composite of All-cause Mortality/MI/Ischemic Stroke/ALI/Major Amputation/TIMI Major Bleeding)
NCT01732822 (24) [back to overview]	Net Clinical Benefit (Composite of All-cause Mortality/MI/Ischemic Stroke/Fatal Bleeding/Intracranial Bleeding)
NCT01732822 (24) [back to overview]	Net Clinical Benefit (Composite of CV Death/MI/Ischemic Stroke/Fatal Bleeding/Intracranial Bleeding)
NCT01732822 (24) [back to overview]	Non-CV Death
NCT01732822 (24) [back to overview]	PLATO Major Bleeding Events
NCT01732822 (24) [back to overview]	TIMI Major Bleeding Events
NCT01732822 (24) [back to overview]	Changes in Rutherford Classification
NCT01732822 (24) [back to overview]	TIMI Major or Minor Bleeding Events
NCT01732822 (24) [back to overview]	Change in ABI/TBI From Baseline
NCT01732822 (24) [back to overview]	Lower Extremity Revascularization
NCT01732822 (24) [back to overview]	Changes in Fontaine Stage
NCT01732822 (24) [back to overview]	ALI
NCT01732822 (24) [back to overview]	Any Amputation Caused by PAD
NCT01732822 (24) [back to overview]	Premature Permanent Discontinuation of Study Drug Due to Any Bleeding Event
NCT01734772 (2) [back to overview]	Total Dabigatran: Maximum Measured Concentration at Steady State (Cmax,ss)
NCT01734772 (2) [back to overview]	Total Dabigatran: Area Under the Concentration-time Curve at Steady State Over the Uniform Dosing Interval τ (AUCτ,ss)
NCT01742117 (4) [back to overview]	Thrombolysis in Myocardial Infarction Major or Minor Bleeding
NCT01742117 (4) [back to overview]	Thrombolysis in Myocardial Infarction Major or Minor Bleeding in Subjects Identified as CPY2C19 LOF Carriers by TaqMan.
NCT01742117 (4) [back to overview]	Occurrence of the a Major Adverse Cardiovascular Event
NCT01742117 (4) [back to overview]	Occurrence of the a Major Adverse Cardiovascular Event in Subjects Identified as CPY2C19 LOF Carriers by TaqMan.
NCT01766466 (3) [back to overview]	Extent of Aggregation Response During Ticagrelor Treatment
NCT01766466 (3) [back to overview]	Extent of Preservation of Inhibitory Effect Compared With Effect Observed During Cangrelor Treatment After Ticagrelor
NCT01766466 (3) [back to overview]	Extent of Preservation of Inhibitory Effect Compared With Effect Observed With Cangrelor Alone (at Timepoint 1, Either at 0.5 Hours or 1.25 Hours) or Ticagrelor Alone (Measured 5.25 Hours After Initiation of Cangrelor on Day 1)
NCT01813435 (9) [back to overview]	Number of Participants With a Stroke
NCT01813435 (9) [back to overview]	Number of Participants With New Q-wave Myocardial Infarction
NCT01813435 (9) [back to overview]	Number of Participants With Myocardial Infarction
NCT01813435 (9) [back to overview]	Number of Participants With All-cause Mortality
NCT01813435 (9) [back to overview]	Number of Participants With a Myocardial Revascularisation
NCT01813435 (9) [back to overview]	Number of Participants With a Definite Stent Thrombosis
NCT01813435 (9) [back to overview]	Number of Participants With a Composite of All-cause Mortality, Stroke, or New Q-wave Myocardial Infarction
NCT01813435 (9) [back to overview]	Number of Participants With a Composite of All-cause Mortality or Non-fatal New Q-wave Myocardial Infarction (MI)
NCT01813435 (9) [back to overview]	Number of Participants With a Bleeding Academic Research Consortium (BARC) 3 or 5 Bleeding
NCT01823510 (4) [back to overview]	Platelet Reactivity Index (PRI)
NCT01823510 (4) [back to overview]	Platelet Reactivity
NCT01823510 (4) [back to overview]	P2Y12 Reaction Unit (PRU)
NCT01823510 (4) [back to overview]	Thrombus Formation
NCT01830543 (9) [back to overview]	Percentage of Participants With Stroke
NCT01830543 (9) [back to overview]	Percentage of Participants With Thrombolysis in Myocardial Infarction (TIMI) Minor Bleeding
NCT01830543 (9) [back to overview]	Percentage of Participants With Bleeding Requiring Medical Attention (BRMA)
NCT01830543 (9) [back to overview]	Percentage of Participants With Cardiovascular Death
NCT01830543 (9) [back to overview]	Percentage of Participants With Composite of Adverse Cardiovascular Events (Cardiovascular Death, Myocardial Infarction (MI) and Stroke)
NCT01830543 (9) [back to overview]	Percentage of Participants With Clinically Significant Bleeding
NCT01830543 (9) [back to overview]	Percentage of Participants With Myocardial Infarction
NCT01830543 (9) [back to overview]	Percentage of Participants With Stent Thrombosis
NCT01830543 (9) [back to overview]	Percentage of Participants With Thrombolysis in Myocardial Infarction (TIMI) Major Bleeding
NCT01852175 (3) [back to overview]	Platelet Reactivity by Vasodilator-stimulated Phosphoprotein (VASP)
NCT01852175 (3) [back to overview]	Platelet Reactivity Measured by Vasodilator-stimulated Phosphoprotein (VASP)
NCT01852175 (3) [back to overview]	Platelet Reactivity Measured by Vasodilator-stimulated Phosphoprotein (VASP)
NCT01852214 (4) [back to overview]	P2Y12 Reaction Units
NCT01852214 (4) [back to overview]	Platelet Reactivity Index
NCT01852214 (4) [back to overview]	Platelet Reactivity Index
NCT01852214 (4) [back to overview]	P2Y12 Reaction Units
NCT01864005 (5) [back to overview]	the Percentage Inhibition of the P2Y12 Receptor
NCT01864005 (5) [back to overview]	the Percentage Inhibition of the P2Y12 Receptor
NCT01864005 (5) [back to overview]	the Percentage Inhibition of the P2Y12 Receptor
NCT01864005 (5) [back to overview]	the Percentage Inhibition of the P2Y12 Receptor
NCT01864005 (5) [back to overview]	the Percentage Inhibition of the P2Y12 Receptor
NCT01870921 (3) [back to overview]	Bleeding Events
NCT01870921 (3) [back to overview]	Serious Adverse Events Other Than Bleeding
NCT01870921 (3) [back to overview]	Major CV Events
NCT01898442 (6) [back to overview]	Platelet Reactivity by VerifyNow P2Y12
NCT01898442 (6) [back to overview]	Pharmacokinetic Profiles of Ticagrelor (Tmax)
NCT01898442 (6) [back to overview]	Pharmacokinetic Profiles of Ticagrelor (Cmax)
NCT01898442 (6) [back to overview]	Pharmacokinetic Profiles of Ticagrelor (AUC0-t)
NCT01898442 (6) [back to overview]	Platelet Reactivity by VerifyNow P2Y12 at Other Time Points
NCT01898442 (6) [back to overview]	Platelet Reactivity by Vasodilator-stimulated Phosphoprotein (VASP) at All Time Points
NCT01919723 (4) [back to overview]	Bleeding Complications
NCT01919723 (4) [back to overview]	Change in Percent Inhibition of Platelet Aggregation (%IPA)
NCT01919723 (4) [back to overview]	Periprocedural Myocardial Infarction (PMI)
NCT01919723 (4) [back to overview]	High On-treatment Platelet Reactivity (HPR)
NCT01962428 (1) [back to overview]	Platelet Reactivity Index(PRI) Measured by VASP-P
NCT01991795 (9) [back to overview]	TIMI Major Bleeding Event (Primary Safety Objective)
NCT01991795 (9) [back to overview]	TIMI Major or Minor Bleeding Event
NCT01991795 (9) [back to overview]	All-cause Death
NCT01991795 (9) [back to overview]	Composite of Cardiovascular (CV) Death, MI or Stroke
NCT01991795 (9) [back to overview]	CV Death
NCT01991795 (9) [back to overview]	Ischaemic Stroke
NCT01991795 (9) [back to overview]	MI
NCT01991795 (9) [back to overview]	Permanent Discontinuation of Study Medication Due to Any Bleeding Event
NCT01991795 (9) [back to overview]	PLATO Major Bleeding Event
NCT01992523 (4) [back to overview]	Bleeding Events
NCT01992523 (4) [back to overview]	Dyspnoea and/or Symptomatic Bradycardia
NCT01992523 (4) [back to overview]	Residual Platelet Reactivity
NCT01992523 (4) [back to overview]	High Residual Platelet Reactivity
NCT01994720 (18) [back to overview]	Number of Participants With Composite of Ischaemic Stroke, MI and CV Death
NCT01994720 (18) [back to overview]	Net Clinical Outcome
NCT01994720 (18) [back to overview]	Number of Participants With All-Cause Death
NCT01994720 (18) [back to overview]	Number of Participants by Severity of Stroke and Overall Disability
NCT01994720 (18) [back to overview]	EQ-5D at Visit 2 (Day 7+-2d)
NCT01994720 (18) [back to overview]	EQ-5D at Visit 1 (Enrolment)
NCT01994720 (18) [back to overview]	EQ-5D (EuroQol Five Dimensions Questionnaire) at Premature Treatment Discontinuation Visit
NCT01994720 (18) [back to overview]	EQ-5D (EuroQol Five Dimensions Questionnaire) at End of Treatment Visit
NCT01994720 (18) [back to overview]	Change in NIHSS
NCT01994720 (18) [back to overview]	Number of Participants With Stroke
NCT01994720 (18) [back to overview]	Number of Participants With Premature Discontinuation of Study Drug Due to Any Bleeding Adverse Event
NCT01994720 (18) [back to overview]	Number of Participants With PLATO Major Bleeding Event
NCT01994720 (18) [back to overview]	Number of Participants With MI
NCT01994720 (18) [back to overview]	Number of Participants With Ischaemic Stroke
NCT01994720 (18) [back to overview]	Number of Participants With Fatal Stroke
NCT01994720 (18) [back to overview]	Number of Participants With Disabling Stroke
NCT01994720 (18) [back to overview]	Number of Participants With CV Death
NCT01994720 (18) [back to overview]	Number of Participants With Composite of Stroke/MI/Death
NCT01998399 (13) [back to overview]	Ventilator Free Days
NCT01998399 (13) [back to overview]	Time to Initiation of Unassisted Breathing
NCT01998399 (13) [back to overview]	Stroke, Myocardial Infarct, Mortality
NCT01998399 (13) [back to overview]	Stroke
NCT01998399 (13) [back to overview]	Hospital Length of Stay
NCT01998399 (13) [back to overview]	Shock Free Days
NCT01998399 (13) [back to overview]	Need for Re-instituting Assisted or Mechanical Ventilation After Achieving 48 Consecutive Hours of Unassisted Breathing or Comfort Care Chosen (Withdrawal of Support)
NCT01998399 (13) [back to overview]	Need for Dialysis
NCT01998399 (13) [back to overview]	Myocardial Infarction
NCT01998399 (13) [back to overview]	In-hospital Mortality
NCT01998399 (13) [back to overview]	ICU Length of Stay
NCT01998399 (13) [back to overview]	All-cause Mortality
NCT01998399 (13) [back to overview]	Hospital Free Days
NCT02016170 (2) [back to overview]	Platelet Reactivity Measured as P2Y12 Reaction Units (PRU) Determined by Verify Now-P2Y12 Assay
NCT02016170 (2) [back to overview]	Platelet Reactivity Index (PRI) Measured by Whole Blood Vasodilator-stimulated Phosphoprotein (VASP).
NCT02022748 (6) [back to overview]	Pharmacokinetic Parameter AUC0-∞ of AR-C124910XX
NCT02022748 (6) [back to overview]	Pharmacokinetic Parameter AUC0-∞ (Area Under the Plasma Concentration-time Curve From Time Zero to Infinity) of Ticagrelor
NCT02022748 (6) [back to overview]	Pharmacokinetic Parameter Cmax of AR-C124910XX
NCT02022748 (6) [back to overview]	Pharmacokinetic Parameter Cmax of Ticagrelor
NCT02022748 (6) [back to overview]	Pharmacokinetic Parameter t1/2 of AR-C124910XX
NCT02022748 (6) [back to overview]	Pharmacokinetic Parameter t1/2 of Ticagrelor
NCT02052635 (2) [back to overview]	P2Y12 Reaction Units (PRU) Using VerifyNow™ at 0.5 Hours After Loading Dose
NCT02052635 (2) [back to overview]	P2Y12 Reaction Units (PRU) Using VerifyNow™ at 1 Hour After Loading Dose
NCT02053909 (2) [back to overview]	Saphenous Vein Graft Stenosis
NCT02053909 (2) [back to overview]	Saphenous Vein Graft Occlusion
NCT02064985 (52) [back to overview]	Pharmacokinetics Parameters of Metabolite (AR-C124910XX) on Day 1(1)
NCT02064985 (52) [back to overview]	Safety---Clinical Chemistry Variables Over Time---Phosphate
NCT02064985 (52) [back to overview]	Pharmacokinetics Parameters of Metabolite (AR-C124910XX) on Day 7(1)
NCT02064985 (52) [back to overview]	Pharmacokinetics Parameters of Metabolite (AR-C124910XX) on Day 7(2)
NCT02064985 (52) [back to overview]	Pharmacokinetics Parameters of Metabolite (AR-C124910XX) on Day 7(3)
NCT02064985 (52) [back to overview]	Pharmacokinetics Parameters of Metabolite (AR-C124910XX) on Day 7(4)
NCT02064985 (52) [back to overview]	Pharmacokinetics Parameters of Ticagrelor on Day 1(1)
NCT02064985 (52) [back to overview]	Safety---Hematology Laboratory Variables Over Time---Hemoglobin
NCT02064985 (52) [back to overview]	Safety---Hematology Laboratory Variables Over Time---Leukocytes
NCT02064985 (52) [back to overview]	Safety---Hematology Laboratory Variables Over Time---Platelets
NCT02064985 (52) [back to overview]	Pharmacokinetics Parameters of Ticagrelor on Day 7(3)
NCT02064985 (52) [back to overview]	Safety---Vital Signs Over Time---Height
NCT02064985 (52) [back to overview]	Safety---Vital Signs Over Time---Weight
NCT02064985 (52) [back to overview]	TIPA(Max)---Day 1
NCT02064985 (52) [back to overview]	TIPA(Max)---Day 7
NCT02064985 (52) [back to overview]	IPA on Day 1
NCT02064985 (52) [back to overview]	IPA on Day 7
NCT02064985 (52) [back to overview]	Pharmacokinetics Parameters of Ticagrelor on Day 7(1)
NCT02064985 (52) [back to overview]	Pharmacokinetics Parameters of Ticagrelor on Day 7(2)
NCT02064985 (52) [back to overview]	Pharmacokinetics Parameters of Ticagrelor on Day 7(4)
NCT02064985 (52) [back to overview]	Safety---Clinical Chemistry Variables Over Time---Alanine Aminotransferase
NCT02064985 (52) [back to overview]	Safety---Clinical Chemistry Variables Over Time---Albumin
NCT02064985 (52) [back to overview]	Safety---Clinical Chemistry Variables Over Time---Alkaline Phosphatase
NCT02064985 (52) [back to overview]	Safety---Clinical Chemistry Variables Over Time---Aspartate Aminotransferase
NCT02064985 (52) [back to overview]	Safety---Clinical Chemistry Variables Over Time---Bicarbonate
NCT02064985 (52) [back to overview]	Safety---Clinical Chemistry Variables Over Time---Blood Urea Nitrogen
NCT02064985 (52) [back to overview]	Safety---Clinical Chemistry Variables Over Time---Chloride
NCT02064985 (52) [back to overview]	Safety---Clinical Chemistry Variables Over Time---Creatinine
NCT02064985 (52) [back to overview]	Safety---Clinical Chemistry Variables Over Time---Glucose
NCT02064985 (52) [back to overview]	Safety---Clinical Chemistry Variables Over Time---Potassium
NCT02064985 (52) [back to overview]	Safety---Clinical Chemistry Variables Over Time---Protein
NCT02064985 (52) [back to overview]	Safety---Clinical Chemistry Variables Over Time---Sodium
NCT02064985 (52) [back to overview]	AUEC(Final Extent) on Day 1
NCT02064985 (52) [back to overview]	Safety---Hematology Laboratory Variables Over Time---Erythrocytes
NCT02064985 (52) [back to overview]	Safety---Hematology Laboratory Variables Over Time---hematocrit
NCT02064985 (52) [back to overview]	Percent Change From Baseline in PRU on Day 1
NCT02064985 (52) [back to overview]	Percent Change From Baseline in PRU on Day 7
NCT02064985 (52) [back to overview]	Pharmacokinetics Parameters of Metabolite (AR-C124910XX) on Day 1(2)
NCT02064985 (52) [back to overview]	Pharmacokinetics Parameters of Metabolite (AR-C124910XX) on Day 1(3)
NCT02064985 (52) [back to overview]	Pharmacokinetics Parameters of Ticagrelor on Day 1(2)
NCT02064985 (52) [back to overview]	Pharmacokinetics Parameters of Ticagrelor on Day 1(3)
NCT02064985 (52) [back to overview]	Safety---All Allowed Concomitant Medications During Study Treatment
NCT02064985 (52) [back to overview]	Safety---Causally Related Adverse Events by System Organ Class and Preferred Term
NCT02064985 (52) [back to overview]	Safety---Physical Examination, Summary of Abnormalities
NCT02064985 (52) [back to overview]	AUEC(Final Extent) on Day 7
NCT02064985 (52) [back to overview]	Safety---Clinical Chemistry Variables Over Time---Total Bilirubin
NCT02064985 (52) [back to overview]	Pharmacokinetics Parameters of Metabolite : Parent on Day 1--AUC(0-inf)
NCT02064985 (52) [back to overview]	Pharmacokinetics Parameters of Metabolite : Parent on Day 1--Cmax
NCT02064985 (52) [back to overview]	Pharmacokinetics Parameters of Metabolite : Parent on Day 7---AUC(0-12h)
NCT02064985 (52) [back to overview]	Pharmacokinetics Parameters of Metabolite : Parent on Day 7---Cmax
NCT02064985 (52) [back to overview]	Safety---Vital Signs Over Time---Blood Pressure
NCT02064985 (52) [back to overview]	Safety---Vital Signs Over Time---Pulse Rate
NCT02065479 (1) [back to overview]	Platelet Reactivity
NCT02075125 (7) [back to overview]	Adverse Drug Reaction
NCT02075125 (7) [back to overview]	Bleeding Event
NCT02075125 (7) [back to overview]	Major Adverse Cardiac and Cerebrovascular Events
NCT02075125 (7) [back to overview]	Pre-procedure P2Y12 Reaction Units (PRU)
NCT02075125 (7) [back to overview]	Pre-procedure Platelet Reactivity Index (PRI)
NCT02075125 (7) [back to overview]	Number of Participants With High Platelet Reactivity
NCT02075125 (7) [back to overview]	Number of Participants With Low Platelet Reactivity
NCT02081443 (3) [back to overview]	Platelet Reactivity Index (PRI) Determined by Whole Blood Vasodilator-stimulated Phosphoprotein (VASP)
NCT02081443 (3) [back to overview]	PRI Measured by VASP
NCT02081443 (3) [back to overview]	PRI Measured by VASP
NCT02091921 (4) [back to overview]	To Determine Platelet Inhibition Before and After Switching for Two Weeks From Clopidogrel to Ticagrelor in Patients With CLI.
NCT02091921 (4) [back to overview]	Establish the Number of Participants in the High On-treatment Platelet Reactivity (HPR) on Clopidogrel Group Who Demonstrated Appropriate Platelet Inhibition (API) After Switching to Ticagrelor for Two Weeks.
NCT02091921 (4) [back to overview]	Evaluate the Correlation Between PRU and VASP-PRI in CLI Patients During Clopidogrel Versus Ticagrelor Antiplatelet Therapy.
NCT02091921 (4) [back to overview]	Establish the Number of Participants With Appropriate Platelet Inhibition on Clopidogrel Who Demonstrated Appropriate Platelet Inhibition After Switching to Ticagrelor for Two Weeks.
NCT02164864 (13) [back to overview]	Time to First Adjudicated Stroke
NCT02164864 (13) [back to overview]	Time to First Adjudicated Unplanned Revascularisation by PCI/CABG
NCT02164864 (13) [back to overview]	Time to First Adjudicated ST
NCT02164864 (13) [back to overview]	Time to First Adjudicated SE
NCT02164864 (13) [back to overview]	Time to First Adjudicated MI
NCT02164864 (13) [back to overview]	Time to First Adjudicated ISTH MBE or CRNMBE
NCT02164864 (13) [back to overview]	Time to Death or First Thrombotic Event or Unplanned Revascularisation by PCI/CABG
NCT02164864 (13) [back to overview]	Time to Composite Endpoint of Death or First Thrombotic Event
NCT02164864 (13) [back to overview]	Time to Composite Endpoint of Death + MI + Stroke
NCT02164864 (13) [back to overview]	Time to Adjudicated Undetermined Cause of Death
NCT02164864 (13) [back to overview]	Time to Adjudicated Non-CV
NCT02164864 (13) [back to overview]	Time to Adjudicated CV
NCT02164864 (13) [back to overview]	Time to Adjudicated All Cause Death
NCT02201394 (2) [back to overview]	P2Y12 Reaction Unit (PRU)
NCT02201394 (2) [back to overview]	Platelet Aggregation Using Multiplate Analyzer
NCT02201771 (6) [back to overview]	The Number of Major Adverse Cardiovascular Event (MACE)
NCT02201771 (6) [back to overview]	Number of the Major Bleeding Events
NCT02201771 (6) [back to overview]	The Rate of Post-operative Atrial Fibrillation After CABG.
NCT02201771 (6) [back to overview]	The Patency of Saphenous Vein Grafts
NCT02201771 (6) [back to overview]	The Patency of Saphenous Vein Grafts
NCT02201771 (6) [back to overview]	The Rate of Freedom From Angina According to Canadian Cardiovascular Society (CCS) Classification
NCT02214121 (30) [back to overview]	Assessment of AR-C124910XX Concentration - Part A
NCT02214121 (30) [back to overview]	P2Y12 Reaction Units (PRU) - Part A
NCT02214121 (30) [back to overview]	P2Y12 Reaction Units (PRU) - Part A
NCT02214121 (30) [back to overview]	P2Y12 Reaction Units (PRU) - Part A
NCT02214121 (30) [back to overview]	P2Y12 Reaction Units (PRU) - Part B
NCT02214121 (30) [back to overview]	Mean Intensity of Pain (Age >=4) - Part B
NCT02214121 (30) [back to overview]	Maximum Plasma Concentration (Cmax) - Part B
NCT02214121 (30) [back to overview]	Area Under the Plasma Concentration Time Curve (AUC) - Part A
NCT02214121 (30) [back to overview]	Area Under the Plasma Concentration Time Curve (AUC) - Part B
NCT02214121 (30) [back to overview]	Haemorrhagic Events - Part A
NCT02214121 (30) [back to overview]	Haemorrhagic Events - Part B
NCT02214121 (30) [back to overview]	Maximum Plasma Concentration (Cmax) - Part A
NCT02214121 (30) [back to overview]	Number of Vaso-occlusive Crises - Part B
NCT02214121 (30) [back to overview]	Number of Vaso-occlusive Crises Requiring Hospitalization or Emergency Department Visits - Part B
NCT02214121 (30) [back to overview]	Oral Clearance (CL/F) - Part A
NCT02214121 (30) [back to overview]	Oral Clearance (CL/F) - Part B
NCT02214121 (30) [back to overview]	Percentage of Days Hospitalized for Vaso-occlusice Crisis or Other Complications of Sickle Cell Disease - Part B
NCT02214121 (30) [back to overview]	Percentage of Days of Absence From School or Work (Age >=6) - Part B
NCT02214121 (30) [back to overview]	Percentage of Days of Analgesic Use (Age >= 4) - Part B
NCT02214121 (30) [back to overview]	Percentage of Days of Opioid Analgesic Use (Age >=4) - Part B
NCT02214121 (30) [back to overview]	Percentage of Days With Pain (Age >=4) - Part B
NCT02214121 (30) [back to overview]	Assessment of AR-C124910XX Concentration - Part A
NCT02214121 (30) [back to overview]	Assessment of AR-C124910XX Concentration - Part A
NCT02214121 (30) [back to overview]	Assessment of AR-C124910XX Concentration - Part A
NCT02214121 (30) [back to overview]	Assessment of AR-C124910XX Concentration - Part B
NCT02214121 (30) [back to overview]	Assessment of Ticagrelor Concentration - Part A
NCT02214121 (30) [back to overview]	Assessment of Ticagrelor Concentration - Part A
NCT02214121 (30) [back to overview]	Assessment of Ticagrelor Concentration - Part A
NCT02214121 (30) [back to overview]	Assessment of Ticagrelor Concentration - Part A
NCT02214121 (30) [back to overview]	Assessment of Ticagrelor Concentration - Part B
NCT02217878 (38) [back to overview]	Area Under the Plasma Concentration-time Curve for Ticagrelor (AUC 0-6h)
NCT02217878 (38) [back to overview]	Maximum Concentration of AR-C124910XX
NCT02217878 (38) [back to overview]	Maximum Concentration of Ticagrelor
NCT02217878 (38) [back to overview]	P2Y12 Reaction Units Assessed by VerifyNow
NCT02217878 (38) [back to overview]	P2Y12 Reaction Units Assessed by VerifyNow
NCT02217878 (38) [back to overview]	P2Y12 Reaction Units Assessed by VerifyNow
NCT02217878 (38) [back to overview]	Area Under the Plasma Concentration-time Curve for AR-C124910XX (AUC 0-12h)
NCT02217878 (38) [back to overview]	Area Under the Plasma Concentration-time Curve for AR-C124910XX (AUC 0-6)
NCT02217878 (38) [back to overview]	P2Y12 Reaction Units Assessed by VerifyNow
NCT02217878 (38) [back to overview]	Area Under the Plasma Concentration-time Curve for Ticagrelor (AUC 0-12h)
NCT02217878 (38) [back to overview]	P2Y12 Reaction Units Assessed by VerifyNow
NCT02217878 (38) [back to overview]	P2Y12 Reaction Units Assessed by VerifyNow
NCT02217878 (38) [back to overview]	P2Y12 Reaction Units Assessed by VerifyNow
NCT02217878 (38) [back to overview]	P2Y12 Reaction Units Assessed by VerifyNow
NCT02217878 (38) [back to overview]	Percentage of Patients With High Platelet Reactivity After the Loading Dose of Ticagrelor Assessed With MEA
NCT02217878 (38) [back to overview]	Percentage of Patients With High Platelet Reactivity After the Loading Dose of Ticagrelor Assessed With VASP
NCT02217878 (38) [back to overview]	Percentage of Patients With High Platelet Reactivity After the Loading Dose of Ticagrelor Assessed With VerifyNow
NCT02217878 (38) [back to overview]	Platelet Arbitrary Aggregation Units Assessed by Multiple Electrode Aggregometry
NCT02217878 (38) [back to overview]	Platelet Arbitrary Aggregation Units Assessed by Multiple Electrode Aggregometry
NCT02217878 (38) [back to overview]	Platelet Arbitrary Aggregation Units Assessed by Multiple Electrode Aggregometry
NCT02217878 (38) [back to overview]	Platelet Arbitrary Aggregation Units Assessed by Multiple Electrode Aggregometry
NCT02217878 (38) [back to overview]	Platelet Arbitrary Aggregation Units Assessed by Multiple Electrode Aggregometry
NCT02217878 (38) [back to overview]	Platelet Arbitrary Aggregation Units Assessed by Multiple Electrode Aggregometry
NCT02217878 (38) [back to overview]	Platelet Arbitrary Aggregation Units Assessed by Multiple Electrode Aggregometry
NCT02217878 (38) [back to overview]	Platelet Arbitrary Aggregation Units Assessed by Multiple Electrode Aggregometry
NCT02217878 (38) [back to overview]	Platelet Reactivity Index Assessed by VASP Assay
NCT02217878 (38) [back to overview]	Platelet Reactivity Index Assessed by VASP Assay
NCT02217878 (38) [back to overview]	Platelet Reactivity Index Assessed by VASP Assay
NCT02217878 (38) [back to overview]	Platelet Reactivity Index Assessed by VASP Assay
NCT02217878 (38) [back to overview]	Platelet Reactivity Index Assessed by VASP Assay
NCT02217878 (38) [back to overview]	Platelet Reactivity Index Assessed by VASP Assay
NCT02217878 (38) [back to overview]	Platelet Reactivity Index Assessed by VASP Assay
NCT02217878 (38) [back to overview]	Platelet Reactivity Index Assessed by VASP Assay
NCT02217878 (38) [back to overview]	Time to Maximum Concentration for AR-C124910XX
NCT02217878 (38) [back to overview]	Time to Maximum Concentration for Ticagrelor
NCT02217878 (38) [back to overview]	Time to Reach Platelet Reactivity Below the Cut-off Value for High Platelet Reactivity Evaluated With MEA
NCT02217878 (38) [back to overview]	Time to Reach Platelet Reactivity Below the Cut-off Value for High Platelet Reactivity Evaluated With VASP
NCT02217878 (38) [back to overview]	Time to Reach Platelet Reactivity Below the Cut-off Value for High Platelet Reactivity Evaluated With VerifyNow
NCT02224274 (3) [back to overview]	Multiplate ADP Test
NCT02224274 (3) [back to overview]	VerifyNow P2Y12Test - % Inhibition
NCT02224274 (3) [back to overview]	VerifyNow P2Y12Test - Platelet Reactivity
NCT02227368 (2) [back to overview]	Change From Baseline in Log Transformed Claudication Onset Time (COT) at Week 26 or Early Termination (ET)
NCT02227368 (2) [back to overview]	Change From Baseline in Log Transformed Peak Walking Time (PWT) at Week 26 or Early Termination (ET)
NCT02230527 (1) [back to overview]	Absolute Change in TcPO2 From Baseline to Month 6
NCT02270242 (2) [back to overview]	Number of Participants With BARC Type 2, 3, or 5
NCT02270242 (2) [back to overview]	Number of Participants With Ischemic Episode
NCT02287909 (1) [back to overview]	Platelet Reactivity Unit
NCT02291419 (6) [back to overview]	Major Adverse Cardiovascular Events
NCT02291419 (6) [back to overview]	Non-fatal Myocardial Infarction or Coronary Revascularization
NCT02291419 (6) [back to overview]	Non-fatal Stroke
NCT02291419 (6) [back to overview]	The Number of Participants With Bleeding According to Bleeding Academic Research Consortium (BARC) Definitions
NCT02291419 (6) [back to overview]	All-cause Death
NCT02291419 (6) [back to overview]	Cardiovascular Death
NCT02293395 (1) [back to overview]	Number of Participants With Non Coronary Artery Bypass Graft-Related (Non CABG-related) Thrombolysis in Myocardial Infarction (TIMI) Clinically Significant Bleeding Events
NCT02325466 (4) [back to overview]	Mean Change in Microvascular Blood Flow Composite Score
NCT02325466 (4) [back to overview]	Mean Change in High Shear Blood Viscosity
NCT02325466 (4) [back to overview]	Mean Change in Peripheral Arterial Blood Flow
NCT02325466 (4) [back to overview]	Mean Change in Low Shear Blood Viscosity
NCT02335099 (2) [back to overview]	Treatment Efficacy of Ticagrelor to Preserve Patency of Hemodialysis Vascular Access
NCT02335099 (2) [back to overview]	Feasibility and Safety of Ticagrelor in Hemodialysis Patients
NCT02376283 (3) [back to overview]	Pharmacodynamic Assessment of Degree of Platelet Inhibition as Determined by Verify Now Point of Care Assay and Expressed as P2Y12 Reaction Units (PRU)
NCT02376283 (3) [back to overview]	Pharmacokinetic Quantification of Plasma Concentration of Clopidogrel and Prasugrel Active Metabolite and Ticagrelor Parent Compound and Active Metabolite Assessed Using Liquid Chromatography in Tandem With Mass Spectrometry (LC-MS/MS) Expressed as ng/ml
NCT02376283 (3) [back to overview]	Pharmacodynamic Assessment of Degree of Platelet Inhibition as Determined by VASP (Vasodilator Stimulated Phosphoprotein Phosphorylation) Flow Cytometry and Expressed as %PRI (Platelet Reactivity Index)
NCT02400333 (13) [back to overview]	Area Under Plasma Concentration-time Curve From Zero to Infinity (AUC [0-∞]).
NCT02400333 (13) [back to overview]	Ratio of Metabolite Cmax to Parent Cmax, Adjusted for Differences in Molecular Weights (MRCmax) of Metabolite AR-C124910XX.
NCT02400333 (13) [back to overview]	Ratio of Metabolite AUC(0-t) to Parent AUC(0-t), Adjusted for Differences in Molecular Weights (MRAUC[0-t]) of Metabolite AR-C124910XX.
NCT02400333 (13) [back to overview]	Ratio of Metabolite AUC [0-∞] to Parent AUC [0-∞], Adjusted for Differences in Molecular Weights (MRAUC [0-∞]) of Metabolite AR-C124910XX.
NCT02400333 (13) [back to overview]	Participants With Significant Findings in 12-Lead Electrocardiography (ECG).
NCT02400333 (13) [back to overview]	Participants With Clinically Significant Findings in Hematology, Clinical Chemistry and Urinalysis.
NCT02400333 (13) [back to overview]	Mean Change From Baseline for Vital Signs in Supine Pulse Rate.
NCT02400333 (13) [back to overview]	Time to Reach Maximum Observed Concentration (Tmax) of Ticagrelor and Its Active Metabolite AR-C124910XX.
NCT02400333 (13) [back to overview]	Percentage of Participants With Adverse Events (AEs).
NCT02400333 (13) [back to overview]	Mean Change From Baseline for Vital Signs of Supine Blood Pressure (SBP) and Diastolic BP (DBP).
NCT02400333 (13) [back to overview]	Maximum Observed Plasma Concentration (Cmax) of Ticagrelor and Its Active Metabolite AR-C124910XX.
NCT02400333 (13) [back to overview]	Half-life Associated With Terminal Slope (λz) of a Semi-logarithmic Concentration-time Curve (t½λz) of Ticagrelor and Its Active Metabolite AR-C124910XX.
NCT02400333 (13) [back to overview]	Area Under the Plasma Concentration-time Curve From Time Zero to Time of Last Quantifiable Analyte Concentration (AUC[0-t]) of Ticagrelor and Its Active Metabolite AR-C124910XX.
NCT02403830 (3) [back to overview]	Platelet Reactivity Measured by VerifyNow P2Y12
NCT02403830 (3) [back to overview]	AUC of Ticagrelor Plasma Levels
NCT02403830 (3) [back to overview]	Platelet Reactivity Measured by VASP
NCT02436577 (16) [back to overview]	MRCmax (Ratio of Metabolite Cmax to Parent Cmax, Adjusted for Differences in Molecular Weights) of Active Metabolite AR-C124910XX
NCT02436577 (16) [back to overview]	Time to Reach Maximum Observed Concentration (Tmax) of Ticagrelor and Its Active Metabolite AR-C124910XX.
NCT02436577 (16) [back to overview]	Terminal Elimination Rate Constant (λz) of Ticagrelor and Its Active Metabolite, AR-C124910XX.
NCT02436577 (16) [back to overview]	Number of Participants With Adverse Events (AEs)
NCT02436577 (16) [back to overview]	Mean Residence Time (MRT) of Ticagrelor and Its Active Metabolite AR-C124910XX
NCT02436577 (16) [back to overview]	Participants With Clinically Significant Findings in Hematology, Clinical Chemistry and Urinalysis.
NCT02436577 (16) [back to overview]	Maximum Observed Plasma Concentration (Cmax) of Ticagrelor and Its Active Metabolite AR-C124910XX.
NCT02436577 (16) [back to overview]	Half-life Associated With Terminal Slope (λz) of a Semi-logarithmic Concentration-time Curve (t½λz) of Ticagrelor and Its Active Metabolite AR-C124910XX.
NCT02436577 (16) [back to overview]	Area Under the Plasma Concentration-time Curve From Time Zero to Time of Last Quantifiable Analyte Concentration AUC (0-t) of Ticagrelor and Its Active Metabolite AR-C124910XX.
NCT02436577 (16) [back to overview]	Mean Change From Baseline for Vital Signs of Supine Blood Pressure (SBP) and Diastolic BP (DBP)
NCT02436577 (16) [back to overview]	Mean Change From Baseline for Vital Signs in Supine Pulse Rate.
NCT02436577 (16) [back to overview]	Area Under Plasma Concentration-time Curve From Zero to Infinity (AUC) of Ticagrelor and Its Active Metabolite AR-C124910XX.
NCT02436577 (16) [back to overview]	Ratio of Metabolite AUC(0-t) to Parent AUC(0-t), Adjusted for Differences in Molecular Weights (MRAUC [0-t]) of Active Metabolite AR-C124910XX
NCT02436577 (16) [back to overview]	Elimination Rate Constant (Kel) of Ticagrelor and Its Active Metabolite AR-C124910XX
NCT02436577 (16) [back to overview]	Ratio of Metabolite AUC to Parent AUC, Adjusted for Differences in Molecular Weights (MRAUC) of Active Metabolite AR-C124910XX
NCT02436577 (16) [back to overview]	Participants With Significant Findings in 12-Lead Electrocardiography (ECG).
NCT02482298 (5) [back to overview]	Number of Major Bleeding or Clinically Relevant Non-major Bleeding Events (Events)
NCT02482298 (5) [back to overview]	Change in Proportion of Days With Analgesic Use Measured by an eDiary
NCT02482298 (5) [back to overview]	Average of the Daily Worst Pain Values Reported Via eDiary
NCT02482298 (5) [back to overview]	Change in Proportion of Days With Pain Due to Sickle Cell Disease as Measured by an eDiary
NCT02482298 (5) [back to overview]	Number of Major Bleeding or Clinically Relevant Non-major Bleeding Events (Patients)
NCT02486367 (8) [back to overview]	Change in IL-6 as Measured by Blood Test.
NCT02486367 (8) [back to overview]	Change in D-Dimer Levels as Measured by Blood Test
NCT02486367 (8) [back to overview]	Change in Mono-2b3a as Measured by Blood Test
NCT02486367 (8) [back to overview]	Change in Mono-CD62P as Measured by Blood Test
NCT02486367 (8) [back to overview]	Change in IL-8 as Measured by Blood Test
NCT02486367 (8) [back to overview]	Platelet Reactivity
NCT02486367 (8) [back to overview]	Inflammatory Monocyte Proportion
NCT02486367 (8) [back to overview]	Change in sCD14 as Measured by Blood Test.
NCT02518464 (1) [back to overview]	Total Number of Responders
NCT02539160 (2) [back to overview]	Platelet Reactivity Measured by Vasodilator Stimulated Phosphoprotein (VASP) Platelet Reactivity Index (PRI %)
NCT02539160 (2) [back to overview]	Platelet Reactivity Measured by VerifyNow P2Y12
NCT02545933 (1) [back to overview]	Maximal Platelet Aggregation
NCT02742987 (1) [back to overview]	Flow-mediated Dilation of the Brachial Artery
NCT02866175 (7) [back to overview]	Number of Participants With Adjudicated Major, Minor, and Minimal Bleeding by Thrombolysis in Myocardial Infarction (TIMI) Definition Following Edoxaban-based Regimen Compared With Vitamin K Antagonist (VKA)-Based Regimen
NCT02866175 (7) [back to overview]	Number of Participants With Adjudicated Major, Clinically Relevant Non-major and Minor Bleeding (All Events) Defined by International Society on Thrombosis and Haemostasis Following Edoxaban-based Regimen Compared With Vitamin K Antagonist-Based Regimen
NCT02866175 (7) [back to overview]	Number of Participants With Adjudicated Major or Clinically Relevant Non-major Bleeding As First Event Defined by International Society on Thrombosis and Haemostasis Following Edoxaban-based Regimen Compared With Vitamin K Antagonist (VKA)-Based Regimen
NCT02866175 (7) [back to overview]	Number of Participants With Bleeding Academic Research Consortium (BARC) Type 1, 2, 3, and 5 Bleeding According to the BARC Definitions Following Edoxaban-based Regimen Compared With Vitamin K Antagonist (VKA)-Based Regimen
NCT02866175 (7) [back to overview]	Number of Participants With Study Drug-related Treatment-emergent Adverse Events (TEAEs) Experienced by 2 or More Participants Following Edoxaban-based Regimen Compared With Vitamin K Antagonist (VKA)-Based Regimen
NCT02866175 (7) [back to overview]	Number of Participants With Treatment-emergent Adverse Events (TEAEs) Following Edoxaban-based Regimen Compared With Vitamin K Antagonist (VKA)-Based Regimen
NCT02866175 (7) [back to overview]	Number of Participants With Main Efficacy Endpoints For the Overall Study Period Following Edoxaban-based Regimen Compared With Vitamin K Antagonist (VKA)-Based Regimen
NCT02874092 (3) [back to overview]	Visual Analog Scale Disease Activity
NCT02874092 (3) [back to overview]	Disease Activity Score for 28-joint Counts (DAS28)
NCT02874092 (3) [back to overview]	Change in Brachial Artery Diameter
NCT02925923 (12) [back to overview]	Number of Participants With a Change in high-on Treatment Platelet Reactivity (HPR)
NCT02925923 (12) [back to overview]	Change in Hemoglobin Levels (g/dL)
NCT02925923 (12) [back to overview]	A Change in Hematocrit Levels
NCT02925923 (12) [back to overview]	Number of Patients With Minor Bleeding Complications
NCT02925923 (12) [back to overview]	Number of Patients With Minor Bleeding Complications
NCT02925923 (12) [back to overview]	Number of Patients With Major Bleeding Complications
NCT02925923 (12) [back to overview]	Number of Patients With Major Bleeding Complications
NCT02925923 (12) [back to overview]	Number of Participants With a Periprocedural Myocardial Infarction and Injury (PMI)
NCT02925923 (12) [back to overview]	Heparin Dose, Unit/Kg
NCT02925923 (12) [back to overview]	Activated Clotting Time (ACT), Seconds
NCT02925923 (12) [back to overview]	Platelet Aggregation Levels
NCT02925923 (12) [back to overview]	Number of Patients With Negative Clinical Outcomes
NCT02931045 (1) [back to overview]	Concentration of Platelet Extracellular Vesicles/ml
NCT03354429 (7) [back to overview]	Composite of Subsequent Stroke or Death
NCT03354429 (7) [back to overview]	ICH or Fatal Bleeding Event
NCT03354429 (7) [back to overview]	Bleeding Event That Fulfils Serious Adverse Event Criteria and is Categorised as GUSTO Moderate/Severe
NCT03354429 (7) [back to overview]	Bleeding Event That Fulfils Serious Adverse Event Criteria and is Categorised as GUSTO Severe
NCT03354429 (7) [back to overview]	Ischaemic Stroke
NCT03354429 (7) [back to overview]	Number of Participants With Modified Rankin Scale (mRS) Score >1 at Visit 3
NCT03354429 (7) [back to overview]	Premature Permanent Discontinuation of IP Due to Bleeding
NCT03381742 (2) [back to overview]	ADP-induced Platelet-fibrin Clot Strength (MA)
NCT03381742 (2) [back to overview]	ADP-induced Inhibition of Platelet Aggregation
NCT03437044 (2) [back to overview]	P2Y12 Reaction Units (PRU)
NCT03437044 (2) [back to overview]	Platelet Reactivity Index (PRI)
NCT03489863 (1) [back to overview]	P2Y12 Reaction Unit (PRU)
NCT03615924 (20) [back to overview]	Percentage of Days of Absence From School or Work Due to Sickle Cell Disease
NCT03615924 (20) [back to overview]	Type of Analgesics Used by Participants During Vaso-Occlusive Crisis Events
NCT03615924 (20) [back to overview]	Number of Vaso-Occlusive Crisis Events Requiring Hospitalization or Emergency Department Visits
NCT03615924 (20) [back to overview]	Number of Sickle Cell-Related Red Blood Cell (RBC) Transfusions
NCT03615924 (20) [back to overview]	Number of Painful Crisis Events
NCT03615924 (20) [back to overview]	Number of Days Hospitalized for Vaso-Occlusive Crisis Events
NCT03615924 (20) [back to overview]	Number of Days Hospitalized for Acute Sickle Cell Disease Complications
NCT03615924 (20) [back to overview]	Number of Acute Sickle Cell Disease Complications
NCT03615924 (20) [back to overview]	Number of Vaso-Occlusive Crisis Events
NCT03615924 (20) [back to overview]	Average Intensity of Worst Pain Daily During Vaso-Occlusive Crisis Events in Participants ≥5 Years of Age
NCT03615924 (20) [back to overview]	Average Intensity of Worst Pain Daily During Vaso-Occlusive Crisis Events in Participants <5 Years of Age
NCT03615924 (20) [back to overview]	Duration of Painful Crises
NCT03615924 (20) [back to overview]	Number of Acute Chest Syndrome Events
NCT03615924 (20) [back to overview]	Swallowability of the Study Treatment Assessed by Study Medication Palatability Assessment in Participants ≤4 Years of Age
NCT03615924 (20) [back to overview]	Palatability of the Study Treatment Assessed by Study Medication Palatability Assessment (SMPA) in Participants ≤4 Years of Age
NCT03615924 (20) [back to overview]	Palatability of the Study Treatment Assessed by Facial Hedonic Scale (FHS) in Participants ≥5 Years of Age
NCT03615924 (20) [back to overview]	Health-Related Quality of Life Total Score Using the Pediatric Quality of Life Inventory (PedsQL) Sickle Cell Disease Module
NCT03615924 (20) [back to overview]	Health-Related Quality of Life Total Score Using the Pediatric Quality of Life Inventory (PedsQL) Sickle Cell Disease Module
NCT03615924 (20) [back to overview]	Fatigue Total Score Using Pediatric Quality of Life Inventory Multidimensional Fatigue Scale
NCT03615924 (20) [back to overview]	Fatigue Total Score Using Pediatric Quality of Life Inventory Multidimensional Fatigue Scale
NCT03649711 (2) [back to overview]	ADP Induced Platelet Aggregation
NCT03649711 (2) [back to overview]	Platelet Surface P-selectin Expression
NCT03708588 (3) [back to overview]	Number of Participants With Major Adverse Cardiac and Cerebrovascular Event (MACCE)
NCT03708588 (3) [back to overview]	Number of Participants With Major Adverse Cardiac and Cerebrovascular Event (MACCE)
NCT03708588 (3) [back to overview]	Concentration of Pharmacodynamics
NCT03822377 (6) [back to overview]	Percent of Patients With Insufficient Antiaggregation
NCT03822377 (6) [back to overview]	Number of Participants With Clinically Relevant Bleeding Events
NCT03822377 (6) [back to overview]	Number of Participants With Morphine-ticagrelor Interaction
NCT03822377 (6) [back to overview]	Number of Participants With Residual Platelet Reactivity at Various Timepoints
NCT03822377 (6) [back to overview]	Evaluation of Platelet Inhibition
NCT03822377 (6) [back to overview]	Incidence of Adverse Events Occurring During Hospital Stay
NCT04006288 (1) [back to overview]	Maximal Platelet Aggregation (MPA%) by Light Transmittance Aggregometry (LTA)
NCT05093790 (5) [back to overview]	Number of Participants Experiencing Clinical Lab Abnormalities
NCT05093790 (5) [back to overview]	Percent Change From Baseline in Thrombus Area
NCT05093790 (5) [back to overview]	Number of Participants Experiencing Adverse Events (AEs)
NCT05093790 (5) [back to overview]	Number of Participants Experiencing Abnormal Electrocardiogram (ECG) Values
NCT05093790 (5) [back to overview]	Number of Participants Experiencing Abnormal Vital Signs

Participants With Any Event From the Composite of All-cause Mortality, MI, and Stroke

Participants with death from any cause, MI, or stroke. If no event, censoring occurs at the earliest of patient withdrawal of consent or date of scheduled withdrawal from therapy. ITT analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months

Intervention	Participants (Number)
TICAGRELOR	901
CLOPIDOGREL	1065

Intervention	percentage inhibition (Mean)
Arm 1 - AZD6140 45 mg bd	56.9
AZD6140 90 mg bd	66.8
Clopidogrel 75 mg od	41.8

Intervention	ng.h/mL (Geometric Mean)
AZD6140 45 mg bd in Japanese Patients	1180
AZD6140 45 mg bd in Non-Japanese Patients	954
AZD6140 90 mg bd in Japanese Patients	2720
AZD6140 90 mg bd in Non-Japanese Patients	3380

Intervention	ng/mL (Geometric Mean)
AZD6140 45 mg bd in Japanese Patients	135
AZD6140 45mg bd in Non-Jpanese Patients	101
AZD6140 90 mg bd in Japanese Patients	326
AZD6140 90 mg bd in Non-Jpanese Patients	381

Intervention	ng.h/mL (Geometric Mean)
AZD6140 45 mg bd in Japanese Patients	3050
AZD6140 45 mg bd in Non-Japanese Patients	2930
AZD6140 90 mg bd in Japanese Patients	6080
AZD6140 90 mg bd in Non-Japanese Patients	10900

Intervention	percentage inhibition (Mean)
AZD6140 45 mg bd	64.5
AZD6140 90 mg bd	73.0
Clopidogrel 75 mg od	38.9

Intervention	percentage inhibition (Mean)
AZD6140 45 mg bd	46.2
AZD6140 90 mg bd	59.1
Clopidogrel 75 mg od	38.0

Intervention	percentage inhibition (Mean)
AZD6140 45 mg bd	67.3
AZD6140 90 mg bd	73.2
Clopidogrel 75 mg od	43.7

Intervention	percentage inhibition (Mean)
AZD6140 45 mg bd	62.7
AZD6140 90 mg bd	68.6
Clopidogrel 75 mg od	42.5

Intervention	ng/mL (Geometric Mean)
	Baseline (0 hours - pre-dose)	0,.5 hours after the loading dose	2 hours after the loading dose - Period 2 N=18	8 hours after the loading dose	0 hours after multiple doses	2 hours after multiple doses	8 hours after multiple doses	End of dosing interval on Day 8 - Period 1 N=17
Ticagrelor (Treatment Period 1)	1.2	206.7	665.4	376.9	248.8	609.3	340.4	283.3
Ticagrelor (Treatment Period 2)	1.1	118.6	758.5	479.6	220.1	466.5	305.2	200.7

Intervention	PRU (Least Squares Mean)
	2 hours on day 7	8 hours on Day 7 -ticagrelor N=36 clopidogrel N=33	End of Dosing Interval on Day 8 - N's per 8 hours
Clopidogrel Arm	179.0	178.9	182.1
Ticagrelor Arm	28.5	38.7	51.5

Intervention	PRU (Least Squares Mean)
	0.5 hours	8 hours
Clopidogrel Arm	269.8	202.8
Ticagrelor Arm	134.6	34.0

Intervention	PRU (Least Squares Mean)
	2 hours on Day 7 (N=27 for clopidogrel)	8 hours on Day 7	End of dosing interval on Day 8
Clopidogrel	157.8	146.5	172.7
Ticagrelor	22.9	28.5	39.3

Intervention	PRU (Least Squares Mean)
	0.5 hours	8 hours (N=28 ticagrelor, N=27 clopidogrel)
Clopidogrel	270.1	192.6
Ticagrelor	166.3	27.2

Intervention	ng/mL (Geometric Mean)
	Baseline (0 pre-dose hours)	0.5 hours after the loading dose	2 hours after the loading dose	8 hours after the loading dose - Period 1 N=19	0 hours after multiple doses - Period 1 N=18	2 hours after multiple doses - Period 1 N=18	8 hours after multiple doses - Period 1 N=18	End of dosing interval on Day 8 - Period 1 N=18
Ticagrelor (Treatment Period 1)	1.0	9.8	222.6	119.0	93.2	136.7	89.8	140.8
Ticagrelor (Treatment Period 2)	1.0	2.3	150.9	54.8	74.5	172.3	112.6	110.3

Intervention	PRU (Least Squares Mean)
	2 hours	4 hours	24 hours	48 hours
Prasugrel Combined Groups	33.7	41.1	126.8	159.3
Prasugrel Loading Dose	22.1	24.1	81.6	118.3
Prasugrel Maintenance Dose	44.8	57.0	167.8	199.0
Ticagrelor	28.9	29.3	47.6	38.6

Intervention	percentage of subjects (Number)
	>= 208 PRU 2 hours post dose	>= 208 PRU 4 hours post dose	>= 208 PRU 24 hours post dose	>= 208 PRU 48 hours post dose	>= 208 PRU 7 days post dose	>= 230 PRU by VerifyNow P2Y12 2 hours post dose	>= 230 PRU by VerifyNow P2Y12 4 hours post dose	>= 230 PRU by VerifyNow P2Y12 24 hours post dose	>= 230 PRU by VerifyNow P2Y12 48 hours post dose	>= 230 PRU by VerifyNow P2Y12 7 days post dose	>50% PRI by VASP assay 2 hours post dose	>50% PRI by VASP assay 4 hours post dose	>50% PRI by VASP assay 24 hours post dose	>50% PRI by VASP assay 48 hours post dose	>50% PRI by VASP assay 7 days post dose
Prasugrel Combined Groups	0	0	17.5	30.2	1.5	0	0	14.3	22.2	1.5	3.5	1.8	21.3	45	15.5
Prasugrel Loading Dose	0	0	3.3	16.1	3.2	0	0	3.3	6.5	3.2	3.6	0	3.4	13.8	23.1
Prasugrel Maintenance Dose	0	0	37.5	43.8	0	0	0	24.2	37.5	0	3.4	3.4	37.5	74.2	9.4
Ticagrelor	0	0	0	0	3	0	0	0	0	3	3.3	3.3	12.9	6.3	3.4

Intervention	percentage PRI (Least Squares Mean)
	2 hours post-dose	4 hours post-dose	24 hours post-dose	48 hours post-dose	7 days post-dose
Prasugrel Combined Groups	18.2	16.3	34.3	48.1	33.5
Prasugrel Loading Dose	15.8	11.4	24.2	38.0	38.8
Prasugrel Maintenance Dose	20.4	20.9	43.7	57.7	29.1
Ticagrelor	13.2	14.3	19.1	18.7	19.8

Intervention	Percent Inhibition (Least Squares Mean)
	2 hours post-dose	4 hours post dose	24 hours post dose	48 hours post dose	7 days psot dose
Prasugrel Combined Groups	88.22	85.06	53.63	41.59	64.97
Prasugrel Loading Dose	92.55	91.36	71.40	57.98	64.97
Prasugrel Maintenance Dose	84.15	79.35	38.01	26.20	64.97
Ticagrelor	89.73	89.26	81.86	85.06	80.69

Intervention	participants (Number)
Dabigatran 220 mg - Part 1	0
Ticagrelor 180 mg - Part 1	0
Dabigatran 220 mg - Part 2	0
Ticagrelor 180 mg - Part 2	0
Dabigatran 75 mg - Part 3	0
Dabigatran + Ticagrelor - Part 3	1

Intervention	ng/mL (Geometric Mean)
Dabi 75 mg	31.47
Dabi + Ticagrelor LD	61.30
Dabi + Ticagrelor MD	49.11

ticagrelor

Description

Cross-References

Synonyms (93)

Research Excerpts

Overview

Effects

Actions

Treatment

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Roles (2)

Drug Classes (5)

Protein Targets (3)

Potency Measurements

Inhibition Measurements

Biological Processes (29)

Molecular Functions (5)

Ceullar Components (7)

Bioassays (73)

Research

Studies (2,358)

Market Indicators

Research Demand Index: 109.16

Study Types

Clinical Trials (400)

Trial Overview

Trial Outcomes

Participants With Any Event From the Composite of All-cause Mortality, MI, and Stroke

Participants With Major or Minor Bleeding

Participants With Non-CABG (Coronary Artery Bypass Graft) Related Major Bleeding

Participants With Stroke

Participants With Ventricular Pauses of Greater Than or Equal to 3 Seconds in Patients Monitored by Holter 24 Hour ECG Recorders for 1 Week at 1 Month Following Randomization

Participants With Ventricular Pauses of Greater Than or Equal to 3 Seconds in Patients Monitored by Holter 24-hour ECG Recorders for 1 Week Following Randomization

Participants With MI Event

Participants With Any Event From the Composite of Death From Vascular Causes, MI (Including Silent), Stroke, Recurrent Ischemia, Transient Ischemic Attack (TIA) and Other Arterial Thrombotic Events.

Participants With Non-procedural Major Bleeding

Participants With Death From Vascular Causes

Participants With Any Event From the Composite of Death From Vascular Causes, MI, and Stroke for the Subgroup of Patients With Intent for Invasive Management at Randomization

Participants With Any Event From the Composite of Death From Vascular Causes, Myocardial Infarction (MI), and Stroke

Participants With Death From Any Cause

Participants With Coronary Artery Bypass Graft (CABG) Major Fatal/Life-threatening Bleeding

Participants With Coronary Artery Bypass Graft (CABG) Major Bleeding

Participants With Any Major Bleeding Event

Cardiopulmonary Parameters at Baseline: Mean Forced Expiratory Flow Between 25% and 75% of the FVC (FEF25-75)

Cardiopulmonary Parameters at Baseline: Functional Residual Capacity (FRC)

Cardiopulmonary Parameters at Baseline: Forced Vital Capacity (FVC)

Cardiopulmonary Parameters at Baseline: Forced Expiratory Volume in 1 Second (FEV1)

Cardiopulmonary Parameters at Baseline: Ejection Fraction (EF)

Cardiopulmonary Parameters at Baseline: Blood Oxygen Saturation Measured by Pulse Oximetry (SpO2)

Final Extent IPA Induced by 20 µM ADP at 8 Hours After Last Dose

Slope of Extent IPA Offset Curve 4 to 72 Hours After Last Dose of Study Drug

Cardiopulmonary Parameters Post 6-week Treatment: RR

Cardiopulmonary Parameters Post 6-week Treatment: RV

Cardiopulmonary Parameters Post 6-week Treatment: SpO2

Cardiopulmonary Parameters Post 6-week Treatment: TLC

Cardiopulmonary Parameters Post 6-week Treatment: VE

Cardiopulmonary Parameters Post 6-week Treatment: VT

Final Extent IPA Induced by 20 µM ADP at 8 Hours After First Dose

Final Extent IPA Induced by 20 µM ADP at 0.5 Hours After First Dose

Final Extent IPA Induced by 20 µM ADP at 1 Hour After First Dose

Final Extent IPA Induced by 20 µM ADP at 120 Hours - Day 5 After Last Dose

Final Extent IPA Induced by 20 µM ADP at 168 Hours - Day 7 After Last Dose

Final Extent IPA Induced by 20 µM ADP at 2 Hours After Last Dose

Final Extent IPA Induced by 20 µM ADP at 24 Hours After First Dose

Final Extent IPA Induced by 20 µM ADP at 24 Hours After Last Dose

Final Extent IPA Induced by 20 µM ADP at 240 Hours - Day 10 After Last Dose

Final Extent IPA Induced by 20 µM ADP at 0 Hour Before Last Dose

Final Extent IPA Induced by 20 µM ADP at 4 Hours After Last Dose

Final Extent IPA Induced by 20 µM ADP at 48 Hours After Last Dose

Final Extent IPA Induced by 20 µM ADP at 72 Hours After Last Dose

Final Extent IPA Induced by 20 µM ADP at 4 Hours After First Dose

Final Extent Inhibition of Platelet Aggregation (IPA) Induced by 20 µM Adenosine Diphosphate (ADP) at 2 Hours After First Dose

Cardiopulmonary Parameters at Baseline: Single Breath Diffusing Capacity for the Lungs Using Carbon Monoxide (DLCOSB)

Cardiopulmonary Parameters at Baseline: Respiratory Rate (RR)

Cardiopulmonary Parameters at Baseline: Residual Volume (RV)

Cardiopulmonary Parameters at Baseline: Ratio of Forced Expiratory Volume in 1 Second Over Forced Vital Capacity (FEV1/FVC Ratio)

Intervention	ng*h/mL (Geometric Mean)
Dabi 75 mg	281.05
Dabi + Ticagrelor LD	485.48
Dabi + Ticagrelor MD	410.46

Intervention	PRU (Mean)
	0.5 hours	8 hours	End of PCI (n=41 for ticagrelor)
Clopidogrel	297.7	202.3	307.8
Ticagrelor	277.3	43.8	264.2

Intervention	percent change (Mean)
Ticagrelor + ASA + Bivalirudin	34.1
Clopidogrel + ASA + Bivalirudin	18.5

Intervention	seconds (Mean)
Ticagrelor + ASA + Bivalirudin	56.1
Clopidogrel + ASA + Bivalirudin	54.3

Intervention	percent inhibition (Mean)
Ticagrelor + ASA + Bivalirudin	67.4
Clopidogrel + ASA + Bivalirudin	53.4

Intervention	percent change (Mean)
Ticagrelor + ASA + Bivalirudin	56.3
Clopidogrel + ASA + Bivalirudin	35.2

Intervention	percent inhibition (Mean)
Ticagrelor + ASA + Bivalirudin	69.4
Clopidogrel + ASA + Bivalirudin	20.1

Intervention	seconds (Mean)
Ticagrelor + ASA + Bivalirudin	53.1
Clopidogrel + ASA + Bivalirudin	51.1

Intervention	seconds (Mean)
Ticagrelor + ASA + Bivalirudin	163.1
Clopidogrel + ASA + Bivalirudin	174.0

Intervention	Participant (Number)
	Category 0 - End of treatment	Category 1/2 - End of treatment	Category 3 - End of treatment	Category 4 - End of treatment	Category 5 - End of treatment	Category 6 - End of treatment	Missing - End of treatment
Clopidogrel - Cat 0	743	230	56	9	2	2	250
Clopidogrel - Cat 1/2	723	1956	311	15	6	1	724
Clopidogrel - Cat 3	198	557	450	23	6	4	370
Clopidogrel - Cat 4	33	33	38	23	4	1	60
Clopidogrel - Cat 5	13	18	12	11	12	0	34
Clopidogrel - Cat 6	6	3	3	1	1	0	11
Ticagrelor - Cat 0	775	227	45	7	5	2	248
Ticagrelor - Cat 3	171	560	469	12	3	2	403
Ticagrelor - Cat 4	15	41	39	31	1	0	59
Ticagrelor - Cat 5	23	23	13	4	11	0	33
Ticagrelor - Cat 6	3	5	6	3	0	2	14
Ticagrelor - Stage II	683	1948	269	24	4	3	743